

COMPLEX I OF THE MITOCHONDRIAL RESPIRATORY CHAIN  
IN HEALTH AND DISEASE

*Jan Loeffen*



# **COMPLEX I OF THE MITOCHONDRIAL RESPIRATORY CHAIN IN HEALTH AND DISEASE**

## **MOLECULAR-GENETIC STUDIES**

Een wetenschappelijke proeve op het gebied  
van de Medische Wetenschappen

## **PROEFSCHRIFT**

ter verkrijging van de graad van doctor aan de Katholieke Universiteit Nijmegen,  
volgens besluit van het College van Decanen in het openbaar te verdedigen  
op donderdag 22 juni 2000  
des ochtends om 11.00 uur precies

door

**Johannes Lambertus Christianus Maria Loeffen**

geboren 6 mei 1970  
te Oss

**Promotor:** Prof dr ir J M F Trijbels

**Co-promotores:** Dr J A M Smeitink

Dr L P van den Heuvel

**Manuscriptcommissie:** Prof dr B Wieringa, voorzitter

Prof dr H G Brunner

Prof dr E A Shoubbridge  
Molecular Neurogenetics Research, Montreal, Canada

Prof dr J L Willems

Prof dr M de Visser

The studies presented in this thesis were performed at the Department of Pediatrics, University Medical Centre Nijmegen, The Netherlands

Financial support for the publication of this thesis was obtained from

- Meubitrend BV, Oss
- Sigma Tau Ethifarma B V , Assen
- MILLUPA B V , Leidschendam
- The FBW foundation of the Pediatric Department, University Medical Centre Nijmegen
- The “Stichting voor kinderen die wel willen maar niet kunnen”, University Medical Centre Nijmegen
- BIOzymTC BV, Landgraaf
- Clean Air Techniek bv, Woerden
- Genzyme BV, Naarden
- Sigma-Aldrich BV, Zwijndrecht

Cover and back were illustrated by Jany

© 2000 Johannes L C M Loeffen, Oss, The Netherlands

Drukkerij Print Partners Ipskamp, Enschede

ISBN 90-9013863-3

NUGI 743



*Voor mijn ouders*

## Abbreviations

### Chapter 1

<i>General introduction and aim of the study</i>	9
<i>ATP synthesis</i>	10
<i>Complex I</i>	13
<i>Human complex I deficiency</i>	17
<i>Genetics of OXPHOS disorders</i>	18
<i>Aim of the study</i>	22

### Chapter 2

<i>Isolated complex I deficiency in children clinical, biochemical and genetic aspects</i>	29
--	----

### Chapter 3

<i>The X-chromosomal NDUFAL gene of complex I in mitochondrial encephalomyopathies tissue expression and mutation detection</i>	45
---	----

### Chapter 4

<i>Molecular characterisation and mutational analysis of the human NDUF B6 (B17) subunit of the mitochondrial respiratory chain complex I</i>	51
---	----

### Chapter 5

<i>The human NADH ubiquinone oxidoreductase NDUF S5 (15 kDa) subunit cDNA cloning, chromosomal localisation, tissue distribution and the absence of mutations in isolated complex I deficient patients</i>	63
--	----

### Chapter 6

<i>cDNA sequence and chromosomal localisation of the remaining three human nuclear encoded Iron-Sulphur protein (IP) subunits of complex I the human IP fraction is completed</i>	75
---	----

### Chapter 7

<i>cDNA of eight nuclear encoded subunits of NADH ubiquinone oxidoreductase human complex I cDNA characterisation completed</i>	89
---	----

### Chapter 8

<i>Demonstration of a new pathogenic mutation in human complex I deficiency a 5-bp duplication in the nuclear gene encoding the NDUF S4 (18 kDa) subunit</i>	103
--	-----

**Chapter 9**

*The first nuclear-encoded complex I mutation in a patient with Leigh syndrome* 115

**Chapter 10**

*Mutations in the complex I NDUF52 gene are associated with hypertrophic cardiomyopathy and encephalomyopathy* 131

**Chapter 11**

*Mutational analysis studies of four nuclear encoded subunits of the complex I Iron-Sulphur protein (IP) fraction which genes next?* 147

**Chapter 12**

*Considerations, conclusions and future perspectives* 157

**Dutch summary, Nederlandse samenvatting**

181

**English summary**

187

**Dankwoord**

195

**Curriculum vitae**

199

**List of publications**

200

ACP	acylcarrier protein
acyl CoA	acyl-Coenzyme A
ADP	adenosine diphosphate
AMP	adenosine monophosphate
ATP	adenosine triphosphate
ATPase	adenosine triphosphatase
BLAST	basic local alignment search tool
bp	base pair
c	cytochrome c
cAMP	cyclic AMP
cDNA	complementary DNA
CO <sub>2</sub>	Carbon-dioxide
CoA	Coenzyme A
CoQ	Coenzyme Q (ubiquinone)
CrP	creatine phosphate
CSF	cerebrospinal fluid
CT	computed tomography
cyt	cytochrome
dCTP	deoxycytidine triphosphate
DIDMOAD	diabetes insipidus diabetes mellitus, optic atrophy and deafness
DNA	deoxyribonucleic acid
e	electron
EPR	electron paramagnetic resonance imaging
EST	expressed sequence tag
et al	et alii, and others
FAD	flavin adenine dinucleotide (oxidised form)
FADH <sub>2</sub>	flavin adenine dinucleotide (reduced form)
Fe-S	Iron Sulphur
FILA	fatal infantile lactic acidosis
FMN	flavin mononucleotide (oxidised form)
FP	flavoprotein
GDP	guanosine diphosphate
GTP	guanosine triphosphate
h	hour
H <sup>+</sup>	proton
HP	hydrophobic protein
IP	iron sulphur protein
IP <sub>3</sub>	inositol triphosphate
kb	kilobase
kDa	kiloDalton
L/P	lactate pyruvate ratio
LHON	Leber's hereditary optic neuropathy
LLS	Leigh-like syndrome
LS	Leigh syndrome
MELAS	mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes
MERRF	myoclonic epilepsy with ragged red fibres

---

MILS	maternally inherited Leigh syndrome
min	minutes
MLD	macrocephaly with leukodystrophy
mM	millimolar
mmol/l	millimol per litre
MNGIE	myoneurogastrointestinal encephalomyopathy
M <sub>r</sub>	calculated molecular weight
MRI	magnetic resonance imaging
mRNA	messenger RNA
mtDNA	mitochondrial DNA
mtETC	mitochondrial electron transport chain
mU	milliUnits
NAD <sup>+</sup>	nicotinamide adenine dinucleotide (oxidised form)
NADH	nicotinamide adenine dinucleotide (reduced form)
NARP	neurogenic muscle weakness ataxia and retinitis pigmentosa
NCBI	national centre for biotechnology information
NCLA	neonatal cardiomyopathy with lactic acidosis
NDH I	NADH dehydrogenase I
NDH II	NADH dehydrogenase II
nDNA	nuclear DNA
ng	nanogram
Nuo	NADH ubiquinone oxidoreductase
OMIM	online Mendelian inheritance in man
ORF	open reading frame
OXPHOS	oxidative phosphorylation
P <sub>i</sub>	phosphate with high energy transfer potential
PCR	polymerase chain reaction
PDHc	pyruvate dehydrogenase complex
PEO	progressive external ophthalmoplegia
PMR	psychomotor retardation
poly a	polyadenylation
RFLP	restriction fragment length polymorphisms
RNA	ribonucleic acid
RRF <sub>s</sub>	ragged red fibres
rRNA	ribosomal RNA
RT	reverse transcriptase
SSCP	single strand conformation polymorphism
STS	sequence tagged site
tRNA	transfer RNA
U	ubiquinone or units
UE	unspecified encephalomyopathy
µg	microgram
µL	microliter
µM	micromolar
µmol/l	micromol per litre
UTR	untranslated region



### GENERAL INTRODUCTION AND AIM OF THE STUDY

**Partially based on:**

**Nuclear genes of human complex I of the mitochondrial electron transport chain: state of the art**

***Human Molecular Genetics* 1998 7:1573-1579**


Energy production, storage and use are just as essential for cells as fuels are to the world economy. The provision of energy in mammalian cells is one of the most intriguing yet immense complex aspects of cellular function, with tentacles spreading to all corners of the cell. Mitochondria are the power plants of eukaryotic cells, which maintain an adequate cellular energy status. By means of a process called respiration, mitochondria convert nutrients into the energy-yielding compound adenosine triphosphate (ATP) to fuel the cell's activities.

### ATP synthesis.

One of the main sources of ATP in the aerobic state of the cell is glucose. The complete oxidation of glucose to  $\text{H}_2\text{O}$  and  $\text{CO}_2$  can be divided in three main parts:

- I. Glycolysis,
- II. Citric acid cycle,
- III. Oxidative phosphorylation.


Glycolysis takes place in the cytoplasm of the cell. The overall reaction contains the conversion of the six-carbon compound glucose into two three-carbon molecules of pyruvate. A total of nine enzymatic steps are necessary to complete this conversion (Fig. 1.1). The net reaction of this transformation is:



**Figure 1.1** The glycolytic pathway 1=Hexokinase; 2=Phosphoglucose isomerase, 3=Phosphofructokinase-1, 4=Aldolase; 5=Triose phosphate isomerase, 6=Glyceraldehyde 3-phosphate dehydrogenase; 7=Phosphoglycerate kinase, 8=Phosphoglyceromutase, 9=Enolase, 10=Pyruvate kinase



Under anaerobic conditions, pyruvate is mainly converted into lactate by the enzyme lactate dehydrogenase, resulting in the overall reaction




The regeneration of  $\text{NAD}^+$  maintains the operation of glycolysis under anaerobic conditions. Lactic acid is mainly secreted into the bloodstream, after which it is processed by the liver. Here the lactate is reoxidised into pyruvate, which is either further metabolised into  $\text{CO}_2$  or converted into glucose. The heart can maintain aerobic metabolism at times when skeletal muscle already converts pyruvate into lactate (e.g. during prolonged exercise). Therefore the heart can provide a serious contribution to the clearance of lactic acid from the blood.

Under aerobic conditions, pyruvate is transported from the cytoplasm into the matrix of the mitochondrion. Immediately on entering the matrix, pyruvate reacts with Coenzyme A to generate  $\text{CO}_2$  and acetyl-CoA. This highly exergonic conversion is catalysed by the Pyruvate Dehydrogenase complex (PDHc).



Acetyl-CoA enters the citric acid cycle (Krebs cycle) where it is further processed (Fig. 1.2).


Fatty acids are released into the blood, from which they are taken up and oxidised by most cells. On the outer mitochondrial membrane, free fatty acids are coupled to Coenzyme A by




**Figure 1.2** The citric acid cycle 1=Citrate synthase 2 + 3= Aconitase 4=Isocitrate dehydrogenase 5=α Ketoglutarate dehydrogenase complex 6=Succinyl CoA synthetase 7=Succinate dehydrogenase 8=Fumarase 9=Malate dehydrogenase

acyl-CoA synthetase to form an acyl-CoA. This is an endergonic reaction, which is linked to the hydrolysis of ATP. Long-chain acyl-CoA molecules cannot traverse the inner mitochondrial membrane and are carried across this membrane by carnitine. Carnitine palmitoyl transferase I transfers the acyl group from acyl-CoA to carnitine, after which the acyl-carnitine is transported across the inner mitochondrial membrane by carnitine acylcarnitine translocase. The acyl group is then reattached to CoA by carnitine palmitoyl transferase II, by which the acyl-CoA is regenerated. In a cyclic process, which is called  $\beta$ -oxidation, the acyl-CoA is shortened by two carbon atoms (acetyl-CoA). Concomitantly, one molecule of  $\text{NAD}^+$  and FAD are reduced to NADH and  $\text{FADH}_2$ . This cycle continues until all carbon atoms are converted into acetyl-CoA, which enters the citric acid cycle.


The citric acid cycle consists of nine reactions (Fig. 1.2) with the net result:



Several reactions of glycolysis, citric acid cycle and  $\beta$ -oxidation result in the reduction of  $\text{NAD}^+$  and FAD to NADH and  $\text{FADH}_2$ , respectively. These reduced coenzymes are reoxidised by molecular oxygen in a multi-step process called oxidative phosphorylation (Fig. 1.3). The overall reaction of the oxidation of NADH is:



During the oxidation of NADH two electrons are released. In contrary to protons, electrons cannot exist in aqueous solutions. The electrons are therefore transported to oxygen via four multi-protein complexes together constituting the respiratory chain, which is embedded in the inner mitochondrial membrane. This transport is thermodynamically downhill and much of the released energy is conserved by the movement of protons from the mitochondrial matrix to the intermitochondrial membrane space.



**Figure 1.3** The oxidative phosphorylation system. I = complex I (NADH:ubiquinone oxidoreductase), II = complex II (succinate:ubiquinone oxidoreductase), U = ubiquinone, III = complex III (ubiquinone:cytochrome *c* oxidoreductase), C = cytochrome *c*, IV = complex IV (cytochrome *c* oxidase), V = complex V (ATP synthase), IMS = intermembrane space;  $e^-$  = electron.

Briefly, NADH donates two electrons to the first complex of the respiratory chain, which is called NADH ubiquinone oxidoreductase or complex I. The electrons travel through the prosthetic groups of complex I towards ubiquinone (U) also called Coenzyme Q (CoQ). FADH<sub>2</sub> also transfers its electrons to ubiquinone but via succinate ubiquinone oxidoreductase or complex II. Ubiquinone transports the electrons to ubiquinone cytochrome  $\epsilon$  oxidoreductase or complex III. Cytochrome  $\epsilon$  accepts the electrons from complex III and transfers them to cytochrome  $\epsilon$  oxidase which catalyses the reduction of oxygen. As mentioned previously, energy which is released by this electron transport is preserved by the translocation of protons across the inner mitochondrial membrane. For each two electrons accepted from NADH, complex I transports four protons towards the intermembrane space, complex III two and complex IV four, which adds up to a total of ten protons. Since complex II does not translocate protons, two electrons donated by FADH<sub>2</sub> result in the total translocation of six protons across the inner mitochondrial membrane. The created proton gradient is used by ATP synthase or complex V to generate ATP. The respiratory chain together with ATP synthase is called the oxidative phosphorylation (OXPHOS) system. In the next section I will focus on the first and largest complex of the respiratory chain (also the main subject of this thesis) complex I.

## Complex I.

### *Evolution, composition and (spatial and functional) organisation of complex I*

Although complex I studies have been performed in many species, most knowledge regarding the composition, spatial and functional organisation of the first mitochondrial electron transport chain (mtETC) enzyme complex has been obtained from *Escherichia coli*, *Neurospora crassa* and *Bos taurus* (Hatefi 1985, Weiss et al 1991, Walker 1992, Walker et al 1992, Weidner et al 1993, Guenebaut et al 1997, Grigorieff 1998). Many bacteria (like *E. coli*) contain two NADH dehydrogenases, which are called NDH-I and NDH-II (Yagi 1993, Weidner et al 1993). NDH-I is like mitochondrial complex I, a multiple-protein enzyme complex and links electron transport to proton translocation. It contains many redox centres, namely one flavine mononucleotide (FMN) and possibly up to nine Fe-S clusters (Friedrich 1998). NDH-I is built up of fourteen subunits, which have been named NADH ubiquinone oxidoreductase (Nuo) A to N (in some bacteria Nuo C and D are fused to NuoCD) and is generally considered to be the minimal form of a proton-pumping NADH ubiquinone oxidoreductase (Leif et al 1993, Table 1.1, page 16). NDH-II is a single polypeptide enzyme, which is in practice a non-proton pumping NADH ubiquinone oxidoreductase.

Complex I of *E. coli* can be fragmented into three parts, an NADH dehydrogenase fragment, a connecting fragment and a membrane fragment (Leif et al 1993). The NADH dehydrogenase part consists of NuoE, F and G containing the NADH binding site, the FMN and four electron paramagnetic detectable iron-sulphur clusters (Friedrich 1998), and is considered to be the electron input part of complex I. The connecting fragment is made up of NuoB, CD and I and contains Iron-Sulphur cluster N2 (Leif et al 1995). Finally, the membrane fragment is built of NuoA, H and J-N. Little is known about the functions of the membrane part of *E. coli* complex I. It probably participates in the binding of ubiquinone and the transport of protons.

(Friedrich 1998)

Complex I of the fungus *N. crassa* has a dual genetic origin. The majority of its proteins are encoded by the nucleus, synthesised in the cytoplasm and imported into mitochondria, where they assemble together with several mitochondrial encoded proteins into the complete complex. *N. crassa* contains a complex I which probably consists of at least 35 different proteins of which 7 are encoded by mtDNA (Weiss et al 1991, Table 1.1). Currently, not all subunits are characterised at cDNA level. All subunits which are present in NDH-I of bacteria are present in the eukaryotic complex I of *N. crassa*. As mentioned previously, *N. crassa* complex I appears under the electron microscope as an L-shaped structure, with one arm embedded in the mitochondrial membrane, while the other arm protrudes into the matrix (Guenebaut et al 1997). So far, the FMN and only four Fe-S clusters have been identified. Besides the subunits which are also present in the minimal form of complex I seen in bacteria, many additional proteins are present in complex I of *N. crassa*. In many cases they do not seem to have similarity to other proteins. It has been speculated that many of these proteins isolate the complex in order to prevent electrons from escaping the enzyme (Friedrich and Weiss 1997).

Experiments performed with *N. crassa* cells, in which radioactivity of pulse-labelled amino acids was followed, showed that the membrane arm and the arm protruding into the matrix are separately assembled (Tuschen et al 1990). These findings were confirmed in *N. crassa* using disruption experiments of single complex I genes. In addition, the membrane arm seems to be synthesised by fusion of two intermediates (Schulte et al 1994). The crystal structure of the *N. crassa* complex has been determined and, by immunolabelling, the 49 kDa subunit has been pinpointed to the matrix-localised protruding arm of the complex (Guenebaut et al 1997). Immunolabelling of other subunits will give further insight into the interrelationships of the various subunits.

The species evolutionarily closest to man of which complex I has been studied extensively is *Bos taurus*. Bovine complex I has ~42 subunits (Table 1.1) with a total molecular mass of ~900 kDa. It consists of seven mitochondrial- and at least 35 nuclear-encoded subunits and has, like in *N. crassa*, an L-shaped configuration of which the peripheral arm protrudes in the mitochondrial matrix (Guenebaut et al 1997, Grigorieff 1998). The bovine complex differs from that of *N. crassa* by having a thin stalk region linking the membrane-bound globular arm with the intrinsic membrane domain. It is however clear that the form of complex I is highly conserved between prokaryotes like *E. coli* and eukaryotes like *N. crassa* and *Bos taurus* (Friedrich 1998, Grigorieff 1998). Most of the electron carriers, which exist of one flavine mononucleotide (FMN) and at least six Fe-S clusters (proven by electron paramagnetic resonance imaging (EPR)), are located in the peripheral arm. With the use of chaotropic agents, the complex can be separated into three different fractions (Galante and Hatefi 1978 and 1979). The flavoprotein (FP) fraction and the iron-sulphur protein (IP) fraction are both water-soluble, whereas the hydrophobic protein (HP) fraction forms a water-insoluble aggregate. The FP fraction (51, 24 and 10 kDa) and the IP fraction (75, 49, 30, 18, 15, 13 kDa, B13 and TYKY) form the principal catalytic sector and are located in the peripheral arm of the complex (Belogradov and Hatefi 1994). Whether the TYKY subunit is present in the IP fraction or in the HP fraction is subject of debate. Masui and co-workers located the TYKY

subunit in the IP fraction (Masui et al 1991), while others did not. Since the prokaryotic TYKY equivalent (NuoI) is present in the connecting fragment (located between the dehydrogenase fragment and the membrane fragment), it could be possible that slight differences in the complex I purification and fractionation process result in the presence of TYKY in different fractions. The HP fraction (containing the seven mitochondrial encoded subunits and ~24 nuclear encoded subunits) is probably involved in proton translocation (Ohnishi et al 1985, Belogradov and Hatefi 1994). This fraction contains, besides hydrophobic subunits, also globular water-soluble ones and the presence of a particular subunit in this fraction should not be taken to imply that the protein is either hydrophobic or a component of the membrane part of the enzyme complex (Walker 1992).

Most aspects of complex I function regarding electron and proton transport are unknown, however some aspects have been elucidated. The 51 kDa FP subunit carries the NADH-binding site (Chen and Guillory 1981, Deng et al 1990), contains an FMN and a tetranuclear iron-sulphur cluster (Pilkington et al 1991). The 24 kDa FP subunit contains a binuclear iron-sulphur cluster (Pilkington and Walker 1989). The 75 kDa IP subunit contains a tetranuclear and a binuclear iron-sulphur cluster (Runswick et al 1989). Sequencing of the bovine TYKY (23 kDa) IP subunit revealed that this subunit contains two cysteine motifs, which probably provide the ligands to accommodate two 4Fe-4S clusters (Dupuis et al 1991). Such a conserved cysteine motif has also been encountered in the PSST (20 kDa) HP subunit (Walker 1992). The FP and IP water-soluble fractions make contact through the 51 kDa FP and 75 kDa IP subunits. The FP and IP subunit stoichiometry, which is a *sine qua non* for the study of the structure of an enzyme complex, and the substrate-induced conformational changes have been partly elucidated by Belogradov and Hatefi in 1996. They showed that the proximity of the three FP subunits to one another, the proximity of the 51 kDa FP subunit to the 75 kDa IP subunit, and the proximity of all studied IP subunits to one another and to some of the HP subunits are altered when the catalytic sector of complex I is reduced by NADH or NADPH prior to the addition of a cross-linking reagent. The authors speculated that these conformational changes may well be the device by which the energy derived from electron transfer through the catalytic components of complex I is transduced and conveyed to the subunits of the membrane sector. Here,  $pK_a$  changes of appropriate residues induced by these conformational changes would result in proton uptake and release on opposite sides of the membrane.

Table 1.1 lists the subunit composition of bacterial complex I (14 subunits), complex I of *N. crassa* (~35 subunits, currently not all molecular-genetically characterised) and *B. taurus* (~42 subunits). The prokaryotic subunits (NuoA-N) are present in all three species and seem to form the catalytic core of the complex. *N. crassa* has numerous additional proteins, several of which do not seem to be conserved in *B. taurus*.

In summary, the overall function of complex I of the mtETC is the dehydrogenation of NADH and the transportation of electrons to ubiquinone. This electron transport device is linked by a yet unknown mechanism to proton transport across the inner mitochondrial membrane to the intermembrane space (~4 protons for each two electrons). This proton gradient is the force used for the production of ATP by  $F_1F_0$  ATP-synthase (complex V).

<i>E. coli</i>		<i>N. crassa</i>		<i>B. taurus</i>	
<i>Name</i>	<i>kDa</i>	<i>Name</i>	<i>kDa</i>	<i>Name</i>	<i>kDa</i>
NuoA	16.5	ND-3	6.0	ND-3	13.1
NuoB	25.1	19.3 kDa	25.0	PSST	23.8
NuoC <sup>1</sup>	68.7	31 kDa	32.3	30 kDa (IP)	30.3
NuoD <sup>1</sup>	68.7	49 kDa	54.0	49 kDa (IP)	49.2
NuoE	18.6	24 kDa	28.8	24 kDa (FP)	27.3
NuoF	49.3	51 kDa	54.3	51 kDa (FP)	50.7
NuoG	100.3	78 kDa	81.7	75 kDa (IP)	79.4
NuoH	36.2	ND-1	41.6	ND-1	35.7
NuoI	20.5	23 kDa	24.9	TYKY (IP)	23.9
NuoJ	19.9	ND-6		ND-6	19.2
NuoK	10.8	ND-L4	9.8	ND-4L	10.8
NuoL	66.4	ND-5	79.8	ND-5	68.3
NuoM	56.5	ND-4		ND-4	53.8
NuoN	45.7	ND-2	65.8	ND-2	39.3
-		-		10 kDa (FP)	11.9
-		21.3 kDa	24.5	AQDQ (IP)	19.8
-		-		15 kDa (IP)	12.7
-		-		13 kDa (IP)	13.4
-		29.9 kDa	30.9	B13 (IP)	13.3
-		-		42 kDa	39.3
-		40 kDa	43.0	39 kDa	42.8
-		-		B22	21.8
-		12.3 kDa		PDSW	21.0
-		-		KFYI	8.8
-		20.8 kDa	20.9	PGIV	20.1
-		-		ASHI	21.7
-		-		SGDH	21.6
-		-		B18	16.4
-		-		B17.2	17.1
-		-		B17	15.5
-		-		B15	15.2
-		14.8 kDa	14.8	B14	15.1
-		-		B14.5a	12.7
-		-		B14.5b	14.1
-		-		B12	11.1
-		9.3 kDa	9.3	B9	9.3
-		10.5 kDa	10.5	B8	11.1
-		9.6 kDa	14.5	SDAP	10.1
-		-		MLRQ	9.3
-		12kDa	12.3	AGGG	12.3
-		-		MWFE	8.1
-		-		MNLL	7.0
-		17.8 kDa	20.1	-	
-		21 kDa	21.0	-	
-		12 kDa	12.3	-	
-		21.3 kDa	21.3	-	
-		9.5 kDa	9.3	-	
-		21.3 kDa	21.4	-	
-		18.3 kDa	21.8	-	

**Table 1.1** Complex I subunit composition of *E. coli*, *N. crassa* and *B. taurus*. All proteins were retrieved from the NCBI protein database, using Basic Local Alignment Search Tool (BLAST, Altschul et al 1990). <sup>1</sup> In some prokaryotes like *E. coli* NuoC and NuoD are fused to NuoCD. Subunits that are in the same row are homologous between the species.

---

**Human complex I deficiency.**

Among the group of mitochondriocytopathies (estimated incidence 1/10,000 live births, Bourgeron et al 1995), isolated complex I deficiency is frequently encountered (von Kleist-Retzow et al 1998). The primary genetic cause of the observed deficiencies may either be at the mtDNA or at the nDNA level. Elucidation of the genetic defects of these disorders is important for genetic counselling and will extend our knowledge of the functional properties of the individual subunits. A great variety in clinical presentation, age of onset, course of the disease and clinical-chemical abnormalities exists in complex I deficient patients. It may therefore not come as a surprise that the diagnostic process is rather complicated and that the judgement of instituted treatments is almost impossible in individual patients.

In general, most affected tissues are those with a high-energy demand, such as the brain, heart, kidney and skeletal muscle. Ophthalmological signs like external ophthalmoplegia, ptosis, cataract and retinopathy are also frequently observed (Pitkanen et al 1996). The diagnosis 'enzymatic complex I deficiency' is often made in early childhood and, although exceptions exist, the course is often that of a multi-system disorder with a fatal outcome. In most patients lactic acidemia (with increased lactate/pyruvate ratios due to the altered redox state of the mitochondria) is present, although we are aware of several cases of complex I deficiency in which lactic acid, even after provocation (exercise, glucose tolerance test), is completely normal (this thesis). In order to correlate genotype to phenotype, a detailed clinical description of patients is of utmost importance. In suspected patients, diagnosis can be made by enzymatic measurements, for which a skeletal muscle biopsy sample is the tissue of choice; cultured fibroblasts can also be used. Noteworthy in this context is that not all deficiencies observed in skeletal muscle specimens are present in fibroblasts (Ruitenbeek et al 1996). This phenomenon, together with the diverse involvement of tissues and organs in affected patients, may be caused by differences in tissue expression of the individual subunits of the complex. In nearly all patients, a considerable residual enzymatic activity is observed. To the best of our knowledge, few patients have been described with an immeasurably low complex I activity. Under certain conditions prenatal diagnosis of respiratory chain disorders is possible at the enzymatic level and has been performed with success in specialised laboratories (Ruitenbeek et al 1992 and 1996). Because of the fact that the interpretation of the results of these measurements is difficult, it would be very helpful if prenatal diagnosis of complex I deficiency would be possible at DNA level. One can easily obtain RNA and DNA from chorionic villi, on which mutational analysis can be performed by means of RT-PCR followed by direct sequencing, or in case of known mutations, by PCR combined with restriction fragment length polymorphisms (RFLP).

## Genetics of OXPHOS disorders.

### a. Mutations in mtDNA.

Since the first description of a patient with a disturbance in the mitochondrial energy-generating system by Ernster in 1959, numerous reviews about the mitochondrial electron transport chain (mtETC) and defects of its individual complexes have been published (Sengers et al 1984, DiMauro et al 1985, Trijbels et al 1988, Lombes et al 1989, Wallace 1992, Morgan-Hughes 1994, Johns 1995, Tein 1996, Schapira 1998a)

One of the most intriguing aspects of the OXPHOS system is its dual genomic control. About 30 years ago, the first structural characterisation of human mitochondrial DNA (mtDNA) appeared in literature (Clayton and Vinograd 1967, Hudson and Vinograd 1967). The mtDNA, a 16,569 base-pair genome is present in several hundred copies per cell, encodes two rRNAs, 22 tRNAs and 13 mRNAs (Anderson et al 1981, Taanman 1999). The mRNAs encode subunits of three of four respiratory chain complexes (7 out of 42 complex I proteins, 1 out of 11 complex III proteins and 3 out of 13 complex IV proteins) as well as ATP synthase (2 out of 14 proteins). The remaining components of the OXPHOS system as well as all proteins involved in its assembly, maintenance and regulation are encoded on the nuclear DNA (nDNA).

Due to its easy accessibility and relatively small genome, mutational analysis studies of disorders of the OXPHOS system have the last ten years concentrated on the mtDNA. Since 1988, numerous mtDNA mutations (rearrangements as well as point mutations) have been reported to occur in patients with mitochondriocytopathies, of which more than one hundred are considered pathogenic (Zeviani et al 1998a, Chinnery and Turnbull 1999). In general, mutations of mtDNA can be divided in major rearrangements and point mutations. In the following sections a brief summary of the most important mtDNA mutations and their accompanying clinical phenotypes are described.

Two aspects of the mitochondrial genome are especially important in the relation between mtDNA and OXPHOS deficiencies. Firstly, mtDNA is transmitted only by the mother (Giles et al 1980). The mtDNA donated by sperm cells to the oocyte after fertilisation is actively degraded (Shitara et al 1998). This maternal inheritance pattern implicates that in the pedigree of patients with mtDNA mutations affected siblings can be expected only in the maternal lineage and only in the offspring of females. Secondly, mutated and wild-type mtDNA can coexist within a single cell, especially in the case of point mutations. This condition is termed heteroplasmy. When there is heteroplasmy for a given mutation (rearrangements as well as point mutations), this suggests either that it arose relatively recent (no time to become homoplasmic) or the mutation cannot be tolerated in the homoplasmic state. Different amounts of heteroplasmy can be present between adjacent cells. It has been hypothesised that this feature of different amounts of mtDNA heteroplasmy between patients is responsible for the diversity in clinical phenotypes seen in carriers of the same mtDNA mutation. Furthermore, it seems likely that a cell needs to cross a certain threshold for mutated mtDNA before it gets affected. For many mtDNA mutations, a relation has been found between the amount of heteroplasmy and the phenotype (MELAS (Chinnery et al 1997), MERRF



(Hammans et al 1993), NARP (Uziel et al 1997) but other lack such a correlation (LHON (Ghosh et al 1996))

*Large-scale rearrangements* At the end of the eighties, large-scale rearrangements of mtDNA were for the first time linked to specific clinical phenotypes

Progressive external ophthalmoplegia (PEO, bilateral ptosis, ophthalmoplegia with or without general muscle weakness, OMIM 157640, 601226, 601227, 603280, 604005) has been linked to large deletions in mtDNA (Moraes et al 1989) It is transmitted in an autosomal-dominant manner with male to male transmission, indicating a nuclear gene predisposing to mtDNA deletions Linkage analysis mapped PEO to three different regions in different families while in a fourth family these three regions were excluded Therefore at least four different nuclear genes are involved in PEO (PEO type 1-4), which remain to be elucidated (Suomalainen et al 1995, Kaukonen et al 1996, Kaukonen et al 1999, Li et al 1999) PEO has also been described to inherit in an autosomal-recessive manner, associated with severe cardiomyopathy (Bohlega et al 1996) Kearns-Sayre syndrome (OMIM 530000), a disease characterised by ophthalmoplegia, pigmentary degeneration of the retina, cardiomyopathy, onset before age of 20 and a high protein content in CSF was also linked to a single large deletion of variable length in the mtDNA (Zeviani et al 1988, Lestienne and Ponsot 1988, Zeviani et al 1998b)

Patients with Pearson syndrome (OMIM 557000) suffer from refractory sideroblastic anemia with vacuolisation of bonemarrow precursors and exocrine pancreas dysfunction, which has been associated with deletions or duplications in the mtDNA (Rotig et al 1989, Superti-Furga et al 1993)

A disorder characterised by multiple deletions of mtDNA is myoneurogastrointestinal encephalopathy syndrome (MNGIE, OMIM 550900) (Hirano et al 1994) Recently, Nishino and colleagues revealed that the primary genetic defect of MNGIE is located in the gene coding for thymidine phosphorylase (Nishino et al 1999) Besides deletions, also partial duplications of the mtDNA are sometimes seen in mitochondrial myopathy (Poulton et al 1989) Finally, a clinical phenotype with diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD, Wolfram syndrome, OMIM 598500) may be linked to large-scale rearrangements (Rotig et al 1993, Barrientos et al 1996) Collier and colleagues however, found linkage in families with DIDMOAD patients to chromosome 4p16.1 (Collier et al 1996) and in 1998 Inoue located the gene responsible for a large percentage of DIDMOAD patients, WFS1 (Inoue et al 1998), which has been confirmed by other groups (Strom et al 1998, Hardy et al 1999)

Usually the inheritance pattern observed in patients with major mtDNA rearrangements is sporadic, probably because they occur in the germ-line In rare cases however, a heteroplasmic duplication of mtDNA and a large deletion is maternally transmitted in diabetes and deafness (Ballinger et al 1992, Dunbar et al 1993)

*Leber's hereditary optic neuropathy (LHON, OMIM 535000)* Many mtDNA point mutations have been reported in literature Several of these mutations are linked to specific clinical phenotypes At the end of the eighties, Wallace and colleagues found the G11778A (ND-4) mutation in patients with Leber's hereditary optic neuropathy (LHON) (Wallace et al 1988a) LHON patients present in mid-life with acute or subacute central vision loss leading to central scotoma Other important mutations linked to LHON are the G3460A (ND-1) (Huoponen et al

1991, Howell et al 1991), G14459A (ND-6) (Jun et al 1994), T14484C (ND-6) (Mackey and Howell 1992) and G15257A (CYT B, Johns and Neufeld 1991) LHON mutations are maternally transmitted and are traditionally considered being familial, yet several patients have been reported as individual cases. Biochemical analysis of the respiratory chain enzymes showed that complex I activity can be deficient in patients with LHON. Since there seems to be a male preponderance present in patients with LHON, influence of an X-linked nuclear gene has been suggested (Vilkkı et al 1991).

*LHON and dystonia* The combination of LHON and dystonia is considered to be a separate clinical phenotype. Two mutations have been found in these patients, namely the G14459A (ND-6) (Jun et al 1994) and the A11696G (ND-4) (De Vries et al 1996).

*Myoclonic epilepsy with ragged red fibres (MERRF, OMIM 545000)* MERRF syndrome is a maternally transmitted clinical phenotype linked by Shoffner in 1990 to the mtDNA mutation A8344G (tRNA<sup>lys</sup>) (Shoffner et al 1990). This mutation accounts for 80-90% of the MERRF patients (Shoffner and Wallace 1992). Biochemical studies of the respiratory chain in these patients often reveal combined deficiencies, with most prominently affected complex I and complex IV (Wallace et al 1988b). The common MERRF mutation has also been found in patients with Leigh syndrome, isolated myoclonus, familial lipomatosis and isolated myopathy (Silvestri et al 1993).

*Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS, OMIM 540000)* Another important clinical syndrome that has been connected to a mitochondrial encoded tRNA gene (tRNA<sup>leu</sup>) is MELAS. Goto and colleagues found in several MELAS patients the A3243G mutation, which turned out to be the most common MELAS mutation (Goto et al 1990). The clinical phenotype of patients with MELAS is extremely diverse (de Vries et al 1994). Diversity is also encountered in the phenotypes associated with the A3243G mutation, which can be MELAS, PEO, isolated myopathy, cardiomyopathy and diabetes mellitus with deafness (Zeviani et al 1998a). As counts for the mutation found in the tRNA<sup>lys</sup> gene seen in MERRF, mutations in the tRNA<sup>leu</sup> gene often result in multiple enzyme deficiencies of the respiratory chain, with a preference for complex I and IV deficiency.

*NARP (OMIM 551500) / MILS (OMIM 516060)* Holt et al found a T to G transversion at nucleotide pair 8993 of the mtDNA (ATPase 6 subunit) in a family with adult-onset maternally inherited neurogenic muscle weakness, ataxia and retinitis pigmentosa (NARP) (Holt et al 1990). The clinical phenotype varied according to the amount of heteroplasmy found in each individual patient. This T8993G mutation has also been found in patients with Leigh syndrome (Tatuch et al 1992, Shoffner et al 1992). This form of Leigh syndrome caused by a mutation in the ATPase 6 gene, is also indicated in literature by the acronym MILS (maternally inherited Leigh syndrome). NARP and MILS can coexist within the same family. In 1994 hypertrophic cardiomyopathy was added to the list of clinical phenotypes associated with the T8993G mutation (Pastores et al 1994). De Vries and colleagues found in 1993 a T to C transition at position 8993 in patients with juvenile Leigh syndrome (De Vries et al 1993). It is believed that the T8993C mutation results in a milder dysfunction of complex V compared to the T8993G mutation. The different phenotypes associated with the same mutation could be caused by a different amount of heteroplasmy of the mutations in tissues. It has been

suggested that a higher percentage of mutated mtDNA (T8993G) results in Leigh syndrome, while lower amounts might result in NARP (Tatuch et al 1992)

*Parkinson disease (PD)*. Mitochondrial involvement in PD was a fact when a complex I deficiency was found in tissue of the substantia nigra of PD patients (Schapira et al 1989). The substantia nigra is the origin of the main clinical features of PD due to degeneration of dopaminergic neurons. Studies of OXPHOS function in PD patients in other parts of the brain and other tissues revealed conflicting results (Schapira 1998b). There is however a uniform opinion that there is a complex I deficiency in platelets of PD patients. The active metabolite 1-methyl-4-phenylpyridinium (MPP) of the toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a selective complex I inhibitor which induces parkinsonism in humans. This again stresses the possible involvement of complex I in the pathogenesis of PD. Several studies have been performed to locate possible mutations in mitochondrially encoded complex I subunits, however with no consistent results. Fusion studies between  $\rho_0$  cells and platelets showed complex I deficiency in cybrids with PD patient platelets compared to normal complex I activity when control platelets were used. This proves that the complex I deficiency in PD patients is of mitochondrial nature (Gu et al 1998). The exact genetic cause remains to be elucidated.

## **b. Mutations in nDNA.**

Mutations in nuclear encoded subunits of the OXPHOS system were at the start of our study in 1997 limited to one. Bourgeron and colleagues found an R554W substitution in the Fp subunit of succinate ubiquinone oxidoreductase (complex II). This mutation was found in two siblings born from consanguineous parents, suffering from Leigh syndrome (Bourgeron et al 1995).

In case of complex I, no mutations were described in nuclear encoded complex I genes at the start of our study. At that time, only a few human nuclear encoded complex I subunits were characterised at mRNA and amino acid level, so naturally, mutational analysis studies were scarce.

## Aim of the study.

Many patients and tissue specimens of patients (mainly skeletal muscle and skin fibroblasts tissue) are referred to our centre under suspicion of malfunctioning of the OXPHOS system. These patients mainly concern children who present their initial symptoms in the first years of life. Isolated complex I deficiency is a large contributor to this group, however the exact percentage at the start of our studies was unknown. Patients diagnosed with complex I deficiency are always checked for common mtDNA mutations. These mutations are seldom encountered, especially in young children. The impression exists that isolated complex I deficient patients (without common mtDNA mutations) express an autosomal recessive inheritance pattern instead of maternal. Furthermore, there seems to be a high frequency of consanguinity in the families presented to our centre. All these factors led to the hypothesis that nuclear-genetic causes may be present in our complex I deficient patients, e.g. situated in the nuclear encoded subunits of complex I. The principle of our complex I enzyme assay is measurement of the amount of NADH which is oxidised to  $\text{NAD}^+$  by complex I in the presence of ubiquinone. This measurement is performed in the absence and presence of rotenone, which is a specific complex I inhibitor. Therefore it mainly measures whether the flux of electrons from NADH to ubiquinone is working properly. Studies performed with *N. crassa* complex I showed that isolates of the peripheral arm of complex I are capable of transporting electrons from NADH to ubiquinone. This fragment (of which the IP fraction is the main contributor) is therefore one of the main candidates to host defective subunits in our complex I deficient patients.

Currently, therapy for the often fatal developing complex I deficiency is not available. It is therefore of utmost importance to elucidate the molecular-genetic cause of isolated complex I deficiency to offer the possibility of genetic counselling and prenatal diagnostics. Furthermore, when the genetic cause(s) of complex I deficiency is (are) elucidated, this could help us forward in the process of understanding complex I deficiency, which eventually should lead to a rational and effective therapy.

At the start of this study the aims were as follows:

- 1 Selection and clinical characterisation of an isolated complex I deficient patient group
- 2 Exclusion of common mtDNA point mutations and major rearrangements within this group
- 3 Elucidation of the cDNA and amino acid sequence of all human nuclear encoded complex I subunits
- 4 Investigation of the presence of mutations in the nuclear genes coding for Iron sulphur protein (IP) fraction subunits of complex I in our patients

## Reference list.

- Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic Local Alignment Search Tool. *J Mol Biol* 215 403-410.
- Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG. 1981. Sequence and organisation of the human mitochondrial genome. *Nature* 290 457-465.
- Ballinger SW, Shoffner JM, Hedaya EV, Trounce I, Polak MA, Koontz DA, Wallace DC. 1992. Maternally transmitted diabetes and deafness associated with a 10.4 kb mitochondrial DNA deletion. *Nat Genet* 1:11-15.
- Barrientos A, Casademont J, Sainz A, Cardellach F, Volpini V, Solans A, Tolosa E, Urbano-Marquez A, Estivill X, Nunes V. 1996. Autosomal recessive Wolfram syndrome associated with an 8.5-kb mtDNA single deletion. *Am J Hum Genet* 58:963-970.
- Belogradov G and Hatefi Y. 1994. Catalytic sector of complex I (NADH ubiquinone oxidoreductase): subunit stoichiometry and substrate-induced conformation changes. *Biochemistry* 33:4571-4576.
- Belogradov G and Hatefi Y. 1996. Intersubunit interactions in the bovine mitochondrial complex I as revealed by ligand blotting. *Biochem Biophys Res Commun* 227 135-139.
- Böhlega S, Tanji K, Santorelli FM, Hirano M, Al-Jishi A, DiMauro S. 1996. Multiple mitochondrial DNA deletions associated with autosomal recessive ophthalmoplegia and severe cardiomyopathy. *Neurology* 46 1329-1334.
- Bourgeron T, Rustin P, Chretien D, Birch-Machin M, Bourgeois M, Viegas-Pequignot E, Munnich A, Rötig A. 1995. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. *Nat Genet* 11:144-149.
- Chen S and Guillory RJ. 1981. Studies on the interaction of arylazido-beta-alanyl NAD<sup>+</sup> with the mitochondrial NADH dehydrogenase. *J Biol Chem* 256:8318-8323.
- Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. 1997. Molecular pathology of MELAS and MERRF: The relationship between mutation load and clinical phenotypes. *Brain* 120:1713-1721.
- Chinnery PF and Turnbull DM. 1999. Mitochondrial DNA and disease. *Lancet* 354 suppl 1:S117-121.
- Clayton DA and Vinograd J. 1967. Circular dimer and catenate forms of mitochondrial DNA in human leukaemic leucocytes. *J Perov* 35:652-657.
- Collier DA, Barrett TG, Curtis D, Macleod A, Arranz MJ, Maassen JA, Bunday S. 1996. Linkage of Wolfram syndrome to chromosome 4p16.1 and evidence for heterogeneity. *Am J Hum Genet* 59:855-863.
- De Vries DD, van Engelen BG, Gabreels FJ, Ruitenbeek W, van Oost BA. 1993. A second missense mutation in the mitochondrial ATPase 6 gene in Leigh's syndrome. *Ann Neurol* 34 410-412.
- de Vries D, de Wijs I, Ruitenbeek W, Begeer J, Smit P, Bentlage H, van Oost B. 1994. Extreme variability of clinical symptoms among sibs in a MELAS family correlated with heteroplasmy for the mitochondrial A3243G mutation. *J Neurol Sci* 124:77-82.
- De Vries DD, Went LN, Bruyn GW, Scholte HR, Hofstra RM, Bolhuis PA, van Oost BA. 1996. Genetic and biochemical impairment of mitochondrial complex I activity in a family with Leber hereditary optic neuropathy and hereditary spastic dystonia. *Am J Hum Genet* 58:703-711.
- Deng PS, Hatefi Y, Chen S. 1990. N-arylazido-beta-alanyl-NAD<sup>+</sup>, a new NAD<sup>+</sup> photoaffinity analogue. Synthesis and labelling of mitochondrial NADH dehydrogenase. *Biochemistry* 29:1094-1098.
- DiMauro S, Bonilla E, Zeviani M, Nakagawa M, DeVivo DC. 1985. Mitochondrial myopathies. *Ann Neurol* 17 521-538.
- Dunbar DR, Moonie PA, Swingler RJ, Davidson D, Roberts R, Holt IJ. 1993. Maternally transmitted partial direct tandem duplication of mitochondrial DNA associated with diabetes mellitus. *Hum Mol Genet* 2:1619-1624.
- Dupuis A, Skehel JM, Walker JE. 1991. A homologue of a nuclear-coded iron-sulphur protein subunit of bovine mitochondrial complex I is encoded in chloroplast genomes. *Biochemistry* 30 2954-2960.
- Ernster L, Ikkos D, Luft R. 1959. Enzymatic activities of human skeletal muscle mitochondria. a tool in clinical metabolic research. *Nature* 184:1851-1854.
- Friedrich T. 1998. The NADH:ubiquinone oxidoreductase (complex I) from *Escherichia coli*. *Biochim Biophys Acta* 1364 134-146.
- Friedrich T and Weiss H. 1997. Modular evolution

- of the respiratory NADH ubiquinone oxidoreductase and the origin of its modules. *J Theor Biol* 187 529-540.
- Galante YM and Hatefi Y.** 1978. Resolution of complex I and isolation of NADH dehydrogenase and an iron-sulphur protein. *Method Enzymol* 53 15-21.
- Galante YM and Hatefi Y.** 1979. Purification and molecular and enzymatic properties of mitochondrial NADH dehydrogenase. *Arch Biochem Biophys* 192:559-568
- Ghosh SS, Fahy E, Bodis-Wollner I, Sherman J, Howell N.** 1996. Longitudinal study of a heteroplasmic 3460 Leber hereditary optic neuropathy family by multiplexed primer-extension analysis and nucleotide sequencing. *Am J Hum Genet* 58:325-334
- Giles RE, Blanc H, Cann HM, Wallace DC.** 1980. Maternal inheritance of human mitochondrial DNA. *Proc Natl Acad Sci USA* 77:6715-6719
- Goto Y, Nonaka I, Horai S.** 1990. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. *Nature* 348 651-653.
- Grigorieff N.** 1998. Three-dimensional structure of bovine NADH:Ubiquinone oxidoreductase (Complex I) at 2.2 Å in ice. *J Mol Biol* 277 1033-1046.
- Gu M, Cooper JM, Taanman JW, Schapira AH.** 1998. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. *Ann Neurol* 44 177-186.
- Guenebaut V, Vincentelli R, Mills D, Weiss H, Leonard KR.** 1997. Three-dimensional structure of NADH:dehydrogenase from *Neurospora crassa* by electron microscopy and conical tilt reconstruction. *J Mol Biol* 265 409-418
- Hammans SR, Sweeney MG, Brockington M, Lennox GG, Lawton NF, Kennedy CR, Morgan-Hughes JA, Harding AE.** 1993. The mitochondrial DNA transfer RNA(Lys)A8344G mutation and the syndrome of myoclonic epilepsy with ragged red fibres (MERRF) Relationship of clinical phenotype to proportion of mutant mitochondrial DNA. *Bram* 116 617-632.
- Hardy C, Khanim F, Torres R, Scott-Brown M, Sellar A, Poulton J, Collier D, Kirk J, Polymeropoulos M, Latif F, Barrett T.** 1999. Clinical and molecular genetic analysis of 19 Wolfram syndrome kindreds demonstrating a wide spectrum of mutations in WFS1. 1999. *Am J Hum Genet* 65 1279-1290
- Hatefi Y.** 1985. The mitochondrial electron transport and oxidative phosphorylation system. *Ann Rev Biochem* 54 1015-1069
- Hirano M, Silvestri G, Blake DM, Lombes A, Minetti C, Bonilla E, Hays AP, Lovelace RE, Butler I, Bertorini TE.** 1994. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. *Neurology* 44:721-727.
- Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA.** 1990. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. *Am J Hum Genet* 46 428-433
- Howell N, Bindoff LA, McCullough DA, Kubacka I, Poulton J, Mackey D, Taylor L, Turnbull DM.** 1991. Leber hereditary optic neuropathy identification of the same mitochondrial ND1 mutation in six pedigrees. *Am J Hum Genet* 49 939-950
- Hudson B and Vinograd J.** 1967. Catenated circular DNA molecules in HeLa cell mitochondria. *Nature* 216 647-652.
- Huoponen K, Vilkkilä J, Aula P, Nikoskelainen EK, Savontaus ML.** 1991. A new mtDNA mutation associated with Leber hereditary optic neuroretinopathy. *Am J Hum Genet* 48 1147-1153
- Inoue H, Tanizawa Y, Wasson J, Behn P, Kalidas K, Bernal-Mizrachi E, Mueckler M, Marshall H, Donis-Keller H, Crock P, Rogers D, Mikuni M, Kumashiro H, Higashi K, Sobue G, Oka Y, Permutt MA.** 1998. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). *Nat genet* 2143-148.
- Johns DR.** 1995. Seminars in medicine of the Beth Israel Hospital, Boston. Mitochondrial DNA and disease. *N Engl J Med* 333:638-644.
- Johns DR and Neufeld MJ.** 1991. Cytochrome b mutations in Leber hereditary optic neuropathy. *Biochem Biophys Res Commun* 181 1358-1364.
- Jun AS, Brown MD, Wallace DC.** 1994. A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia. *Proc Natl Acad Sci USA* 91 6206-6210.
- Kaukonen JA, Amati P, Suomalainen A, Rötig A, Piscaglia MG, Salvi F, Weissenbach J, Fratta G, Comi G, Peltonen L, Zeviani M.** 1996. An

- autosomal locus predisposing to multiple deletions of mtDNA on chromosome 3p *Am J Hum Genet* 58:763-769.
- Kaukonen J, Zeviani M, Comi GP, Piscaglia MG, Peltonen L, Suomalainen A.** 1999. A third locus predisposing to multiple deletions of mtDNA in autosomal dominant progressive external ophthalmoplegia. *Am J Hum Genet* 65 256-261
- Leif H, Weidner U, Berger A, Spehr V, Braun M, van Heek P, Friedrich T, Ohnishi T, Weiss H.** 1993. *Escherichia coli* NADH dehydrogenase I, a minimal form of the mitochondrial complex I. *Biochem Soc Trans* 21 998-1001.
- Leif H, Sled VD, Ohnishi T, Weiss H, Friedrich T.** 1995. Isolation and characterisation of the proton-translocating NADH ubiquinone oxidoreductase from *Escherichia coli*. *Eur J Biochem* 230 538-548
- Lestienne P and Ponsot G.** 1988. Kearns-Sayre syndrome with muscle mitochondrial DNA deletion *Lancet* 1 885
- Li FY, Tariq M, Croxen R, Morten K, Squier W, Newsom-Davis J, Beeson D, Larsson C.** 1999. Mapping of autosomal dominant progressive external ophthalmoplegia to a 7-cM critical region on 10q24 *Neurology* 53 1265-1271.
- Lombes A, Bonilla E, DiMauro S.** 1989. Mitochondrial encephalomyopathies *Rev Neurol (Paris)* 145:671-689.
- Mackey D and Howell N.** 1992. A variant of Leber hereditary optic neuropathy characterised by recovery of vision and by an unusual mitochondrial genetic aetiology. *Am J Hum Genet* 51:1218-1228.
- Masui R, Wakabayashi S, Matsubara H, Hatefi Y.** 1991. The amino acid sequences of two 13 kDa polypeptides and partial amino acid sequence of a 30 kDa polypeptide of complex I from bovine heart mitochondria: possible location of iron-sulphur clusters. *J Biochem* 109 534-543
- Moraes CT, DiMauro S, Zeviani M, Lombes A, Shanske S, Miranda AF, Nakase H, Bonilla E, Werneck LC, Servidei S.** 1989. Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome *N Engl J Med* 320:1293-1299
- Morgan-Hughes JA.** 1994. Mitochondrial diseases of muscle. *Curr Opin Neurol* 7 457-462
- Nishino I, Spinazzola A, Hirano M.** 1999. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder *Science* 283 689-692.
- Ohnishi T, Ragan CI, Hatefi Y.** 1985. EPR studies of iron-sulphur clusters in isolated subunits and subfractions of NADH-ubiquinone oxidoreductase. *J Biol Chem* 260:2782-2788.
- Pastores GM, Santorelli FM, Shanske S, Gelb BD, Fyfe B, Wolfe D, Willner JP.** 1994. Leigh syndrome and hypertrophic cardiomyopathy in an infant with a mitochondrial DNA point mutation (T8993G) *Am J Med Genet* 50 265-271
- Pilkington SJ, Skehel JM, Gennis RB, Walker JE.** 1991. Relationship between mitochondrial NADH-ubiquinone reductase and a bacterial NAD-reducing hydrogenase *Biochemistry* 30 2166-2175.
- Pilkington SJ and Walker JE.** 1989. Mitochondrial NADH-ubiquinone reductase: complementary DNA sequences of import precursors of the bovine and human 24-kDa subunit. *Biochemistry* 28 3257-3264.
- Pitkänen S, Raha S, Robinson BH.** 1996. Diagnosis of complex I deficiency in patients with lactic acidemia using skin fibroblast cultures. *Biochem Mol Med* 59:134-137.
- Poulton J, Deadman M, Gardiner RM.** 1989. Duplications of mitochondrial DNA in mitochondrial myopathy *Lancet* 1 236-240
- Rötig A, Colonna M, Bonnefont JP, Blanche S, Fischer A, Saudubray JM, Munnich A.** 1989. Mitochondrial DNA deletion in Pearson's marrow/pancreas syndrome. *Lancet* 1 902-903
- Rötig A, Cormier V, chatelain P, Francois R, Saudubray JM, Rustin P, Munnich A.** 1993. Deletion of mitochondrial DNA in a case of early-onset diabetes mellitus, optic atrophy and deafness (Wolfram syndrome) *J Clin Invest* 91.1095-1098
- Ruitenbeek W, Sengers RC, Trijbels JM, Janssen AJ, Bakkeren JA.** 1992. The use of chorionic villi in prenatal diagnosis of mitochondrialopathies. *J Inher Metab Dis* 15 303-306
- Ruitenbeek W, Wendel U, Hamel BC, Trijbels JM.** 1996. Genetic counselling and prenatal diagnosis in disorders of the mitochondrial energy metabolism *J Inher Metab Dis* 19:581-587.
- Runswick MJ, Gennis RB, Fearnley IM, Walker JE.** 1989. Mitochondrial NADH:ubiquinone reductase complementary DNA sequence of the import precursor of the bovine 75-kDa subunit. *Biochemistry* 28.9452-9459.
- Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD.** 1989. Mitochondrial complex I deficiency in Parkinson's disease. *Lancet* 1 1269.
- Schapira AH.** 1998a. Inborn and induced defects of mitochondria *Arch Neurol* 55:1293-1296.

- Schapira AH.** 1998b. Human complex I defects in neurodegenerative diseases. *Biochim Biophys Acta* 1364:261-270.
- Schulte U, Fecke W, Krull C, Nehls U, Schmiede A, Schneider R, Ohnishi T, Weiss H.** 1994. In vivo dissection of the mitochondrial respiratory NADH:ubiquinone oxidoreductase (complex I). *Biochim Biophys Acta* 1187:121-124.
- Sengers RC, Stadhouders AM, Trijbels JM.** 1984. Mitochondrial myopathies. Clinical, morphological and biochemical aspects. *Eur J Pediatr* 141:192-207.
- Shitara H, Hayashi JI, Takahama S, Kaneda H, Yonekawa H.** 1998. Maternal inheritance of mouse mtDNA in interspecific hybrids: segregation of the leaked paternal mtDNA followed by the prevention of subsequent paternal leakage. *Genetics* 148 851-857.
- Shoffner JM, Lott MT, Lezza AM, Seibel P, Ballinger SW, Wallace DC.** 1990. Myoclonic epilepsy and ragged-red fibre disease (MERRF) is associated with a mitochondrial DNA (rRNA(Lys) mutation. *Cell* 61:931-937.
- Shoffner JM, Fernhoff PM, Krawiecki NS, Caplan DB, Holt PJ, Koontz DA, Takei Y, Newman NJ, Ortiz RG, Polak M.** 1992. Subacute necrotising encephalopathy oxidative phosphorylation defects and the ATPase 6 point mutation. *Neurology* 42:2168-2174.
- Shoffner JM and Wallace DC.** 1992. Mitochondrial genetics principles and practice. *Am J Hum Genet* 51 1179-1186.
- Silvestri G, Cialfalonì E, Santorelli FM, Shanske S, Servidei S, Graf WD, Sumi M, DiMauro S.** 1993. Clinical features associated with the A→G transition at nucleotide 8344 of mtDNA ("MERRF mutation"). *Neurology* 43 1200-1206.
- Strom TM, Hortnagel K, Hofmann S, Gekeler F, Scharfe C, Rabl W, Gerbitz KD, Meitinger T.** 1998. Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (Wolframin) coding a specific transmembrane protein. *Hum Mol Genet* 7 2021-2028.
- Suomalainen A, Kaukonen J, Amati P, Timonen R, Haltia M, Weissenbach J, Zeviani M, Somer H, Peltonen L.** 1995. An autosomal locus predisposing to deletions of mitochondrial DNA. *Nat Genet* 9 146-151.
- Superti-Furga A, Schoenle E, Tuchschnid P, Caduff R, Sabato V, DeMattia D, Gitzelmann R, Steinmann B.** 1993. Pearson bone marrow-pancreas syndrome with insulin-dependent diabetes, progressive renal tubulopathy, organic aciduria and elevated foetal haemoglobin caused by deletion and duplication of mitochondrial DNA. *Eur J Pediatr* 152 44-50.
- Taanman JW.** 1999. The mitochondrial genome: structure, transcription, translation and replication. *Biochim Biophys Acta* 1410 103-123.
- Tatuch Y, Christodoulou J, Feigenbaum A, Clarke JT, Wherret J, Smith C, Rudd N, Petrova-Benedict R, Robinson BH.** 1992. Heteroplasmic mtDNA mutation (T→G) at 8993 can cause Leigh disease when the percentage of abnormal mtDNA is high. *Am J Hum Genet* 50 852-858.
- Tein I.** 1996. Metabolic myopathies. *Semin Pediatr Neurol* 3 59-98.
- Trijbels JM, Sengers RC, Ruitenbeek W, Fischer JC, Bakkeren JA, Janssen AJ.** 1988. Disorders of the mitochondrial respiratory chain: clinical manifestations and diagnostic approach. *Eur J Pediatr* 148:92-97.
- Tuschen G, Sackmann U, Nehls U, Haiker H, Buse G, Weiss H.** 1990. Assembly of NADH: ubiquinone reductase (complex I) in *Neurospora* mitochondria. Independent pathways of nuclear-encoded and mitochondrially encoded subunits. *J Mol Biol* 213 845-857.
- Uziel G, Moroni I, Lamantea E, Fratta GM, Cicieri E, Carrara F, Zeviani M.** 1997. Mitochondrial disease associated with the T8993G mutation of the mitochondrial ATPase 6 gene: a clinical, biochemical, and molecular study in six families. *J Neurol Neurosurg Psychiatry* 63 16-22.
- Vilkkij J, Savontaus ML, Aula P, Nikoskelainen E.** 1991. Optic atrophy in Leber hereditary optic neuroretinopathy is determined by an x-chromosomal gene closely linked to DXS7. *Am J Hum Genet* 48 486-491.
- von Kleist-Retzow JC, Cormier-Daire V, de Lonlay P, Parfait B, Chretien D, Rustin P, Feingold J, Rötig A, Munnich A.** 1998. A high rate (20%-30%) of parental consanguinity in cytochrome-oxidase deficiency. *Am J Hum Genet* 63 428-435.
- Walker JE.** 1992. The NADH ubiquinone oxidoreductase (complex I) of respiratory chains. *Q Rev Biophys* 25:253-324.
- Walker JE, Arizmendi JM, Dupuis A, Fearnley IM, Finel M, Medd SM, Pilkington SJ, Runswick MJ, Skehel JM.** 1992. Sequences of 20 subunits of NADH:Ubiquinone oxidoreductase from bovine



- heart mitochondria *J Mol Biol* 226 1051-1072
- Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, Elsas LJ, Nikoskelainen EK.** 1988a Mitochondrial DNA mutation associated with Lebers hereditary optic neuropathy *Science* 242 1427-1430
- Wallace DC, Zheng XX, Lott MT, Shoffner JM, Hodge JA, Kelley RI, Epstein CM, Hopkins LC.** 1988b Familial mitochondrial encephalomyopathy (MERRF) genetic, pathophysiological, and biochemical characterisation of a mitochondrial DNA disease *Cell* 55 601-610
- Wallace DC.** 1992 Diseases of the mitochondrial DNA *Annu Rev Biochem* 61 1175-1212
- Weidner U, Geier S, Ptock A, Friedrich T, Leif H, Weiss H.** 1993 The gene locus of the proton translocating NADH ubiquinone oxidoreductase in *Escherichia coli* organisation of the 14 genes and relationship between the derived proteins and subunits of the mitochondrial complex I *J Mol Biol* 233 109-122
- Weiss H, Friedrich T, Hofhaus G, Preis D.** 1991 The respiratory-chain complex NADH dehydrogenase (complex I) of mitochondria *Eur J Biochem* 197 563-576
- Yagi T.** 1993 The bacterial energy transducing NADH-quinone oxidoreductases *Biochim Biophys Acta* 1141 1-17
- Zeviani M, Moraes CT, DiMauro S, Nakase H, Bonilla E, Schon EA, Rowland LP.** 1988 Deletions of mitochondrial DNA in Kearns Sayre syndrome *Neurology* 38 1339-1346
- Zeviani M, Tiranti V, Piantadosi C.** 1998a Mitochondrial disorders *Medicine (Baltimore)* 77 59-72
- Zeviani M, Moraes CT, DiMauro S, Nakase H, Bonilla E, Schon EA, Rowland LP.** 1998b Deletions of mitochondrial DNA in Kearns-Sayre syndrome *Neurology* 38 1339-1346



### ISOLATED COMPLEX I DEFICIENCY IN CHILDREN: CLINICAL, BIOCHEMICAL AND GENETIC ASPECTS

*Human Mutation* 2000 15:123-134


#### **Abstract.**

We retrospectively examined clinical and biochemical characteristics of 27 patients with isolated enzymatic complex I deficiency (established in cultured skin fibroblasts) in whom common pathogenic mtDNA point mutations and major rearrangements were absent. Clinical phenotypes present in this group are Leigh syndrome (n=7), Leigh-like syndrome (n=6), fatal infantile lactic acidosis (n=3), neonatal cardiomyopathy with lactic acidosis (n=3), macrocephaly with progressive leukodystrophy (n=2) and a residual group of unspecified encephalomyopathy (n=6) subdivided into progressive (n=4) and stable (n=2) variants. Isolated complex I deficiency is one of the most frequently observed disturbances of the OXPHOS system. In general, respiratory chain enzyme assays performed in cultured fibroblasts and skeletal muscle tissue reveal similar results, but for complete diagnostics we recommend enzyme measurements to be performed in at least two different tissues to minimise the possibility of overlooking the enzymatic diagnosis. Lactate levels in blood and CSF and cerebral CT/MRI studies are highly informative, although normal findings do not exclude complex I deficiency. With the discovery of mutations in nuclear encoded complex I subunits, adequate pre- and postnatal counselling becomes available. Finally, considering information currently available, isolated complex I deficiency in children seems in the majority to be caused by mutations in nuclear DNA.

## Introduction.

Since the first report of a patient with a decreased activity of NADH:ubiquinone oxidoreductase (complex I, OMIM 252010) of the mitochondrial respiratory chain by Morgan-Hughes and co-workers in 1979, over 100 cases followed, which placed isolated complex I deficiency on the map as an important inborn error of energy metabolism. Recent studies revealed that within the group of respiratory chain disorders, isolated complex I deficiency is a major contributor (33%; von Kleist-Retzow et al 1998).

Complex I is a large multi-protein assembly, which is partly located in the mitochondrial inner membrane and partly protruding into the matrix (Fig. 2.1). Its main function is transport of electrons from NADH to ubiquinone with simultaneous shunting of protons across the inner mitochondrial membrane to the intermembrane space. The subunit composition of complex I has been elucidated in several eukaryotes, such as *Neurospora crassa* (Weiss et al 1991) and *Bos taurus* (Walker 1992, Skehel et al 1998), which appears to consist of ~35 and ~42 proteins, respectively. Of the 42 subunits present in human complex I, seven are encoded by mitochondrial DNA (mtDNA) (Chomyn et al 1986). Complex I can be fragmented by chaotropic agents in three different parts (Galante and Hatefi 1979). These parts represent the Flavoprotein fraction (FP; composed of three subunits, which contain the NADH-, Flavin mononucleotide- and several Fe-S cluster binding sites), the Iron-Sulphur protein fraction (IP; composed of approximately seven subunits, which contain several Fe-S cluster binding sites) and the residual membrane part called the Hydrophobic protein fraction (HP; contains among



**Figure 2.1** Human complex I Schematic overview of human complex I. Electrons are transferred from NADH to ubiquinone through three distinct parts of complex I, namely the Flavoprotein (FP) fraction, Iron-Sulphur protein (IP) fraction and the Hydrophobic protein (HP) fraction. Simultaneously with this electron transport, protons are transported towards the intermembrane space. U = ubiquinone; FMN = flavin mononucleotide; Fe-S = Iron-Sulphur cluster, e<sup>-</sup> = electron

others all mitochondrial encoded subunits) In the past few years, 34 of at least 35 human nuclear encoded complex I subunits have been characterised (Loeffen et al 1998a, Smeitink and van den Heuvel 1999)

Disorders of the oxidative phosphorylation (OXPHOS) system express a great variety in clinical symptoms (De Vivo 1993, Morris et al 1995, Jackson et al 1995, Munnich et al 1996) First presentation can occur in infancy with severe encephalopathy leading to early death, as well as in adulthood with mild exercise intolerance Similarly, the heredity patterns are also diverse varying from evident maternal, autosomal-dominant, autosomal-recessive to sporadic and X-linked In the early 1990s, Robinson and colleagues published about 40-isolated complex I deficient patients (Robinson 1993, Pitkanen et al 1996a) These patients expressed mainly four clinical phenotypes *severe neonatal lactic acidosis* (OMIM 245400 Hoppel et al 1987), *Leigh syndrome* (OMIM 256000, Leigh 1951), *cardiomyopathy with cataract and lactic acidosis* (OMIM 212350, Pitkanen et al 1996b) and *hepatomegaly with renal tubulopathy* (Robinson 1993)

Some of these well-described clinical entities are clearly associated with mutations in the mtDNA Important characteristics of mtDNA mutations are the maternal inheritance pattern (Giles et al 1980), age of disease presentation (often late childhood and adulthood) and variability in clinical course and intrafamilial presentation Previously identified mtDNA defects causing isolated complex I deficiency are listed in Table 2.1 In general, these abnormalities can be divided in two important groups, namely major rearrangements and point mutations The mtDNA point mutations linked to isolated complex I deficiency seem to concentrate in the tRNA<sup>Lys</sup> gene (OMIM 590050), tRNA<sup>Leu</sup> gene (OMIM 590060) and the ND genes (OMIM 516000-516006) No mutations in nuclear genes have been previously reported to cause isolated complex I deficiency

Our centre examines many tissue specimens of children suspected of OXPHOS disorders Respiratory chain enzyme activities are preferably measured in fresh skeletal muscle tissue and additionally in cultured skin fibroblasts Evaluation of enzymatic OXPHOS system measurements in skeletal muscle over a five year period revealed in 23% of the patients an isolated complex I deficiency, which makes it the most frequently found deficiency of the OXPHOS system diagnosed in our centre (Table 2.2) Family data concerning these patients usually points to autosomal-recessive traits In our experience, screening for common mtDNA mutations in these patients is unsatisfactory (in less than 5% of patients suspected of OXPHOS disorders, common mtDNA mutations are encountered) Therefore, we started a research project concerning mutational analyses studies in nuclear encoded complex I subunits as a first step in resolving the suspected nuclear cause of isolated complex I deficiency This approach has been successful since we encountered up to now mutations in five different pedigrees (OMIM 602141 Loeffen et al 1998b, OMIM 602694 van den Heuvel et al 1998, OMIM 601825 Triepels et al 1999a, OMIM 161015 Schuelke et al 1999)

In the present communication we review clinical, biochemical and genetic characteristics of our isolated complex I deficient patient group as established in cultured skin fibroblasts (n = 27), who all presented in infancy and young childhood In addition, we summarise data concerning mutations in nuclear encoded subunits as encountered in this group up to now and discuss the possible role of mtDNA and nuclear DNA (nDNA) mutations in isolated complex I deficiency

<i>mtDNA abnormality</i>	<i>Clinical phenotype</i>	<i>Reference</i>
<b>Deletion</b>	<ul style="list-style-type: none"><li>• diabetes, Fanconi syndrome</li><li>• cerebellar ataxia, hypogonadotropic hypogonadism, choroidal dystrophy</li></ul>	Luder and Barash 1994 Barrientos et al 1997
<b>A3243G</b> tRNA <sup>leu</sup>	<ul style="list-style-type: none"><li>• MELAS</li></ul>	Goto et al 1992
<b>T3250C</b> tRNA <sup>leu</sup>	<ul style="list-style-type: none"><li>• isolated myopathy</li></ul>	Ogle et al 1997
<b>A3251G</b> tRNA <sup>leu</sup>	<ul style="list-style-type: none"><li>• myopathy with lactic acidosis</li></ul>	Houshmand et al 1996
<b>T3271C</b> tRNA <sup>leu</sup>	<ul style="list-style-type: none"><li>• MELAS</li></ul>	Kirby et al 1999
<b>C3303T</b> tRNA <sup>leu</sup>	<ul style="list-style-type: none"><li>• isolated myopathy</li></ul>	Kirby et al 1999
<b>T3394C</b> ND1	<ul style="list-style-type: none"><li>• long QT syndrome</li></ul>	Matsuoka et al 1999
<b>G3460A</b> ND1	<ul style="list-style-type: none"><li>• LHON</li></ul>	Howell et al 1991, Majander et al 1991
<b>A8344G</b> tRNA <sup>lys</sup>	<ul style="list-style-type: none"><li>• MERFF</li></ul>	Shoffner et al 1990
<b>G8363A</b> tRNA <sup>lys</sup>	<ul style="list-style-type: none"><li>• MERRF</li></ul>	Arenas et al 1999
<b>G11778A</b> ND4	<ul style="list-style-type: none"><li>• LHON</li></ul>	Larsson et al 1991
<b>G14459A</b> ND6	<ul style="list-style-type: none"><li>• Leigh syndrome</li></ul>	Kirby et al 1999
<b>T14484C</b> ND6	<ul style="list-style-type: none"><li>• LHON</li></ul>	Oostra et al 1995

**Table 2.1** mtDNA deletions and point mutations related to isolated complex I deficiency.

<i>Isolated deficiencies</i>	<i>%</i>	<i>Combined deficiencies</i>	<i>%</i>
<b>Complex I</b>	22.7%	<b>Complex I+IV</b>	7.9%
<b>PDHc</b>	19.9%	<b>Complex I+III</b>	3.0%
<b>Complex III</b>	10.3%	<b>Complex I+III+IV</b>	3.9%
<b>Complex IV</b>	10.0%	<b>Complex I+PDHc</b>	3.6%
<b>Suc. cyt. c oxidoreductase</b>	3.3%	<b>Complex I+IV+PDHc</b>	3.3%
<b>Complex II</b>	1.3%	<b>Complex IV+PDHc</b>	4.8%
		<b>Other combinations</b>	6.0%
<b>Total</b>	67.5%	<b>Total</b>	32.5%

**Table 2.2** Occurrence percentages of isolated and combined OXPHOS disorders (and combinations with Pyruvate Dehydrogenase complex (PDHc) deficiency) diagnosed in skeletal muscle tissue, assembled at our centre over a five year period (n=331 diagnosed patients). Suc. cyt. c = succinate:cytochrome c.

## **Clinical phenotypes.**

We studied clinical, biochemical and genetic aspects of 27 patients (21 males, 6 females), all diagnosed with isolated complex I deficiency in fibroblasts. Several distinct phenotypes could be distinguished. Clinical, biochemical and genetic details of these patients are listed in Table 2.3. The group Fatal Infantile Lactic Acidosis (FILA) is classified separately since they suffered from isolated complex I deficiency in fibroblasts, but combined complex I and IV deficiency in muscle tissue.

### ***Isolated complex I deficiency in cultured fibroblasts.***

#### *Leigh syndrome (LS)<sup>01-07</sup> and Leigh like syndrome (LLS)<sup>08-13</sup>*

Clinical criteria for the diagnosis of Leigh syndrome (Rahman et al 1996) are summarised in Table 2.4. We did not use the criteria concerning increased lactate levels in blood and/or CSF, because several of our patients, some with neuropathologically proven Leigh syndrome, do not have increased lactate levels in blood and/or CSF. The main symptoms observed in our patients are listed in Table 2.3. Leigh syndrome was confirmed by the histopathological findings post mortem in seven families, but no neuropathological studies were available in six patients who are classified as suffering from Leigh-like syndrome. All but one patient died within the first 5 years of life, six of them died within the first year. Two patients showed normal lactate levels in blood and CSF (van den Heuvel et al 1998, Tjepels et al 1999a), and in one of them (05), lactate levels remained within normal limits even after glucose loading.

#### *Macrocephaly with progressive leukodystrophy (MLD)*

Macrocephaly in association with progressive leukodystrophy was the major clinical feature in two of our patients (Table 2.3). Clinical details of these patients have been reported previously (Dionisi-Vici et al 1997, Schuelke et al 1999).

#### *Neonatal cardiomyopathy with lactic acidosis (NCLA)*

Cardiomyopathy, congestive as well as hypertrophic, is a not uncommon sign in respiratory chain disorders (Antozzi and Zeviani 1997). Three patients presented at the first day of life with symptoms of hypertrophic cardiomyopathy and lactic acidosis. One child died after 4 days, one at the age of 1.5 months, whereas the third child is currently alive at the age of 6 months. The metabolic acidosis together with the neonatal cardiomyopathy are the only abnormalities observed in this latter patient. In all three patients there was no sign of cataract (the combination of cardiomyopathy, lactic acidosis and cataract has been described as a separate clinical entity in complex I deficiency (Pitkanen et al 1996b)).

#### *Unspecified encephalomyopathy (UE)*

Six of our patients showed variable neuromuscular symptoms that could not be assigned to a specific phenotype. Virtually all of these patients were psychomotor retarded and had decreased muscle tone. Four of these patients deteriorated and died within 3 years after presentation. Two patients with a milder disease course expressed relatively unusual phenotypes. Patient 23 presented at 7.4 years with extrapyramidal signs, muscle weakness and

Clinical characteristics															Biochemistry		Enzyme activity		Genetics						
Patient	Sex	Age of onset (mths)	Age of death (mths)	PMR	Seizures	Hypotonia	Pyramidal signs	Ataxia	Nystagmus	Macrocephaly	Microcephaly	Cardiomyopathy	Resp. disturbance + Family history	Consanguinity	Abnormal CT/MRI	RRFs	Blood lactate <sup>3</sup>	L/P ratio <sup>4</sup>	CSF lactate <sup>5</sup>	Fibroblasts % <sup>6</sup>	Fresh muscle % <sup>7</sup>	Frozen muscle % <sup>8a+b</sup>	Affected gene	Mutation	
Isolated complex I deficiency in cultured fibroblasts																									
Leigh and Leigh-like syndrome (LS and LLS)																									
01	m	4	7	×	×		×						×		×		3.7	21	3.8	67		n <sup>a</sup>			
02	m	2	6	×	×	×	×		×				×	×	×		7.3	32	3.6	64					
03	f	0.5	3	×		×			×			×	×	×	×		6.1			25		13 <sup>a</sup>			
04	m	1	2	×	×	×	×					×	×		×		3.4	20	5.6	63		23 <sup>a</sup>	NDUFS8	P79L, R102H	
05	m	11	60	×		×	×						×	×	×		n	n	n	62	23		NDUFS7	V122M	
06	f	0	1		×	×							×		×		5.4			33	26				
07	m	26	28	×		×			×				×		×		4.2		3.2	59					
08	m	8	16	×	×	×							×		×		n		n	68			NDUFS4	5 bp dupl.	
09	m	6	24	×		×	×		×			×	×	×	×	×	9.9		7.8	39		39 <sup>b</sup>			
10	f	0.3	4			×					×		×	×	×	×	5.5	34	7.6	54					
11	f	0	23	×	×	×	×					×	×	×	×	×	6.2	50	5.8	35		24 <sup>a</sup>			
12	m	9	-	×	×	×	×		×						×		6.7	41	5.0	38	44				
13	m	9	48	×	×	×							×		×		3.6	52	3.0	33		38 <sup>a</sup>			
Neonatal Cardiomyopathy with Lactic Acidosis (NCLA)																									
14	m	0	1.5			×						×	×	×	×	×	4.9	38	3.8	61					
15	m	0	-									×					4.3	51	5.0	55	14				
16	m	0	4d									×					24			36	24				

Table 2.3 continued.



Clinical characteristics									
Biochemistry									
Enzyme activity									
Genetics									
Patient	Sex	Age of onset (mths)	Age of death (mths)	PMR	Seizures	Hypotonia	Pyramidal signs	Ataxia	Nystagmus
				Macrocephaly	Microcephaly	Cardiomyopathy	Resp. disturbance	+ Family history	Consanguinity
				Abnormal CT/MRI	RRFs	Blood lactate <sup>3</sup>	L/P ratio <sup>4</sup>	CSF lactate <sup>5</sup>	Fibroblasts % <sup>6</sup>
									Fresh muscle % <sup>7</sup>
									Frozen muscle % <sup>8b+c</sup>
									Affected gene
									Mutation
Macrocephaly with progressive Leukodystrophy (MLD)									
17	m	2	6	×	×	×	×	×	×
18	f	6	-	×	×	×	×	×	×
Unspecified encephalomyopathy (UE)									
a. Progressive									
19 <sup>1</sup>	m	5	14	×	×	×	×	×	×
20 <sup>1</sup>	m	7	17	×	×	×	×	×	×
21	m	10	36	×	×	×	×	×	×
22	f	0	14	×	×	×	×	×	×
b. Stable									
23	m	89	-	×	×	×	×	×	×
24	m	9	-	×	×	×	×	×	×
Isolated complex I deficiency in cultured fibroblasts and combined complex I and IV deficiency in muscle tissue									
Fatal Infantile Lactic Acidosis (FILA)									
25 <sup>2</sup>	m	0	0.5	×	×	×	×	×	×
26 <sup>2</sup>	m	0	0.5	×	×	×	×	×	×
27	m	0	2	×	×	×	×	×	×
4.6 12.7 49 32 <sup>10</sup>									

**Table 2.3** Clinical, biochemical and genetic characteristics as encountered in our patient group. PMR = psychomotor retardation; Resp. = respiratory; RRFs = ragged red fibres; mths = months. <sup>1+2</sup> patients are brothers; <sup>3</sup> control range 0.6-2.1 mmol/l; <sup>4</sup> control range 11.5-16.5; <sup>5</sup> control range 1.4-1.9 mmol/l; <sup>6</sup> control range 0.11-0.28 mU/mU cytochrome *c* oxidase (n=14); <sup>7</sup> control range 0.070-0.25 mU/mU citrate synthase (n=20); <sup>8a</sup> control range 0.084-0.273 mU/mU citrate synthase (n=13) (homogenate); <sup>8b</sup> control range 0.101-0.389 mU/mU cytochrome *c* oxidase (600×g); <sup>8c</sup> control range 8.9-27 mU/mg protein (600×g); <sup>9</sup> congestive; <sup>10</sup> average of residual complex I activity in fresh and frozen muscle tissue. All complex I activities are expressed as percentage of the lowest reference value. Bottom row lists mean values.

<i>Criteria of Leigh syndrome.</i>	
<i>Clinical (Leigh and Leigh-like syndrome):</i>	<i>Neuropathological (Leigh syndrome):</i>
1. Progressive neurological disease with motor and intellectual developmental delay	1. Bilateral, symmetrical spongiform lesions
2. Signs and symptoms of brainstem and/or basal ganglia disease	2. Vacuolation of the neuropil
3. Characteristic features of Leigh disease on neuroimaging	3. Relative sparing of neurons
	4. Demyelination
	5. Gliosis
	6. Capillary proliferation

**Table 2.4** Clinical and neuropathological criteria of Leigh syndrome as published by Rahman et al 1996. Patients whom we classified under Leigh syndrome met the clinical as well as the neuropathological criteria, while in patients with Leigh-like disease no neuropathological studies were performed.

optic nerve atrophy. The previous history was unremarkable except for mild psychomotor retardation. CSF lactate was elevated, but brain MRI and muscle histochemical studies revealed no abnormalities. He has remained relatively stable and is currently 10 years old. The other patient presented at the age of 9 months with severe ataxia and mild psychomotor retardation. Brain MRI showed severe cerebellar destruction while other brain parts were completely intact. The boy has subsequently remained stable and is currently 6 years old.

***Isolated complex I deficiency in cultured fibroblasts, combined I and IV deficiency in muscle tissue.***

*Fatal infantile lactic acidosis (FILA).*

One of the most serious phenotypes associated with OXPHOS disorders in general and complex I deficiency in particular is FILA. This phenotype is characterised by extremely high lactate levels in blood and CSF and high L/P ratios, indicating a severely disturbed NADH/NAD<sup>+</sup> ratio and demanding rigorous intervention of respiratory complications and severe metabolic acidosis. Three of our patients (all males, two are siblings) presented shortly after birth with tachypnoea and extreme metabolic acidosis caused by persistently high levels of lactate (Table 2.3). The two brothers rapidly deteriorated, eventually resulting in severe cardiorespiratory insufficiency and died within two weeks after birth. The third male infant (described previously by Bentlage et al in 1996) presented at birth with similar characteristics. All three infants expressed isolated complex I deficiency in fibroblasts (complex IV activity was repeatedly completely normal in different fibroblast cultures); however in skeletal muscle tissue severe complex I and IV deficiencies were found.

**Enzyme studies.**

Activities of respiratory chain enzyme complexes, pyruvate dehydrogenase complex (PDHc) and citrate synthase in muscle cells (quadriceps muscle biopsy) and skin fibroblasts (culture) were measured using the following enzyme assays (slightly modified): NADH:ubiquinone oxidoreductase and succinate:cytochrome *c* oxidoreductase as described by Fischer et al (1985 and 1986); cytochrome *c* oxidase by Cooperstein and Lazarow (1951); citrate synthase by Srere (1969); and PDHc according to van Laack et al (1988). In muscle tissue, enzyme

assays were performed in crude homogenates or 600g supernatants of crude homogenates, while in fibroblasts mitochondrial enriched fractions were used. The enzyme assays performed in cultured skin fibroblasts were slightly modified according to procedures as described by Bentlage and co-workers in 1996. We considered a patient isolated complex I deficient when the activity was evidently decreased below the reference interval (0.11-0.28 mU/mU cytochrome *c* oxidase) in two different fibroblast preparations. In contrast to the complex I activity in muscle tissue which is usually referenced to citrate synthase activity, cytochrome *c* oxidase has been used as marker enzyme in fibroblasts. This is because the activity of citrate synthase can be artificially decreased during the mitochondria enrichment process of fibroblasts due to leakage out of the mitochondrial matrix. The other fibroblast respiratory chain enzyme activities had to be within normal limits as determined in a representative control population. Complex I activity in fibroblasts was reduced in all patients (inclusion criterion), with a mean residual activity of 49% of the lowest control value (range 24% to 73%, Table 2.3). The complex I activity in skeletal muscle has been measured in 20 patients. In half of these patients, enzyme assays were performed in fresh muscle tissue, while in the other half muscle tissue has been deep frozen in liquid nitrogen after biopsy. Measurements in fresh tissue preserve the possibility to measure oxidation rates and ATP and CrP production rates. All but one patient showed reduced complex I activity (mean 32% of the lowest control value, range 9% to 68%, Table 2.3). When residual complex I activities of muscle tissue are compared to those of fibroblasts, 8 patients showed a more severely decreased activity in skeletal muscle (>15% additional decrease compared to fibroblasts), 10 patients expressed comparable values (between 0% to 15% variation), while in only 2 patients complex I activity was actually higher in skeletal muscle (>15%).

### Molecular-genetic studies.

All patients included in our study were screened for major mtDNA rearrangements by a previously developed long template PCR technique (Li et al 1995). This revealed a fragment of approximately 16.5 kb in all patients. Furthermore, the following common pathogenic mtDNA mutations were excluded in fibroblasts in our patient group by restriction enzyme analysis: A3243G (tRNA<sup>I<sup>eu</sup></sup>), T3271C (tRNA<sup>L<sup>eu</sup></sup>), G3460A (ND 1), T4160A (ND-1), A4317G (tRNA<sup>Gln</sup>), A8344G (tRNA<sup>Lys</sup>), T8356C (tRNA<sup>Lys</sup>), T8993G/C (ATPase 6), G11778A (ND-4), G14459A (ND-6), T14484C (ND-6).

Up till now, 10 nuclear encoded complex I subunits have been screened in twenty of our patients by a combination of RT-PCR and direct DNA sequencing. Candidate genes for mutational analysis studies were chosen on the basis of strong conservation during evolution and/or speculated functional aspects. The *NDUFV1* (51 kDa) gene revealed an A341V mutation in a patient with macrocephaly and progressive leukodystrophy (18) and compound heterozygous mutations resulting in a R59X and T423M in two brothers (19 and 20) suffering from a progressive unspecified encephalomyopathy (Schuelke et al 1999). The *NDUFS4* (18 kDa) gene contained a 5 bp duplication in a patient with Leigh-like syndrome (08, van den Heuvel et al 1998). A mutation was also found in the *NDUFS7* gene (V122M) in two brothers with Leigh syndrome (05, Triepels et al 1999a) and in the *NDUFS8* gene (compound heterozygous mutations resulting in P79L and R102H) in a patient with Leigh syndrome (04,

Loeffen et al 1998b) Direct sequencing of the *NDUFS5* (15 kDa) (Loeffen et al 1999), *NDUFA1* (MWFE) (Loeffen et al 1998c), *NDUFB3* (B12), *NDUFB6* (B17) (Smeitink et al 1998a), *NDUFAB1* (SDAP) (Triepels et al 1999b) and the *NDUFA8* (PGIV) (Triepels et al 1998) cDNAs revealed no mutations

## Discussion.

During the last decade substantial progression has been made in the elucidation of complex I composition and its physiological aspects of many prokaryotes and eukaryotes, including man (for a review see Smeitink et al 1998b) The cDNA structure has been elucidated for almost all known human complex I subunits, while the gene structure has been solved of about seven genes Many important genetic aspects of the complex I subunits remain to be elucidated, like transcription and translation regulation, possible tissue specificity, but also interaction processes between the nuclear and mitochondrial genomes Also largely unknown is the targeting of complex I proteins towards and into mitochondria, the assembly of complex I and the implantation into the inner mitochondrial membrane

Information concerning pathophysiological aspects of complex I deficiency remains also scarce Studies discussing clinical aspects of complex I deficient patients published by the group of Robinson and very recently by the group of Thorburn and Dahl (Robinson 1993, Pitkanen et al 1996a, Kirby et al 1999) describe important clinical aspects, however differences with our patient population remain

In our group of 27 patients a strong male preponderance is present (male : female = 3.5 : 1) Male predominance in complex I deficiency has been reported previously (Zhuchenko et al 1996, von Kleist-Retzow et al 1998, Kirby et al 1999) Only one complex I subunit is known to be encoded on the X-chromosome (*NDUFA1*), in which no mutations have been reported The mean age at presentation in the entire group was 4.6 months All but five patients have died within the first five years of life (mean age of survival after first presentation among the deceased patients was 8.6 months) 67% of our patients died in the first two years of life Four of the survivors express a relatively stable course though severely disabled From this data it can be concluded that life expectancy of patients with an isolated complex I deficiency is very poor

We distinguished six different phenotypes within our patient group Leigh syndrome, Leigh-like syndrome, macrocephaly with progressive leukodystrophy, neonatal cardiomyopathy with lactic acidosis, unspecified encephalomyopathy (progressive or stable) and fatal infantile lactic acidosis (FILA) Compared to the phenotypes described by Robinson and Thorburn similarities, but also differences can be observed Both studies describe in keeping with our study Leigh syndrome as an important, if not the most important phenotype in isolated complex I deficiency 26% of our patient group was neuropathologically proven to suffer from this clinical entity When Leigh-like patients are added to this group the percentage increases to 48% Leigh syndrome is more and more recognised as an important phenotype in disorders of energy metabolism in general and complex I deficiency in particular (Morris et al 1996, Rahman et al 1996) It is possible that most if not all patients present in our Leigh-like group are actually patients suffering from Leigh syndrome Neuropathological studies, which provide the ultimate evidence, were not performed in these patients

Cardiomyopathy is an important and often observed finding in disorders of energy metabolism. In this study, eight patients suffered from cardiomyopathy (30%), which was in 7 patients hypertrophic and in 1 patient congestive (Table 2.3). The only two patients in our group with signs of RRFs suffered from cardiomyopathy. RRFs are often associated with mutations in structural genes of the mtDNA. We excluded the most common mtDNA mutations, however the possibility of unrecognised mutations remains. The facts that family history in both patients (especially the maternal lineage) was negative for neuromuscular disorders and parents were consanguineous points in the direction of autosomal-recessive inheritance. The phenotype of the two patients with RRFs did not differ significantly from the other patients in their group. Robinson and colleagues have published several patients with cardiomyopathy, cataract and complex I deficiency. All eight patients with cardiomyopathy in our group showed no signs of lens opacities. Several patients have been described by our centre with a characteristic phenotype of cardiomyopathy and cataract but without complex I deficiency (Sengers et al 1985, Smeitink et al 1989). Patients classified in our residual group presented mainly with symptoms of encephalomyopathy. Additional diagnostic studies could not provide further clues for a more defined phenotype and autopsy has not been performed. Two patients in this group are alive at this moment and express a relatively stable course. It is possible that mtDNA mutations, which tend to cause a more prolonged stable course are present in these latter two patients, yet family history did not provide evidence for maternal inheritance and common mtDNA mutations were not encountered.

An important diagnostic determinant in disorders of energy metabolism is the lactate concentration in blood and CSF. Twenty-three of our patients (85%) clearly expressed elevated blood lactate levels, while in four patients blood lactate remained within normal limits. CSF lactate was measured in twenty-one patients, and turned out elevated in all but two patients (90%). The two patients with normal lactate levels in CSF also expressed normal lactate levels in blood. Importantly, in both of these patients mutations have been found in nuclear encoded subunits of complex I (*NDUFS7* and *NDUFS4*, respectively). Two of the patients with normal lactate levels in blood actually did have elevated lactate levels in CSF. Strikingly, both patients expressed a relatively stable course. It is possible that lactate levels change during the disease process. They can be normal in relatively “good” disease periods, while they increase during disease worsening. Many of the patients admitted to our centre have been referred by physicians from general hospitals. Increased lactate levels in blood or CSF remain an important determinant whether or not to refer to a metabolic disease centre. It is therefore quite possible that the percentage of elevated lactate levels in complex I deficiency is an overestimation of the actual situation. Respiratory chain disorders with normal lactate levels could remain undetected, although generally lactic acid elevation is the rule rather than the exception. The results of our study indicate that lactate measurements have to be performed in blood as well as CSF. However, normal values in blood and CSF certainly do not exclude complex I deficiency.

Neuroimaging studies performed in patients suspected of or suffering from disorders of energy metabolism are generally considered to be very useful. Many abnormalities have been reported varying from general brain destruction with wide cavitations, spotlike hypodense (CT) or hyperdense (T2 weighted MRI) lesions, cortical atrophy and generalised demyelination. In our patient group, CT and/or MRI scans have been made in eighteen

patients. These resulted in typical lesions e.g. in basal ganglia in all patients with Leigh and Leigh-like syndrome. Cortical atrophy was observed in five patients (distributed in different clinical subgroups). One patient with clear ataxic symptoms only expressed destructive lesions in the cerebellum. Brain scans were normal in only one patient. Since abnormalities seen with neuroimaging are often present in patients with disorders of energy metabolism, it is not generally used for specific diagnostic purposes. The importance of (successive) neuroimaging is to provide information about the extent of disease and disease progression as well as therapeutic effects.

Differences in residual respiratory chain enzyme activities between tissues have been previously reported (Bentlage et al 1996). This is especially the case in the three FILA patients with isolated complex I deficiency in fibroblasts (complex IV activity repeatedly normal), whereas complex I and IV were decreased in muscle tissue. Fatal infantile lactic acidosis (FILA) is characterised by extremely high lactate levels in blood and CSF and high L/P ratios, indicating a severely disturbed NADH/NAD<sup>+</sup> ratio and demanding rigorous intervention of respiratory complications and severe metabolic acidosis. There are several explanations possible for these intriguing tissue specific phenomena. Tissues can express isoforms of proteins involved in complex I function as, for example, has been described for complex IV. This may concern proteins, which are actually within the complex, but also assembly or chaperone proteins. In addition, differences in tissue stoichiometry of individual subunits may result in different residual complex I activities. Since virtually all pathogenic mtDNA mutations are heteroplasmic it is also possible that tissues express different amounts of mutated mtDNA resulting in different residual activities (especially tRNA mutations are prone to result in combined deficiencies). Furthermore, it is possible that complex IV is secondarily affected by complex I (e.g. by oxygen radical production due to malfunctioning of complex I), which could be more pronounced in muscle tissue due to its higher energy demand. Several of these intriguing phenomena are subjects of future studies. In several patients presented to our centre, respiratory chain enzyme deficiencies were found in muscle tissue, while enzyme assays performed in cultured fibroblasts turned out completely normal. It is therefore important to perform diagnostic studies of the OXPHOS system in at least two different tissues.

From the end of the eighties up to now, mutational analysis studies performed in patients with OXPHOS disorders mainly concerned mtDNA. Shoffner (1996) reported common pathogenic mtDNA point mutations and rearrangements in patients with OXPHOS disorders to occur in 30% of investigated adults and only in 4% of children. Many reports of pathogenic mtDNA mutations describe patients who clinically presented in late childhood and adulthood, nevertheless onset in infancy has also been reported. A literature study concerning mtDNA deletions and point mutations which have been related to isolated complex I deficiency revealed 14 mutations (two deletions and twelve point mutations). However, several patients have been described with mtDNA mutations in which respiratory chain enzyme assays were not performed. Most mutations in mitochondrial encoded tRNAs and rRNAs result in multiple respiratory chain complex deficiencies, but the possibility of single affected complexes in individual patients always remains. Mutations in the mitochondrial encoded tRNA<sup>Leu</sup> gene can result in isolated complex I deficiency. In some of our patients the complete mitochondrial encoded tRNA<sup>Leu</sup> gene has been sequenced which revealed no

mutations (unpublished results) In the study performed by Kirby and colleagues (Kirby et al 1999) sequencing of the tRNA<sup>Leu</sup> of 51 complex I deficient patients revealed just one novel mutation and five known mutations

Many pedigrees in our patient population indicate autosomal-recessive inheritance and family history did not reveal patients with similar phenotypes in the maternal lineage Seven non-related patients were born from consanguineous parents (26%) As a start to elucidate the hypothesised nuclear cause of isolated complex I deficiency we sequenced the highly conserved structural complex I genes of twenty isolated complex I deficient patients, which revealed mutations in seven patients (five pedigrees) Strikingly, five of these patients (three pedigrees) expressed a Leigh(-like) phenotype, which was also the case in the published patient with a complex II mutation, as well as in the patients with mutations in the Surfeit-1 gene (Bourgeron et al 1995, van den Heuvel et al 1998, Loeffen et al 1998b, Tiranti et al 1998, Zhu et al 1998, Triepels et al 1999a) In both families with more than one affected child in which nuclear mutations have been found (V122M in NDUFS7 subunit and R59X and T423M in NDUFV1 subunit) the brothers expressed a strongly resembling clinical phenotype This is in contrast with mutations found in mtDNA, where affected relatives often express variable clinical phenotypes

In summary, we presented, biochemical, genetic and clinical data concerning 27 patients with isolated complex I deficiency expressed in cultured fibroblasts OXPHOS system enzyme assays in cultured fibroblasts and skeletal muscle tissue in general reveal similar results, but for complete diagnostics, we recommend enzyme measurements to be performed in at least two different tissues to minimise the possibility of overlooking the enzymatic diagnosis Lactate levels in blood and CSF and cerebral CT/MRI studies are highly informative, though normal findings do not exclude complex I deficiency With the discovery of mutations in nuclear encoded complex I subunits, adequate pre- and postnatal counselling becomes available Finally, considering information currently available, isolated complex I deficiency in children seems in the majority to be caused by mutations in the nuclear DNA

### **Acknowledgements.**

We gratefully acknowledge all referring clinicians for their kind co-operation in the data collection process This study was possible due to grants administered by “De Stichting Voor Kinderen Die Wel Willen Maar Niet Kunnen” and the FBW foundation, granted to JS and LvdH.

## Reference list.

- Antozzi C and Zeviani M.** 1997 Cardiomyopathies in disorders of oxidative metabolism *Cardiovasc Res* 35 184-199
- Arenas J, Campos Y, Bornstein B, Ribacoba R, Martin MA, Rubio JC, Santorelli FM, Zeviani M, DiMauro S, Garesse R.** 1999 A double mutation (A8296G and G8363A) in the mitochondrial DNA tRNA (Lys) gene associated with myoclonus epilepsy with ragged-red fibers. *Neurology* 52:377-382
- Barrientos A, Casademont J, Genis D, Cardellach F, Fernandez-Real JM, Grau JM, Urbano-Marquez A, Estivill X, Nunes V.** 1997 Sporadic heteroplasmic single 5.5 kb mitochondrial DNA deletion associated with cerebellar ataxia, hypogonadotropic hypogonadism, choroidal dystrophy, and mitochondrial respiratory chain complex I deficiency *Hum Mutat* 10 212-216
- Bentlage H, Wendel U, Schagger H, ter Laak H, Janssen A, Trijbels F.** 1996. Lethal infantile mitochondrial disease with isolated complex I deficiency in fibroblasts with combined complex I and IV deficiencies in muscle *Neurology* 47 243-8
- Bourgeron T, Rustin P, Chretien D, Birch-Machin M, Bourgeois M, Viegas-Pequignot E, Munnich A, Rötig A.** 1995. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency *Nat Genet* 11 144-149
- Chomyn A, Cleeter MWJ, Ragan CI, Riley M, Doolittle RF, Attardi G.** 1986 URF6, Last unidentified reading frame of human mtDNA, codes for an NADH dehydrogenase subunit *Science* 234:614-618.
- Cooperstein SJ, Lazarow A.** 1951. A microspectrophotometry method for the determination of cytochrome c oxidase *J Biol Chem* 189:665-670.
- De Vivo DC.** 1993 The expanding clinical spectrum of mitochondrial diseases *Brain Dev* 15 1-22
- Dionisi-Vici C, Ruitenbeek W, Fariello G, Bentlage H, Wanders RJ, Schagger H, Bosman C, Piantadosi C, Sabetta G, Bertini E.** 1997 New familial mitochondrial encephalopathy with macrocephaly, cardiomyopathy, and complex I deficiency *Ann Neurol* 42 661-665
- Fischer JC, Ruitenbeek W, Berden JA, Trijbels JM, Veerkamp JH, Stadhouders AM, Sengers RC, Janssen AJ.** 1985 Differential investigation of the capacity of succinate oxidation in human skeletal muscle. *Clin Chim Acta* 153 23-36
- Fischer JC, Ruitenbeek W, Trijbels JM, Veerkamp JH, Stadhouders AM, Sengers RC, Janssen AJ.** 1986 Estimation of NADH oxidation in human skeletal muscle mitochondria. *Clin Chim Acta* 155:263-273.
- Galante YM and Hatefi Y.** 1979. Purification and molecular and enzymatic properties of mitochondrial NADH dehydrogenase. *Arch Biochem Biophys* 192 559-568
- Giles RE, Blanc H, Cann HM, Wallace DC.** 1980 Maternal inheritance of human mitochondrial DNA *Proc Natl Acad Sci USA* 77 6715-6719
- Goto Y, Horai S, Matsuoka T, Koga Y, Nihei K, Kobayashi M, Nonaka I.** 1992 Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS): a correlative study of the clinical features and mitochondrial DNA mutation. *Neurology* 42 545-550
- Hoppel CL, Kerr DS, Dahms B, Roessmann U.** 1987. Deficiency of the reduced nicotinamide adenine dinucleotide dehydrogenase component of complex I of mitochondrial electron transport Fatal infantile lactic acidosis and hypermetabolism with skeletal-cardiac myopathy and encephalopathy. *J Clin Invest* 80:71-77.
- Houshmand M, Larsson NG, Oldfors A, Tulinius M, Holme E.** 1996 Fatal mitochondrial myopathy, lactic acidosis, and complex I deficiency associated with a heteroplasmic A→G mutation at position 3251 in the mitochondrial tRNA<sup>Leu</sup>(UUR) gene *Hum Genet* 97 269-273.
- Howell N, Bindoff LA, McCullough DA, Kubacka I, Poulton J, Mackey D, Taylor L, Turnbull DM.** 1991. Leber hereditary optic neuropathy identification of the same mitochondrial ND1 mutation in six pedigrees. *Am J Hum Genet* 49 939-950.
- Jackson MJ, Schaefer JA, Johnson MA, Morris AA, Turnbull DM, Bindoff LA.** 1995. Presentation and clinical investigation of mitochondrial respiratory chain disease. A study of 51 patients. *Brain* 118 339-357
- Kirby DM, Crawford M, Cleary MA, Dahl HHM, Dennett X, Thorburn DR.** 1999 Respiratory chain complex I deficiency An underdiagnosed energy generation disorder *Neurology* 1999 52:1255-1264.
- Larsson NG, Andersen O, Holme E, Oldfors A, Wahlstrom J.** 1991. Leber's hereditary optic neuropathy and complex I deficiency in muscle *Ann Neurol* 30 701-708



- Leigh D. 1951 Subacute necrotising encephalomyelopathy in an infant *J Neurol Neurosurg Psychiatr* 14:216-221
- Li YY, Hengstenberg C, Maisch B. 1995 Whole mitochondrial genome amplifications reveals basal level multiple deletions in mtDNA of patients with dilated cardiomyopathy *Biochem Biophys Res Commun* 210:211-218.
- Loeffen JLCM, Triepels RH, van den Heuvel LP, Schuelke M, Buskens CAF, Smeets RJP, Trijbels JMF, Smeitink JAM. 1998a cDNA of eight nuclear encoded subunits of NADH ubiquinone oxidoreductase human Complex I cDNA characterisation completed. *Biochem Biophys Res Commun* 253:415-422.
- Loeffen J, Smeitink J, Triepels R, Smeets R, Schuelke M, Sengers R, Trijbels F, Hamel B, Mullaart R, van den Heuvel L. 1998b. The First Nuclear-Encoded Complex I Mutation in a Patient with Leigh Syndrome *Am J Hum Genet* 63 1598-1608.
- Loeffen J, Smeets R, Smeitink J, Ruitenbeek W, Janssen A, Mariman E, Sengers R, Trijbels F, van den Heuvel L. 1998c The X-chromosomal *NDUFA1* gene of complex I in mitochondrial encephalomyopathies tissue expression and mutation detection *J Inherit Metab Dis* 21 210-215
- Loeffen J, Smeets R, Smeitink J, Triepels R, Sengers R, Trijbels F, van den Heuvel L. 1999. The human NADH.ubiquinone oxidoreductase *NDUFS5* (15 kDa): cDNA cloning, chromosomal localisation, tissue distribution and the absence of mutations in isolated complex I-deficient patients. *J Inherit Metab Dis* 22.19-28
- Luder A and Barash V. 1994 Complex I deficiency with diabetes, Fanconi syndrome and mtDNA deletion. *J Inherit Metab Dis* 17 298-300
- Majander A, Huoponen K, Savontaus ML, Nikoskelainen E, Wikstrom M. 1991. Electron transfer properties of NADH ubiquinone reductase in the ND1/3460 and the ND4/11778 mutations of the Leber hereditary optic neuroretinopathy (LHON). *FEBS Lett* 292:289-292
- Matsuoka R, Furutani M, Hayashi JI, Isobe K, Akimoto K, Shibata T, Imamura Si, Tatsuguchi M, Furutani Y, Takao A, Ohnishi S, Kasanuki H, Momma K. 1999 A mitochondrial DNA mutation cosegregates with the pathophysiological U wave *Biochem Biophys Res Commun* 257:228-233
- Morgan-Hughes JA, Darveniza P, Landon DN, Land JM, Clark JB. 1979 A mitochondrial myopathy with a deficiency of respiratory chain NADH- CoQ reductase activity. *J Neurol Sci* 43 27-46
- Morris AAMM, Jackson MJ, Bindoff LA, Turnbull DM. 1995. The investigation of mitochondrial respiratory chain disease. *J R Soc Med* 88:217-222
- Morris AA, Leonard JV, Brown GK, Bidouki SK, Bindoff LA, Woodward CE, Harding AE, Lake BD, Harding BN, Farrell MA, Bell JE, Mirakhur M, Turnbull DM. 1996. Deficiency of respiratory chain complex I is a common cause of Leigh disease *Ann Neurol* 40 25-30
- Munnich A, Rötig A, Chretien D, Saudubray JM, Cormier V, Rustin P. 1996. Clinical presentations and laboratory investigations in respiratory chain deficiency *Eur J Pediatr* 155:262-274
- Ogle RF, Christodoulou J, Fagan E, Blok RB, Kirby DM, Seller KL, Dahl HH, Thorburn DR. 1997. Mitochondrial myopathy with tRNA(Leu(UUR)) mutation and complex I deficiency responsive to riboflavin *J Pediatr* 130:138-145
- Oostra RJ, Van Galen MJ, Bolhuis PA, Bleeker-Wagemakers EM, Van den Bogert C. 1995. The mitochondrial DNA mutation ND6\*14,484C associated with Leber hereditary optic neuropathy, leads to deficiency of complex I of the respiratory chain. *Biochem Biophys Res Commun* 215:1001-1005
- Pitkänen S, Feigenbaum A, Laframboise R, Robinson BH. 1996a. NADH-coenzyme Q reductase (complex I) deficiency: heterogeneity in phenotype and biochemical findings. *J Inherit Metab Dis* 19:675-686
- Pitkänen S, Merante F, McLeod DR, Applegarth D, Tong T, Robinson BH. 1996b Familial cardiomyopathy with cataracts and lactic acidosis: a defect in complex I (NADH-dehydrogenase) of the mitochondria respiratory chain. *Pediatr Res* 39:513-521.
- Rahman S, Blok RB, Dahl HH, Danks DM, Kirby DM, Chow CW, Christodoulou J, Thorburn DR. 1996 Leigh syndrome: clinical features and biochemical and DNA abnormalities *Ann Neurol* 39 343-351
- Robinson BH. 1993. Lacticacidemia. *Biochim Biophys Acta* 1182 231-244.
- Schuelke M, Smeitink J, Mariman E, Loeffen J, Plecko B, Trijbels F, Stockler-Ipsiroglu S, van den Heuvel L. 1999. Mutant *NDUFV1* subunit of mitochondrial complex I causes leukodystrophy and myoclonic epilepsy. *Nat Genet* 21:260-261.
- Sengers RC, Stadhouders AM, van Lakwijk-Vondrovicova E, Kubat K, Ruitenbeek W. 1985

- Hypertrophic cardiomyopathy associated with a mitochondrial myopathy of voluntary muscles and congenital cataract *Br Heart J* 54 543-547
- Shoffner JM, Lott MT, Lezza AM, Seibel P, Ballinger SW, Wallace DC.** 1990 Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. *Cell* 61:931-937.
- Shoffner JM.** 1996 Maternal inheritance and the evaluation of oxidative phosphorylation diseases. *Lancet* 348:1283-1288
- Skehel JM, Fearnley IM, Walker JE.** 1998 NADH ubiquinone oxidoreductase from bovine heart mitochondria: sequence of a novel 17.2-kDa subunit. *FEBS Lett* 438:301-305.
- Smeitink JA, Sengers RC, Trijbels JM, Ruitenbeek W, Daniels O, Stadhouders AM, Kock-Jansen MJ.** (1989) Fatal neonatal cardiomyopathy associated with cataract and mitochondrial myopathy *Eur J Pediatr* 148 656-659
- Smeitink J, Loeffen J, Smeets HJM, Trijbels F, van den Heuvel L.** 1998a Molecular characterisation and mutational analysis of the human B17 subunit of the mitochondrial respiratory chain complex I *Hum Genet* 103 245-250
- Smeitink J, Loeffen J, Triepels R, Smeets R, Trijbels F, van den Heuvel L.** 1998b Nuclear genes of human complex I of the mitochondrial electron transport chain: state of the art. *Hum Mol Genet* 7:1573-1579.
- Smeitink J and van den Heuvel L.** 1999. Human mitochondrial complex I in health and disease *Am J Hum Genet* 64:1505-1510.
- Srere PA.** 1969. Citrate synthase, EC 4.1.3.7 citrate oxaloacetate lyase (CO-A-acetylating) *Meth enzymol* XIII(Academic Press):3-11
- Tiranti V, Hoertnagel K, Carozzo R, Galimberti C, Munaro M, Granatiero M, Zelante L, Gasparini P, Marzella R, Rocchi M, Bayona-Bafaluy MP, Enriquez JA, Uziel G, Bertini E, Dionisi-Vici C, Franco B, Meitinger T, Zeviani M.** 1998. Mutations of SURF-1 in Leigh Disease Associated with Cytochrome c Oxidase Deficiency *Am J Hum Genet* 63 1609-1621.
- Triepels R, van den Heuvel L, Loeffen J, Smeets R, Trijbels F, Smeitink J.** 1998 The nuclear encoded human NADH:ubiquinone oxidoreductase NDUF8 subunit: cDNA cloning, chromosomal localisation, tissue distribution, and mutation detection in complex-I-deficient patients *Hum Genet* 103:557-563
- Triepels R, van den Heuvel L, Loeffen J, Buskens C, Smeets R, Rubio-Gozalbo M, Budde S, Mariman E, Wijburg F, Barth P, Trijbels F, Smeitink J.** 1999a. Leigh syndrome associated with a mutation in the NDUF87 (PSST) nuclear encoded subunit of complex I. *Ann Neurol* 45 787-790
- Triepels R, Smeitink J, Loeffen J, Smeets R, Buskens C, Trijbels F, van den Heuvel L.** 1999b. The human nuclear encoded acyl carrier subunit (NDUFAB1) of the mitochondrial complex I in human pathology. *J Inher Metab Dis* 22:163-173
- van den Heuvel L, Ruitenbeek W, Smeets R, Gelman-Kohan Z, Elpeleg O, Loeffen J, Trijbels F, Mariman E, de Bruijn D, Smeitink J.** 1998 Demonstration of a new pathogenic mutation in human complex I deficiency: a 5-bp duplication in the nuclear gene encoding the 18-kD (AQDQ) subunit. *Am J Hum Genet* 62:262-268
- van Laack HL, Ruitenbeek W, Trijbels JM, Sengers RC, Gabreels FJ, Janssen AJ, Kerkhof CM.** 1988. Estimation of pyruvate dehydrogenase (E1) activity in human skeletal muscle, three cases with E1 deficiency *Clin Chim Acta* 171:109-118
- von Kleist-Retzow JC, Cormier-Daire V, de Lonlay P, Parfait B, Chretien D, Rustin P, Feingold J, Rötig A, Munnich A.** 1998 A high rate (20%-30%) of parental consanguinity in cytochrome-oxidase deficiency. *Am J Hum Genet* 63 428-435
- Walker JE.** 1992 The NADH ubiquinone oxidoreductase (complex I) of respiratory chains *Q Rev Biophys* 25 253-324
- Weiss H, Friedrich T, Hofhaus G, Preis D.** 1991. The respiratory-chain complex NADH dehydrogenase (complex I) of mitochondria. *Eur J Biochem* 197 563-576
- Zhu Z, Yao J, Johns T, Fu K, De Bie I, Macmillan C, Cuthbert AP, Newbold RF, Wang J, Chevrette M, Brown GK, Brown RM, Shoubbridge EA.** 1998. SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome *Nat Genet* 20 337-343.
- Zhuchenko O, Wehnert M, Bailey J, Sheng Sun Z, Chi Lee C.** 1996 Isolation, mapping and genomic structure of an X-Linked gene for a subunit of human mitochondrial complex I *Genomics* 37 281-288.

**THE X-CHROMOSOMAL *NDUFA1* GENE OF COMPLEX I IN MITOCHONDRIAL ENCEPHALOMYOPATHIES: TISSUE EXPRESSION AND MUTATION DETECTION**

*Journal of Inherited Metabolic Disease* 1998 21:210-215

## Introduction.

The electron transport chain, the final step in the generation of ATP, consists of four protein enzyme complexes, of which NADH:ubiquinone oxidoreductase (complex I) is the largest. Complex I contains at least 42 subunits, seven of which are encoded by the mitochondrial DNA (ND1-6 and ND4L), nuclear genes encode the remainder (Hatefi 1985, Walker et al 1992, Robinson 1993). Complex I catalyses the transfer of electrons from NADH to ubiquinone, which is coupled to the translocation of hydrogen atoms across the inner mitochondrial membrane. Patients described with a (partially) complex I deficiency can generally be categorised in two major clinical phenotypes: an isolated myopathy, and a multisystem disorder, with predominantly encephalopathy.

Respiratory chain defects may be inherited as autosomal or X-linked Mendelian traits (Orstavik et al 1993, Zhuchenko et al 1996), or in case of certain mutations in mitochondrial DNA, as maternal traits. To date, no mutations in a nuclear encoded subunit of complex I have been described. In our biochemically proven complex I deficient patients as well as among the affected sibs, (latter actually not all biochemically evaluated), we observed a strong male preponderance, suggestive for X-linked inheritance.

Recently, the *NDUFA1* gene, one of the nuclear encoded complex I genes, was isolated, and mapped to chromosome Xq24 (Zhuchenko et al 1996). The *NDUFA1* gene is composed of three exons, and spans about 5.0 kb of genomic DNA. It shows 80% homology to the bovine MWFE subunit of complex I. The knowledge of function of the human *NDUFA1*, and the bovine MWFE subunit is very limited. The bovine MWFE subunit is thought to be situated in the extrinsic membrane domain of complex I (Walker 1992).

We now report the results of a mutation analysis study of the *NDUFA1* gene in a patient group with an isolated decreased activity of complex I in cultured skin fibroblasts. We describe the offspring distribution of patient families, and we give an outline of the pattern of tissue distribution of the mRNA transcript from the *NDUFA1* gene.

## Patients, material and methods.

Seventeen patients (three females, and fourteen males, sex ratio 0.18), with an isolated decreased activity of NADH:ubiquinone oxidoreductase measured in cultured skin fibroblasts, were selected for a mutation analysis study of the cDNA sequence of the *NDUFA1* gene. Frequently encountered clinical features in our patient group were hypotonia (generalised, and/or axial), failure to thrive, seizures, psychomotor retardation, and respiratory distress. Lactic acidemia, increased blood lactate/pyruvate ratio's, and increased cerebrospinal fluid lactate, were present in most patients. The patients come from fifteen families (two families have two sons represented in the patient group). In eleven families the pedigree could be retrieved. Three families (two male, and one female patient) were known with consanguinity. The enzymatic activity of complex I was measured in cultured skin fibroblasts according to established techniques (Bentlage et al 1996). Reference values ranged from 0.11-0.28 mU/mU cytochrome *c* oxidase. Patient values ranged from 0.026 to 0.080 mU/mU cytochrome *c* oxidase.

To examine whether mutations in the *NDUFA1* gene are a common cause of isolated complex I deficiency, skin fibroblasts from all patients were cultured, and harvested after reaching confluency. Total RNA was extracted, and 5 µg of RNA was reverse transcribed to cDNA by Superscript II RNase H reverse transcriptase (Life Technologies, The Netherlands), using oligo(dT), and random hexanucleotides (Ploos van Amstel et al 1996). A sample of the cDNA was amplified by Polymerase Chain Reaction (PCR), using primers designed according to the published sequence of the *NDUFA1* gene. The generated PCR fragment spanned the entire coding region of the *NDUFA1* cDNA. Both strands were screened for the presence of mutations in the cDNA of the *NDUFA1* subunit by direct sequencing, performed by automated sequencing (ABI Prism, model 377 version 2.1.2), using the ABI Prism Taq DyeDeoxy terminator cycle sequencing ready reaction kit (Perkin Elmer, The Netherlands).

A master blot, containing poly(A)<sup>+</sup> RNA isolated from various human tissues was purchased from Clontech, The Netherlands. The quantity of mRNA spotted for each tissue onto the master blot was normalised using eight different housekeeping gene transcripts as probes (ribosomal protein S9, ubiquitin, 23 kDa highly basic protein, hypoxanthine guanine phosphoribosyl transferase, tubulin, β-actin, phospholipase, and glyceraldehyde triphosphate dehydrogenase). A cDNA probe homologous to human *NDUFA1* was prepared by random primed labelling (Sambrook et al 1989), and hybridised to the master blot. The filter was washed under stringent conditions, and analysed by autoradiography.


## **Results.**

The offspring distribution could be determined in eleven families, and consisted of seventeen subjects. Seven were female, all healthy, ten were male, two healthy, and eight with proven decreased activity of complex I, or expressing a clinical phenotype strongly resembling the symptoms of the brother/sister in the patient group.

We analysed the cDNA of the *NDUFA1* gene of all patients with complex I deficiency for abnormalities by direct sequencing, which revealed no mutations, nor polymorphisms. We compared the transcription levels of *NDUFA1* mRNA in foetal, and adult human tissues to quantify the relative abundance of *NDUFA1* mRNA. We used a dot blot containing carefully normalised quantities of poly (A<sup>+</sup>) RNA from a wide range of human tissues. In foetal stages, *NDUFA1* mRNA was detected in all tissues tested without marked differences, but a clearly high amount was observed in foetal heart. In adult stages dots with higher intensity were seen in (in descending order) human heart, skeletal muscle, liver, kidney, and gland tissues (see Fig 3.1). A diversity of brain structures expressed a moderate activity of the *NDUFA1* subunit compared to human heart and skeletal muscle.

	1	2	3	4	5	6	7	8
a	whole brain	amygdala	caudate nucleus	cerebellum	cerebral cortex	frontal lobe	hippocampus	medulla oblongata
b	occipital lobe	putamen	substantia nigra	temporal lobe	thalamus	subthal. nucleus	spinal cord	
c	heart	aorta	skeletal muscle	colon	bladder	uterus	prostate	stomach
d	testis	ovary	pancreas	pituitary gland	adrenal gland	thyroid gland	salivary gland	mammary gland
e	kidney	liver	small intestine	spleen	thymus	peripheral leukocyte	lymph node	bone marrow
f	appendix	lung	trachea	placenta				
g	foetal brain	foetal heart	foetal kidney	foetal liver	foetal spleen	foetal thymus	foetal lung	
h	yeast RNA 100 ng	yeast tRNA 100 ng	<i>E. coli</i> rRNA 100 ng	<i>E. coli</i> DNA 100 ng	poly r(A) 100 ng	human C <sub>0</sub> t1 DNA 100 ng	human DNA 100 ng	human DNA 500 ng

**Fig. 3.1a Multiple tissue Master blot.** The type and position of poly(A<sup>+</sup>) RNAs and controls dotted on the positively charged nylon membrane. subthal. = subthalamic.



**Figure 3.1b Human RNA multiple tissue blot data.** Hybridisation was performed with a <sup>32</sup>P-labelled cDNA probe of the NDUFA1 subunit.

## **Discussion.**

The purpose of this mutation analysis study was to investigate the hypothesis of X-linked inheritance patterns in complex I disease as suggested by the strong male preponderance in our patient group and among the affected children in the sibs group.

In literature many mutations in mitochondrial encoded genes of subunits of NADH:ubiquinone oxidoreductase have been described and linked to specific clinical presentations (for a review see Zeviani and Taroni 1994). The fact that in many patients with an isolated decreased activity of complex I, a molecular defect in mtDNA has not been found, combined with the fact that at least 35 subunits are encoded on the nuclear genome, make defects in nuclear encoded subunits of the NADH:ubiquinone oxidoreductase certainly possible.

Several human nuclear genes encoding for subunits of complex I have been cloned, and mapped to a specific chromosome (Procaccio et al 1997, Pata et al 1997, Gu et al 1996, Hyslop et al 1996, Hattori et al 1995, de Coo et al 1995, Ali et al 1993), but until now only one gene has been located on the X chromosome (Zhuchenko et al 1996). Up to now, no mutation analysis studies in nuclear encoded NADH:ubiquinone oxidoreductase subunits have been described in literature.

We selected patients with an isolated decreased activity of complex I measured in cultured skin fibroblasts. The mutation analysis study was performed on cDNA obtained from RNA isolated out of cultured skin fibroblasts. This study revealed no mutations in the *NDUFA1* cDNA, so we conclude that mutations in this gene are not a frequent cause of isolated complex I deficiency. For many genes encoding subunits of NADH:ubiquinone oxidoreductase the sequence, and chromosomal localisation remain to be elucidated, so other genes responsible for complex I disease might be located on the X chromosome.

We studied the tissue, and developmental expression of the *NDUFA1* mRNA because measurements of complex I activity in different tissues are not always conclusive. Some patients express reduced complex I activity in fibroblasts, others only in muscle or liver. In addition, isolated complex I disease gives a variety of clinical phenotypes, possibly because of tissue specific, or developmental expression of complex I subunits. The human RNA master blot expressed the *NDUFA1* mRNA in all human tissues present on the blot, and as expected a high expression was found in human heart, foetal heart, skeletal muscle, liver, and kidney (tissues with high metabolic activity). The central nervous system, known for its high energy demand, is very often affected in complex I disease. Especially the basal nuclei are frequently involved in the disease process, which could be reflected in an increased dot intensity seen in the putamen compared to whole brain. An alternative explanation for differences of cDNA expression of the *NDUFA1* gene seen on the master blot, is the fact that it reflects the mRNA expression of the *NDUFA1* gene, so there may be a discrepancy between the mRNA expression, and the actual enzyme activity.

We remain looking for other nuclear encoded genes in general, and X-linked genes in particular, as candidate for complex I deficiency in our patients.

## Reference list.

- Ali ST, Duncan AMV, Schappert K, Heng HHQ, Tsui LC, Chow W, Robinson BH. 1993 Chromosomal localisation of the human gene encoding the 51 kDa subunit of mitochondrial complex I (*NDUFV1*) to 11q13 *Genomics* 18 435-439
- Bentlage H, Wendel U, Schagger H, ter Laak H, Janssen A, Trijbels F. 1996 Lethal infantile mitochondrial disease with isolated complex I deficiency in fibroblasts with combined complex I and IV deficiencies in muscle *Neurology* 47 243-248
- de Coo R, Buddiger P, Smeets HJM, Geurts van Kessel A, Morgan-Hughes J, Olde Weghuis D, Overhauser J, van Oost BA. 1995 Molecular cloning and characterisation of the active human mitochondrial NADH ubiquinone oxidoreductase 24-kDa gene (*NDUFV2*) and its pseudogene *Genomics* 26 461-466
- Gu ZG, Lin X, Wells DE. 1996 The human B22 subunit of the NADH ubiquinone oxidoreductase maps to the region of chromosome 8 involved in Branchio Oto Renal syndrome *Genomics* 35 6-10
- Hatefi Y. 1985 The mitochondrial electron transport and oxidative phosphorylation system *Ann Rev Biochem* 54 1015-1069
- Hattori N, Suzuki H, Wang Y, Minoshima S, Shimizu N, Yoshino H, Kurashima R, Tanaka M, Ozawa T, Mizuno Y. 1995 Structural organisation and chromosomal localisation of the human nuclear gene (*NDUFV2*) for the 24-kDa iron-sulphur subunit of complex I in mitochondrial respiratory chain *Biochem Biophys Res Commun* 216 771-777
- Hyslop SJ, Duncan AMV, Pitkanen S, Robinson BH. 1996 Assignment of the PSST subunit gene of human mitochondrial complex I to chromosome 19p13 *Genomics* 37 375-380
- Orstavik KH, Skjorten F, Hellebostad M, Haga P, Langslet A. 1993 Possible X linked congenital mitochondrial cardiomyopathy in three families *J Med Genet* 30 269-272
- Pata I, Tensing K, Metspalu A. 1997 A human cDNA encoding the homologue of NADH ubiquinone oxidoreductase subunit B13 *Biochim Biophys Acta* 1350 115-118
- Ploos van Amstel JK, Bergman AJIW, van Beurden EACM, Roijers JFM, Peelen T, van den Berg IET, Poll-The BT, Kvittingen EA, Berger R. 1996 Hereditary tyrosinemia type I novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene variability of the genotype-phenotype relationship *Hum Genet* 97 51-59
- Procaccio V, Depetris D, Soularue P, Mattei MG, Lunardi J, Issartel JP. 1997 cDNA sequence and chromosomal localisation of the *NDUFS8* human gene coding for the 23 kDa subunit of the mitochondrial complex I *Biochim Biophys Acta* 1351 37-41
- Robinson BH. 1993 Lacticacidemia *Biochim Biophys Acta* 1182 231-244
- Sambrook J, Fritsch EF, Maniatis E (eds). 1989 *Molecular cloning a laboratory manual 2<sup>nd</sup> edn* Cold Spring Harbor Cold Spring Harbor Laboratory Press
- Walker JE. 1992 The NADH ubiquinone oxidoreductase (complex I) of respiratory chains *Q Rev Biophys* 25 253-324
- Walker JE, Arizmendi JM, Dupuis A, Fearnley IM, Finel M, Medd SM, Pilkington SJ, Runswick MJ, Skehel JM. 1992 Sequences of 20 subunits of NADH ubiquinone oxidoreductase from bovine heart mitochondria *J Mol Biol* 226 1051-1072
- Zeviani M and Taroni F. 1994 Mitochondrial diseases *Baill Clin Neurol* 3 315-334
- Zhuchenko O, Wehnert M, Bailey J, Sheng Sun Z, Chi Lee C. 1996 Isolation, mapping and genomic structure of an X-Linked gene for a subunit of human mitochondrial complex I *Genomics* 37 281-288



### MOLECULAR CHARACTERISATION AND MUTATIONAL ANALYSIS OF THE HUMAN NDUFB6 (B17) SUBUNIT OF THE MITOCHONDRIAL RESPIRATORY CHAIN COMPLEX I

*Human Genetics* 1998 103:245-250

#### **Abstract.**

Bovine NADH ubiquinone oxidoreductase (complex I) of the mitochondrial respiratory chain consists of about 35 nuclear-encoded subunits. We review the current knowledge of the 15 human complex I subunits cloned so far, and report the 567-bp cDNA sequence, the chromosomal localisation and the tissue expression of an additional subunit, the NDUFB6 subunit. The cDNA open reading frame of *NDUFB6* comprises 387 bp and encodes a protein of 128 amino acids (calculated  $M_r$  15.5 kDa). There is 82.7% and 78.1% homology, respectively, at the cDNA and amino acid level with the bovine counterpart. The gene of the NDUFB6 subunit has been mapped to chromosome 2. A multiple-tissue dot-blot showed ubiquitous expression of the mRNA with relatively higher expression in tissues known for their high-energy demand. Of these, kidney showed the highest expression. Mutational analysis of the subunit revealed no mutations or polymorphisms in 20 patients with isolated enzymatic complex I deficiency in cultured skin fibroblasts.

## Introduction.

The molecular biology of complex I (NADH ubiquinone oxidoreductase), the first multi-subunit enzyme complex of the mitochondrial respiratory chain, has been thoroughly investigated in *Bos taurus*. The complex has about 42 subunits with a combined molecular mass of 970 kDa (Fearnley et al 1989, Walker 1992, Fearnley et al 1994, Walker 1995, Walker et al 1995, Skehel et al 1998). Of these, seven subunits are encoded by the mitochondrial genome (ND1 6, ND4L) (Gibb and Ragan 1990). The remaining subunits are encoded by the nuclear genome. The results of studies with the fungus *Neurospora crassa* and bovine studies have revealed important information concerning the spatial and functional organisation of complex I (Hatefi 1985, Walker 1992, Belogrudov and Hatefi 1994, Guenebaut et al 1997). It is likely that, as in *N. crassa*, bovine complex I has an L-shaped configuration with an extrinsic globular domain attached to an intrinsic domain (Walker 1995, Guenebaut et al 1997). In the late 1960s, it was found that most of the electron carriers of complex I, which are predominantly located in the extramembranous part of complex I, can be isolated as two water-soluble complexes: a flavoprotein (FP) and an iron-sulphur protein (IP) fraction (Hatefi and Stempel 1967). Both subcomplexes make contact through the 51- and 75-kDa subunits (Belogrudov and Hatefi 1994). The FP fraction (51, 24 and 10 kDa) has, in contrast to the IP and the water-insoluble aggregate HP (hydrophobic protein fraction), catalytic properties (Ohnishi et al 1985). The IP fraction contains at least the 75-, 49-, 30-, 18-, 15-, 13 kDa and B13 subunits. The HP fraction contains the seven mitochondrial (mt) DNA-encoded subunits and about 25 nuclear encoded subunits. In man the cDNA or gene structure of complex I has currently been determined for 15 nuclear encoded subunits (Pilkington and Walker 1989, Chow et al 1991, Spencer et al 1992, Hyslop et al 1996, Zhuchenko et al 1996, Kim et al 1997, Pata et al 1997, Procaccio et al 1997, Ton et al 1997, van den Heuvel et al 1998). These human complex I subunits, and, if known, their chromosomal localisation are summarised in Table 4.1. Information about the function of the individual human subunits is limited in man, and only a few mutational analyses have been performed (van den Heuvel et al 1998, Loeffen et al 1998). Our most important reasons for investigating the nuclear encoded complex I subunits in man are (1) to unravel the origin of the phenotypic complexity encountered in patients with inherited complex I deficiency and (2) to develop reliable tools for prenatal diagnosis. Furthermore, assessment of nuclear mutations in complex I-deficient patients will extend our knowledge of the functional properties of the individual subunits. The incidence of mitochondrial disorders, to which complex I deficiencies of the respiratory chain belong is approximately 1/10,000 living births (Bourgeron et al 1995). The clinical presentation and course of complex I-deficient patients vary greatly: from neonatal death due to a multisystem disorder to mild exercise intolerance (Pitkanen et al 1996a). The observed differences in complex I-deficient phenotypes may, at least partially, be explained by genetic differences in the various complex I subunits. So far, only a few mtDNA mutations have been associated with complex I deficiency (Pitkanen et al 1996b). The exact composition of complex I, the number of individual subunits and their functional properties may differ in various developmental stages as well as in various tissues. Clay and Ragan (1988), for example, showed that rat liver, kidney and lung were lacking the 17- and 18 kDa proteins

found in brain, heart and skeletal muscle.

In an attempt to elucidate the molecular defects in complex I-deficient patients we recently, started a research program in order to (1) determine the human cDNA and gene structure of all nuclear-encoded subunits of the respiratory chain complex I, (2) determine the chromosomal localisation of the various genes of these subunits, (3) obtain information regarding the tissues in which this complex is expressed, and, finally, (4) perform a mutational analysis of our complex I-deficient patients. By this approach we very recently found the first patient with a pathological mutation in one of the nuclear-encoded subunits of this intriguing enzyme complex (van den Heuvel et al 1998). Here, we review the present knowledge of human nuclear-encoded complex I subunits, and report the characterisation and the results of a mutational study of the human NDUFB6 subunit of this complex.

<i>Human name</i>	<i>Bovine name</i>	<i>Chromosome</i>	<i>Reference</i>
NDUFV1	51 kDa	11q13	Spencer et al 1992
NDUFV2*	24 kDa	18p11.31-11.2	Pilkington & Walker 1989
NDUFV3	10 kDa	21q22.3	de Co0 et al 1997
NDUFS1	75 kDa	2q33-34	Chow et al 1991
NDUFS4	18 kDa (AQDQ)	5	van den Heuvel et al 1998
NDUFS7	PSST	19p13	Hyslop et al 1996
NDUFS8	TYKY	11	Procaccio et al 1997
NDUFA1	MWFE	Xq24-25	Zhuchenko et al 1996
NDUFA2	B8		Ton et al 1997
NDUFA4	MLRQ		Kim et al 1997
NDUFA5	B13	7q32	Pata et al 1997
NDUFA6	B14		Ton et al 1997
NDUFB3	B12		Ton et al 1997
NDUFB5	SGDH		Ton et al 1997
NDUFC1	KFYI		Ton et al 1997

**Table 4.1** Details of the presently known nuclear-encoded subunits of human complex I (human gene nomenclature according to (White et al 1997). \* pseudogene known (*NDUFV2P1*: chromosome 19q13.3-ter).

## Material and methods.

### *Cloning of the human NDUFB6 cDNA.*

Human *NDUFB6* cDNA was obtained by reverse transcription using oligo(dT) and random hexamer primers on poly(A)<sup>+</sup> RNA isolated from human heart tissue (Clontech, USA). Amplification by the polymerase chain reaction (PCR) was performed with cDNA as template

according to the protocol for Taq polymerase (Life Technologies, The Netherlands) using oligonucleotides 5' AACTAGTCCGTAGTTCGAGGG 3' and 5' GGAACAACTTAGGCTCATAAG 3'. Oligonucleotide sequences were based on several human expressed sequence tags (ESTs) resembling the bovine 5' and 3' open reading frame (ORF) of the *NDUFB6* subunit. The PCR product was purified for direct DNA sequencing. DNA sequence analysis of both DNA strands was performed using Dye-deoxy terminators on an automated ABI 377 sequencer according to a protocol provided by the manufacturer (Perkin Elmer, The Netherlands).

#### *Chromosomal localisation of the human NDUFB6 gene*

We searched the Genbank sequence-tagged site (STS) database using the cDNA sequence of the human *NDUFB6* subunit. This revealed an STS (Genbank accession number G30177) of 75 bp (100% match with the corresponding part of the human *NDUFB6* transcript).

#### *Tissue distribution*

To determine the tissue- and developmental stage specific expression of the *NDUFB6* mRNA, we used a Human RNA Master Blot (Clontech, USA). The blot was hybridised with an [ $\alpha$ - $^{32}$ P]dCTP-labelled *NDUFB6* cDNA probe using Standard Hybridisation Solution (Sambrook et al 1989), washed twice with 2× SSC, 1% SDS at 65°C, and subjected to autoradiography. The quantity of mRNA spotted for each tissue on the Master Blot was normalised using eight different housekeeping gene transcripts as probes (ribosomal protein S9, ubiquitin, highly basic 23-kDa protein, hypoxanthine guanine phosphoribosyl transferase, tubulin,  $\beta$ -actin, phospholipase and glyceraldehyde triphosphate dehydrogenase).

#### *Protein analysis*

The average hydropathy of the human *NDUFB6* subunit was calculated according to the procedure described by Kyte and Doolittle (1982), using computer software provided by CAOS/CAMM, University of Nijmegen, The Netherlands.

#### *Mutation detection*

Total RNA was extracted from cultured skin fibroblasts of 20 patients (16 males, 4 females) with isolated complex I deficiency (Loeffen et al 1998). A 5- $\mu$ g sample of RNA was reverse transcribed to cDNA in 1 h at 42°C with 200 U of Superscript II reverse transcriptase (Life Technologies, The Netherlands), using oligo(dT) and random hexamer primers (Ploos van Amstel et al 1996). One microliter of cDNA was subjected to PCR amplification. A fragment encompassing the entire coding region was generated using the synthetic oligonucleotide primers described previously. The PCR program consisted of 35 cycles of 60 s 94°C, 60 s 55°C and 60 s 72°C. The cycles were preceded by an initial denaturation step of 2 min at 94°C and were followed by a final extension of 10 min at 72°C. The products of the PCR were analysed on a 2% TBE agarose gel with 0.5  $\mu$ g/ml ethidium bromide. The nucleotide sequences of the PCR products were analysed by direct sequencing using the Taq Dye Deoxy Terminator Cycle Sequencing Kit according to the manufacturer's recommendations (Perkin Elmer, The Netherlands).

## Results.

By reverse transcription-PCR using human heart RNA and oligonucleotide primers based upon the *NDUFB6* cDNA sequence from cow and human ESTs, we obtained a 489-bp cDNA fragment of the human nuclear-encoded *NDUFB6* gene. This comprises the ORF of 387 bp, which encodes a protein of 128 amino acids (Genbank accession number AF035840). The human *NDUFB6* ORF showed 82.7% homology with the bovine equivalent (Fig. 4.1). The amino acid sequence showed 78.1% homology with the bovine *NDUFB6* amino acid sequence. The calculated molecular weight of the protein encoded by the human *NDUFB6* ORF is 15.5 kDa.

In contrast to, for example, the 18-kDa subunit (van den Heuvel et al 1998), the human *NDUFB6* subunit contains no phosphorylation consensus site. Furthermore, no cysteine-rich motifs were present in the amino acid sequence. The prediction of the hydropathy of the protein, essentially calculated as described by Kyte and Doolittle (1982), revealed that approximately 20% of the protein has hydrophobic properties (data not shown). A search of the Genbank STS database using the determined human *NDUFB6* cDNA sequence revealed a specific STS (Genbank accession number G30177) of 75 bp (100% match with the corresponding part of the human *NDUFB6* subunit transcript), which has been mapped to chromosome 2.

Determination of the tissue distribution showed the highest mRNA level in kidney (Fig. 4.2). Expression was also high in putamen, heart, skeletal muscle, liver and lung. In our group of 20 isolated complex I-deficient patients, none of the following mtDNA mutations were present: A3243G (MELAS), T3271C (MELAS), A4317G (MELAS), A8344G (MERFF), T8993G/C (NARP/Leigh syndrome). Deletions of mtDNA were excluded by means of the long template PCR technique (Li et al 1995), which revealed a single band of 16.5-kb representing the full-length linearised mtDNA. Furthermore, no mutations or polymorphisms were detected in any patient by complete sequencing of the human *NDUFB6* ORF. Mutations in the nuclear-encoded *NDUFA1* and 18-kDa (AQDQ) subunits have been previously excluded in this cohort of patients.

	<b>1</b>	<b>11</b>	<b>21</b>	<b>31</b>	<b>41</b>
<b>Human</b>	MTGYTPDEKL	RLQQLRELRR	RWLKDQELSP	REPVLPPQKM	GPMEKFWNKF
	: : : : : : :	: : : : : : :	: : : : : : :	: : : : : : .	: . : : : : :
<b>Bovine</b>	MSGYTPEEKL	RLQQLRELRR	RWLKDQELSP	REPVLPPQRV	SPVERFWNKF
	<b>51</b>	<b>61</b>	<b>71</b>	<b>81</b>	<b>91</b>
<b>Human</b>	LENKSPWRKM	VHGVYKKSIF	VFTHVLVPVW	IIHYYMKYHV	SEKPYGIVEK
	: . . : . . .	: . : : : : :	: : : : : : :	: : : : : : :	: . : : : : :
<b>Bovine</b>	LQDGALWKNV	IYKTYRHSIF	AFTHVLIPVW	IIHYYIKYHV	TTKPYTIVEK
	<b>101</b>	<b>111</b>	<b>121</b>		
<b>Human</b>	KSRIFFPGDTI	LETGEVIPP	KEFPDQHH		
	: : : : : : :	: : : : : : :	: : : : : :		
<b>Bovine</b>	KPRIFFPGDTI	LETGEVIPP	KEFPDQHH		


Figure 4.1 (continued)

				-70	-60
				cgcgctta	agtaactagt
Human	-50	-40	-30	-20	-10
Human	<u>ccgtagttcg</u>	<u>aggggtgcgcc</u>	gtgtcctttt	gcgttggtac	cagcggcgac
	1	11	21	31	41
Human	ATGACGGGGT	ACACTCCGGA	TGAGAACTG	CGGCTGCAGC	AGCTGCGAGA
	::: :::::	: : : : :	: : : : :	: : : : :	: : : : :
Bovine	ATGTCGGGGT	ATACGCCCGA	GGAGAACTG	CGGCTGCAGC	AGCTTCGAGA
	51	61	71	81	91
Human	GCTGAGAAGG	CGATGGCTGA	AGGACCAGGA	GCTGAGCCCT	CGGGAGCCGG
	::: :::::	: : : : :	: : : : :	: : : : :	: : : : :
Bovine	GCTAAGAAGG	CGATGGCTGA	AAGATCAGGA	GCTGAGCCCC	CGGGAAACCCG
	101	111	121	131	141
Human	TGCTGCCCCC	ACAGAAGATG	GGGCCTATGG	AGAAATTCTG	GAATAAAATT
	: : : : : :	: : : : : :	: : : : : :	: : : : : :	: : : : : :
Bovine	TGCTGCCTCC	GCAGAGGGTG	TCGCCTGTGG	AGCGATTCTG	GAATAAAATT
	151	161	171	181	191
Human	TTGGAGAATA	AATCCCCCTG	GAGGAAAATG	GTCCATGGGG	TATACAAAAA
	: : : : :	: : : : :	: : : : :	: : : : :	: : : : :
Bovine	TTGCAAGACG	GAGCTCTCTG	GAAGAACGTG	ATCTATAAGA	CATATCGACA
	201	211	221	231	241
Human	GAGTATCTTT	GTTTTCACTC	ATGTACTTGT	ACCTGTCTGG	ATTATTCATT
	: : : : : :	: : : : : :	: : : : : :	: : : : : :	: : : : : :
Bovine	CAGTATCTTT	GCTTTTACTC	ATGTACTTAT	TCCTGTCTGG	ATTATTCATT
	251	261	271	281	291
Human	ATTACATGAA	GTATCATGTT	TCTGAAAAAC	CATATGGCAT	AGTTGAAAAG
	: : : : :	: : : : : :	: : : : : :	: : : : : :	: : : : : :
Bovine	ATTATCTCAA	GTATCACGTG	ACTACAAAAC	CATATACCAT	CGTTGAAAAG
	301	311	321	331	341
Human	AAGTCCAGAA	TATTCCTGG	TGATACAATT	CTGGAGACTG	GAGAAGTAAT
	: : : : : :	: : : : : :	: : : : : :	: : : : : :	: : : : : :
Bovine	AAGCCCAGAA	TATTTCCAGG	TGATACAATT	CTGGAGACTG	GAGAAGTAAT
	351	361	371	381	391
Human	TCCACCAATG	AAAGAATTTC	CTGATCAACA	TCATTAAaga	ttatgtaaaa
	: : : : : :	: : : : : :	: : : : : :	: : : : : :	
Bovine	CCCACCCATG	AAAGAATTTC	CCGATCAACA	TCATTGA	
	401	411	421	431	441
Human	agttaaaagg	<u>cttatgagcc</u>	<u>taagtttggt</u>	<u>cctatattac</u>	catatttact
	451	461	471	481	491
Human	gaattttctg	gaaaagtaac	tttaataaag	tttaatctca	gaaattgtca
	501		poly a signal		
Human	aaaaaaaaaa				
	poly a site				

Figure 4.1 Human and bovine amino acid and cDNA sequences of the NDUFB6 subunit of NADH:ubiquinone oxidoreductase. The human and bovine cDNA sequences show 82.7% homology. The bovine sequence was obtained from Genbank, USA (accession number X63212). Primers used to generate fragments encoding the complete sequence of the human *NDUFB6* cDNA with the polymerase chain reaction are underlined. The open reading frame obtained after sequencing is supplemented with bases prior to the ATG and after the TGA with the use of expressed sequence tags obtained via Genbank. In the part of the figure, which shows amino acid similarity between human and bovine, one dot indicates that the amino acids are not identical but have similar chemical characteristics.

	1	2	3	4	5	6	7	8
a	whole brain	amygdala	caudate nucleus	cerebellum	cerebral cortex	frontal lobe	hippocampus	medulla oblongata
b	occipital lobe	putamen	substantia nigra	temporal lobe	thalamus	subthal. nucleus	spinal cord	
c	heart	aorta	skeletal muscle	colon	bladder	uterus	prostate	stomach
d	testis	ovary	pancreas	pituitary gland	adrenal gland	thyroid gland	salivary gland	mammary gland
e	kidney	liver	small intestine	spleen	thymus	peripheral leukocyte	lymph node	bone marrow
f	appendix	lung	trachea	placenta				
g	foetal brain	foetal heart	foetal kidney	foetal liver	foetal spleen	foetal thymus	foetal lung	
h	yeast RNA	yeast tRNA	<i>E. coli</i> rRNA	<i>E. coli</i> DNA	poly r(A)	human C <sub>0</sub> t1 DNA	human DNA	human DNA
	100 ng	100 ng	100 ng	100 ng	100 ng	100 ng	100 ng	500 ng

**Figure 4.1a Multiple tissue Master blot.** The type and position of poly(A<sup>+</sup>) RNAs and controls dotted on the positively charged nylon membrane. subthal. = subthalamic.



**Figure 4.1b Human RNA multiple tissue Master blot data.** Hybridisation was performed with a <sup>32</sup>P-labelled cDNA probe for the NDUFB6 gene.

## Discussion.

Complex I of the respiratory chain is embedded in the lipid bilayer of the inner mitochondrial membrane. In *N. crassa* the multiple subunits of this complex form an L-shaped configuration of which the extrinsic peripheral arm protrudes into the mitochondrial matrix (Guenebaut et al 1997). The three-dimensional structure of the human counterpart is not known. The bovine NDUF6 subunit is located in the intrinsic membrane domain of the complex (Walker 1992). Based upon the predicted protein analysis, revealing an important hydrophobic segment sufficiently long to form a transmembrane  $\alpha$ -helix, we assume that, as in bovine, the human NDUF6 subunit is part of the intrinsic membrane domain of complex I. Presumably, the human NDUF6 subunit is, as assumed for bovine (Walker 1992), anchored into the inner mitochondrial membrane. The more hydrophilic parts of the sequence probably interact with globular proteins in the large extrinsic membrane domain of the complex, which protrudes into the mitochondrial matrix (Walker 1992).

Presently, information concerning the function of the human NDUF6 subunit is lacking. Based on the obtained results we assume that this subunit has no phosphorylation site. Owing to the lack of cysteine-rich motifs it is highly unlikely that the human NDUF6 subunit contains a binding site for an Iron-Sulphur cluster. The human *NDUF6* ORF is 387 bp long and its nucleotide sequence has 82.7% homology with that of the cow. The molecular weight calculated from the cDNA deduced amino acid sequence is 15.5 kDa. The use of STSs has enabled the localisation of the *NDUF6* gene to chromosome 2. Multiple tissue dot-blot analysis showed the highest mRNA expression of the NDUF6 subunit in organs known for their high-energy demand, with kidney showing the highest expression. The latter result differs from the mRNA expression we observed in the NDUF1 NADH ubiquinone oxidoreductase subunit (Loeffen et al 1998).

Deficient activity of complex I of the respiratory chain may result directly from mutations in the mtDNA- or nuclear DNA-encoded subunits. Apart from the recently found mutation in the nuclear-encoded complex I NDUF54 subunit, various mtDNA mutations have been associated with complex I deficiency (Wallace 1992, Robinson 1993). Deletions and common mtDNA mutations were not present in our patients. However, defects in other classes of genes, such as those involved in the regulation and assembly of the complex may also be involved. We performed a mutational detection study at the RNA level in 20 complex I-deficient patients. Neither mutations nor polymorphisms were detected in the ORF of the *NDUF6* cDNA of these patients. However, the promoter region of the *NDUF6* gene was not included in this study. At the moment we are in the process of mutational analysis of the presently known nuclear-encoded subunits and characterising presently unknown human nuclear-encoded complex I cDNA sequences in order to extend our mutation detection studies. By this approach we are trying to extend indirectly our knowledge of the function of the individual subunits of this vital complex. Elucidation of the molecular defects in patients may be of great importance for genetic counselling and prenatal diagnosis. Currently this is only possible by enzymatic measurements in chorionic villi and amniocytes. Interpretation of the results of mutational analysis studies will be more reliable.



## **Acknowledgements.**

This study was made possible by a grant from "De stichting voor kinderen die wel willen maar niet kunnen", the "Fonds voor Beoefening Wetenschap" from the University Children's Hospital, Nijmegen, The Netherlands. and the "Prinses Beatrix Fonds", supplied to Jan Smeitink and Bert van den Heuvel. We greatly acknowledge Antoon Janssen for his outstanding technical assistance. Professor Rob Sengers is highly acknowledged for his ongoing enthusiastic support. We thank Dr. Edwin Mariman (Department of Human Genetics, Nijmegen Centre for Mitochondrial Disorders) for mitochondrial DNA analysis. The reported cDNA sequence has been submitted to Genbank: accession number AF035840.

## Reference List.

- Belogrudov G and Hatefi Y.** 1994 Catalytic sector of complex I (NADH ubiquinone oxidoreductase) subunit stoichiometry and substrate-induced conformation changes *Biochemistry* 33 4571-4576
- Bourgeron T, Rustin P, Chretien D, Birch-Machin M, Bourgeois M, Viegas-Pequignot E, Munnich A, Rotig A.** 1995 Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency *Nat Genet* 11 144-149
- Chow W, Ragan CI, Robinson BH.** 1991 Determination of the cDNA sequence for the human mitochondrial 75-kDa Fe-S protein of NADH-coenzyme Q reductase *Eur J Biochem* 201 547-550
- Clay VJ and Ragan CI.** 1988 Evidence for the existence of tissue specific isoenzymes of mitochondrial NADH dehydrogenase *Biochem Biophys Res Commun* 157 1423-1428
- de Coo R, Buddiger P, Smeets HJM, van Oost BA.** 1997 Molecular cloning and characterisation of the human mitochondrial NADH oxidoreductase 10-kDa gene (*NDUFV3*) *Genomics* 45 434-437
- Fearnley IM, Runswick MJ, Walker JE.** 1989 A homologue of the nuclear coded 49 kd subunit of bovine mitochondrial NADH-ubiquinone reductase is coded in chloroplast DNA *EMBO J* 8 665-672
- Fearnley IM, Skehel JM, Walker JE.** 1994 Electrospray ionisation mass spectrometric analysis of subunits of NADH ubiquinone oxidoreductase (complex I) from bovine heart mitochondria *Biochem Soc Trans* 22 551-555
- Gibb GM and Ragan CI.** 1990 Identification of the subunits of bovine NADH dehydrogenase which are encoded by the mitochondrial genome *Biochem J* 265 903-906
- Guenebaut V, Vincentelli R, Mills D, Weiss H, Leonard KR.** 1997 Three-dimensional structure of NADH-dehydrogenase from *Neurospora crassa* by electron microscopy and conical tilt reconstruction *J Mol Biol* 265 409-418
- Hatefi Y and Stempel KE.** 1967 Resolution of complex I (DPNH-coenzyme Q reductase) of the mitochondrial electron transfer system *Biochem Biophys Res Commun* 26 301-308
- Hatefi Y.** 1985 The mitochondrial electron transport and oxidative phosphorylation system *Ann Rev Biochem* 54 1015-1069
- Hyslop SJ, Duncan AMV, Pitkanen S, Robinson BH.** 1996 Assignment of the PSST subunit gene of human mitochondrial complex I to chromosome 19p13 *Genomics* 37 375-380
- Kim JWL, Lee Y, Kang HB, Choe YK, Chung TW, Chang SY, Lee KS, Choe IS.** 1997 Cloning of the human cDNA sequence encoding the NADH ubiquinone oxidoreductase MLRQ subunit *Biochem Mol Biol Int* 43 669-675
- Kyte J and Doolittle RF.** 1982 A simple method for displaying the hydropathic character of a protein *J Mol Biol* 157 105-132
- Li YY, Hengstenberg C, Maisch B.** 1995 Whole mitochondrial genome amplification reveals basal level multiple deletions in mtDNA of patients with dilated cardiomyopathy *Biochem Biophys Res Commun* 210 211-218
- Loeffen J, Smeets R, Smeitink J, Ruitenbeek W, Janssen A, Mariman E, Sengers R, Trijbels F, van den Heuvel L.** 1998 The X-chromosomal *NDUFA1* gene of complex I in mitochondrial encephalomyopathies tissue expression and mutation detection *J Inher Metab Dis* 21 210-215
- Ohnishi T, Ragan CI, Hatefi Y.** 1985 EPR studies of iron-sulphur clusters in isolated subunits and subfractions of NADH-ubiquinone oxidoreductase *J Biol Chem* 260 2782-2788
- Pata I, Tensing K, Metspalu A.** 1997 A human cDNA encoding the homologue of NADH ubiquinone oxidoreductase subunit B13 *Biochim Biophys Acta* 1350 115-118
- Pilkington SJ and Walker JE.** 1989 Mitochondrial NADH-ubiquinone reductase complementary DNA sequences of import precursors of the bovine and human 24 kDa subunit *Biochemistry* 28 3257-3264
- Pitkanen S, Raha S, Robinson BH.** 1996a Diagnosis of complex I deficiency in patients with lactic acidemia using skin fibroblast cultures *Biochem Mol Med* 59 134-137
- Pitkanen S, Merante F, McLeod DR, Applegarth D, Tong T, Robinson BH.** 1996b Familial cardiomyopathy with cataracts and lactic acidosis: a defect in complex I (NADH-dehydrogenase) of the mitochondria respiratory chain *Pediatr Res* 39 513-521
- Ploos van Amstel JK, Bergman AJIW, van Beurden EACM, Roijers JFM, Peelen T, van den Berg IET, Poll-The BT, Kvittingen EA, Berger R.** 1996 Hereditary tyrosinemia type I novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene, variability of the genotype phenotype relationship

- Hum Genet* 97 51-59
- Procaccio V, Depetris D, Soularue P, Mattei MG, Lunardi J, Issartel JP.** 1997. cDNA sequence and chromosomal localisation of the *NDUFS8* human gene coding for the 23 kDa subunit of the mitochondrial complex I. *Biochim Biophys Acta* 1351 37-41
- Robinson BH.** 1993. Lacticacidemia. *Biochim Biophys Acta* 1182 231-244
- Sambrook J, Fritsch EF, Maniatis E (eds).** 1989. *Molecular cloning: a laboratory manual, 2<sup>nd</sup> edn* Cold Spring Harbor. Cold Spring Harbor Laboratory Press.
- Skehel JM, Fearnley IM, Walker JE.** 1998. NADH:ubiquinone oxidoreductase from bovine heart mitochondria: sequence of a novel 17.2-kDa subunit. *FEBS Lett* 438:301-305.
- Spencer SR, Taylor JB, Cowell IG, Xia CL, Pemble SE, Ketterer B.** 1992. The human mitochondrial NADH:ubiquinone oxidoreductase 51-kDa subunit maps adjacent to the glutathione S-transferase P1-1 gene on chromosome 11q13. *Genomics* 14:1116-1118
- Ton C, Hwang DM, Dempsey AA, Liew CC.** 1997. Identification and primary structure of five NADH ubiquinone oxidoreductase subunits. *Biochem Biophys Res Commun* 241 589-594
- van den Heuvel L, Ruitenbeek W, Smeets R, Gelman-Kohan Z, Elpeleg O, Loeffen J, Trijbels F, Mariman E, de Bruijn D, Smeitink J.** 1998. Demonstration of a new pathogenic mutation in human complex I deficiency: a 5-bp duplication in the nuclear gene encoding the 18-kD (AQDQ) subunit. *Am J Hum Genet* 62 262-268.
- Walker JE.** 1992. The NADH ubiquinone oxidoreductase (complex I) of respiratory chains. *Q Rev Biophys* 25 253-324
- Walker JE.** 1995. Determination of the structures of respiratory enzyme complexes from mammalian mitochondria. *Biochim Biophys Acta* 1271 221-227.
- Walker JE, Skehel JM, Buchanan SK.** 1995. Structural analysis of NADH ubiquinone oxidoreductase from bovine heart mitochondria. *Method Enzymol* 260:14-34.
- Wallace DC.** 1992. Diseases of the mitochondrial DNA. *Annu Rev Biochem* 61 1175-1212
- White JA, McAlpine PJ, Antonarakis S, Cann H, Eppig JT, Frazer K, Frezal J, Lancet D, Nahmias J, Pearson P, Peters J, Scott A, Scott H, Spurr N, Talbot C Jr, Povey S.** 1997. Guidelines for human gene nomenclature (1997) HUGO Nomenclature Committee *Genomics* 45 468-471
- Zhuchenko O, Wehnert M, Bailey J, Sheng Sun Z, Chi Lee C.** 1996. Isolation, mapping and genomic structure of an X-Linked gene for a subunit of human mitochondrial complex I. *Genomics* 37:281-288



### **THE HUMAN NADH:UBIQUINONE OXIDOREDUCTASE NDUF5 (15 kDa) SUBUNIT: cDNA CLONING, CHROMOSOMAL LOCALISATION, TISSUE DISTRIBUTION AND THE ABSENCE OF MUTATIONS IN ISOLATED COMPLEX I DEFICIENT PATIENTS**

*Journal of Inherited Metabolic Disease* 1999 22:19-28

#### **Abstract.**

We have cloned the cDNA of the NDUF5 subunit (15 kDa) of the human mitochondrial respiratory chain complex NADH ubiquinone oxidoreductase (complex I). The open reading frame consists of 321 base-pairs, coding for 106 amino acids, with a calculated molecular weight ( $M_r$ ) of 12.5 kDa. There is an 81.0% identity with the bovine equivalent on cDNA level and 75.5% identity on amino acid basis. PCR analysis of rodent-human somatic cell hybrids revealed that the human *NDUF5* gene maps to chromosome 1. The *NDUF5* mRNA is expressed ubiquitously in human tissues, with a relative higher expression in human heart, skeletal muscle, liver, kidney and foetal heart. A mutation detection study of twenty isolated enzymatic complex I deficient patients revealed no mutations, or polymorphisms.

## Introduction.

NADH ubiquinone oxidoreductase (complex I), the first multisubunit inner membrane protein complex of the mitochondrial electron transport chain, transfers two electrons with a high energy transfer potential from NADH to ubiquinone. Simultaneously to this electron transfer, protons are translocated from the mitochondrial matrix, across the inner mitochondrial membrane, to the intermembrane space. Subsequently, protons are returned to the mitochondrial matrix by complex V, resulting in the generation of ATP, the main carrier of free energy in pro- and eukaryotic cells.

Complex I consists of about 42 polypeptides, seven of which are encoded by the mitochondrial genome, nuclear genes encode the remainder (Walker 1992, Walker et al 1992, Robinson 1993, Walker 1995). Defects in mitochondrial encoded subunits of complex I have been described (Zeviani and Taroni 1994). Up till now, only one mutation in a nuclear encoded subunit of complex I has been reported in literature (this thesis, van den Heuvel et al 1998).

Bovine complex I contains a number of prosthetic groups which are involved in the transfer of electrons, namely flavin mononucleotide (FMN), and at least six and possibly eight iron-sulphur clusters (binuclear and tetranuclear) (Runswick et al 1991, Yamaguchi and Hatefi 1993, Albracht et al 1996). The bovine 15 kDa subunit is thought to be part of the complex I iron-sulphur protein fraction (IP) which is built up of ~8 subunits (75, 49, 30, 18, 15, and 13 kDa subunit, TYKY and the B13 subunit) (Hatefi 1985, Ragan and Hatefi 1986, Masui et al 1991). It is hypothesised that subunits of the IP fraction play a part in the redox reactions catalysed by the iron-sulphur clusters.

In the past decade numerous patients with a deficient enzymatic activity of complex I have been reported. Clinical phenotypes associated with complex I deficiency are fatal neonatal lactic acidosis, myopathy with exercise intolerance and lactic acidosis, MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes), MERRF (myoclonus epilepsy, and ragged red fibres), encephalomyopathy of childhood and adult life, Leigh syndrome, and Alpers disease (Morris et al 1995). In patients clinically suspected to suffer from a deficiency of complex I (or one of the other complexes of the respiratory chain), definitive confirmation is usually obtained by biochemical analysis of a skeletal muscle biopsy.

Molecular characterisation of nuclear encoded complex I subunits is of utmost importance, since in many isolated complex I deficient patients, no mutations in mitochondrial encoded genes related to complex I have been found. Mutational analysis studies could reveal nuclear defects, which hopefully will increase the understanding of the function of complex I and its individual subunits. Genetic diagnostics in chorion villi as well as in patient skin fibroblasts (preferred over biochemical diagnostics) then become available.

The cDNA of the Flavoprotein group (FP) subunits (NDUFV1, NDUFV2 and NDUFV3) was sequenced by Buddiger et al in 1997, which revealed no pathogenic mutations in a group of 20 complex I deficient patients. We focus in our patient group on the second important subgroup, namely the Iron-Sulphur protein fraction (IP). The human cDNA sequence is known for the NDUF54 (18 kDa) subunit of complex I (van den Heuvel et al 1998), and a mutation

detection study revealed the first mutation in a nuclear encoded subunit in our group of isolated complex I deficient patients. This finding suggests other nuclear encoded complex I subunits should be taken into consideration as well.

In order to extend our current knowledge regarding the molecular defects of complex I deficiency, cloning of the human nuclear encoded complex I subunits is warranted. In the present communication we report the cDNA sequence, and chromosomal localisation of the human NDUF55 subunit, we describe the tissue distribution of the messenger RNA transcript, and data of a mutation detection study performed in twenty patients with an isolated deficiency of NADH ubiquinone oxidoreductase determined in cultured skin fibroblasts.

## **Patients, material and methods.**

*Patient group* Twenty patients (four females, sixteen males, sex ratio 1:4) with an isolated decreased activity of complex I (measured in all cases in cultured skin fibroblasts), were selected for mutation detection on RNA level in the NDUF55 subunit. Age of clinical onset varied from a few days after birth, to the age of ten months. Thirteen patients deceased before the age of two years. Clinical phenotypes varied from severe neonatal metabolic acidosis, followed by cardiorespiratory distress proceeding to death, to hypotonia and psychomotor retardation at the age of eight months. Four families were known with consanguinity. Strikingly, four patients (20%) had a cardiomyopathy (Loeffen et al 1998). Neither mitochondrial DNA deletions, nor common mtDNA pathogenic mutations (A3243G (MELAS), T3271C (MELAS), A4317G (MELAS), A8344G (MERRF), T8993G/C (NARP/Leigh syndrome)) were present in this patient group. In previous studies we searched for mutations in the cDNA of the nuclear encoded NDUF41 (MWFE) and NDUF54 (18 kDa) subunits in our patient group (Loeffen et al 1998, van den Heuvel et al 1998).

*Tissue culture and enzyme measurements* Deep-frozen skin fibroblasts of patients were cultured in M-199 medium, after addition of foetal calf serum, glutamine and antibiotics (penicillin and streptomycin) according to established procedures. Cells were harvested after reaching confluency. The enzymatic activity of complex I was measured according to procedures described by Bentlage et al in 1996. Reference values used ranged from 0.11-0.28 mU/mU cytochrome *c* oxidase. Patient values ranged from 0.026 to 0.080 mU/mU cytochrome *c* oxidase.

*Cloning of the human NDUF55 subunit* Wild type mRNA was obtained from a human heart poly A<sup>+</sup> RNA pool (Clontech, USA). The pool consisted of seven normal Caucasian males and females, age range 20-78. First-strand cDNA was obtained by reverse transcription of mRNA by Superscript II Rnase H reverse transcriptase (Life Technologies, The Netherlands), during 1 hour at 42°C in a total volume of 40 µl according to established procedures (Ploos van Amstel et al 1996).

Human ESTs (retrieved from Genbank, USA, accession no. W72456, W76515), resembling the bovine 15 kDa cDNA were used for PCR primer design. Amplification was carried out in a total volume of 25 µl, containing 1 µl of cDNA, 2.5 µl 10× PCR buffer, 50 ng forward

(5'-GCCAGAGAAGAGTCAAGGGC-3'), and reverse primer (5'-CGTAAACAACCTTCCAGTGG-3'), 0.25 mM dNTPs, 1.5 mM MgCl<sub>2</sub>, and 0.5 unit of Taq Polymerase (Life Technologies, The Netherlands). Amplification parameters were as follows: 35 cycles, 1 min denaturation at 94°C, 1 min. annealing at 55°C, and 1 min primer extension at 72°C. The cycles were preceded by an initial denaturation step of 1 min at 94°C, and were followed by a final extension of 10 min. at 72°C.

*Mutation detection studies in complex I deficient patients* Patient total RNA was isolated from cultured skin fibroblasts using RNeasy<sup>™</sup> B (Biosolve, The Netherlands) (Chomczynski and Sacchi 1987). RNA was reverse transcribed to first strand cDNA as described before. PCR conditions were similar as those described for cloning of the human NDUF5 subunit. Patient PCR product was purified from a 1% agarose gel, using the QIAquick GEL purification kit according to procedures as described by the manufacturer (Qiagen, The Netherlands). Both strands were screened for the presence of mutations by direct sequencing (ABI Prism, model 377 version 2.1.2), using the ABI Prism<sup>™</sup> Taq DyeDeoxy terminator cycle sequencing ready reaction kit (Perkin Elmer, The Netherlands).

#### *Chromosomal localisation of the human NDUF5 gene*

To determine the chromosomal localisation of the *NDUF5* gene, we performed a PCR on genomic DNA extracted from human-rodent somatic hybrid cells, containing defined human chromosomes (NIGMS mapping panel 2, Coriell Cell Repository, USA). The forward and reverse oligonucleotide used were respectively 5'-CACATTGGCAAGGGGAG-3' and 5'-ATTTTACACACTTTGACAAGGAGG-3'. PCR product was visualised using a 4% agarose gel.

*Tissue distribution of the NDUF5 mRNA* For specific tissue and developmental stage expression of the *NDUF5* mRNA, a Human RNA Master Blot<sup>™</sup> (Clontech, USA) was used. The quantity of RNA spotted for each tissue onto the master blot was normalised using eight different housekeeping gene transcripts as probes (ribosomal protein S9, ubiquitin, 23 kDa highly basic protein, hypoxanthine guanine phosphoribosyl transferase, tubulin,  $\beta$ -actin, phospholipase, and glyceraldehyde triphosphate dehydrogenase). Blots were hybridised with a  $\alpha$ -<sup>32</sup>P-dCTP labelled cDNA probe, using Standard Hybridisation Solution (Sambrook et al 1989), washed twice with 2 $\times$  SSC, 1% SDS at 65°C, and were subjected to autoradiography.

*Calculated hydropathy of the human NDUF5 subunit.* We calculated the average hydropathy of the NDUF5 subunit, using a method based on the procedure described by Kyte and Doolittle (1982). Computer software was used from the National Centre for Computer Aided Chemistry and Bioinformatics (CAOS/CAMM, Nijmegen, The Netherlands).



## **Results.**

### *cDNA cloning of the human NDUF55 subunit*

We performed a blast search (Genbank, USA) with the bovine cDNA sequence of the 15 kDa subunit of complex I, which revealed several human ESTs, which we used for designing a forward and reverse oligonucleotide to clone the human homologue cDNA obtained after reverse transcription of mRNA from a Human Heart Poly A<sup>+</sup> RNA pool was used as template for PCR. We produced a 428 base-pair product (Genbank accession no AF020352), which constituted the full-length open reading frame of the human *NDUF55* transcript. Fifteen expressed sequence tags (ESTs) retrieved from Genbank, which were not available at time of sequencing, were used to complete the 5'UTR and 3'UTR (Fig. 5 1a). The human *NDUF55* subunit was named according to guidelines for Human Gene Nomenclature (White et al 1997).

### *cDNA sequence and protein characteristics of the human NDUF55 subunit*

The human as well as the bovine (15 kDa) *NDUF55* open reading frame consist of 321 nucleotides coding for 106 amino acids. Comparison of the open reading frame of the bovine 15 kDa cDNA with the human equivalent revealed an 81.0% homology on nucleotide sequence level (Fig. 5 1a). Concerning the amino acid sequence, there was a 75.5% homology (Fig. 5 1b). When amino acids with similar characteristics are considered equal, there is a 95.3% homology. The molecular weight calculated from the amino acid sequence ( $M_r$ ) is 12.5 kDa, the hypothetical isoelectric point (pI) is 9.8. The prediction of the hydropathy showed an overall hydrophilic protein. The 3'UTR contains an AATAAA polyadenylation signal at nucleotide position 419 to 424. A poly A site is positioned 16 base-pairs downstream of the poly adenylation signal.

A blast search with the human *NDUF55* cDNA-, and amino acid sequence revealed the bovine sequence mentioned above and several human ESTs. A blast search in mouse and residual EST databases (Genbank), revealed several significant matches for mouse (82% identity in 152 base pair overlap, Genbank accession no AA529094) and rat (83% identity in 119 base pair overlap, Genbank accession no H35001).

### *Mutation detection in isolated complex I deficient patients*

Mutation detection on cDNA level was performed by PCR using primers specific for the human *NDUF55* subunit, followed by automatic DNA sequence analyses of the entire open reading frame of both DNA strands. No mutations or polymorphisms were observed in the *NDUF55* transcript.

### *Chromosomal localisation of the human NDUF55 gene*

To determine the chromosomal localisation of the *NDUF55* gene, we amplified an intronless 130 base pair part of the 3' region by PCR with genomic DNA extracted from human-rodent somatic hybrid cells as template. The obtained PCR product was specific for man, and equal in size compared to the cDNA fragment. A signal was observed in the lane containing chromosome 1 (results not shown).

	-50	-40	-30	-20	-10
Human	agtgggagcg	gcggccagag	aagagtcaag	ggcacgagca	tcgggtagcc
	1	11	21	31	41
Human	ATGCCTTTCT	TGGACATCCA	GAAAAGGTTT	GGCCTTAACA	TAGATCGATG
	: : : : : :	: : : : : :	: : : : : :	: : : : : :	: : : : : :
Bovine	ATGCCTTTCT	TTGATGTGCA	GAAAAGGCTG	GGTGTTGACC	TAGATCGCTG
	51	61	71	81	91
Human	GTTGACAATC	CAGAGTGGTG	AACAGCCCTA	CAAGATGGCT	GGTCGATGCC
	: : : : : :	: : : : : :	: : : : : :	: : : : : :	: : : : : :
Bovine	GATGACAATC	CAGAGTGTCT	AGCAGCCCTA	CAAGATCCCA	TCCCAGATGCC
	101	111	121	131	141
Human	ATGCTTTTGA	AAAAGAATGG	ATAGAATGTG	CACATGGAAT	CGGTTATACT
	: : : : : :	: : : : : :	: : : : : :	: : : : : :	: : : : : :
Bovine	ATGCTTTTGA	GAAGGAATGG	ATAGAGTGTG	CACATGGAAT	CGGCAGTATC
	151	161	171	181	191
Human	CGGGCAGAGA	AAGAGTGCAA	GATAGAATAT	GATGATTTCG	TAGAGTGTTC
	: : : : : :	: : : : : :	: : : : : :	: : : : : :	: : : : : :
Bovine	CGAGCAGAGA	AGGAGTGCAA	AATAGAATTT	GAGGATTTC	GAGAGTGCTC
	201	211	221	231	241
Human	GCTTCGGCAG	AAAACGATGA	GACGTGCAGG	TACCATCAGG	AACAGCGGGG
	: : : : : :	: : : : : :	: : : : : :	: : : : : :	: : : : : :
Bovine	GCTTCGACAG	AAAACGATGA	AACGTCTGCA	TGCCATCAGG	AGCAGCGGGG
	251	261	271	281	291
Human	ATAAGCTGAT	AAAGGAAGGA	AAGTACACCC	CTCCACCTCA	CCACATTGGC
	: : : : : :	: : : : : :	: : : : : :	: : : : : :	: : : : : :
Bovine	AAAAGCTAAT	CAAGGAAGGG	AAGTACACAC	CCCCACCTCA	CCACTCAGGC
	301	311	321	331	341
Human	AAGGGGGAGC	CTCGGCCCTG	Aacagagcag	ctgctgatgt	ctggaggctg
	: : : : : :	: : : : : :	: : : : : :	: : : : : :	: : : : : :
Bovine	CAGGAGGAAC	CTCGGTCCTG	A		
	351	361	371	381	391
Human	attttctctgt	tctctgttct	ccactggaaa	ggttggtttac	gacaaaacctc
	401	411	421	431	441
Human	cttgtcaaaag	tgtgtaaaaa	taaaggattg	ctccatccta	aaaaaaaaaa

Figure 5.1a Human and bovine cDNA sequence of the NDUFS5 subunit of complex I. Comparison of human and bovine cDNA sequence of the NDUFS5 subunit of complex I (Genbank accession numbers AF020352 and X63220, respectively) revealed 81.0% homology. Primers used to generate fragments encoding the complete open reading frame of the human *NDUFS5* cDNA by PCR, are underlined. Primers used for chromosomal localisation of the *NDUFS5* gene are double underlined. The 5'UTR, and 3'UTR of the *NDUFS5* cDNA were completed with sequences of human ESTs resembling the human *NDUFS5* open reading frame.

	1	11	21	31	41
Human	MPFLDIQKRF	GLNIDRWLTI	QSGEQPYKMA	GRCHAFEKEW	IECAHGIGYT
	: : : : : :	: : : : : :	: : : : : :	: : : : : :	: : : : : :
Bovine	MPFFDVQKRL	GVDLDRWMTI	QSAEQPHKIP	SRCHAFEKEW	IECAHGIGSI
	51	61	71	81	91
Human	RAEKECKIEY	DDFVECLLRQ	KTMRRAGTIR	KQRDKLIKEG	KYTPPPHHIG
	: : : : : :	: : : : : :	: : : : : :	: : : : : :	: : : : : :
Bovine	RAEKECKIEF	EDFRECLLRQ	KTMKRLHAIR	RQREKLIKEG	KYTPPPHHSG
	101				
Human	KGEPRP				
	: : : : : :				
Bovine	QEEPRS				

Figure 5.1b Human and bovine amino acid sequence of the NDUFS5 subunit of complex I. Comparison of human and bovine amino acid sequence of the NDUFS5 subunit of complex I revealed a 75.5% homology (: = identical amino acid, = amino acid with similar characteristics).

### *Tissue distribution of the NDUF55 subunit mRNA*

The multiple tissue dot blot was hybridised using a  $^{32}\text{P}$ -labeled *NDUF55* cDNA probe, and was subjected to autoradiography (Fig 5.2). All human tissues expressed the *NDUF55* mRNA. A signal was also seen at the 100 and 500 ng human genomic DNA dots. High intensity dots were seen in human tissues as (in descending order) heart, kidney, lung, liver, ovary, and skeletal muscle. The foetal tissues loaded on the blot all expressed the *NDUF55* mRNA, dots with high intensity are foetal heart, and foetal lung.

### **Discussion.**

Mitochondrial respiratory chain deficiency, with isolated complex I deficiency as a major contributor, occurs in approximately 1/10,000 live births (Bourgeron et al 1995). Complex I consists of seven mitochondrial encoded subunits (Chomyn et al 1985 and 1986), the remainder are nuclear encoded of which sixteen have been cloned, and reported in literature (Chow et al 1991, Spencer et al 1992, Hattori et al 1995, de Coo et al 1995, Zhuchenko et al 1996, Gu et al 1996, Hyslop et al 1996, Pata et al 1997, de Coo et al 1997, Procaccio et al 1997, Kim et al 1997, Ton et al 1997, van den Heuvel et al 1998). Recently, the first mutation has been described in a nuclear encoded complex I subunit, which consisted of a five base pair duplication in the 18 kDa (AQDQ) subunit (van den Heuvel et al 1998). Hence, it seems worthwhile to analyse the nuclear encoded complex I genes for mutations in complex I deficient patients.

The human *NDUF55* subunit contains four cysteine residues, but not in a motif that provides ligands for binuclear and tetranuclear iron-sulphur centres. There is therefore no indication that the *NDUF55* subunit is an iron-sulphur protein. The same conclusion was drawn for the bovine 15 kDa subunit (Walker et al 1992). Alternatively, a ubiquinone binding protein can be isolated from bovine complex I with a molecular weight of 15 kDa. It is suggested, based on molecular weight resemblance, that this ubiquinone binding protein is the *NDUF55* subunit (Suzuki and Ozawa 1986). In the IP fraction however there are two proteins with a molecular weight of 15 kDa, namely the *NDUF55*, and the *NDUFA5* (B13) subunit (Walker 1992). So whether the *NDUF55* subunit plays a direct role in the transfer of electrons or in the binding of ubiquinone remains to be elucidated.

The bovine 15 kDa subunit consists of 106 amino acids, which are not post translationally modified (Walker 1992). The knowledge of the three dimensional structure and function of complex I in general, and from the *NDUF55* subunit in particular remains very limited. The calculated hydropathy curve of the human *NDUF55* subunit expresses an overall hydrophilic protein, strongly resembling the curve published by Walker et al (1992) for the bovine equivalent. This suggests that the *NDUF55* subunit is part of the extrinsic membrane domain of complex I. This is in agreement with the *NDUF55* subunit being part of the 1 $\alpha$  fraction, which is thought to represent the external membrane part of complex I (Finel et al 1992).

Because antibodies for Western Blotting were not available for the *NDUF55* subunit, we studied the tissue and developmental expression of the mRNA using a multiple tissue RNA master blot. In our experience (Sperl et al 1990, Bentlage et al 1996), measurement of

complex I activity for diagnostics in only one tissue (e.g. heart, liver, muscle, fibroblasts) is not always conclusive. Some patients express enzyme defects only in muscle, others in fibroblasts. In 1996 Pitkanen et al published patients with a complex I deficiency in fibroblasts and heart tissue, but not in skeletal muscle (Pitkanen et al 1996). With  $^{32}\text{P}$ -labeled *NDUF55* cDNA as a probe, we studied the expression of the mRNA in a diversity of human tissues, different human developmental stages, and some lower organisms (yeast and *E. coli*). The probe was expressed in all human tissues present on the blot. Dots with relative high expression were human heart, kidney, skeletal muscle, liver, lung, ovary, and foetal heart, all tissues with high metabolic activities, which are often clinically affected in complex I deficient patients. The frequent involvement of basal ganglia seen in complex I deficient patients, is in agreement with the observed relative high expression of the *NDUF55* mRNA transcript in the putamen (as compared to whole brain). Also, the human genomic DNA dots display a hybridisation signal. This may be caused by the presence of pseudogenes, or homology of the *NDUF55* cDNA sequence with repetitive nucleotide sequences in the human genome. RNA samples are probably devoid of large quantities of genomic DNA contamination.

Our centre has wide experience with measurements of respiratory chain enzyme activities in different tissues, but especially difficulties with interpreting the measured values in chorion villi and amniocytes remain, making prenatal diagnosis rather complicated. It would facilitate diagnostic procedures, and genetic counselling when molecular defects on genomic DNA level in complex I deficient patients could be established. We are especially interested in the chromosomal localisation of the complex I subunits, considering the strong male preponderance present in our patient group. In a previous study we sequenced therefore, the only known X-linked complex I subunit, namely the *NDUFA1*. This revealed neither mutations nor polymorphisms (Loefen et al 1998). The *NDUF55* subunit has been mapped on chromosome 1.


We have chosen for RT-PCR followed by direct sequencing as mutation detection method, because the possibility of missing mutations using this method is significant lower as with Single Strand Conformation Polymorphism (SSCP). We found no mutations in the *NDUF55* cDNA. We therefore hypothesise that mutations in the open reading frame of the *NDUF55* subunit are not a frequent cause of complex I deficiency. We remain searching for mutations in other nuclear encoded subunits of NADH ubiquinone oxidoreductase in our patient group.

### **Acknowledgements.**

We especially want to thank Antoon Janssen, Frans van den Brandt, Jeanette Elsink, and Ronnie de Abreu for technical assistance. This study was financially supported by the "Stichting Voor Kinderen Die Wel Willen Maar Niet Kunnen" to LvdH and JS.

	1	2	3	4	5	6	7	8
a	whole brain	amygdala	caudate nucleus	cerebellum	cerebral cortex	frontal lobe	hippocampus	medulla oblongata
b	occipital lobe	putamen	substantia nigra	temporal lobe	thalamus	subthal. nucleus	spinal cord	
c	heart	aorta	skeletal muscle	colon	bladder	uterus	prostate	stomach
d	testis	ovary	pancreas	pituitary gland	adrenal gland	thyroid gland	salivary gland	mammary gland
e	kidney	liver	small intestine	spleen	thymus	peripheral leukocyte	lymph node	bone marrow
f	appendix	lung	trachea	placenta				
g	foetal brain	foetal heart	foetal kidney	foetal liver	foetal spleen	foetal thymus	foetal lung	
h	yeast RNA	yeast tRNA	<i>E. coli</i> rRNA	<i>E. coli</i> DNA	poly r(A)	human C <sub>α</sub> 1 DNA	human DNA	human DNA
	100 ng	100 ng	100 ng	100 ng	100 ng	100 ng	100 ng	500 ng

**Fig. 5.2a Multiple tissue Master blot.** The type and position of poly(A<sup>+</sup>) RNAs and controls dotted on the positively charged nylon membrane.



**Fig. 5.2b mRNA tissue distribution of the NDUF55 subunit.** The multiple tissue dot blot (Clontech, USA) was hybridised using a <sup>32</sup>P-labeled NDUF55 cDNA probe, and was subjected to autoradiography. The probe was ubiquitously expressed, especially in tissues with high-energy demand.

## Reference List.

- Albracht PJ, Mariette A, Jong de Ph.** 1996 Bovine heart NADH ubiquinone oxidoreductase is a monomer with 8 Fe-S clusters and 2 FMN groups. *Biochim Biophys Acta* 1318:92-106
- Bentlage H, Wendel U, Schagger H, ter Laak H, Janssen A, Trijbels F.** 1996 Lethal infantile mitochondrial disease with isolated complex I deficiency in fibroblasts with combined complex I and IV deficiencies in muscle. *Neurology* 47 243-248.
- Bourgeron T, Rustin P, Chretien D, Birch-Machin M, Bourgeois M, Viegas-Perquignot E, Munnich A, Rötig A.** 1995. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. *Nat Genet* 11:144-149
- Buddiger P, Ruitenbeek W, Scholte HR, van Oost BA, Smeets HJM, de Coo R.** 1997 Molecular genetic analysis of complex I genes in patients with a deficiency of complex I of the respiratory chain. *Am J Hum Genet* supplement to volume 61:A3051997 (Abstract)
- Chomczynski P and Sacchi N.** 1987 Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 162:156-159.
- Chomyn A, Mariottini P, Cleeter MWJ, Ragan CI, Matsuno-Yagi A, Hatefi Y, Doolittle RF, Attardi G** 1985 Six unidentified reading frames of human mitochondrial DNA encode components of the respiratory-chain NADH dehydrogenase. *Nature* 314:592-597.
- Chomyn A, Cleeter MWJ, Ragan CI, Riley M, Doolittle RF, Attardi G.** 1986 URF6, Last unidentified reading frame of human mtDNA, codes for an NADH dehydrogenase subunit. *Science* 234 614-618
- Chow W, Ragan CI, Robinson BH.** 1991 Determination of the cDNA sequence for the human mitochondrial 75-kDa Fe-S protein of NADH-coenzyme Q reductase. *Eur J Biochem* 201:547-550.
- de Coo R, Buddiger P, Smeets HJM, Geurts van Kessel A, Morgan-Hughes J, Olde Weghuis D, Overhauser J, van Oost BA.** 1995. Molecular cloning and characterisation of the active human mitochondrial NADH:ubiquinone oxidoreductase 24-kDa gene (*NDUFV2*) and its pseudogene. *Genomics* 26 461-466
- de Coo R, Buddiger P, Smeets HJM, van Oost BA.** 1997 Molecular cloning and characterisation of the human mitochondrial NADH oxidoreductase 10-kDa gene (*NDUFV3*). *Genomics* 45 434-437.
- Finel M, Skehel JM, Albracht PJ, Fearnley IM, Walker JE.** 1992. Resolution of NADH ubiquinone oxidoreductase from bovine heart mitochondria into two subcomplexes, one of which contains the redox centres of the enzyme. *Biochemistry* 31 11425-11434.
- Gu ZG, Lin X, Wells DE.** 1996. The human B22 subunit of the NADH ubiquinone oxidoreductase maps to the region of chromosome 8 involved in Branchio-Oto-Renal syndrome. *Genomics* 35:6-10
- Hatefi Y.** 1985. The mitochondrial electron transport and oxidative phosphorylation system. *Ann Rev Biochem* 54:1015-1069.
- Hattori N, Suzuki H, Wang Y, Minoshima S, Shimizu N, Yoshino H, Kurashima R, Tanaka M, Ozawa T, Mizuno Y.** 1995 Structural organisation and chromosomal localisation of the human nuclear gene (*NDUFV2*) for the 24-kDa iron-sulphur subunit of complex I in mitochondrial respiratory chain. *Biochem Biophys Res Commun* 216:771-777.
- Hyslop SJ, Duncan AMV, Pitkänen S, Robinson BH.** 1996. Assignment of the PSST subunit gene of human mitochondrial complex I to chromosome 19p13. *Genomics* 37:375-380
- Kim JW, Lee Y, Kang HB, Kim JW, Lee Y, Kang HB, Choe YK, Chung TW, Chang SY, Lee KS, Chung TW, Chang SY, Lee KS, Choe IS.** 1997. Cloning of the human cDNA sequence encoding the NADH:ubiquinone oxidoreductase MLRQ subunit. *Biochem Mol Biol Int* 43:669-675.
- Kyte J and Doolittle RF.** 1982 A simple method for displaying the hydropathic character of a protein. *J Mol Biol* 157 105-132.
- Loeffen J, Smeets R, Smeitink J, Ruitenbeek W, Janssen A, Mariman E, Sengers R, Trijbels F, van den Heuvel L.** 1998 The X-chromosomal *NDUFA1* gene of complex I in mitochondrial encephalomyopathies tissue expression and mutation detection. *J Inherit Metab Dis* 21 210-215
- Masui R, Wakabayashi S, Matsubara H, Hatefi Y.** 1991 The amino acid sequences of two 13 kDa polypeptides and partial amino acid sequence of 30 kDa polypeptide of complex I from bovine heart mitochondria possible location of iron-sulphur clusters. *J Biochem (Tokyo)* 109 534-543
- Morris AAMM, Jackson MJ, Bindof LA, Turnbull**

- DM. 1995. The investigation of mitochondrial respiratory chain disease. *J Royal Soc Med* 88:217-222.
- Pata I, Tensing K, Metspalu AA 1997 Human cDNA encoding the homologue of NADH:ubiquinone oxidoreductase subunit B13. *Biochim Biophys Acta* 1350:115-118.
- Pitkänen S, Merante F, McLeod DR, Applegarth D, Tong T, Robinson BH. 1996 Familial cardiomyopathy with cataracts and lactic acidosis: a defect in complex I (NADH-dehydrogenase) of the mitochondria respiratory chain. *Pediatr Res* 39 513-521.
- Ploos van Amstel JK, Bergman AJIW, van Beurden EACM, Roijers JFM, Peelen T, van den Berg IET, Poll-The BT, Kvittingen EA, Berger R. 1996 Hereditary tyrosinemia type I novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene: variability of the genotype-phenotype relationship. *Hum Gen* 97 51-59.
- Procaccio V, Depetris D, Soularue P, Mattei MG, Lunardi J, Issartel JP. 1997. cDNA sequence and chromosomal localisation of the *NDUF58* human gene coding for the 23 kDa subunit of the mitochondrial complex I. *Biochim Biophys Acta* 1351:37-41.
- Ragan CI and Hatefi Y. 1986. Isolation of the iron-sulphur containing polypeptides of NADH:ubiquinone oxidoreductase. *Methods Enzymol* 126 360-369.
- Robinson BH. 1993 Lacticacidemia. *Biochim Biophys Acta* 1182:231-244.
- Runswick MJ, Fearnley IM, Skehel JM, Walker JE. 1991. Presence of an acyl carrier protein in NADH:ubiquinone oxidoreductase from bovine heart mitochondria. *FEBS Lett* 286:121-124.
- Sambrook J, Maniatis T, Fritsch EF (eds). 1989 *Molecular cloning: a laboratory manual*.
- Spencer SR, Taylor JB, Cowell IG, Xia CL, Pemble SE, Ketterer B. 1992 The human mitochondrial NADH ubiquinone oxidoreductase 51-kDa subunit maps adjacent to the glutathione S-transferase P1-1 gene on chromosome 11q13. *Genomics* 14 1116-1118.
- Sperl W, Ruitenbeek W, Trijbels JM, Korenke GC, Sengers RC. 1990 Heterogeneous tissue expression of enzyme defects in mitochondrial myopathies. *J Inheret Metab Dis* 13:359-362.
- Suzuki H and Ozawa T. 1986 An ubiquinone-binding protein in mitochondrial NADH-ubiquinone reductase (Complex I). *Biochem Biophys Res Commun* 138 1237-1242.
- Ton C, Hwang DM, Dempsey AA, Liew CC. 1997 Identification and primary structure of five NADH:ubiquinone oxidoreductase subunits. *Biochem Biophys Res Commun* 241 589-594.
- van den Heuvel L, Ruitenbeek W, Smeets R, Gelman-Kohan Z, Elpeleg O, Loeffen J, Trijbels F, Mariman E, de Bruijn D, Smeitink J. 1998 Demonstration of a new pathogenic mutation in human complex I deficiency: a 5-bp duplication in the nuclear gene encoding the 18-kD (AQDQ) subunit. *Am J Hum Genet* 62 262-268.
- Walker JE. 1992. The NADH:ubiquinone oxidoreductase (complex I) of respiratory chains. *Q Rev Biophys* 25 253-324.
- Walker JE, Arizmendi JM, Dupuis A, Fearnley IM, Finel M, Medd SM, Pilkington SJ, Runswick MJ, Skehel JM. 1992 Sequences of 20 subunits of NADH:Ubiquinone oxidoreductase from bovine heart mitochondria. *J Mol Biol* 226:1051-1072.
- Walker JE. 1995. Determination of the structures of respiratory enzyme complexes from mammalian mitochondria. *Biochim Biophys Acta* 1271:221-227.
- White JA, McAlpine PJ, Antonarakis S, Cann H, Eppig JT, Frazer K, Frezal J, Lancet D, Nahmias J, Pearson P, Peters J, Scott A, Scott H, Spurr N, Talbot C Jr, Povey S. 1997 Guidelines for human gene nomenclature (1997) HUGO Nomenclature Committee. *Genomics* 45 468-471.
- Yamaguchi M and Hatefi Y. 1993 Mitochondrial NADH-ubiquinone oxidoreductase (complex I): proximity of the subunits of the flavoprotein and the iron-sulfur protein subcomplexes. *Biochemistry* 32:1935-1939.
- Zeviani M and Taroni F. 1994. Mitochondrial diseases. *Baill Clin Neurol* 3:315-334.
- Zhuchenko O, Wehnert M, Bailey J, Sheng Sun Z, Chi Lee C. 1996. Isolation, mapping and genomic structure of an X-Linked gene for a subunit of human mitochondrial complex I. *Genomics* 37:281-288.





### **cDNA SEQUENCE AND CHROMOSOMAL LOCALISATION OF THE REMAINING THREE HUMAN NUCLEAR ENCODED IRON SULPHUR PROTEIN (IP) SUBUNITS OF COMPLEX I: THE HUMAN IP FRACTION IS COMPLETED**

*Biochemical and Biophysical Research Communications* 1998 247:751-758

#### **Abstract.**

NADH ubiquinone oxidoreductase (complex I) of the mitochondrial respiratory chain can be fragmented in a Flavoprotein (FP), Iron-Sulphur protein (IP) and Hydrophobic protein (HP) subfraction. The IP subfraction is hypothesised to be significant, since it contains important prosthetic groups highly conserved among species. We cloned the cDNA of three remaining human NADH ubiquinone oxidoreductase subunits of this IP fraction: the NDUF52 (49 kDa), NDUF53 (30 kDa), and NDUF56 (13 kDa) subunit. All presented cDNAs include the complete open reading frame (ORF), which consists of 1392, 795, and 375 base pairs, coding for 463, 264, and 124 amino acids, respectively. The latter show 96%, 90%, and 83% homology with the corresponding bovine translation products. The 3' untranslated regions (UTR) are complete in all three cDNAs.

Polymerase chain reaction performed with DNA isolated from somatic human-rodent cell hybrids containing defined human chromosomes as template, gave a human specific signal which mapped the *NDUF52* and *NDUF53* gene to chromosome 1 and 11, respectively. In case of the NDUF56 subunit a pseudogene may be present since signals were seen in the lanes containing chromosome 5 and 6.

The NDUF52 contains a highly conserved protein kinase C phosphorylation site and the NDUF53 subunit contains a highly conserved casein kinase II phosphorylation site which make them strong candidates for future mutation detection studies in enzymatic complex I deficient patients.

## Introduction.

The energy generation of human cells is highly dependent on an adequate functioning of the respiratory chain, which is situated in the mitochondrial inner membrane. Four multiple-subunit enzyme complexes, ubiquinone, and cytochrome *c* together constitute the respiratory chain, of which NADH:ubiquinone oxidoreductase (complex I) is the largest complex. Each complex, with the exception of succinate dehydrogenase (complex II), has one or more subunits encoded by the mitochondrial DNA (mtDNA). Bovine complex I consists of about 42 subunits (Walker et al 1995, Walker 1995), seven of which are encoded by mtDNA (Chomyn et al 1985 and 1986). The remainder are nuclear encoded, and must be transported from the cytosol to the inner mitochondrial membrane. At present, almost all cDNA sequences coding for bovine NADH:ubiquinone oxidoreductase subunits have been cloned (Walker 1992, Walker et al 1992, Arizmendi et al 1992). Complex I of the fungus *Neurospora crassa* is also almost completely elucidated, and consists of approximately 35 subunits (Weiss et al 1991), purple bacteria as *Escherichia coli* contain a less complex variant with only 14 subunits (Weidner et al 1993).

Complex I accepts electrons from the electron carrier NADH and transfers them to ubiquinone. This electron transport is accompanied by the translocation of protons across the inner mitochondrial membrane to the intermembrane space. Complex V ( $F_1F_0$ -ATP synthase) uses this proton gradient to generate ATP. Several prosthetic groups facilitate this transport of electrons. At present, these are hypothesised to be one, or two Flavin Mononucleotides (FMN) molecules, and six to eight binuclear and tetranuclear Iron-sulphur clusters (Runswick et al 1991, Yamaguchi and Hatefi 1993, Albracht et al 1996). For the majority of the complex I subunits, position within the complex as well as the function are unknown.

Bovine complex I can be fragmented with chaotropic agents, like perchlorate. This reveals a soluble component, consisting of the Flavoprotein fraction (FP) and the Iron-Sulphur protein fraction (IP), and a precipitate known as the hydrophobic protein fraction (HP) (Galante and Hatefi 1978 and 1979). The FP fraction contains three subunits, namely the NDUFV1 (51 kDa), NDUFV2 (24 kDa) and NDUFV3 (10 kDa) subunit, of which the cDNA and nDNA have been cloned in man (Spencer et al 1992, Ali et al 1993, Hattori et al 1995, de Coo et al 1995, de Coo et al 1997, Schuelke et al 1998). The IP fraction consists of the NDUFS1 (75 kDa), NDUFS2 (49 kDa), NDUFS3 (30 kDa), NDUFS4 (18 kDa), NDUFS5 (15 kDa), NDUFS6 (13 kDa), NDUFS8 (TYKY), and the NDUFAS (B13) subunit, of which NDUFS1, NDUFS4, NDUFS5, and NDUFAS have been cloned (Chow et al 1991, Pata et al 1997, Procaccio et al 1997, van den Heuvel et al 1998, Loeffen et al 1999). The HP fraction, which contains globular water-soluble as well as hydrophobic subunits, consists of about 24 subunits. The (partial) cDNA structure of ten of the 24 subunits (NDUFA1, NDUFA2, NDUFA4, NDUFA6, NDUFB3, NDUFB5, NDUFB6, NDUFB9, NDUFS7, NDUFCL1) has been reported in literature (Zhuchenko et al 1996, Gu et al 1996, Hyslop et al 1996, Ton et al 1997, Kim et al 1997, Smeitink et al 1998).

The clinical phenotype expressed in complex I deficient patients is very heterogeneous, ranging from neonatal respiratory distress with extreme lactic acidosis at birth, to hypotonia with psychomotor retardation in the first years of life. Since several studies mention a possible

male preponderance in respiratory chain deficiencies (Orstavik et al 1993, Zhuchenko et al 1996, Loeffen et al 1998) suggesting an X-linked inheritance pattern, chromosomal mapping of complex I subunits is warranted.

Most proteins incorporated in complex I are encoded by the nuclear DNA. In the past, much research has been performed on mtDNA in relation to complex I disease (Shoffner et al 1990, Goto et al 1990, Holt et al 1990). Recently, Buddiger published 20 complex I deficient patients who had no mutations in mitochondrial encoded subunits of complex I as well as in the three subunits situated in the FP subfraction (Buddiger et al 1997). We focus on the second important subgroup of complex I, the IP subfraction, which contains subunits with important prosthetic groups highly conserved among species. Therefore, elucidation of the cDNA structures and determination of the chromosomal localisation of all IP subunits is a rational prerequisite for future mutation detection studies in enzymatic complex I deficient patients.

In the present communication we report the cloning and chromosomal mapping of the remaining three so far not characterised nuclear encoded IP subunits (NDUFS2, NDUFS3, and NDUFS6) of human complex I.

## **Material and methods.**

*Material.* The following materials were obtained from commercial sources. Molecular size markers, Taq DNA polymerase, superscript II RNase H<sup>-</sup> reverse transcriptase, and custom made oligonucleotide primers were purchased from Life Technologies Inc., the dRhodamine Dye Terminator Sequencing kit from Perkin Elmer, gel purification systems from Qiagen, poly A<sup>+</sup> RNA pool from Clontech, NIGMS mapping panel 2 from Coriell Cell Repository, and RNazol from Biosolve BV. All other chemicals used were of analytical grade or as previously reported (van den Heuvel et al 1998).

*Software.* Sequence alignments were performed with Sequence Navigator of Perkin Elmer. Homology searches were performed with the Basic Local Alignment Search Tool (BLAST) on the Internet at the server of the National Centre for Biotechnology Information (NCBI) (Altschul et al 1990). Molecular characteristics of cDNAs, and amino acid sequences were calculated using the OMIGA molecular biological software package (Hitachi). The average hydropathy was calculated using a window of 17 amino acids, according to the method described by Kyte and Doolittle (1982). We searched for amino acid motifs with use of PROSITE ([http://www.embl-ebi.ac.uk/searches/prosite\\_input.html](http://www.embl-ebi.ac.uk/searches/prosite_input.html)). Mitochondrial import sequences were determined with the program MitoProtII (Claros and Vincens 1996).

*cDNA cloning of the human NDUFS2, NDUFS3 and NDUFS6 subunit.* Bovine cDNA sequences of the NDUFS2, NDUFS3 and NDUFS6 subunits (Genbank accession no. X14338,

M58469, X63221) were used for a BLAST search in the Genbank (USA) human Expressed Sequence Tag (EST) database. This revealed for each subunit several human ESTs, which were used in designing forward and reverse subunit specific oligonucleotides (Table 6.1). These oligonucleotides were applied in polymerase chain reaction

mRNA obtained from a human heart poly A<sup>+</sup> RNA pool (twelve normal Caucasian males and females, age range 20-78), was reverse transcribed to cDNA. This process was carried out in 1 hour at 42°C, and catalysed by superscript II RNase H reverse transcriptase. The reaction mix (total volume 40 µl) contained RNA, oligo(dT) and random hexanucleotide primers (Ploos van Amstel et al 1996).

PCR amplification was carried out in a reaction volume of 25 µl, containing 1 µl template, 2.5 µl 10× PCR buffer, 50 ng forward and reverse primer, 0.25 mM MgCl<sub>2</sub>, 0.25 mM dNTPs, and 0.5 unit of Taq DNA Polymerase. Polymerase chain reaction parameters are listed in Table 6.1. PCR product was purified using the QIAquick PCR purification kit. Wild type reaction products were cycle sequenced (ABI Prism, model 377 version 2.1.2) according to procedures as described by the manufacturer.

*Chromosomal localisation of the NDUF52, NDUF53 and NDUF56 gene* To determine the chromosomal localisation of the *NDUF52*, *NDUF53*, and *NDUF56* gene, we designed a forward oligonucleotide primer in the 3' terminal part of the open reading frame, and a reverse oligonucleotide primer in the 3' untranslated region (UTR) of each subunit. With these oligonucleotides (reaction conditions are listed in Table 6.1), PCR was performed with as template genomic DNA extracted from human-rodent somatic cell hybrids, containing defined human chromosomes (NIGMS mapping panel 2). PCR product was analysed using a 4% agarose gel. The obtained cDNA fragments were sequenced using the ABI Prism, model 377 version 2.1.2 in combination with the ABI<sup>™</sup> Taq Dye-deoxy terminator cycle ready reaction kit.

## Results and discussion.

Isolated complex I disease is a major contributor to respiratory chain deficiencies, which are estimated to occur in 1/10,000 live births (Bourgeron et al 1995). Molecular biological studies performed on mitochondrial encoded complex I subunits revealed in some patients a mutation in one of the mitochondrial tRNAs (Tiranti et al 1995, Houshmand et al 1996) or in one of the mitochondrial genes coding for complex I subunits (Oostra et al 1995, de Vries et al 1996). Yet many patients remain genotypic undiagnosed. Recently we described a patient with a 5 bp duplication present in the *NDUF54* gene (18 kDa, van den Heuvel et al 1998). Both findings stress the need to characterise all nuclear encoded complex I subunits, especially those with a putative important function like the various IP subunits.

Subunits		Forward oligonucleotides	Reverse oligonucleotides	
<b>NDUFS2</b> <b>(49 kDa)</b>	NDUFS2F1	TAAGATGGCGGCGCTGAGG	NDUFS2R1	AGCTTCTCAGTGCCTCGGTG
	NDUFS2F2	GATTTCAGCCCAGCAGAGGTG	NDUFS2R2	GACACTCGCTCGTAGAACTC
	NDUFS2F3	ATGGTGCGGAAGTGTGATCCTCA	NDUFS2R3	ATCATAGGGCTGGGTCTTCC
	NDUFS2F4	CCCTTTCTTCTGGCTGTTTG	NDUFS2R4	GGTAGCCCTCAGTATACAAC
	NDUFS2F5	GACAATTGACATGGGGTG	NDUFS2R5	CACAGAAGAAGCTGATAGGC
	NDUFS2F6	AAGCGAGCAGAGATGAAGAC		
	NDUFS2F7	CAGATGTCGTTGCCATCATAGG		
<b>NDUFS3</b> <b>(30 kDa)</b>	NDUFS3F1	CATCTGAGTAACATGGCGG	NDUFS3R1	CTGTGCATTGGTGTGATCCC
	NDUFS3F2	GTTAGAGGTCTGTATCCATCC	NDUFS3R2	GGATCCTTCTTAGATCAGGG
	NDUFS3F3	AGCCAACTGGTATGAAAGGG	NDUFS3R3	CGCTGTCTAGGATCCACATGC
	NDUFS3F4	GAGAGTCTCAAGCTTGAAGCC		
<b>NDUFS6</b> <b>(13 kDa)</b>	NDUFS6F1	AAATGGCGGCGGCGATGACC	NDUFS6R1	CATAAACCTGGCCAGTGTGCG
	NDUFS6F2	AAGACTACAGGAGAATTCGG	NDUFS6R2	GCACAGAACCAGCGAGCTTCAC
	NDUFS6F3	CCAGTTACAGACAGCACCACCAC		
PCR conditions				

NDUFS2F1 + NDUFS2R5	94°C/1 min.; 94°C/1 min., 58 °C/1 min., 72 °C/1 min. (34 cycles); 72 °C/10 min.
NDUFS3F1 + NDUFS3R3	94°C/1 min.; 94°C/1 min., 57 °C/1 min., 72 °C/1 min. (34 cycles); 72 °C/10 min.
NDUFS6F1 + NDUFS6R2	94°C/1 min.; 94°C/1 min., 57 °C/1 min., 72 °C/1 min. (34 cycles); 72 °C/10 min.
NDUFS2F7 + NDUFS2R5	94°C/1 min.; 94°C/1 min., 60 °C/1 min., 72 °C/5 min. (34 cycles); 72 °C/10 min.
NDUFS3F4 + NDUFS3R3	94°C/1 min.; 94°C/1 min., 60 °C/1 min., 72 °C/5 min. (34 cycles); 72 °C/10 min.
NDUFS6F3 + NDUFS6R2	94°C/1 min.; 94°C/1 min., 60 °C/1 min., 72 °C/5 min. (34 cycles); 72 °C/10 min.

**Table 6.1** Oligonucleotides listed here were used for cloning of the *NDUFS2*, *NDUFS3* and *NDUFS6* cDNAs (NDUFS2F1 + NDUFS2R5, NDUFS3F1 + NDUFS3R3, NDUFS6F1 + NDUFS6R2), for direct DNA sequencing reactions (NDUFS2F1, NDUFS2F2, NDUFS2F3, NDUFS2F4, NDUFS2F5, NDUFS2F6, NDUFS2R1, NDUFS2R2, NDUFS2R3, NDUFS2R4, NDUFS2R5, NDUFS3F1, NDUFS3F2, NDUFS3F3, NDUFS3R1, NDUFS3R2, NDUFS3R3, NDUFS6F1, NDUFS6F2, NDUFS6R1, NDUFS6R2), and in PCR with DNA isolated from human-rodent somatic cell hybrids as template (NDUFS2F7 + NDUFS2R5, NDUFS3F4 + NDUFS3R3, NDUFS6F3 + NDUFS6R2) F = Forward primer; R = Reverse primer. The lower part of Table 6.1 contains the PCR conditions for each oligonucleotide pair used. Listed are respectively: preceding denaturation step; denaturation, annealing, extension; final extension step.

The human *NDUFS2*, *NDUFS3*, and *NDUFS6* cDNAs were amplified with PCR using the following oligonucleotide combinations: NDUFS2F1 + NDUFS2R5, NDUFS3F1 + NDUFS3R3, and NDUFS6F1 + NDUFS6R2 (Table 6.1 and Fig. 6.1). The oligonucleotides listed in Table 6.1 with exception of NDUFS2F7 and NDUFS3F4 were used in direct DNA sequencing reactions using the Dyedeoxy terminators. All three cDNAs contain the complete ORF (1392, 795, and 375 base pairs), coding for 463, 264, and 124 amino acids, respectively

(Table 6.2). Molecular weights calculated from amino acid sequences are respectively 52.5, 30.2, and 13.7 kDa. The 3' untranslated regions (UTR) were completed using several human ESTs retrieved from Genbank (poly A signals (AATAAA) and poly A tails are present). Comparison of amino acid sequences of bovine and human subunit equivalents revealed a similarity of 96% (NDUFS2), 90% (NDUFS3), and 83% (NDUFS6). High similarity between human and bovine housekeeping proteins is not uncommon (similarity of published nuclear encoded complex I proteins ranges from 79% to 95%). It can be hypothesised that high similarity percentages reflect strong conservation among species and therefore possible functional importance. cDNA similarity is highest in the region coding for the mature protein. We calculated the theoretical existence of a mitochondrial targeting sequence (MTS) with MitoProtII software, and compared the results with the experimental bovine data published by Walker et al 1992 (the bovine N-terminal part of the mature protein was sequenced by Edman degradation prior to the complete ORF). In man, possible cleavage sites are present between amino acid positions 20 and 21 in the NDUFS2, 36 and 37 in the NDUFS3 and 28 and 29 in the NDUFS6 subunit. In case of the bovine NDUFS2 subunit, the N-terminus of the mitochondrial targeting sequence is incomplete. For the NDUFS3 and NDUFS6 the cleavage site between MTS and mature protein was similar as predicted for man. The untranslated regions, as well as MTS coding regions clear reflect lower similarity percentages between man and *Bos taurus*. The NDUFS3 and NDUFS6 MTS are 55.6% and 60.7% similar, while the mature proteins are 94.7% and 89.6% similar.

PCR performed with DNA extracted from somatic human-rodent cell hybrids containing defined human chromosomes as template gave signals specific for man in all three subunits. In case of the NDUFS2 subunit this fragment contained two (partial) exons and an intron, for the NDUFS3 and NDUFS6 the fragment was equal to the fragment when cDNA was used as template. The NDUFS2 fragment was present in the lane containing chromosome 1, the NDUFS3 in the lane containing chromosome 11, and unfortunately the NDUFS6 fragment was present in both the lanes containing chromosome 5, as chromosome 6. One of the bands is likely caused by a pseudogene. We could not differentiate which of the two was the pseudogene, since both bands contained the same nucleotide sequence in this short fragment.

Subunit	Genbank accession no.	cDNA size	ORF size	No. a.a.	M <sub>r</sub> kDa	Signal peptide	H B	H N	H E	No. cysteine			
										H	B	N	E
NDUFS2	AF050640	1565	1392	463	52.5	1-20	96%	62%	38%	7	6	6	4
NDUFS3	AF067139	887	795	264	30.2	1-36	90%	46%	30%	2	3	3	0
NDUFS6	AF044959	515	375	124	13.7	1-28	83%	-	-	6	4	-	-

**Table 6.2** Characteristics of the NDUFS2, NDUFS3, and NDUFS6 subunit.  
ORF = open reading frame, a.a. = amino acids; M<sub>r</sub> = calculated molecular weight; H = *H. sapiens*;  
B = *B. taurus*; N = *N. crassa*; E = *E. coli*.

NDUFS2F1 75  
agtaagATGCGCGCGCTGAGGGCTTTGTGCGGCTTCCGGGGCGTCGCGGCCAGGTGCTGCGGCCTGGGGCTGGA  
M A A L R A L C G F R G V A A Q V L R P G A G  
NDUFS2F2 150  
GTCCGATTGCCGATTCAAGCCCAAGCAGAGGTGTTCCGGCAGTGGCAGCCAGATGTGGAATGGGCACAGCAGTTTGGG  
V R L P I Q P S R G V R Q W Q P D V E W A Q Q F G  
225  
GGAGCTGTTATGTACCAAGCAAAGAAACAGCCCACTGGAAGCCTCCACCTTGGAAATGATGTGGACCCCTCCAAAG  
G A V M Y P S K E T A H W K P P P W N D V D P P K  
300  
GACACAATGTGAAGAACATTACCTTGAACCTTTGGGCCCCAACCCAGCAGCGCATGGTGTCTCGGACTAGTG  
D T I V K N I T L N F G P Q H P A A H G V L R L V  
NDUFS2F3 375 NDUFS2R1  
ATTGGAATTGAGTGGGGAGATGCTGCGGAAAGTGTGATCCTCACATCGGGCTCCTCGACCGAGGCCTGAGAGCTC  
M E L S G E M V R K C D P H I G L L H R G T E K L  
450  
ATTGAATACAAGACCTATCTTCAGGCCCTTCCATACCTTGGACCGCTAGACATATGTGTCCATGATGTGTGAACGAA  
I E Y K T Y L Q A L P Y F D R L D Y V S M M C N E  
525  
CAGGCCCTATTCTCTAGCTGTGGAGAAGTTGCTAAACATCCGGCCCTCCTCCTCGGGCACAGTGGATCCGAGTGCTG  
Q A Y S L A V E K L L N I R P P P R A Q W I R V L  
600  
TTTGGAGAAATCACACGTTTGTGTAACACATCATGGCTGTGACCACACATGCCCTGGACCTTGGGGCCATGACC  
F G E I T R L L N H I M A V T T H A L D L G A M T  
NDUFS2F4 675 NDUFS2R2  
CCTTTCTCTGCGCTGTTGAAGAAAGGAGAAGATGTTTGAAGTTCTACGAGCGAGTGTCTGGAGCCCCGAATGCAT  
P F F W L F E E R E K M F E F Y E R V S G A R M H  
750  
GCTGCTTATATCCGGCCAGGAGGAGTGCCACGAGACCTACCCCTTGGGCTTATGGATGACATTTATCAGTTTCT  
A A Y I R P G G V H Q D L P L G L M D D I Y Q F S  
825  
AAGAACTTCTCTCTTCGGCTTGATGAGTTGGAGGAGTTGCTGACCAACAATAGGATCTGGCGAAATCGGCAAT  
K N F S L R L D E L E E L L T N N R I W R N R T I  
NDUFS2F5 900  
GACATTTGGGCTTTGAACAGCAGAAGAAGCACTTAACATATGGTTTATGTTGAGTGTATGCTTCGGGGCTCAGGCATC  
D I G V V T A E E A L N Y G F S G V M L R G S G I  
NDUFS2R3 975  
CAGTGGGACCTCGGGAAGCCAGCCCTATGATGTTTACGACCAGGTTGAGTTTGTATGTTCTGTGTGGTTCTCGA  
Q W D L R K T Q P Y D V Y D Q V E F D V P V G S R  
1050  
GGGACTGCTATGATAGGTACCTGTGCGCGGTGGAGGAGATGCCAGTCCCTGAGAATTATCGCACAGTGTCTA  
G D C Y D R Y L C R V E E M R Q S L R I I A Q C L  
NDUFS2F6 1125  
AACAAGATGCCCTCCTGGGAGATCAAGGTTGATGATGCCAAAGTGTCTCCACCTAAGCGAGCAGAGATGAAGACT  
N K M P P G E I K V D D A K V S P P K R A E M K T  
NDUFS2R4 1200  
TCCATGGAGTCACTGATTCATCACTTTAAAGTTGTATACTGAGGGCTACCAAGTCTCCTCCAGGAGCCACATATACT  
S M E S L I H H F K L Y T E G Y Q V P P G A T Y T  
1275  
GCCATTGAGGCTCCCAAGGGAGAGTTTGGGGTGTACCTGGTGTCTGATGGCAGCAGCCGCCCTTATCGATGCAAG  
A I E A P K G E F G V Y L V S D G S S R P Y R C K  
1350  
ATCAAGGCTCCTGGTTTGGCCCATCTGGCTGGTTTGGACAAGATGTCTAAGGACACATGTTGGCAGATGTCCTT  
I K A P G F A H L A G L D K M S K G H M L A D V V  
NDUFS2F7 1425  
GCCATCATAGGTACCCAAGATATTGTATTGGAGAAGTAGATCGGTGAagcaggggagcagcggtttgatccccct  
A I I G T Q D I V F G E V D R \*  
NDUFS2R5 1500  
gcctatcagctctctctgtgagagcctgttctcactggaaattggcctcatgttcatgtacacttggctgtcagg  
poly a signal 1575  
ctttctgtgcatgtactaaaaaaggagaattataataaattagccgtcttgcgccccctaggcctaaaaaaaaa  
poly a site

Fig 6.1 (continued) cDNA and amino acid sequence of the NDUFS2 subunit

NDUFS3F1 75  
catctgagtaac**ATGGCGCGCGCGCGGTAGCCAGGCTGTGGTGGCGCGGGATCTTGGGGGCTCGCGCGCTGACC**  
M A A A A V A R L W W R G I L G A S A L T  
150  
AGGGGGACTGGGCGACCCCTCCGTTCTGTGTGCTGCCGTGAGGCGGGAGAGCGCCGGGGCGGACACGCGCCCACT  
R G T G R P S V L L L P V R R E S A G A D T R P T  
225  
GTCAGACCACGGAATGATGTGGCCACAAAGCAGCTCTCAGCTTTTGGAGAGTATGTGGCTGAAATCTTGCCCAAG  
V R P R N D V A H K Q L S A F G E Y V A E I L P K  
NDUFS3F2 300  
TATGTCCAACAAGTTCAAGGTGCTCTGCTTCAATGAGTTAGAGGCTCTGATCCATCCTGATGGCGTCATCCCACTG  
Y V Q Q V Q V S C F N E L E V C I H P D G V I P V  
NDUFS3R1 375  
CTGACTTTCTCAGGGATCACACCAATGCACAGTTCAAATCTCTGGTGTGACTTGCAGCAGTGGACGCTCCCAACT  
L T F L R D H T N A Q F K S L V D L T A V D V P T  
450  
CGGCAAAACCGTTTGTAGATTGTCTACAACCTGTTGTCTCTGCGCTTCAAATCACGGATCCGTGTGAAGACCTAC  
R Q N R F E I V Y N L L S L R F N S R I R V K T Y  
NDUFS3F3 525  
ACAGATGAGCTGACGCCCCATTGAGTGTGCTGTCTGTGTTCAAAGGCAGCCAAC**TGGTATGAAAGGGAGATCTGG**  
T D E L T P I E S A V S V F K A A N W Y E R E I V  
NDUFS3R2 600  
GACATGTTTGGAGTCTTCTTTGCTAACCACCCCTGATCTAAGAAGGATCCTGACAGATTATGGCTTCGAGGGACAT  
D M F G V F F A N H P D L R R I L T D Y G F E G H  
675  
CCTTTCGGAAAGACTTCTCTATCTGGCTATGTTGAGTTACGTTATGATGATGAAGTGAAGCGGGTGGTGGCA  
P F R K D F P L S G Y V E L R Y D D E V K R V V A  
750  
GAGCCGGTGGAGTTGGCCCAAGAGTTCGCCAAATTTGACCTGAACAGCCCCCTGGGAGGCTTTCCAGTCTATCGC  
E P V E L A Q E F R K F D L N S P W E A F P V Y R  
NDUFS3F4 825  
CAACCCCCGGAGCTCTCAAGCTTGAAGCCGGAGACAAGAAGCCCTGATGCCAAGTAGctccagggaacgcattgtg  
Q P P E S L K L E A G D K K P D A K \*  
NDUFS3R3 poly a signal poly a site 900  
gatcctagacagcgcccttatctatgattgagtgctccgtgtaataataattcctacttagacttaaaaaaaaaaaaa

Fig 6.1 (continued) cDNA and amino acid sequence of the NDUFS3 subunit

NDUFS6F1 75  
cgggcgcaaa**ATGGCGCGCGCGATGACCTTCTGCCGGCTGTGAACCGGTGTGGCGAGGCGCGCGGAGCCTGCC**  
M A A A M T F C R L L N R C G E A A R S L P  
NDUFS6R1 150  
CTGGGCGCCAGGTGTTTCGGGGTGGCGGTCTCGCCGACCGGGGAGAAGGTACGGCACACTGGCCAGGTTTATGAT  
L G A R C F G V R V S P T G E K V T H T G Q V Y D  
NDUFS6F2 225  
GATAAAGACTACAGGAGAAATTCGGTTTGTAGGTCGTCAGAAAAGAGGTGAATGAAAACCTTGGCATTGATTTGATA  
D K D Y R R I R F V G R Q K E V N E N F A I D L I  
300  
GCAGAGCAGCCCGTGAGCGAGGTGGAGACTCGGGTGATAGCGTGCGATGGCGGCGGGGAGCTCTTGGCCACCCCA  
A E Q P V S E V E T R V I A C D G G G G A L G H P  
NDUFS6F3 375  
AAAGTGTATATAAACTTGGACAAAGAAACAAAAACCGGCACATGCGGTTACTGTGGGCTCCAGTTACAGACAGC  
K V Y I N L D K E T K T G T C G Y C G L Q F R Q H  
450  
CACCACTAGagcgtgtggcacgccccgggtccccgcagcatcctgtgagcatttccgcggggaagctgagcacgtg  
H H \*  
NDUFS6R2 poly a signal poly a site 525  
aagctcgtgtgttctgtgcgaaggtattcctggtgctgaataaagggtgttgctgtcatggctgaaaaaaaaaa

Fig 6.1 (continued) cDNA and amino acid sequence of the NDUFS6 subunit. Primers used for PCR and sequence reactions are shaded. Primers are also listed in Table 6.1. Positions of poly a signal and site have been indicated for each subunit. 5'UTR and 3'UTR were completed (when possible) with use of ESTs retrieved from Genbank, USA



Consensus amino acid patterns				
	Name	No.	A.A. position	Also present in:
NDUFS2 (49 kDa)	N-glycosylation site (NITL; NFSL; NRTI)	3	79 250 270	<i>B. taurus</i> <i>B. taurus</i> <i>B. taurus</i>
	Casein kinase II phosphorylation site (TAEE; SRGD; TSME; TAIE)	4	279 322 373 398	<i>B. taurus</i> , <i>N. crassa</i> <i>B. taurus</i> <i>B. taurus</i> <i>B. taurus</i> , <i>N. crassa</i>
	N-myristoylation site (GVVTAE; GATYTA)	2	276 394	<i>B. taurus</i> , <i>N. crassa</i> <i>B. taurus</i>
	Protein kinase C phosphorylation site (TEK; SLR; SLR; RGD)	4	120 252 340 416	<i>B. taurus</i> , <i>N. crassa</i> <i>B. taurus</i> <i>B. taurus</i> , <i>N. crassa</i> , <i>E. coli</i> <i>B. taurus</i> , <i>N. crassa</i>
	Tyrosine phosphorylation site (KLIEYKTY)	1	122	<i>B. taurus</i> , <i>N. crassa</i>
	cAMP phosphorylation site (RRES)	1	37	<i>B. taurus</i>
	Casein kinase II phosphorylation site (SLVD; TAVD; TYTD; TPIE; SPWE)	5	110 115 145 151 237	<i>B. taurus</i> <i>B. taurus</i> , <i>N. crassa</i> , <i>E. coli</i> <i>B. taurus</i> , <i>N. crassa</i> <i>B. taurus</i> <i>B. taurus</i> , <i>N. crassa</i>
	N-myristoylation site (GILGAS, GVFFAN)	2	13 175	- <i>B. taurus</i> , <i>N. crassa</i>
	Protein kinase C phosphorylation site (TGR; TVR; SLR; SLK)	4	24 46 134 251	<i>N. crassa</i> <i>B. taurus</i> <i>B. taurus</i> , <i>N. crassa</i> <i>B. taurus</i> , <i>N. crassa</i>
	Casein kinase II phosphorylation site (SEVE)	1	78	-
NDUFS3 (30 kDa)				
NDUFS6 (13 kDa)	N-myristoylation site (GGGGAL; GGALGH)	2	89 91	<i>B. taurus</i> <i>B. taurus</i>

**Table 6.3** Amino acid consensus patterns were searched with PROSITE. A consensus amino acid sequence pattern was titled conserved when in multiple alignment a similar consensus pattern was present. All data listed in this Table concern the human subunits.

In order to speculate about functional properties of the human NDUFS2, NDUFS3 and NDUFS6 subunit we searched for conserved consensus amino acid patterns among eu- and prokaryotes. For this search we included besides man the subunit equivalents of *B. taurus*, *N. crassa* and *E. coli*, since complex I has been almost completely characterised in these organisms. The Swissprot accession numbers for *B. taurus*, *N. crassa* and *E. coli* are: NDUFS2: P17694, P22142, P33600; NDUFS3: G163416, P23710, P33599; NDUFS6: P23934. NDUFS2 and NDUFS3 are represented in man, *B. taurus*, *N. crassa*, and *E. coli*, while the NDUFS6 is not present in *N. crassa*, and *E. coli*. Since *E. coli* contains a complex I consisting of only 14 subunits, a large amount of the nuclear encoded subunits of human complex I have no representative in bacteria. The *N. crassa* complex I contains about 35

subunits, and yet there is no representative present of the NDUF56 Subunits with no obvious equivalent present in lower life forms could have emerged late in evolution when these species had already diverged or they diverged fast so that detection of homology is impossible. In multiple alignment we considered besides identical patterns, a pattern with different amino acids coding for the same consensus motif conserved. The pattern search performed with PROSITE revealed for each subunit several consensus amino acid motif patterns (Table 6.3), but only two were conserved among all four species. The NDUF52 subunit contains a conserved SLR protein kinase C phosphorylation site at the C terminus of the protein. The NDUF53 transcript contains a conserved casein kinase II phosphorylation site (TAVD) at amino acid position 115. This high conservation among eukaryotes and prokaryotes is suggestive for functional significance. The NDUF56 subunit has a conserved N-myristoylation site between amino acid 89 and 96. In the past suggestions were made that the NDUF52, and NDUF53 subunit could contain Fe-S clusters (Preis et al 1990, Fearnley and Walker 1992), which are commonly reflected by consensus cysteine patterns. The human NDUF52 contains seven cysteine residues, six of which are conserved in *B. taurus*, and three in *N. crassa*. The NDUF53 has two cysteine residues, both conserved in *B. taurus*, but none in *N. crassa*. The human NDUF56 transcript contains six cysteine residues, four are conserved in *B. taurus*. Considering the consensus patterns for Fe-S clusters, none of the three subunits seems to meet the criteria, but further experimental studies are warranted.

The average hydropathy was calculated using the OMIGA molecular biological software package (Hitachi). All subunits express an overall hydrophilic pattern. The NDUF52 subunit contains a hydrophobic segment of about 25 amino acids, which is long enough to form a transmembrane  $\alpha$  helix. Bovine NDUF52, NDUF53 and NDUF56 are located in the 1 $\alpha$  fraction of complex I (which is likely to be the part protruding into the mitochondrial matrix) (Finel et al 1992), which is in accordance to the overall hydrophilic pattern of the human equivalents. In addition, the NDUF52 has been localised by immuno-labelling on the peripheral arm (protruding into the mitochondrial matrix) of complex I in *N. crassa* (Guenebaut et al 1997).

Mammalian NADH ubiquinone oxidoreductase has proven to be a very large and complicated protein complex. The NDUF52 and NDUF53 subunits are highly conserved in prokaryotes and eukaryotes, since homologues are found in many species and even in chloroplast (Fearnley et al 1989, Dupuis et al 1991). Furthermore they contain highly conserved phosphorylation sites which might be involved in regulatory function. We therefore consider the NDUF52 and NDUF53 strong candidates for mutation detection studies in isolated complex I deficient patients.

## Acknowledgements.

The authors are grateful to Markus Schuelke, Sandy Budde, and Carin Buskens for stimulating discussions. The presented work was possible due to grants from the "Stichting voor kinderen die wel willen maar niet kunnen" and the "Prinses Beatrix Fonds" granted to L.P. van den H and J.S.

## Reference List.

- Albracht PJ, Mariette A, Jong de Ph. 1996. Bovine heart NADH ubiquinone oxidoreductase is a monomer with 8 Fe-S clusters and 2 FMN groups. *Biochim Biophys Acta* 1318:92-106.
- Ali ST, Duncan AMV, Schappert K, Heng HHQ, Tsui LC, Chow W, Robinson BH. 1993. Chromosomal localisation of the human gene encoding the 51-kDa subunit of mitochondrial complex I (*NDUFV1*) to 11q13. *Genomics* 18:435-439
- Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool *J Mol Biol* 215 403-410
- Arizmendi JM, Skehel JM, Runswick MJ, Fearnley IM, Walker JE. 1992. Complementary DNA sequences of two 14.5 kDa subunits of NADH ubiquinone oxidoreductase from bovine heart mitochondria Completion of the primary structure of the complex? *FEBS Lett* 313 80-84.
- Bourgeron T, Rustin P, Chretien D, Birch-Machin M, Bourgeois M, Viegas-Pequignot E, Munnich A, Rötig A. 1995. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency *Nat Genet* 11:144-149
- Buddiger P, Ruitenbeek W, Scholte HR, van Oost BA, Smeets HJM, de Coo R. 1997. Molecular genetic analysis of complex I genes in patients with a deficiency of complex I of the respiratory chain *Am J Hum Genet* supplm. to vol. 61:A305
- Chomyn A, Mariottini P, Cleeter MWJ, Ragan CI, Matsuno-Yagi A, Hatefi Y, Doolittle RF, Attardi G. 1985 Six unidentified reading frames of human mitochondrial DNA encode components of the respiratory-chain NADH dehydrogenase. *Nature* 314:592-597
- Chomyn A, Cleeter MWJ, Ragan CI, Riley M, Doolittle RF, Attardi G. 1986. URF6, last unidentified reading frame of human mtDNA, codes for an NADH dehydrogenase subunit. *Science* 234:614-618.
- Chow W, Ragan CI, Robinson BH. 1991 Determination of the cDNA sequence for the human mitochondrial 75-kDa Fe-S protein of NADH-coenzyme Q reductase. *Eur J Biochem* 201 547-550.
- Claros MG and Vincens P. 1996 Computational method to predict mitochondrially imported proteins and their targeting sequences *Eur J Biochem* 241:779-786
- de Coo R, Buddiger P, Smeets HJM, Geurts van Kessel A, Morgan-Hughes J, Olde Weghuis D, Overhauser J, van Oost BA. 1995 Molecular cloning and characterisation of the active human mitochondrial NADH ubiquinone oxidoreductase 24-kDa gene (*NDUFV2*) and its pseudogene *Genomics* 26:461-466.
- de Coo R, Buddiger P, Smeets HJM, van Oost BA. 1997. Molecular cloning and characterisation of the human mitochondrial NADH oxidoreductase 10-kDa gene (*NDUFV3*) *Genomics* 45:434-437
- de Vries D, Went LN, Bruyn GW, Ruitenbeek W, Hofstra RM, Bolhuis PA, van Oost B. 1996 Two mutations in mitochondrial NADH dehydrogenase genes in a family with Leber hereditary optic neuropathy and hereditary spastic dystonia quantification of heteroplasmy by primer extension. *Thesis, University Hospital Nijmegen, Department of Human Genetics* 72-83.
- Dupuis A, Skehel JM, Walker JE. 1991 A homologue of a nuclear-coded iron-sulphur protein subunit of bovine mitochondrial complex I is encoded in chloroplast genomes. *Biochemistry* 30 2954-2960
- Fearnley IM, Runswick MJ, Walker JE. 1989. A homologue of the nuclear coded 49 kd subunit of bovine mitochondrial NADH-ubiquinone reductase is coded in chloroplast DNA *EMBO J* 8 665-672.
- Fearnley IM and Walker JE. 1992 Conservation of sequences of subunits of mitochondrial complex I and their relationships with other proteins. *Biochim Biophys Acta* 1140:105-134
- Finel M, Skehel JM, Albracht PJ, Fearnley IM, Walker JE. 1992. Resolution of NADH:Ubiquinone oxidoreductase from bovine heart mitochondria into two subcomplexes, one of which contains the redox centres of the enzyme. *Biochemistry* 31:11425-11434
- Galante YM and Hatefi Y. 1978. Resolution of complex I and isolation of NADH dehydrogenase and an iron-sulfur protein *Method Enzymol* 53 15-21
- Galante YM and Hatefi Y. 1979 Purification and molecular and enzymic properties of mitochondrial NADH dehydrogenase *Arch Biochem Biophys* 192:559-568.
- Goto Y, Nonaka I, Horai S. 1990. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. *Nature* 348 651-653

- Gu ZG, Lin X, Wells DE. 1996 The human B22 subunit of the NADH ubiquinone oxidoreductase maps to the region of chromosome 8 involved in Branchio-Oto-Renal syndrome *Genomics* 35 6-10
- Guenebaut V, Vincentelli R, Mills D, Weiss H, Leonard KR. 1997 Three-dimensional structure of NADH-dehydrogenase from *Neurospora crassa* by electron microscopy and conical tilt reconstruction *J Mol Biol* 265 409-418
- Hattori N, Suzuki H, Wang Y, Minoshima S, Shimizu N, Yoshino H, Kurashima R, Tanaka M, Ozawa T, Mizuno Y. 1995 Structural organisation and chromosomal localisation of the human nuclear gene (*NDUFV2*) for the 24-kDa iron-sulfur subunit of complex I in mitochondrial respiratory chain *Biochem Biophys Res Commun* 216 771-777
- Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA. 1990 A new mitochondrial disease associated with mitochondrial DNA heteroplasmy *Am J Hum Genet* 46 428-433
- Houshmand M, Larsson NG, Oldfors A, Tulinius M, Holme E. 1996 Fatal mitochondrial myopathy, lactic acidosis, and complex I deficiency associated with a heteroplasmic A → G mutation at position 3251 in the mitochondrial tRNA<sup>Leu</sup>(UUR) gene *Hum Genet* 97 269-273
- Hyslop SJ, Duncan AMV, Pitkanen S, Robinson BH. 1996 Assignment of the PSST subunit gene of human mitochondrial complex I to chromosome 19p13 *Genomics* 37 375-380
- Kim JWL, Lee Y, Kang HB, Choe YK, Chung TW, Chang SY, Lee KS, Choe IS. 1997 Cloning of the human cDNA sequence encoding the NADH ubiquinone oxidoreductase MLRQ subunit *Biochem Mol Biol Int* 43 669-675
- Kyte J and Doolittle RF. 1982 A simple method for displaying the hydropathic character of a protein *J Mol Biol* 157 105-132
- Loeffen J, Smeets R, Smeitink J, Ruitenbeek W, Janssen A, Mariman E, Sengers R, Trijbels F, van den Heuvel L. 1998 The X-chromosomal *NDUFA1* gene of complex I in mitochondrial encephalomyopathies tissue expression and mutation detection *J Inheret Metab Dis* 21 210-215
- Loeffen J, Smeets R, Smeitink J, Triepels R, Sengers R, Trijbels F, van den Heuvel L. 1999 The human NADH ubiquinone oxidoreductase NDUF55 (15 kDa) subunit cDNA cloning chromosomal localisation, tissue distribution and the absence of mutations in isolated complex I-deficient patients *J Inheret Metab Dis* 22 19-28
- Oostra RJ, Van Galen MJ, Bolhuis PA, Bleeker-Wagemakers EM, Van den Bogert C. 1995 The mitochondrial DNA mutation ND6\*14,484C associated with Leber hereditary optic neuropathy, leads to deficiency of complex I of the respiratory chain *Biochem Biophys Res Commun* 215 1001-1005
- Orstavik KH, Skjorten F, Hellebostad M, Haga P, Langslet A. 1993 Possible X linked congenital mitochondrial cardiomyopathy in three families *J Med Genet* 30 269-272
- Pata I, Tensing K, Metspalu A. 1997 A human cDNA encoding the homologue of NADH ubiquinone oxidoreductase subunit B13 *Biochim Biophys Acta* 1350 115-118
- Ploos van Amstel JK, Bergman AJIW, van Beurden EACM, Roijers JFM, Peelen T, van den Berg IET, Poll-The BT, Kvittingen EA, Berger R. 1996 Hereditary tyrosinemia type I novel missence nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene variability of the genotype phenotype relationship *Hum Genet* 97 51-59
- Preis D, van der Pas JC, Nehls U, Rohlen DA, Sackmann U, Jahnke U, Weiss H. 1990 The 49 kDa subunit of NADH ubiquinone reductase (complex I) from *Neurospora crassa* mitochondria primary structure of the gene and the protein *Curr Genet* 18 59-64
- Procaccio V, Depetris D, Soularue P, Mattei MG, Lunardi J, Issartel JP. 1997 cDNA sequence and chromosomal localisation of the *NDUFS8* human gene coding for the 23 kDa subunit of the mitochondrial complex I *Biochim Biophys Acta* 1351 37-41
- Runswick MJ, Fearnley IM, Skehel JM, Walker JE. 1991 Presence of an acyl carrier protein in NADH ubiquinone oxidoreductase from bovine heart mitochondria *FEBS Lett* 286 121-124
- Schuelke M, Loeffen J, Mariman E, Smeitink J, van den Heuvel L. 1998 Cloning of the human mitochondrial 51 kDa subunit (*NDUFV1*) reveals a 100% antisense homology of its 3'UTR with the 5'UTR of the gamma interferon inducible protein (IP 30) precursor is this a link between mitochondrial myopathy and inflammation? *Biochem Biophys Res Commun* 245 599-606
- Shoffner JM, Lott MT, Lezza AM, Seibel P, Ballinger SW, Wallace DC. 1990 Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys)

- mutation *Cell* 61:931-937.
- Smeitink J, Loeffen J, Smeets HJM, Trijbels F, van den Heuvel L.** 1998. B17 subunit of human NADH ubiquinone oxidoreductase: cDNA cloning, tissue distribution and mutation detection in isolated complex I deficient patients. *Hum Genet* 103 245-250.
- Spencer SR, Taylor JB, Cowell IG, Xia CL, Pemble SE, Ketterer B.** 1992 The human mitochondrial NADH ubiquinone oxidoreductase 51-kDa subunit maps adjacent to the glutathione S-transferase P1-1 gene on chromosome 11q13 *Genomics* 14:1116-1118.
- Tiranti V, Chariot P, Carella F, Toscano A, Soliveri P, Girlanda P, Carrara F, Fratta GM, Reid FM, Mariotti C.** 1995 Maternally inherited hearing loss, ataxia and myoclonus associated with a novel point mutation in mitochondrial tRNAScr(UCN) gene. *Hum Mol Genet* 4:1421-1427
- Ton C, Hwang DM, Dempsey AA, Liew CC.** 1997 Identification and primary structure of five NADH ubiquinone oxidoreductase subunits *Biochem Biophys Res Commun* 241:589-594
- van den Heuvel L, Ruitenbeek W, Smeets R, Gelman-Kohan Z, Elpeleg O, Loeffen J, Trijbels F, Mariman E, de Bruijn D, Smeitink J.** 1998. Demonstration of a new pathogenic mutation in human complex I deficiency a 5-bp duplication in the nuclear gene encoding the 18-kD (AQDQ) subunit *Am J Hum Genet* 62:262-268.
- Walker JE.** 1992 The NADH ubiquinone oxidoreductase (complex I) of respiratory chains. *Q Rev of Biophys* 25 253-324.
- Walker JE, Arizmendi JM, Dupuis A, Fearnley IM, Finel M, Medd SM, Pilkington SJ, Runswick MJ, Skehel JM.** 1992 Sequences of 20 subunits of NADH Ubiquinone oxidoreductase from bovine heart mitochondria. *J Mol Biol* 226:1051-1072
- Walker JE.** 1995. Determination of the structures of respiratory enzyme complexes from mammalian mitochondria *Biochim Biophys Acta* 1271:221-227
- Walker JE, Skehel JM, Buchanan SK.** 1995. Structural analysis of NADH:Ubiquinone oxidoreductase from bovine heart mitochondria. *Method Enzymol* 260:14-34.
- Weidner U, Geier S, Ptock A, Friedrich T, Leif H, Weiss H.** 1993. The gene locus of the proton-translocating NADH ubiquinone oxidoreductase in *Escherichia coli* Organisation of the 14 genes and relationship between the derived proteins and subunits of mitochondrial complex I *J Mol Biol* 233:109-122.
- Weiss H, Friedrich T, Hofhaus G, Preis D.** 1991 The respiratory-chain NADH dehydrogenase (complex I) of mitochondria *Eur J Biochem* 197 563-576.
- Yamaguchi M and Hatefi Y.** 1993 Mitochondrial NADH:ubiquinone oxidoreductase (complex I) proximity of the subunits of the flavoprotein and the iron-sulfur protein subcomplexes. *Biochemistry* 32:1935-1939
- Zhuchenko O, Wehnert M, Bailey J, Sheng Sun Z, Chi Lee C.** 1996 Isolation, mapping and genomic structure of an X-Linked gene for a subunit of human mitochondrial complex I *Genomics* 37:281-288.



### **cDNA OF EIGHT NUCLEAR ENCODED SUBUNITS OF NADH:UBIQUINONE OXIDOREDUCTASE: HUMAN COMPLEX I cDNA CHARACTERISATION COMPLETED?**

*Biochemical and Biophysical Research Communications* 1998 253:415-422

#### **Abstract.**

NADH:ubiquinone oxidoreductase (complex I) is an extremely complicated multi-protein complex located in the inner mitochondrial membrane. Its main function is the transport of electrons from NADH to ubiquinone, which is accompanied by translocation of protons from the mitochondrial matrix to the intermembrane space. Human complex I appears to consist of forty-one subunits of which thirty-four are encoded by nDNA. Here we report the cDNA sequences of the hitherto uncharacterised eight nuclear encoded subunits, all located within the Hydrophobic Protein (HP) fraction of complex I. Now all currently known forty-one proteins of human NADH:ubiquinone oxidoreductase have been characterised and reported in literature, which enables more complete mutational analysis studies of isolated complex I deficient patients.

## Introduction.

NADH ubiquinone oxidoreductase of the mitochondrial respiratory chain is one of the most complicated multi-protein enzyme complexes present in the human cell (Smeitink et al 1998a). Its main function is transport of electrons by oxidation of NADH followed by reduction of ubiquinone. This process is accompanied by the translocation of protons from the mitochondrial matrix to the intermembrane space, a process of which much has to be learned. Several prosthetic groups catalyse these electron transport reactions, which are hypothesised to be at least one Flavin Mononucleotide (FMN) and six to eight Iron-Sulphur clusters (Albracht et al 1996, Ohnishi 1998). One of the most extensively studied mammals with regard to complex I is *Bos taurus*. Bovine complex I consists of about forty-one subunits, which have mainly been characterised by the research group of Walker (Walker 1992 and references therein). Seven are encoded by mitochondrial DNA (ND1-ND6, ND4L, (Chomyn et al 1985 and 1986), the remainder are nuclear encoded and imported into mitochondria.

By using chaotropic agents, complex I can be fragmented into three different fractions (Galante and Hatefi 1978 and 1979). The Flavoprotein (FP) fraction contains three subunits all of which have been characterised in man on complementary DNA (cDNA) as well as nuclear DNA (nDNA) level, namely NDUFV1 (51 kDa), NDUFV2 (24 kDa) and NDUFV3 (10 kDa) (Spencer et al 1992, Ali et al 1993, de Coo et al 1995, Hattori et al 1995, de Coo et al 1997, Schuelke et al 1998). The NADH binding site of complex I has been assigned to the NDUFV1 subunit (Chen and Guillory 1981, Deng et al 1990). In addition, the NDUFV1 contains the FMN and a tetranuclear Iron-Sulphur cluster (Pilkington et al 1991). The NDUFV2 subunit contains a binuclear Iron-Sulphur cluster (Pilkington and Walker 1989), while the NDUFV3 does not contain any known redox centres. The second fraction is the so-called Iron-Sulphur Protein (IP) fraction. The IP fraction contains at least seven subunits all of which are fully characterised on cDNA level, namely the NDUFS1 (75 kDa), NDUFS2 (49 kDa), NDUFS3 (30 kDa), NDUFS4 (18 kDa), NDUFS5 (15 kDa), NDUFS6 (13 kDa) and NDUF A5 (B13) (Chow et al 1991, Pata et al 1997, Loeffen et al 1998, van den Heuvel et al 1998, Loeffen et al 1999). Several functional properties have been postulated concerning the IP subunits. The NDUFS1 contains a tetra-nuclear and probably also a bi-nuclear Iron-Sulphur cluster (Runswick et al 1989). Furthermore, an active cAMP consensus phosphorylation site has been encountered in the NDUFS4 subunit (Papa et al 1996).

The final subgroup of complex I is the Hydrophobic Protein (HP) fraction. This is a large group containing 24 nuclear encoded subunits, of which in man the cDNA has been characterised for 16 subunits: NDUF A1 (MWFE), NDUF A2 (B8), NDUF A4 (MLRQ), NDUF A6 (B14), NDUF A8 (PGIV), NDUF A9 (39 kDa), NDUF B1 (SDAP), NDUF B1 (MNLL), NDUF B3 (B12), NDUF B5 (SGDH), NDUF B6 (B17), NDUF B7 (B18), NDUF B9 (B22), NDUFS7 (PSST), NDUFS8 (TYKY), and NDUF C1 (KFYI) (Wong et al 1990, Baens et al 1994, Zhuchenko et al 1996, Gu et al 1996, Hyslop et al 1996, Ton et al 1997, Kim et al 1997, Procaccio et al 1997, Triepels et al 1998a, Triepels et al 1998b, Smeitink et al 1998). A complete list of Genbank accession numbers for all human complex I subunits is presented in Table 7.1. The complete nDNA structure of subunits present in the HP fraction has only been elucidated for the *NDUFS8* and *NDUF A1* gene (Zhuchenko et al 1996, de Sury et al 1998).



Electron Paramagnetic Resonance (EPR) spectroscopy studies performed with bovine complex I revealed that all known Iron-Sulphur clusters are located in the extra membranous part (Finel et al 1992), which accommodates the FP and IP subfractions. Little is understood about functional properties of the individual subunits of the HP fraction, which also accounts for functional properties of this fraction as a unit. Worth mentioning are the two consensus tetranuclear Iron-Sulphur cluster patterns present in NDUFS8 (Dupuis et al 1991a), a consensus binuclear Iron-Sulfur cluster pattern in NDUFS7 (Arizmendi et al 1992) and NDUF8 (Dupuis et al 1991b) and the NDUFAB1 subunit being an acyl-carrying protein (Runswick et al 1991).

Up to now, isolated complex I deficiency has been mostly connected to mutations in mtDNA, of which several have been described (Zeviani et al 1998). Yet, in our isolated complex I deficient patient group (measured in cultured skin fibroblasts) consisting of mainly young children, common mtDNA mutations and major mtDNA rearrangements cannot be found. It is therefore likely, that many defects of respiratory chain disorders will be at nuclear level. As a prerequisite to mutational analysis studies of nuclear encoded subunits of complex I in our patient group, we cloned all remaining uncharacterised complex I subunits.

Here we report the cDNA sequences of these remaining eight uncharacterised subunits, which are all part of the HP fraction. Now all known mammalian complex I cDNAs have been cloned in man. Furthermore we examined to what extent these subunits are conserved in evolution and speculate about functional properties.

## **Material and methods.**

### *Commercial purchased materials*

Oligonucleotide primers, Taq DNA polymerase, Superscript II RNase H<sup>-</sup> reverse transcriptase were purchased from Life Technologies Inc (Breda, The Netherlands), the dRhodamine Dye Terminator Sequencing kit was purchased from Perkin Elmer (Warrington, England), PCR purification systems were purchased from Qiagen (Leusden, The Netherlands), RNazol was purchased from Biosolve BV (Watford, England), and a human heart poly A<sup>+</sup> RNA pool was purchased from Clontech (Palo Alto, USA).

### *Software*

Homology searches in protein and nucleotide databases were performed with the Basic Local Alignment Search Tool (BLAST) on the internet at the server of the National Centre for Biotechnology Information (NCBI) (Altschul et al 1990). Hydropathy was plotted using methods based on the procedures described by Kyte and Doolittle (1982). Computer software was used from the National Centre for Computer Aided Chemistry and Bioinformatics (CAOS/CAMM, Nijmegen, The Netherlands).

<i>H. sapiens</i> / <i>Bos taurus</i>	Genbank accession no.	Reference
<i>NDUFV1</i> / 51 kDa	AF053070	Schuelke et al 1998
<i>NDUFV2</i> / 24 kDa	M25484	De Co0 et al 1995, Hattori et al 1995
<i>NDUFV3</i> / 10 kDa	X99726-8	De Co0 et al 1997
<i>NDUFA1</i> / MWFE	X81900	Zhuchenko et al 1996
<i>NDUFA2</i> / B8	AF047185	Ton et al 1997
<i>NDUFA3</i> / B9	AF044955	CP
<i>NDUFA4</i> / MLRQ	U94586	Kim et al 1997
<i>NDUFA5</i> / B13	U53468	Pata et al 1997
<i>NDUFA6</i> / B14	AF047182	Ton et al 1997
<i>NDUFA7</i> / B14.5A	AF050637	CP
<i>NDUFA8</i> / PGIV	AF044953	Triepels et al 1998b
<i>NDUFA9</i> / 39 kDa	G189048	Baens et al 1994
<i>NDUFA10</i> / 42 kDa	AF087661	CP
<i>NDUFAB1</i> / SDAP	AF087660	Triepels et al 1998a
<i>NDUFB1</i> / MNLL	AF054181	-
<i>NDUFB2</i> / AGGG	AF050639	CP
<i>NDUFB3</i> / B12	AF047183	Ton et al 1997
<i>NDUFB4</i> / B15	AF044957	CP
<i>NDUFB5</i> / SGDH	AF047181	Ton et al 1997
<i>NDUFB6</i> / B17	AF035840	Smeitink et al 1998
<i>NDUFB7</i> / B18	M33374	Wong et al 1990
<i>NDUFB8</i> / ASHI	AF044958	CP
<i>NDUFB9</i> / B22	S82655	Gu et al 1996
<i>NDUFB10</i> / PDSW	AF044954	CP
<i>NDUFS1</i> / 75 kDa	X61100	Pilkington et al 1991
<i>NDUFS2</i> / 49 kDa	AF050640	Loeffen et al 1998, Procaccio et al 1998
<i>NDUFS3</i> / 30 kDa	AF067139	Loeffen et al 1998
<i>NDUFS4</i> / 18 kDa	AF020351	Van den Heuvel et al 1998
<i>NDUFS5</i> / 15 kDa	AF020352	Loeffen et al 1999
<i>NDUFS6</i> / 13 kDa	AF044959	Loeffen et al 1998
<i>NDUFS7</i> / PSST	-	Hyslop et al 1996
<i>NDUFS8</i> / TYKY	U65579	Procaccio et al 1997
<i>NDUFC1</i> / KFYI	AF047184	Ton et al 1997
<i>NDUFC2</i> / B14.5B	AF087659	CP

**Table 7.1** Complete list of all published human nuclear encoded complex I subunit cDNAs. CP = current paper. In case of the NDUFV3 and NDUFS7, an accession no. of the cDNA sequence could not be retrieved. We listed the exon accession no. of the NDUFV3 subunit instead. The NDUFB1 cDNA sequence is not published, but has been submitted to Genbank.

*cDNA cloning.*

200 ng heart poly A<sup>+</sup> RNA obtained from a pool of twelve healthy male and female Caucasians, age range 20-78 years, was reverse transcribed to cDNA by superscript II RNase H<sup>-</sup> reverse transcriptase in one hour at 42°C (Ploos van Amstel et al 1996). Bovine cDNA sequences of the remaining eight nuclear encoded subunits of complex I were BLASTed in

the NCBI human Expressed Sequence Tags (EST) database, which revealed for each subunit several hits. Oligonucleotide primers were chosen (when possible) in the 5' and 3' untranslated region (UTR) in order to clone the complete open reading frame (ORF). Primers used for cloning of the cDNAs as well as for direct sequencing reactions are listed in Table 7.2. PCR reactions were performed in a reaction volume of 50 µl, after addition of 1µl cDNA template, 5 µl 10× PCR buffer, 100 ng Forward and Reverse primer, 0.25 mM dNTPs, 1.5 mM MgCl<sub>2</sub>, and 1 U Taq DNA polymerase. PCR products were purified using the QIAquick PCR purification kit. Both strands were analysed by direct sequencing (ABI Prism, model 377 version 2.1.2), using the ABI Prism<sup>™</sup> dRhodamine terminator cycle sequencing ready reaction kit.

Subunits	Forward oligonucleotides		Reverse oligonucleotides	
NDUFA3 B9	NDUFA3F	CCC GCC GCG GAG ACA AG	NDUFA3R	GGC CGC CTCTGTCAGTGGAG
NDUFA7 B14.5A	NDUFA7F	CGCGGACGGAAGATGGC	NDUFA7R	GAGGAAATCCAAGGAGGCAAGTAG
NDUFA10 42 kDa	NDUFA10F1	TCCTGAGCTGACCGGGTAG	NDUFA10R1	TGTCTGGATAATGAATCCCC
	NDUFA10F2	GTGGCATTTCCTACTTGGGG	NDUFA10R2	GGTTGTACATCGCCTCCAGG
	NDUFA10F3	CTGGTTGTACAGCAGTCGCC	NDUFA10R3	TTTTCACTCATCTCAGGGAG
	NDUFA10F4	AGGCGGATT CAGAAGAAAGG	NDUFA10R4	CTGAACTGATGTAAGACACGG
	NDUFA10F5	CAGGATAAGTTTGAGGTGCTG	NDUFA10R5	TGGCCTTTCACAGCAGACC
NDUFB2 AGGG	NDUFB2F	GAAGCGAAGTAGGCAGGGGC	NDUFB2R	CCTTGAAATTCTCACCTGGCTCTTG
NDUFB4 B15	NDUFB4F1	GCTCCCAAGATGTCGTTCCC	NDUFB4R1	GGCAGGATTTTTCGATGAGC
	NDUFB4F2	CATGGGAGCTCTGTGTGGATTG	NDUFB4R2	GGCAGGAATACATATAGTCATCATTG
NDUFB8 ASHI	NDUFB8F1	GGCATGTGGAAGAAGGTG	NDUFB8R1	CAGGGAGCTTCGGGTAGTC
	NDUFB8F2	TAGGACCCCAAGAAGACGG	NDUFB8R2	AAGCCAGGAAACCGAAGAGC
NDUFB10 PDSW	NDUFB10F1	AGGCCCGGGACCCGACGG	NDUFB8R3	TTCTAGGAATGAGGGAGTCC
	NDUFB10F2	CAGTACCGCCGCGTGCCAG	NDUFB10R1	GTTGATAATTTCTTGGTCGACTTTG
NDUFC2 14.5B	NDUFC2F1	TCGTCGTGGTTTTCCTTGTAG	NDUFB10R2	CAGTCATACAGAGCCACACAGCAG
	NDUFC2F2	CTACCTGTATGCTGTGAGGG	NDUFC2R1	GGCCGTAATATATAGAAGCTGG
			NDUFC2R2	CAAATT CAGAAACAGCAGGTATCAG

**Table 7.2** List of oligonucleotide primers used in PCR amplification and direct DNA sequencing reactions of all eight nuclear encoded complex I cDNAs presented in this study.

**Results and discussion.**

NADH:ubiquinone oxidoreductase has been fully characterised on cDNA level in several species like *B. taurus* (Walker 1992), *Neurospora crassa* (Weiss et al 1991) and *Escherichia coli*, (Weidner et al 1993). The complexity of this multi-protein complex varies from a minimal structural unit of fourteen subunits present in many bacteria like *E. coli* to the currently known maximum of at least 41 subunits present in cow. With the additional eight cDNAs presented in this study, all known 41 subunits of human NADH:ubiquinone oxidoreductase have been characterised, which clears the way for more complete mutational analysis studies of nuclear encoded subunits in isolated complex I deficient patients. The HP fraction to which all eight presented subunits belong is a precipitate, which remains after fragmentation with chaotropic agents. At least 31 subunits belong to this fraction

including the seven, which are mitochondrially encoded. Little is known about the retained functional integrity of this precipitate. There is speculation that the HP fraction participates in the transfer of protons from the mitochondrial matrix to the intermembrane space (Belogrudov and Hatefi 1994).

Human subunit	Size ORF	No. a.a.	M <sub>r</sub> (kDa)	Leader peptide in B	H / B identity (a.a.)	Homology
NDUFA3	255	84	9.3	-	83.3%	<i>Bos taurus</i>
NDUFA7	342	113	12.6	-	88.5%	<i>Bos taurus</i> <i>Caenorhabditis elegans</i>
NDUFA10	1068	355	40.8	+	80.2%	<i>Bos taurus</i> <i>Caenorhabditis elegans</i>
NDUFB2	318	105	12.1	+	83.8%	<i>Bos taurus</i> <i>Caenorhabditis elegans</i>
NDUFB4	390	129	15.2	-	73.6%	<i>Bos taurus</i>
NDUFB8	561	186	21.8	+	84.9%	<i>Gallus gallus</i> <i>Bos taurus</i>
NDUFB10	519	172	20.8	-	82.4%	<i>Bos taurus</i> <i>Caenorhabditis elegans</i>
NDUFC2	360	119	14.2	-	73.9%	<i>Bos taurus</i>

**Table 7.3** Molecular characteristics of the presented eight human complex I subunits. ORF = open reading frame, M<sub>r</sub> = calculated molecular weight, a.a. = amino acids, H = *Homo sapiens*, B = *Bos taurus*. Homology between man and other species was investigated with use of BLAST search at the server of NCBI.

PCR amplification with subunit specific oligonucleotide primers revealed the complete Open Reading Frame (ORF) of all eight remaining subunits: *NDUFA3* (B9) 255 bp, *NDUFA7* (B14.5A) 342 bp, *NDUFA10* (42 kDa) 1068 bp, *NDUFB2* (AGGG) 318 bp, *NDUFB4* (B15) 390 bp, *NDUFB8* (ASHI) 561 bp, *NDUFB10* (PDSW) 519 bp and *NDUFC2* (B14.5B) 360 bp (Fig. 7.1). Molecular characteristics of these subunits are listed in Table 7.3. Several of the eight subunit amino acid chains are different in length in man compared to *B. taurus*. The first three amino acids of the bovine *NDUFB2* (AGGG) subunit are not present in man, in case of the *NDUFB10* (PDSW) subunit, man misses six amino acids on the N-terminal side whereas there are an extra two at the C-terminal side, the *NDUFA10* (42 kDa) of man is twelve amino acids longer (situated at the N-terminal side) and finally, bovine *NDUFC2* (B14.5B) starts with two methionine residues, whereas man contains only one. The identity on amino acid level between man and *B. taurus* ranges between 73% and 89%. These identity percentages are slightly less than seen in nuclear encoded subunits located in the minimal structural unit as e.g. present in *E. coli*, where identity percentages between man and *Bos taurus* vary from 90% to 97%. Yet, for many subunits of NADH:ubiquinone oxidoreductase the interspecies conservation is extremely high, which underlines the functional importance of this complex. Average hydropathy calculation using a range of 17 amino acids revealed an overall hydrophilic pattern for five subunits (*NDUFA7*, *NDUFA10*, *NDUFB2*, *NDUFB4* and *NDUFB10*). The other three subunits contain one or more continuous hydrophobic parts of at least twenty amino acids. The presence of hydrophilic proteins in the insoluble hydrophobic fraction of complex I has been reported previously for *Bos taurus* (Walker 1992). One can speculate that the hydrophilic proteins present in the HP fraction contribute to the outer

sections of the membranal part of complex I which communicate with mitochondrial matrix or intermembrane space, while the purely hydrophobic proteins present in this fraction like the mtDNA encoded ND genes are actually in the lipid bilayer. In cow, three of eight subunits presented in this paper appear to have a leader peptide. It is reasonable to assume that these Mitochondrial Targeting Sequences (MTS) will also be present in man. Interestingly, in cow all FP fraction subunits and five of seven IP fraction subunits (71%) appear to have an N-terminal targeting sequence whereas this applies for only nine of twenty-four (38%) of the HP fraction subunits.

EPR spectroscopy studies of bovine, *N. crassa* and *E. coli* complex I revealed several Iron-Sulfur redox centres (Ohnishi 1998). Six nuclear encoded subunits contain conserved cysteine patterns corresponding with consensus Iron-Sulfur clusters as listed in the introduction. Three of those cysteine-rich subunits are present in the HP fraction, namely NDUFS7, NDUFS8 and NDUFAB8. Of all eight subunits presented in this paper, the NDUFAB10 and NDUFAB10 are the only two with more than two cysteine residues among its amino acids. The NDUFAB10 subunit contains six cysteine residues and the NDUFAB10 five, all of which are conserved in *B. taurus*, with the exception of the first NDUFAB10 cysteine residue. Yet, the cysteine residues are not grouped resembling a consensus Iron-Sulfur cluster pattern.

When three-dimensional structures of *N. crassa* (at least 35 subunits) and *E. coli* (14 subunits) are compared, the main difference appears to be the size (Guenebaut et al 1998). The core of fourteen proteins seems to be equal, higher species appear to have more subunits moulded around this core. The eight characterised cDNAs presented in this study do not appear to be highly conserved among species. A BLAST search with the amino acid sequences of these subunits revealed (apart from the obvious matches with bovine subunits) only matches (although weak in some occasions) in *Caenorhabditis elegans* (NDUFAB7, NDUFAB10, NDUFAB2 and NDUFAB10) and *Gallus gallus* (NDUFAB4).

Isolated complex I deficiency is a major cause of abnormalities in the energy generating system present in mitochondria. Great efforts have been made in the past to link a genetic cause to this enzyme defect. Several mtDNA mutations have been described, but these certainly cannot explain all isolated complex I deficiencies, especially not the most frequently observed phenotype which presents in infancy, expressing a highly progressive lethal course. Therapeutic possibilities regarding complex I deficiency are out of reach for the time being. Therefore, mutational analysis offers the possibility for early detection and if desired for prenatal diagnosis. We presented the remaining eight nuclear encoded complex I cDNAs, which completes human complex I on cDNA level.

## **Acknowledgements.**

We especially are grateful to Antoon Janssen, Frans van den Brandt, Jorrit Ebben, Ronnie De Abreu for technical assistance and stimulating discussions. Rob Sengers, together with Frans Tryjbels founders of our centre is acknowledged for his continuous support. This research was possible due to grants administered by "De Stichting Voor Kinderen Die Wel Willen Maar Niet Kunnen" and "Het Prinses Beatrix Fonds", granted to JS and LvdH.

NDUFA3F 75  
ccccgccgagacaaagATGGCTGCGAGAGTCGGCGCCTTCTCTCAAGAATGCCTGGGACAAGGAGCCAGTGTGTG  
M A A R V G A F L K N A W D K E P V L  
150  
GTCTGTCTCTTCGTCTGCGGGGGCCTCGCTGTAATTCTGCCCCATTGAGCCCCCTACTTCAAGTACTCCGTCATG  
V V S F V V G G L A V I L P P L S P Y F K Y S V M  
225  
ATCAACAAGGCCACGCGCTACAAC TACCCAGTGCCTCGTCCGTGATGATGGGAACATGCCCGACGTGCCAGCCAC  
I N K A T P Y N Y P V P V R D D G N M P D V P S H  
300  
CCCCAGGACCTCAGGGCCCCAGCCTGGAGTGGCTGAAGAACTGTGA<sup>NDUFA3R</sup>gcacctccactgacagaggcgccct  
P Q D P Q G P S L E W L K K L \*  
340  
cccacggctcccaataaaaaatgtgaaaaccccccccccc  
poly A signal poly A site

Fig 7.1 (continued) cDNA and amino acid sequence of the NDUFA3 subunit

NDUFA7F 75  
cgccggacggaagATGGCGTCCGCCACCCGCTCTCATCCAGCGGTGCGGAAC TGGCGTCCGGGCATGACCTGCAG  
M A S A T R L I Q R L R N W A S G H D L Q  
150  
GGGAAGCTGCAGCTACGCTACCAGGAGATCTCCAAGCGAACTCAGCCTCCTCCCAAGCTCCCTGTGGGTCTTAGC  
G K L Q L R Y Q E I S K R T Q P P P K L P V G P S  
225  
CACAAAGCTCTCCAACAATTACTATTCGACTCGCGATGGCCGCGGGAATCTGTGCCCTTCCATCATCATGTCTG  
H K L S N N Y Y C T R D G R R E S V P P S I I M S  
300  
TCGCAGAAGCGCTGGTGTTCAGGCAAGCCAGCAGAGAGCTCTGCTGTAGCTGCCACTGAGAAGAAGCGGTGACT  
S Q K A L V S G K P A E S S A V A A T E K K A V T  
375  
CCAGCTCTCCCATAAAGAGGTGGGAGCTGTCTCTCGGACCAGCCTTACCTGTGA<sup>NDUFA7R</sup>cactgcacctcaaggccacc  
P A P P I K R W E L S S D Q P Y L \*  
450  
cgactactttgacctcttgatttctccaggagagaatgtgacctaatattatgacaaatacgtagagctcaggt  
500  
tcacttctagttttactttaaaaaataaaaaaatagagacagaaaaaaa  
poly A signal poly A site

Figure 7.1 (continued) cDNA and amino acid sequence of the NDUFA7 subunit

NDUFB2F 75  
gaagcgaaagtaggcagggcgaggcggtctggggaccgcgggcgggacgggagcgagtATGTCCGCTCTGACTCGG  
M S A L T R  
150  
CTGGCGTCTTTTCGCTCGCGTTGGAGGCCCGCTTTTCAGAAAGCGGCTGCGCACGGACTGCTGGAGATGGTGGAGTC  
L A S F A R V G G R L F R S G C A R T A G D G G V  
225  
CGTCATGCCGGTGGTGGTGTGCACATTGAGCCCCGGTATAGACAGTTCCCCAGCTGACCAGATCCCAGGTGTTTC  
R H A G G G V H I E P R Y R Q F P Q L T R S Q V F  
300  
CAGAGCGAGTTCTTCAGCGGACTCATGTGGTTCTTGGATTCTCTGGCGCTTTTGGCATGACTCAGAAGAGGTGCTG  
Q S E F F S G L M W F W I L W R F W H D S E E V L  
375  
GGTCACTTTCGCTATCTGATCCTTCCCAGTGGACAGATGAAGAAATTAGGTATCCCTCCTGATGATGAAGACTGA  
G H F P Y P D P S Q W T D E E L G I P P D D E D \*  
450  
agggtgtagactcagcctcactctgtacaagagccaggtgagaatttcaaggattatcgacttcatattgcacatt  
490  
aaagttacaaattaaagtggcttggtcaagaatgaaaaaa  
poly A signal poly A site

Figure 7.1 (continued) cDNA and amino acid sequence of the NDUFB2 subunit

NDUFA10F1 75  
tcctgagctgaccgggtagccATGGCCTTGGCGCTCCTGAAAGCTGGCAGCGACGTCGCGCTCCGCCCGGGTCGTG  
M A L R L L K L A A T S A S A R V V 150  
GCGCGGGGCGCCAGCGCGTGAGAGGAATTCATAGCAGTGTGCAGTGCAAGCTGCGCTATGGAATGTGGCATTTC  
A A G A Q R V R G I H S S V Q C K L R Y G M W H F 225  
NDUFA10F2  
CTACTTGGGGATAAAAGCAAGCAAAAGACTGCAGAACGCAGCAGAGTGATAACTGTAGATGGCAATATATGTACT  
L L G D K A S K R L T E R S R V I T V D G N I C T 300  
NDUFA10R1  
GGAAAAGGCAAACTTGCAAAAAGAAATAGCAGAGAACTAGGCTTCAAGCACTTTCTGAAAGCGGGATTTCATTAT  
G K G K L A K E I A E K L G F K H F P E A G I H Y 375  
CCAGACAGTACCACAGGAGATGGGAAGCCCTCGCCACCGACTATAATGGCACTGTAGTTTGGAGAAATTTTAC  
P D S T T G D G K P L A T D Y N G N C S L E K F Y 450  
NDUFA10F3  
GATGATCCGAGAAGCAATGATGGCAACAGTTACCGCCTGCAGTCTCTGTTGTACAGCACTCGCCTGCTGCAGTAC  
D D P R S N D G N S Y R L Q S W L Y S S R L L Q Y 525  
TCAGATGCCTTGGAGCACTTGCTGACCACAGGACAAGGTGTGTGTGGAGCGCTCCATCTTCAGTGACTTTGTG  
S D A L E H L L T T G Q G V V L E R S I F S D F V 600  
NDUFA10R2  
TTCTTGGAGCGGATGTACAAACAGGGATTTCATCCGAAAGCAGTGTGTGGACCACTACAACGAGGTGAAGAGCGTC  
F L E A M Y N Q G F I R K Q C V D H Y N E V K S V 675  
ACCATCTGCGATTACCTGCCCCCCCCACCTGGTGATTTCATCGATGTGCCCGTTCCAGAGGTCCAGAGCGCGATT  
T I C D Y L P P H L V I Y I D V P V P E V Q R R I 750  
NDUFA10F4  
CAGAGAAAAGGAGATCCACATGAAATGAAGATCACCTCTGCCATCTACAGGACATTGAGAATGCCTATAAGAAA  
Q K K G D P H E M K I T S A Y L Q D I E N A Y K K 825  
NDUFA10R3  
ACCTTTCTCCCTCGAGTGAAGTGAATAATGTGAGGTTTACAGTATTCTGCAAGGGAAGCTCAAGATTCAAAAAAG  
T F L P E M S E K C E V L Q Y S A R E A Q D S K K 900  
GTGGTAGAGGACATTGAATACCTGAAGTTCGATAAAGGGCCGTGGCTCAAGCAGGACAATCGCACTTTTATACCAC  
V V E D I E Y L K F D K G P W L K Q D N R T L Y H 975  
NDUFA10F5  
CTGCGATTACTGGTTCAGGATAAAGTTTGAGGTGCTGAATTACACAAGCATTCTATCTTTCTCCCGGAAGTCACC  
L R L L V Q D K F E V L N Y T S I P I F L P E V T 1050  
NDUFA10R4  
ATTGGAGCTCATCAGACTGACCGTGTCTTACATCAGTTTCAGAGAGCTGCCGGGCCGAAGTACAGCCCTGGGTAC  
I G A H Q T D R V L H Q F R E L P G R K Y S P G Y 1125  
AACACCGAGGTGGGAGACAAGTGGATCTGGCTGAAAGTGAacggggccgccttctgtctccagctgcatcacagtgat  
N T E V G D K W I W L K \* 1200  
ggccaagctgcatcagccgcactctcctggagcccatatagctttaagatcgggggagggtaaataatgcaaaaa 1275  
ttgcacagtgaagaagggtctcacaaaaagcaatccatcctgtagtagtggaatggaggtgggggaagcagc 1350  
ttccattctggatgtttggaacccttttagctttgttttggaatggccaccattctcactggaaaacagtggtct 1425  
NDUFA10R5  
gctgtgaagggccagctctctggcagccctgtggtttcagcgtgccgctctgtgtcattcaggttgtgcattgt 1475  
tttttcttctgacttccagaaaaaaagtgtttccatgggaaaaaaaaa  
poly a signal poly A site

Figure 7.1 (continued) cDNA and amino acid sequence of the NDUFA10 subunit.

NDUF84F1 75  
gctcccaag**ATGTCGTTCCCAAAGTATAAGCCGTCGAGCCTGCGCACTCTGCCTTGAGACCCTCGACCCAGCCGAA**  
M S F P K Y K P S S L R T L P E T L D P A E  
150  
TACAACATATCTCCGAAACCCGGCGGGCGCAAGCCGAGCGGTTGGCCATAAGAGCCCAGCTGAAACGAGAGTAC  
Y N I S P E T R R A Q A E R L A I R A Q L K R E Y  
NDUF84R1 225  
CTGCTTCAGTACAACGATCCCAACCCGCGAGGGCTCATCGAAATCCTGCCTTGCTTCGTTGGGCCTATGCAAGA  
L L Q Y N D P N R R G L I E N P A L L R W A Y A R  
NDUF84F2 300  
ACAATAAATGTCTATCCTAATTTAGACCCACTCCTAAAACTCACTCATGGGAGCTCTGTGTGGATTGGGCC  
T I N V Y P N F R P T P K N S L M G A L C G F G P  
375  
CTCATCTTCATTTATTATATTATCAAACTGAGAGGGATAGGAAAGAAAACTTATCCAGGAAGGAAAATTGGAT  
L I F I Y Y I I K T E R D R K E K L I Q E G K L D  
NDUF84R2 450  
CGAATTTTCACTCTCATATTAAgtcttggcaatgatgactatatgtattctctgctaaataaatcatctattaa  
R T F H L S Y \* poly A signal  
465  
tcattaaaaaaaaa  
poly A site

Figure 7.1 (continued) cDNA and amino acid sequence of the NDUF84 subunit

NDUF88F1 75  
ggcatgtggaagaaggtgaagATGGCGGTGGCCAGGGCGGGGTCTTGGGAGTCCAGTGGCTGCAAAGGGCATCC  
M A V A R A G V L G V Q W L Q R A S  
150  
CGGAACGTGATGCCGCTGGGCGCACGGACAGCCTCCACATGACCAAGGACATGTTCCCGGGGCCCTATCTAGG  
R N V M P L G A R T A S H M T K D M F P G P Y P R  
NDUF88F2 225  
ACCCAGAGAGACGGCCGCCGCCCAAGAAGTATAATATGCGTGTGGAAGACTACGAACCTTACCCGGATGAT  
T P E E R A A A A K K Y N M R V E D Y E P Y P D D  
NDUF88R1 300  
GGCATGGGGTATGGCGACTACCCGAGCTCCCTGACCGCTCACAGCATGAGAGAGATCCATGGTATAGCTGGGAC  
G M G Y G D Y P K L P D R S Q H E R D P W Y S W D  
375  
CAGCCGGGCCGTGAGGTTGAACTGGGGTGAACCGATGCACTGGCACCTAGACATGTACAACAGGAACCGTGTGGAT  
Q P G L R L N W G E P M H W H L D M Y N R N R V D  
NDUF88R2 450  
ACATCCCCCACACCTGTTTCTTGGCATGTCATGTGTATGCAGCTCTTCGTTTCTGGCTTTCATGATATTCATG  
T S P T P V S W H V M C M Q L F G F L A F M I F M  
525  
TGCTGGGTGGGGACGTGTACCTGTCTACCAGCCTGTGGACCAAGCAGTATCCTTACAATAATCTGTACCTG  
C W V G D V Y P V Y Q P V G P K Q Y P Y N N L Y L  
600  
GAACGAGGCGGTGATCCCTCCAAAGAACCAGAGCGGGTGGTTCACTATGAGATCTGAaggaggtctctgtgggcttt  
E R G G D P S K E P E R V V H Y E I \*  
NDUF88R3 675  
tggtgctcttaactaggactccctcattcctagaaaatttaaccttaatgaatccctaaataaaactcagtgtctgt  
poly A signal  
688  
gttaaaaaaaaaa  
poly A site

Figure 7.1 (continued) cDNA and amino acid sequence of the NDUF88 subunit



```

NDUFB10F1
aggccccgggacccggacggaggttagagccagggcagcgcggtccgggagcggagtcgcgccccgccgccATG 75
M
150
CCGGACAGCTGGGACAAGGATGTGTACCTGAGCCCCGCGCCGCACGCCGGTGCAGCCCAATCCCATCGTCTAC
P D S W D K D V Y P E P P R R T P V Q P N P I V Y
225
ATGATGAAAGCGTTCGACCTCATCGTGGACCGACCCGTGACCTCGTGAGAGAATTTATAGACGGCAGCAGCGCA
M M K A F D L I V D R P V T L V R E F I E R Q H A
NDUFB10F2 300
AAGAACAGGTATTACTACTACCACCGGCAGTACCGCCGCGTGCCAGACATCACTGAGTGCAAGGAGGAGGACATC
K N R Y Y Y Y H R Q Y R R V P D I T E C K E E D I
NDUFB10R1 375
ATGTGCATGTATGAAGCCGAAATGCAGTGGAAGAGGGACTACAAAGTCGACCAAGAAATTTATCAACATTATGCAG
M C M Y E A E M Q W K R D Y K V D Q E I I N I M Q
450
GATCGGCTCAAAGCCTGTGTCAGCAGAGGGAAGGACAGAACTACCAGCAGAACTGTATCAAGGAAGTGGAGCAGTTTC
D R L K A C Q Q R E G Q N Y Q Q N C I K E V E Q F
525
ACCCAGGTGGCCAAAGCCTACCAGGACCGCTATCAGGACCTGGGGGCCCTACAGTTTCTGCCAGGAAGTGCCTGGCC
T Q V A K A Y Q D R Y Q D L G A Y S S A R K C L A
600
AAACAGAGGCAGAGGATGCTGCAAGAGAGAAAAGCTGCAAAAGAGGCCCGCGTGCACCTCTCTGAaggcagctgt
K Q R Q R M L Q E R K A A K E A A A A T S *
NDUFB10R2 670
gggtgccccctgctgtgtggctctgtatgactgtttgctgaaatataaagccctgcaacctgaaaaaaaaa
poly A site

```

Figure 7.1 (continued) cDNA and amino acid sequence of the NDUFB10 subunit.

```

NDUFC2F1
tcgtcgtggttttccctgtagttcgtggtctgagaccaggcctcaagtggaaacggcgctcaccATGATCGCACGG 75
M I A R
150
CGGAACCCAGAACCTTTACGGTTTCTGCCGGATGAGGCCCGGAGCCTGCCCCGCCCAAGCTGACCGACCCGCGG
R N P E P L R F L P D E A R S L P P P K L T D P R
225
CTCCTCTACATCGGCTTCTTGGGCTACTGCTCCGGCCTGATTGATAACCTGATCCGGCGGAGGCCGATCGCGACG
L L Y I G F L G Y C S G L I D N L I R R R P I A T
NDUFC2R1 300
GCTGGTTTGCAATGCCAGCTTCTATATATTACGGCCTTTTTTTTGTGGATATTATCTTGTAAGAACTGAAGAC
A G L H R Q L L Y I T A F F F A G Y Y L V K R E D
NDUFC2F2 375
TACCTGTATGCTGTGAGGACCGTGAAATGTTTGGATATATGAAATACATCCAGAGGATTTTCTGAAGAAGAT
Y L Y A V R D R E M F G Y M K L H P E D F P E E D
450
AAGAAAAATATGGTGAAATTTTGAAGAAATCCATCCAATACGTTGAagtcttcaaatgcttgctccagtttc
K K T Y G E I F E K F H P I R *
NDUFC2R2 500
actgataccctgctgttttctgaatttgatggaacatgtttcttatgacagt

```

Figure 7.1 (continued) cDNA and amino acid sequence of the NDUFC2 subunit  
Primers used for PCR and sequence reactions are shaded Primers are also listed in Table 7.1

## Reference List.

- Albracht PJ, Mariette A, Jong de Ph.** 1996 Bovine-heart NADH ubiquinone oxidoreductase is a monomer with 8 Fe-S clusters and 2 FMN groups *Biochim Biophys Acta* 1318 92-106
- Ali ST, Duncan AMV, Schappert K, Heng HHQ, Tsui LC, Chow W, Robinson BH.** 1993 Chromosomal localisation of the human gene encoding the 51-kDa subunit of mitochondrial complex I (NDUFV1) to 11q13 *Genomics* 18 435-439
- Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ.** 1990 Basic local alignment search tool *J Mol Biol* 215 403-410
- Arimendi JM, Runswick MJ, Skehel JM, Walker JE.** 1992 NADH ubiquinone oxidoreductase from bovine heart mitochondria. A fourth nuclear encoded subunit with a homologue encoded in chloroplast genomes *FEBS Lett* 301 237-242
- Baens M, Chaffanet M, Aerssens J, Cassiman JJ, Marynen P.** 1994 Assignment of the gene for the human proliferating cell nucleolar protein P120 (NOL1) to chromosome 12p13 by fluorescence in situ hybridisation and polymerase chain reaction with somatic cell hybrids *Genomics* 21 296-297
- Belogradov G and Hatefi Y.** 1994 Catalytic sector of complex I (NADH ubiquinone oxidoreductase) subunit stoichiometry and substrate-induced conformation changes *Biochemistry* 33 4571-4576
- Chen S and Guillory RJ.** 1981 Studies on the interaction of arylazido-beta-alanyl NAD<sup>+</sup> with the mitochondrial NADH dehydrogenase *J Biol Chem* 256 8318-8323
- Chomyn A, Mariottini P, Cleeter MWJ, Ragan CI, Matsuno-Yagi A, Hatefi Y, Doolittle RF, Attardi G.** 1985 Six unidentified reading frames of human mitochondrial DNA encode components of the respiratory-chain NADH dehydrogenase *Nature* 314 592-597
- Chomyn A, Cleeter MWJ, Ragan CI, Riley M, Doolittle RF, Attardi G.** 1986 URF6. Last unidentified reading frame of human mtDNA, codes for an NADH dehydrogenase subunit *Science* 234 614-618
- Chow W, Ragan CI, Robinson BH.** 1991 Determination of the cDNA sequence for the human mitochondrial 75-kDa Fe-S protein of NADH coenzyme Q reductase *Eur J Biochem* 201 547-550
- de Coo R, Buddiger P, Smeets HJM, Geurts van Kessel A, Morgan-Hughes J, Olde Weghuis D, Overhauser J, van Oost BA.** 1995 Molecular cloning and characterisation of the active human mitochondrial NADH ubiquinone oxidoreductase 24 kDa gene (NDUFV2) and its pseudogene *Genomics* 26 461-466
- de Coo R, Buddiger P, Smeets HJM, van Oost BA.** 1997 Molecular cloning and characterisation of the human mitochondrial NADH oxidoreductase 10 kDa gene (NDUFV3) *Genomics* 45 434-437
- de Sury R, Martinez P, Procaccio V, Lunardi J, Issartel JP.** 1998 Genomic structure of the human NDUFV8 gene coding for the iron-sulphur TYKY subunit of the mitochondrial NADH ubiquinone oxidoreductase *Gene* 215 1-10
- Deng PS, Hatefi Y, Chen S.** 1990 N-arylazido beta-alanyl NAD<sup>+</sup>, a new NAD<sup>+</sup> photoaffinity analogue. Synthesis and labelling of mitochondrial NADH dehydrogenase *Biochemistry* 29 1094-1098
- Dupuis A, Skehel JM, Walker JE.** 1991a A homologue of a nuclear-coded iron sulphur protein subunit of bovine mitochondrial complex I is encoded in chloroplast genomes *Biochemistry* 30 2954-2960
- Dupuis A, Skehel JM, Walker JE.** 1991b NADH ubiquinone oxidoreductase from bovine mitochondria. cDNA sequence of a 19 kDa cysteine-rich subunit *Biochem J* 277 11-15
- Finel M, Skehel JM, Albracht PJ, Fearnley IM, Walker JE.** 1992 Resolution of NADH ubiquinone oxidoreductase from bovine heart mitochondria into two subcomplexes, one of which contains the redox centres of the enzyme *Biochemistry* 31 11425-11434
- Galante YM and Hatefi Y.** 1978 Resolution of complex I and isolation of NADH dehydrogenase and an iron-sulphur protein *Method Enzymol* 53 15-21
- Galante YM and Hatefi Y.** 1979 Purification and molecular and enzymatic properties of mitochondrial NADH dehydrogenase *Arch Biochem Biophys* 192 559-568
- Gu ZG, Lin X, Wells DE.** 1996 The human B22 subunit of the NADH ubiquinone oxidoreductase maps to the region of chromosome 8 involved in Branchio-Oto-Renal syndrome *Genomics* 35 6-10
- Guenebaut V, Schlitt A, Weiss H, Leonard K, Friedrich T.** 1998 Consistent structure between bacterial and mitochondrial NADH ubiquinone oxidoreductase (complex I) *J Mol Biol* 276 105

112.

- Hattori N, Suzuki H, Wang Y, Minoshima S, Shimizu N, Yoshino H, Kurashima R, Tanaka M, Ozawa T, Mizuno Y.** 1995 Structural organisation and chromosomal localisation of the human nuclear gene (*NDUFV2*) for the 24-kDa iron-sulphur subunit of complex I in mitochondrial respiratory chain. *Biochem Biophys Res Commun* 216 771-777
- Hyslop SJ, Duncan AMV, Pitkänen S, Robinson BH.** 1996. Assignment of the PSST subunit gene of human mitochondrial complex I to chromosome 19p13. *Genomics* 37:375-380.
- Kim JWL, Lee Y, Kang HB, Choe YK, Chung TW, Chang SY, Lee KS, Choe IS.** 1997. Cloning of the human cDNA sequence encoding the NADH ubiquinone oxidoreductase MLRQ subunit *Biochem Mol Biol Int* 43:669-675.
- Kyte J and Doolittle RF.** 1982. A simple method for displaying the hydrophobic character of a protein. *J Mol Biol* 157 105-132.
- Loeffen J, van den Heuvel L, Smeets R, Triepels R, Sengers R, Trijbels F, Smeitink J.** 1998. cDNA sequence and chromosomal localisation of the remaining three human nuclear encoded iron sulphur protein (IP) subunits of complex I the human IP fraction is completed *Biochem Biophys Res Commun* 247 751-758
- Loeffen J, Smeets R, Smeitink J, Triepels R, Sengers R, Trijbels F, van den Heuvel L.** 1999. The human NADH:ubiquinone oxidoreductase NDUF5 (15 kDa) subunit: cDNA cloning, chromosomal localisation, tissue distribution and the absence of mutations in isolated complex I-deficient patients. *J Inheret Metab Dis* 22:19-28
- Ohnishi T.** 1998 Iron-sulphur clusters/semiquinones in Complex I *Biochim Biophys Acta* 1364:186-206
- Papa S, Sardanelli AM, Cocco T, Speranza F, Scacco SC, Technikova-Dobrova Z.** 1996. The nuclear-encoded 18 kDa (IP) AQDQ subunit of bovine heart complex I is phosphorylated by the mitochondrial cAMP-dependent protein kinase *FEBS Lett* 379:299-301
- Pata I, Tensing K, Metspalu A.** 1997. A human cDNA encoding the homologue of NADH ubiquinone oxidoreductase subunit B13. *Biochim Biophys Acta* 1350:115-118.
- Pilkington SJ and Walker JE.** 1989 Mitochondrial NADH-ubiquinone reductase: complementary DNA sequences of import precursors of the bovine and human 24-kDa subunit. *Biochemistry* 28 3257-3264.
- Pilkington SJ, Skehel JM, Gennis RB, Walker JE.** 1991. Relationship between mitochondrial NADH-ubiquinone reductase and a bacterial NAD-reducing hydrogenase *Biochemistry* 30 2166-2175.
- Ploos van Amstel JK, Bergman AJW, van Beurden EACM, Roijers JFM, Peelen T, van den Berg IET, Poll-The BT, Kvittingen EA, Berger R.** 1996. Hereditary tyrosinemia type I novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene, variability of the genotype-phenotype relationship. *Hum Genet* 97:51-59
- Procaccio V, Depetris D, Soularue P, Mattei MG, Lunardi J, Issartel JP.** 1997 cDNA sequence and chromosomal localisation of the NDUF58 human gene coding for the 23 kDa subunit of the mitochondrial complex I *Biochim Biophys Acta* 1351 37-41
- Procaccio V, de Sury R, Martinez P, Depetris D, Rabilloud T, Soularue P, Lunardi J, Issartel J.** 1998 Mapping to 1q23 of the human gene (NDUF52) encoding the 49-kDa subunit of the mitochondrial respiratory Complex I and immunodetection of the mature protein in mitochondria *Human Genome* 9:482-484.
- Runswick MJ, Gennis RB, Fearnley IM, Walker JE.** 1989 Mitochondrial NADH:ubiquinone reductase complementary DNA sequence of the import precursor of the bovine 75-kDa subunit. *Biochemistry* 28 9452-9459.
- Runswick MJ, Fearnley IM, Skehel JM, Walker JE.** 1991 Presence of an acyl carrier protein in NADH:ubiquinone oxidoreductase from bovine heart mitochondria *FEBS Lett* 286:121-124.
- Schuelke M, Loeffen J, Mariman E, Smeitink J, van den Heuvel LP.** 1998. Cloning of the human mitochondrial 51 kDa subunit (NDUFV1) reveals a 100% antisense homology of its 3'UTR with the 5'UTR of the gamma-interferon inducible protein (IP-30) precursor is this a link between mitochondrial myopathy and inflammation? *Biochem Biophys Res Commun* 245:599-606.
- Smeitink J, Loeffen J, Triepels R, Smeets R, Trijbels F, van den Heuvel L.** 1998a. Nuclear genes of human complex I of the mitochondrial electron transport chain: state of the art *Hum Mol Genet* 7:1573-1579.
- Smeitink J, Loeffen J, Smeets HJM, Trijbels F, van den Heuvel L.** 1998b B17 subunit of human NADH:ubiquinone oxidoreductase: cDNA cloning, tissue distribution and mutation detection in isolated complex I deficient patients *Hum Genet* 103 245-

- 250.
- Spencer SR, Taylor JB, Cowell IG, Xia CL, Pemble SE, Ketterer B.** 1992. The human mitochondrial NADH ubiquinone oxidoreductase 51-kDa subunit maps adjacent to the glutathione S-transferase P1-1 gene on chromosome 11q13. *Genomics* 14:1116-1118.
- Ton C, Hwang DM, Dempsey AA, Liew CC.** 1997. Identification and primary structure of five NADH:ubiquinone oxidoreductase subunits. *Biochem Biophys Res Commun* 241:589-594.
- Triepels R, Smeitink J, Loeffen J, Smeets R, Buskens C, Trijbels F, van den Heuvel L.** 1998a. The human nuclear encoded acyl carrier subunit (NDUFAB1) of the mitochondrial complex I in human pathology. *J Inher Metab Dis* 22:163-173.
- Triepels R, van den Heuvel L, Loeffen J, Smeets R, Trijbels F, Smeitink J.** 1998b. The nuclear-encoded human NADH ubiquinone oxidoreductase NDUF8 subunit: cDNA cloning, chromosomal localisation, tissue distribution, and mutation detection in complex-I-deficient patients. *Hum Genet* 103:557-563.
- van den Heuvel L, Ruitenbeek W, Smeets R, Gelman-Kohan Z, Elpeleg O, Loeffen J, Trijbels F, Mariman E, de Bruijn D, Smeitink J.** 1998. Demonstration of a new pathogenic mutation in human complex I deficiency: a 5-bp duplication in the nuclear gene encoding the 18-kD (AQDQ) subunit. *Am J Hum Genet* 62:262-268.
- Walker JE.** 1992. The NADH ubiquinone oxidoreductase (complex I) of respiratory chains. *Q Rev Biophys* 25:253-324.
- Weidner U, Geier S, Ptock A, Friedrich T, Leif H, Weiss H.** 1993. The gene locus of the proton-translocating NADH ubiquinone oxidoreductase in *Escherichia coli*. Organisation of the 14 genes and relationship between the derived proteins and subunits of mitochondrial complex I. *J Mol Biol* 233:109-122.
- Weiss H, Friedrich T, Hofhaus G, Preis D.** 1991. The respiratory-chain NADH dehydrogenase (complex I) of mitochondria. *Eur J Biochem* 197:563-576.
- Wong YC, Tsao SW, Kakefuda M, Bernal SD.** 1990. cDNA cloning of a novel cell adhesion protein expressed in human squamous carcinoma cells. *Biochem Biophys Res Commun* 166:984-992.
- Zeviani M, Tiranti V, Piantadosi C.** 1998. Mitochondrial disorders. *Medicine (Baltimore)* 77:59-72.
- Zhuchenko O, Wehnert M, Bailey J, Sheng Sun Z, Chi Lee C.** 1996. Isolation, mapping and genomic structure of an X-Linked gene for a subunit of human mitochondrial complex I. *Genomics* 37:281-288.

### DEMONSTRATION OF A NEW PATHOGENIC MUTATION IN HUMAN COMPLEX I DEFICIENCY: A 5-bp DUPLICATION IN THE NUCLEAR GENE ENCODING THE NDUFS4 (18 kDa) SUBUNIT

*American Journal of Human Genetics* 1998 62:262-268.

#### **Abstract.**

We report the cDNA cloning, chromosomal localisation, and a mutation in the human nuclear gene encoding the NDUFS4 (18 kDa) subunit of the mitochondrial respiratory chain complex I. The cDNA has an open reading frame of 175 amino acids and codes for a protein with a molecular mass of 20.1 kDa. Its gene was mapped to chromosome 5. A homozygous 5-bp duplication, destroying a consensus phosphorylation site, in the *NDUFS4* cDNA was found in a complex I-deficient patient. The patient showed normal muscle morphology and a remarkably non-specific fatal progressive phenotype without increased lactate concentrations in body fluids. The child's parents were heterozygous for the mutation. In 19 other complex I-deficient patients, no mutations were found in the *NDUFS4* gene.

## Introduction.

Among the inborn errors of metabolism, disturbances in the mitochondrial energy metabolism form a quantitatively major group, occurring in 1/10,000 live births (Bourgeron et al 1995). In case of a defective pyruvate oxidation, skeletal muscle and brain tissue are often involved. In these mitochondrial encephalomyopathies (OMIM 251900), the most frequently observed enzyme deficiencies are located in the pyruvate dehydrogenase complex and complexes I (OMIM 252010) and/or IV of the respiratory chain (Wallace 1992, Ruitenbeek et al 1996). Numerous patients with isolated complex I deficiency have been reported (Korenke et al 1990, DiMauro and Moraes 1993, Shoffner and Wallace 1994). Their clinical presentation in general is that of a very severe, often fatal, multisystemic disorder frequently dominated by brain and skeletal muscle abnormalities. Less severe phenotypes have also been described (Wallace 1992, Trijbels et al 1996). Until now, only one mutation in a nuclear gene has been described in a patient with a defective respiratory chain enzyme complex: a point mutation in the flavoprotein (FP) subunit of complex II (Bourgeron et al 1995). No mutations in the nuclear genome of one of the other respiratory chain complexes have been reported. The relatively high frequency of complex I-deficient patients prompted us to investigate the molecular cause of this enzyme deficiency. Complex I or NADH:ubiquinone oxidoreductase, the first multisubunit enzyme complex of the mitochondrial respiratory chain, plays a vital role in cellular ATP production, the primary source of energy for many crucial processes in living cells (Walker 1992, Pilkington et al 1993, Trijbels et al 1996). It removes electrons from NADH and passes them via a series of different protein-coupled redox centres (FMN and FeS clusters) to the electron acceptor ubiquinone (Yamaguchi and Hatefi 1993). In well-coupled mitochondria, the electron flux leads to ATP generation via the building of a proton gradient over the inner membrane.

Complex I is composed of  $\geq 41$  subunits, of which 7 are encoded by the mitochondrial genome (NDI-6, ND4L) and the remaining by nuclear genes (Fearnley and Walker 1992). Limited information is available concerning the precise location and function of the individual subunits. Very recently, a low-resolution three-dimensional structure of complex I from *Neurospora crassa* has been elucidated (Guenebaut et al 1997). A number of different subunits contribute to binding sites for FMN, NADH, and 4Fe-4S and 2Fe-2S centres (Walker 1992, Pilkington et al 1993). It is hypothesised that subunits of the FP fraction play a role in FMN and NADH binding. Proteins in the IP (iron-sulphur protein) fraction likely function in reduction-oxidation reactions via different iron-sulphur clusters. Very recently, it has been shown that the nuclear-encoded 18-kDa subunit of bovine heart complex I can be phosphorylated by a mitochondrial cyclic adenosine 5'-monophosphate (cAMP)-dependent protein kinase (Papa et al 1996). It is well established that the 18-kDa (AQDQ) subunit is in the extrinsic domain of complex I (Walker 1992).

In some patients (i.e. in Leber hereditary optic neuropathy) a mutation in the ND4 subunit of the mitochondrial genome has been established (Brown et al 1997). So far, the human cDNA sequences of seven nuclear-encoded subunits (e.g. NDUFV1, NDUFV2, NDUFS1, NDUFS7, NDUFA1, NDUFA5, NDUFB9) have been published (Chow et al 1991, Spencer et al 1992, de Coo et al 1995, Hattori et al 1995, Gu et al 1996, Hyslop et al 1996, Zhuchenko et al 1996,

Pata et al 1997) The availability of the bovine cDNA sequence for the 18-kDa (AQDQ) protein (Walker et al 1992) enabled us to apply a PCR-based strategy for generating the cDNA for the human NDUFS4 (18-kDa) protein from human heart

In this article, we present the human cDNA sequence of the nuclear-encoded NDUFS4 subunit, the chromosomal localisation of the gene, and the results of mutation detection in 20 complex I-deficient patients all exhibiting a multisystem disorder Detailed information is presented about the clinical symptoms of one patient in whom we found a 5-bp duplication in the *NDUFS4* gene This is the first report of a pathological mutation in a nuclear complex I gene of the mitochondrial respiratory chain

## **Patient, material and methods.**

### *Case history*

A male patient, born after an uncomplicated pregnancy as the second child of healthy nonconsanguineous Caucasian parents, was first admitted at the age of 8 mo with severe vomiting, failure to thrive, and hypotonia Despite supportive care, his clinical condition deteriorated in the following months At the age of 13 mo, he showed severe psychomotor retardation, convulsions, bradypnoea, cyanosis, hypotonia, and depressed tendon reflexes Results of routine clinical chemical blood and urine investigations, as well as amino acid and organic-acid analyses in blood and urine, were normal Lactic acid concentrations in blood and cerebrospinal fluid were within the range of controls Electromyographic parameters were normal Cerebral magnetic resonance imaging revealed generalised brain atrophy and symmetrical basal ganglia abnormalities When the patient was 14 mo of age, a skeletal muscle biopsy (musculus quadriceps femori) was performed to investigate the mitochondrial energy-generating system (see Biochemical methods) Light and electron microscopy and histochemistry did not reveal abnormalities No ragged-red fibres were present The child's condition deteriorated severely, and he died of cardiorespiratory failure at the age of 16 mo The family history is normal for neuromuscular disorders A younger brother and older sister of the proband are healthy

### *Cloning of the human NDUFS4 cDNA*

Human *NDUFS4* cDNA was obtained by reverse transcription using oligo(dT) and random hexamer primers on poly A<sup>+</sup> RNA isolated from human heart (Clontech) PCR amplification was performed with cDNA as template according to the protocol for *Taq* polymerase (Life Technologies) by use of oligonucleotides 5-ATGGCGGCGGTCTCAATGTC 3' and 5' CTATTTTGTGGATACTCTTGTC 3' Oligonucleotide sequences were based on homology with bovine 18-kDa cDNA sequence (Walker et al 1992) and known human expressed sequence tags (ESTs) The PCR product was purified for direct DNA sequencing DNA sequence analysis of both DNA strands was performed using the dyedexy-terminators on an automated ABI 377 sequencer according to a protocol provided by the manufacturer (Applied Biosystems)

### *Chromosomal localisation of the NDUFS4 gene*

Genomic DNA was isolated from human-rodent somatic cell hybrids containing all 24 human chromosomes (Coriell Cell Depositories) digested with *EcoRI*, fractionated, and blotted to Hybond nylon membrane. The blot was hybridised with  $\alpha^{32}\text{P}$ -dCTP-labeled human *NDUFS4* cDNA probe (of 528 bp). Binding of the probe was visualised by autoradiography.

### *Mutation detection*

Total RNA was extracted (Chomczynski and Sacchi 1987) from cultured skin fibroblasts (Bentlage et al 1996) and stored as ethanol precipitate at  $-80^{\circ}\text{C}$ . A 5- $\mu\text{g}$  sample of RNA was reverse transcribed to cDNA in 1 h at  $42^{\circ}\text{C}$  with 200 U of Superscript II reverse transcriptase (RT) (Life Technologies), using oligo(dT) and random hexamer primers. One microliter of cDNA was subjected to PCR amplification. By PCR we generated one fragment covering the entire coding region, using the synthetic oligonucleotide primers described before. The PCR program consisted of 35 cycles of 30 s at  $94^{\circ}\text{C}$ , 30 s at  $55^{\circ}\text{C}$ , and 1 min at  $72^{\circ}\text{C}$ . The cycles were preceded by an initial denaturation step of 3 min at  $95^{\circ}\text{C}$  and were followed by a final extension of 10 min at  $72^{\circ}\text{C}$ . The PCR reaction was analysed on a 1.0% agarose gel with 0.5  $\mu\text{g}/\text{ml}$  ethidium bromide in 1 $\times$  Trisborate EDTA. The nucleotide sequences of the PCR products were analysed by direct sequencing using the *Taq* Dye Deoxy terminator cycle sequencing kit according to the manufacturer's recommendations (Applied Biosystems).

To confirm the mutation at the genomic DNA level, a fragment consisting of 96 bp was amplified in the same PCR buffer as described above, using forward primer 5' TATGACATTGAAGAGAGGAAGG 3' and reverse primer as described above. PCR fragments were resolved in a 20% polyacrylamide gel. Ethidium bromide was used to visualise the PCR fragments, and the presence of the duplication could be checked by size.

## **Results.**

### *Biochemical results*

From the decreased activity of NADH ferricyanide oxidoreductase as well as NADH cytochrome *c* reductase, a deficiency in complex I in skeletal muscle mitochondria can be concluded (see Table 8.1). The NADH  $\text{Q}_1$  oxidoreductase assay revealed a complex I deficiency in cultured skin fibroblasts also. The activities of the other respiratory chain enzyme complexes and  $\text{Mg}^{2+}$ -ATPase were all normal.

### *Cloning of the human NDUF54 cDNA*

We obtained a 528-bp cDNA fragment of the human nuclear-encoded NDUF54 subunit by RT-PCR using human heart RNA and oligonucleotide primers based on the *NDUF54* cDNA sequence from cow (Walker et al 1992) and known human ESTs (Adams et al 1995). Sequence analysis of the human *NDUF54* cDNA clone revealed an open reading frame which encodes 175 amino acids (Fig. 8.1). The amino acid sequence showed 91% homology with the bovine 18-kDa amino acid sequence (data not shown). The calculated molecular weight of the protein encoded by the human *NDUF54* cDNA is 20.1 kDa. As in the cow, the protein contains a leader sequence (amino acids 1-42) for import into the mitochondria. In the cow,



this signal peptide is removed after import. There is a phosphorylation consensus site (RVS) at amino acid positions 171-173 (Pearson and Kemp 1991, Kemp et al 1994). The human protein has no cysteine residues.

	Enzyme activity	
	Patient	Control range
<b>Skeletal muscle</b>		
• cytochrome <i>c</i> oxidase	7.2 <sup>a</sup>	2.8-11.8 <sup>a</sup>
• NADH:ferricyanide oxidoreductase	1.16 <sup>b</sup>	1.7-4.1 <sup>b</sup>
• NADH:cytochrome <i>c</i> oxidoreductase	27 <sup>c</sup>	63-529 <sup>c</sup>
• succinate:cyt <i>c</i> oxidoreductase	100 <sup>c</sup>	39-249 <sup>c</sup>
• citrate synthase	1.28 <sup>b</sup>	1.0-2.1 <sup>b</sup>
• Mg <sup>2+</sup> -ATPase	634 <sup>d</sup>	213-553 <sup>d</sup>
• pyruvate dehydrogenase complex	18.3 <sup>c</sup>	27-61 <sup>c</sup>
<b>Fibroblasts</b>		
• NADH:Q <sub>1</sub> oxidoreductase	0.075 <sup>e</sup>	0.11-0.28 <sup>e</sup>
• Succinate:cyt <i>c</i> oxidoreductase	0.23 <sup>e</sup>	0.21-0.44 <sup>e</sup>
• decylubiquinol:cyt <i>c</i> oxidoreductase	1.22 <sup>e</sup>	1.25-2.62 <sup>e</sup>
• cytochrome <i>c</i> oxidase	239.0 <sup>c</sup>	147-252 <sup>c</sup>
• citrate synthase	311.0 <sup>c</sup>	144-257 <sup>c</sup>

**Table 8.1** Respiratory chain enzyme activities in index patient's tissue specimens. Patient's individual respiratory-chain enzyme and PDHc activities measured in skeletal muscle tissue and cultured skin fibroblasts. Complex I activity is reduced in both tissue specimens.

<sup>a</sup> = in k/mg protein; <sup>b</sup> = in U/mg protein; <sup>c</sup> = in mU/mg protein; <sup>d</sup> = in mU/g protein; <sup>e</sup> = in mU/mU cytochrome *c* oxidase.

#### *Chromosomal localisation of the human NDUF54 gene.*

A Southern blot with genomic DNA from human-rodent somatic cell hybrids containing all human chromosomes has been used for hybridisation with human *NDUF54* cDNA as probe. A specific hybridisation signal was detected only for chromosome 5, indicating that the nuclear-encoded *NDUF54* (18 kDa) gene maps to this chromosome (Fig. 8.2).

#### *Mutation detection in the human NDUF54 subunit.*

A template of human cDNA was produced by first-strand synthesis of human fibroblast RNA originating from 20 patients with a complex I deficiency enzymatically established in fibroblasts and, when available, also in skeletal muscle and other tissues. One set of oligonucleotide primers enabled us to amplify the entire coding region of the *NDUF54* cDNA. Direct sequencing of this region revealed a novel homozygous 5-bp duplication of the cDNA sequence at positions 466-470 (AAGTC) in one patient (Fig. 8.3a). No other sequence aberrations could be detected in the *NDUF54* cDNA of all other patients. The 5-bp duplication results in a frameshift at codon K158 and destroys a phosphorylation site present at the carboxy-terminus of the *NDUF54* protein. Furthermore, the duplication changes the amino acid sequence of the *NDUF54* protein from amino acid 158 to the carboxy terminus and expands the length of the protein by 14 amino acids (Fig. 8.3b). The mutation was

confirmed on the genomic DNA level by PCR combined with PAGE. Both parents appeared to be heterozygous for the mutation (Fig. 8.3c). The segregation of this mutation in the family is consistent with an autosomal recessive mode of inheritance. The duplication was not present in 100 control alleles and the 19 other complex I-deficient patients.



Figure 8.1 cDNA and amino acid sequence of the human *NDUFS4* subunit. The cDNA and amino acid sequence are submitted to Genbank (accession no. NM002495).






Figure 8.2 Chromosomal localisation of the human *NDUFS4* (18 kDa) gene. The *NDUFS4* gene was localised to chromosome 5 by chromosomal somatic cell hybrid analysis. Genomic DNA was isolated from a panel of mouse or hamster/human cells, each containing a single human chromosome. The DNA was digested with *Eco*RI, fractionated, transferred to Hybond nylon, and probed with a 528-bp *NDUFS4* cDNA. A positive signal was observed in the sample of total DNA of human origin (left arrow). Mouse (M) and hamster (H) genomic DNA showed no *NDUFS4* signal. A strong signal for the *NDUFS4* was seen only on hybrids containing chromosome 5 (right arrow).



**Figure 8.3a** DNA sequence of the *NDUFS4* cDNA segments for wild type (top) and patient with the mutation (bottom). In case of the patient, a 5 bp duplication (AAGTC) was observed, resulting in a frameshift and extension of the C terminus of the *NDUFS4* protein.

Wildtype	NGWSYDIEER	KVPKPKSKSY	GANFSWNKRT	RVSTK*
Patient	NGWSYDIEER	KVPKPKSSPS	LMVQTFGLGK	EQEYPQNRLA LTISLLDCE*
	150	160	170	180 190

**Figure 8.3b** Primary C-terminal amino acid sequence of wild-type and patient's *NDUFS4* protein.



**Figure 8.3c** Molecular analysis of the *NDUF54* (18 kDa) gene. Segregation of the 5-bp duplication in the *NDUF54* gene in the family, detected by PCR on genomic DNA and by PAGE. Mutant and wild-type alleles are 101 bp and 96 bp, respectively. Lane 1 contains the molecular size marker, lane 2 brother, lane 3 father, lane 4 mother and lane 5 index patient.

## Discussion.

Complex I deficiencies, whether or not as part of multiple enzyme deficiencies, are a major cause of mitochondrial encephalomyopathies. So far, no mutation in a nuclear gene of one of the numerous complex I subunits has been described. The multi-systemic progressive clinical presentation of our patient was highly suggestive for a mitochondriocytopathy (Munnich et al 1992, DiMauro and Moraes 1993, Shoffner and Wallace 1994, Ruitenbeek et al 1996). Despite normal clinical chemical features, biochemical analyses indeed revealed a reduced complex I activity both in skeletal muscle and cultured skin fibroblasts. In addition, a 5-bp duplication in the cDNA and genomic DNA encoding the nuclear-encoded *NDUF54* (18 kDa) subunit of complex I of the respiratory chain could be demonstrated. Both parents were heterozygous for this mutation.

We started our mutation analysis in complex I-deficient patients with examination of the *NDUF54* gene, because Papa et al (1996) found that the bovine 18-kDa subunit can be phosphorylated. A mitochondrial inner membrane-bound kinase acts via a cAMP-dependent mechanism. The presence of a phosphorylation/dephosphorylation site is frequently associated with regulation of biological processes. In the case of phosphorylation of the *NDUF54* subunit, one can hypothesise an influence on complex I activity or a role in posttranslational processes. The cDNA, encoding the 18-kDa subunit of bovine complex I, had already been cloned. We cloned the human *NDUF54* subunit by RT-PCR, using human heart mRNA as template. The protein encoded by the human *NDUF54* gene is 175 amino acids long, and its calculated molecular mass is 20.1 kDa. The amino acid sequence of the human *NDUF54* protein is highly conserved. There is ~91% identity between the human and bovine counterparts. The bovine consensus phosphorylation site (RVS) is also present in the human subunit. As in the cow, the human *NDUF54* subunit has a leader sequence for import into the mitochondria. Although the human, like the bovine, *NDUF54* protein is supposed to be part of the IP fraction (Walker et al 1992), it has no cysteine residues that might provide ligands

for iron-sulphur centres. A Blast search for homologous sequences revealed two different EST clones (AA258924 and N29566) originating from different human tissues.

We have included in this study 20 patients with a complex I deficiency in fibroblasts and, in most patients, in at least one other tissue as well. Direct sequencing of the entire *NDUF54* cDNA of these patients revealed in one patient a homozygous 5-bp duplication. A mistake made by the RT or *Taq* DNA polymerase in the RT-PCR was excluded by repeating the RT-PCR and DNA sequencing of this patient, all of which revealed the homozygous duplication in the patient's cDNA. The presence of the duplication in the patient was confirmed on the genomic DNA level. The 5-bp duplication causes a shift in the translational reading frame. The shift results in (1) an elongation of the mature protein by 14 amino acids and (2) destroys the phosphorylation consensus site. Although the gene product belongs to the IP fraction and therefore is probably involved in crucial redox reactions, its relation to the adjacent subunits and its exact function are still obscure. Our results, a mutation with an autosomal recessive mode of inheritance, associated with a fatal multisystemic complex I deficiency biochemically established in two different tissue types, stress the physiological importance of this subunit in humans. Because the phosphorylation site in the NDUF54 subunit is disrupted in the patient, we speculate that the mutation in this vital site for regulation of protein function in eukaryotic cells is responsible for the observed complex I deficiency. Alternatively, the obviously changed C-terminus of the NDUF54 subunit of the patient has caused the complex I deficiency. The protein has been elongated by 14 amino acids, and amino acids 158-175 have been modified. A proper transport and/or folding and orientation of the NDUF54 protein in the enzyme complex or in the mitochondrial inner membrane may be hindered. Perhaps the alterations in the patient NDUF54 subunit also lead to instability and premature breakdown of the protein.

In conclusion, we present the first mutation in a nuclear gene of one of the subunits of complex I of the human respiratory chain. Although the frequency of the described mutation must be further established, the finding improves the potentials for genetic counselling and prenatal diagnosis. These preventive tools are of utmost importance, because therapeutic intervention is unsuccessful in the majority of complex I deficient patients. Mutation analysis of other nuclear genes in patients with a complex I deficiency is in progress.

### **Acknowledgements.**

We are very grateful to Antoon Janssen, Frans van den Brandt, Janette Elsink, and Ronney de Abreu for technical assistance. Asher Barak and Ann Saada are gratefully acknowledged, for clinical and biochemical assistance, and Rob Sengers, for critical reading the manuscript and ongoing enthusiastic support. This study was financially supported by the Stichting Voor Kinderen Die Wel Willen Maar Niet Kunnen to L.H. and J.S.

## Reference List.

- Adams MD, Kerlavage AR, Fleischmann RD, Fuldner RA, Bult CJ, Lee NH, Kirkness EF, Weinstock KG, Gocayne JD, White O. 1995 Initial assessment of human gene diversity and expression patterns based upon 83 million nucleotides of cDNA sequence. *Nature* 377:3-174.
- Bentlage H, Wendel U, Schagger H, ter Laak H, Janssen A, Trijbels F. 1996 Lethal infantile mitochondrial disease with isolated complex I deficiency in fibroblasts with combined complex I and IV deficiencies in muscle. *Neurology* 47 243-248.
- Bourgeron T, Rustin P, Chretien D, Birch-Machin M, Bourgeois M, Viegas-Pequignot E, Munnich A, Rötig A. 1995. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. *Nat Genet* 11:144-149.
- Brown MD, Sun F, Wallace DC. 1997. Clustering of Caucasian Leber hereditary optic neuropathy patients containing the 11778 or 14484 mutations on a mtDNA lineage. *Am J Hum Genet* 60 381-387.
- Chomczynski P and Sacchi N. 1987 Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 162:156-159.
- Chow W, Ragan CI, Robinson BH. 1991 Determination of the cDNA sequence for the human mitochondrial 75-kDa Fe-S protein of NADH-coenzyme Q reductase. *Eur J Biochem* 201:547-550.
- de Coo R, Buddiger P, Smeets HJM, Geurts van Kessel A, Morgan-Hughes J, Olde Weghuis D, Overhauser J, van Oost BA. 1995 Molecular cloning and characterisation of the active human mitochondrial NADH:ubiquinone oxidoreductase 24-kDa gene (*NDUFV2*) and its pseudogene. *Genomics* 26 461-466.
- DiMauro S and Moraes CT. 1993 Mitochondrial encephalomyopathies. *Arch Neurol* 50 1197-1208.
- Fearnley IM and Walker JE. 1992. Conservation of sequences of subunits of mitochondrial complex I and their relationships with other proteins. *Biochim Biophys Acta* 1140:105-134.
- Gu ZG, Lin X, Wells DE. 1996. The human B22 subunit of the NADH ubiquinone oxidoreductase maps to the region of chromosome 8 involved in Branchio-Oto-Renal syndrome. *Genomics* 35 6-10.
- Guenebaut V, Vincentelli R, Mills D, Weiss H, Leonard KR. 1997 Three-dimensional structure of NADH-dehydrogenase from *Neurospora crassa* by electron microscopy and conical tilt reconstruction. *J Mol Biol* 265 409-418.
- Hattori N, Suzuki H, Wang Y, Minoshima S, Shimizu N, Yoshino H, Kurashima R, Tanaka M, Ozawa T, Mizuno Y. 1995. Structural organisation and chromosomal localisation of the human nuclear gene (*NDUFV2*) for the 24-kDa iron-sulphur subunit of complex I in mitochondrial respiratory chain. *Biochem Biophys Res Commun* 216:771-777.
- Hyslop SJ, Duncan AMV, Pitkänen S, Robinson BH. 1996 Assignment of the PSST subunit gene of human mitochondrial complex I to chromosome 19p13. *Genomics* 37:375-380.
- Kemp BE, Parker MW, Hu S, Tiganis T, House C. 1994 Substrate and pseudosubstrate interactions with protein kinases: determinants of specificity. *Trends Biochem Sci* 19 440-444.
- Korenke GC, Bentlage HA, Ruitenbeek W, Sengers RC, Sperl W, Trijbels JM, Gabreels FJ, Wijburg FA, Wiedermann V, Hanefeld F. 1990 Isolated and combined deficiencies of NADH dehydrogenase (complex I) in muscle tissue of children with mitochondrial myopathies. *Eur J Pediatr* 150 104-108.
- Munnich A, Rustin P, Rötig A, Chretien D, Bonnefont JP, Nutton C, Cormier V, Vassault A, Parvy P, Bardet J. 1992. Clinical aspects of mitochondrial disorders. *J Inher Metab Dis* 15 448-455.
- Papa S, Sardanelli AM, Cocco T, Speranza F, Scacco SC, Technikova-Dobrova Z. 1996 The nuclear-encoded 18 kDa (IP) AQPQ subunit of bovine heart complex I is phosphorylated by the mitochondrial cAMP-dependent protein kinase. *FEBS Lett* 379 299-301.
- Pata I, Tensing K, Metspalu A. 1997. A human cDNA encoding the homologue of NADH ubiquinone oxidoreductase subunit B13. *Biochim Biophys Acta* 1350:115-118.
- Pearson RB and Kemp BE. 1991. Protein kinase phosphorylation site sequences and consensus specificity motifs tabulations. *Methods Enzymol* 200:62-81.
- Pilkington SJ, Arizmendi JM, Fearnley IM, Runswick MJ, Skehel JM, Walker JE. 1993 Structural organisation of complex I from bovine mitochondria. *Biochem Soc Trans* 21 23-26.
- Ruitenbeek W, Wendel U, Trijbels F, Sengers R. 1996. Mitochondrial energy metabolism. *Physician's*

guide to the laboratory diagnosis of metabolic diseases 391-406.

**Shoffner JM and Wallace DC.** 1994 Oxidative phosphorylation diseases and mitochondrial DNA mutations: diagnosis and treatment *Annu Rev Nutr* 14 535-568.

**Spencer SR, Taylor JB, Cowell IG, Xia CL, Pemble SE, Ketterer B.** 1992 The human mitochondrial NADH:ubiquinone oxidoreductase 51-kDa subunit maps adjacent to the glutathione S-transferase P1-1 gene on chromosome 11q13. *Genomics* 14:1116-1118.

**Trijbels F, Ruitenbeek W, Sengers R, Janssen A, van Oost B.** 1996 Benign mitochondrial encephalomyopathy in a patient with complex I deficiency. *J Inher Metab Dis* 19:149-152

**Walker JE.** 1992. The NADH:ubiquinone oxidoreductase (complex I) of respiratory chains *Q Rev Biophys* 25:253-324.

**Walker JE, Arizmendi JM, Dupuis A, Fearnley IM, Finel M, Medd SM, Pilkington SJ, Runswick MJ, Skehel JM.** 1992 Sequences of 20 subunits of NADH:Ubiquinone oxidoreductase from bovine heart mitochondria *J Mol Biol* 226 1051-1072.

**Wallace DC.** 1992. Diseases of the mitochondrial DNA *Annu Rev Biochem* 61 1175-1212

**Yamaguchi M and Hatefi Y.** 1993. Mitochondrial NADH:ubiquinone oxidoreductase (complex I): proximity of the subunits of the flavoprotein and the iron-sulphur protein subcomplexes. *Biochemistry* 32.1935-1939.

**Zhuchenko O, Wehnert M, Bailey J, Sheng Sun Z, Chi Lee C.** 1996. Isolation, mapping and genomic structure of an X-Linked gene for a subunit of human mitochondrial complex I *Genomics* 37:281-288.





### THE FIRST NUCLEAR-ENCODED COMPLEX I MUTATION IN A PATIENT WITH LEIGH SYNDROME

*American Journal of Human Genetics* 1998 63:1598-1608

#### **Abstract.**

Nicotinamide adenine dinucleotide (NADH):ubiquinone oxidoreductase (complex I) is the largest multi-protein enzyme complex of the respiratory chain. The nuclear-encoded NDUFS8 (TYKY) subunit of complex I is highly conserved among eukaryotes and prokaryotes and contains two 4Fe4S ferredoxin consensus patterns, which have long been thought to provide the binding site for the iron-sulphur cluster N-2. The *NDUFS8* cDNA contains an open reading frame of 633 bp, coding for 210 amino acids. Cycle sequencing of amplified *NDUFS8* cDNA of 20 patients with isolated enzymatic complex I deficiency revealed two compound heterozygous transitions in a patient with neuropathologically proven Leigh syndrome. The first mutation was a C236T (P79L), and the second mutation was a G305A (R102H). Both mutations were absent in 70 control alleles and co-segregated within the family. A progressive clinical phenotype proceeding to death in the first months of life was expressed in the patient. In the 19 other patients with enzymatic complex I deficiency, no mutations were found in the *NDUFS8* cDNA. This article describes the first molecular genetic link between a nuclear-encoded subunit of complex I and Leigh syndrome.

## Introduction.

The oxidative phosphorylation (OXPHOS) system of mammals consists of five complicated multi-protein complexes (complexes I-V). Complexes I and II accept electrons from the reduced coenzymes nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH<sub>2</sub>), respectively. These electrons are transported along the electron transport chain, and coupled to this transport a proton gradient is created by complexes I, III, and IV across the inner mitochondrial membrane. ATP synthase (complex V) couples proton movement down its electrochemical gradient with the synthesis of ATP from adenosine diphosphate and P<sub>i</sub>.

Complex I has been widely studied in prokaryotes as well as eukaryotes. Genetic characteristics of NADH ubiquinone oxidoreductase are best documented in *Bos taurus* (Walker 1992), *Neurospora crassa* (Weiss et al 1991), and *Escherichia coli* (Weidner et al 1993, Friedrich 1998). *E. coli* complex I consists of the 14 subunits that together are considered to be the minimal structural unit for enzymatic activity. In humans, the exact number of complex I subunits is unknown (for a review see Smeitink et al 1998a). *B. taurus* is the mammal nearest to humans whose complex I has been structurally elucidated (Walker 1992, Grigorieff 1998). It contains ~42 subunits (Walker 1995, Walker et al 1995), 35 of which are encoded by the nucleus and the remaining 7 by mtDNA (Chomyn et al 1985 and 1986). Complex I contains several redox centres to facilitate electron transport. These are hypothesised to be one non-covalently bound flavin mononucleotide and 6-8 iron-sulphur clusters (Yamaguchi and Hatefi 1993, Albracht et al 1996, Ohnishi 1998).

One of the most frequently encountered syndromes associated with defects of the OXPHOS system was named after the man who first described a young patient suffering from a progressive neurodegenerative disorder with characteristic neuropathology, namely, Leigh syndrome (MIM 256000, Leigh 1951). The estimated incidence of Leigh syndrome is ~1/40,000 live births (Rahman et al 1996). Several inheritance patterns can be differentiated in Leigh syndrome (DiMauro and De Vivo 1996): autosomal recessive, with defects described in biotinidase (Baumgartner et al 1989), pyruvate dehydrogenase complex (PDHc), OXPHOS complex II (Bourgeron et al 1995) and complex IV (Willems et al 1977), X-linked recessive, with defects in the E<sub>1</sub> $\alpha$  subunit of PDHc (Matthews et al 1993), and maternal, with defects in subunit 6 of ATP synthase (Shoffner et al 1992, Tatuch et al 1992), tRNA(Lys) (Hammans et al 1993), tRNA(Trp) (Santorelli et al 1997), tRNA(Val) (Chalmers et al 1997), and tRNA(Leu) (Graeber and Muller 1998), MERFF mutation A8344G (Berkovic et al 1991), and A3243G (Rahman et al 1996). Recently, respiratory-chain enzyme assays performed in patients with Leigh syndrome revealed that complex I deficiency (MIM 252010) is a major contributor to this disease entity (Morris et al 1996, Rahman et al 1996), but until now molecular genetic defects have not been described.

The NDUF8 (TYKY) is a highly conserved nuclear-encoded complex I subunit with equivalents present in many species, best documented in humans (Procaccio et al 1997), *B. taurus* (Walker 1992), *N. crassa* (Duarte et al 1996), *E. coli* (Weidner et al 1993), and *Rhodobacter capsulatus* (Chevallet et al 1997). The position of the NDUF8 subunit in different fractions of complex I (flavoprotein [FP] fraction, iron-sulphur protein [IP] fraction,

and hydrophobic protein [HP] fraction) has not been firmly established Masui et al (1991) located the bovine TYKY subunit in the IP fraction, but it is also considered to belong to the HP fraction (Walker 1992) The amino acid sequence contains two 4Fe4S ferredoxin consensus patterns (PROSITE pattern P500198 CIACKLCEAICP and CIYCGFCQEACP) Whether these consensus patterns provide the binding site for iron-sulphur cluster N-2 is still under debate (Dupuis et al 1991, Albracht et al 1997, Duarte et al 1997) Albracht and coworkers proposed in 1997 that the NDUFS8 subunit has functional significance in the reduction of ubiquinone coupled to the pumping of protons Recently, homologous recombination studies performed with the NuoI subunit of *R. capsulatus* (equivalent to human NDUFS8) showed that NuoI plays an important role in the assembly of complex I, which emphasises the importance of this subunit (Chevallet et al 1997)

Herein we report the results of a mutational analysis study of the NDUFS8 subunit performed in 20 patients with isolated complex I deficiency Our study revealed two new compound heterozygous transition mutations in one patient with Leigh syndrome Detailed information concerning the clinical characteristics of this patient is presented This is the first molecular genetic link between Leigh syndrome and a nuclear-encoded subunit of NADH ubiquinone oxidoreductase In addition, we studied the mRNA tissue distribution of the NDUFS8 subunit and discuss possible connections between tissue expression and the clinical phenotype of the patient

## **Patients, material, and methods.**

### *Case report*

In May 1990, a 5-wk-old male infant presented with poor feeding and episodes of apnoea and cyanosis The symptoms, which had existed since the first day of life, escalated in the course of an acute gastro-enteritis He was the second child of healthy, non-consanguineous parents of Dutch origin Pregnancy, birth, and first hours of life were uneventful The family history was negative for major neurological disorders At admission, the main symptoms were mild cyanosis, severe hypercarbia, a cardiac murmur (grade 2/4), drowsiness with absent optical and acoustical blink, eye flutter, intense hypotonia, brisk tendon reflexes with ankle clonus, and erratic seizures A weak cry, rudimentary sucking and primitive reflexes were still present The occipitofrontal circumference was normal Dysmorphic features or hepatomegaly were absent Cardiac investigation revealed a moderate hypertrophic obstructive cardiomyopathy Computed tomography of the brain showed extensive white-matter hypodensity, mild ventricular enlargement, and, at a later occasion, also hypodense symmetric lesions in putamen and mesencephalon Evoked potentials were delayed for all modalities tested Blood tests showed increased lactate (3.4 mmol/l, normal range 0.6-2.1 mmol/l) and pyruvate (167 µmol/l, normal range 30-80 µmol/l) levels Cerebrospinal fluid (CSF) lactate and pyruvate levels were elevated to 5.6 mmol/l (normal range 1.4-1.9 mmol/l) and 193 µmol/l (normal range 96-145 µmol/l), respectively The CSF lactate/pyruvate ratio was also increased (29.0, normal range 1.1-7.16.5), and the CSF protein content was slightly increased (504 mg/l, normal range 245-460 mg/l)

On the basis of these findings, a clinical diagnosis of subacute necrotising

encephalomyelopathy, or Leigh syndrome, was made. Light microscopy studies of a quadriceps femoris muscle biopsy sample obtained when the infant was 10 wk of age showed a reduced number of small type I fibres (16%, normal 50%), ragged red fibres were not seen. Electron microscopy (EM) studies were not performed. At the age of 11 wk, the infant died of cardiorespiratory failure. Biochemical examinations performed on skin fibroblasts, skeletal muscle, heart muscle, and liver and brain tissue, obtained at autopsy performed <1 h after death, revealed severely reduced activity of NADH ubiquinone oxidoreductase (39% residual activity of the lowest reference value in muscle tissue, see Table 9 I), whereas all other complexes of the respiratory chain expressed normal activity. PDHc activity was slightly reduced in muscle. In cultured skin fibroblasts, an isolated NADH ubiquinone oxidoreductase deficiency was observed (69% residual activity of the lowest reference value, see Table 9 I). Biochemical studies of heart, liver, and brain tissue (also obtained at autopsy) revealed an overall reduced activity of NADH ubiquinone oxidoreductase, with respectively, virtually 0%, 53%, and 3% residual activity of the lowest reference value (Table 9 I). The completely deficient complex I activity in heart tissue was repeatedly confirmed. Macroscopically, the brain had a normal appearance. Microscopic investigation of the brain showed extensive bilateral symmetrical degeneration, predominantly in the rostral and caudal brain stem, diencephalon, and central nuclei, but also elsewhere, including the spinal cord and semioval centre. The lesions consisted of spongiform degeneration, capillary proliferation with endothelial swelling, demyelination, and gliosis. Neuronal damage was variable in different brain slides, partly because there was a relative sparing of neurons in comparison to the surrounding tissue. EM studies of heart and liver tissue were not performed. On the basis of data obtained at autopsy, the patient was neuropathologically diagnosed with Leigh syndrome.

#### *Patient group*

Twenty patients with isolated complex I deficiency (4 females and 16 males) were included in this study. Concise clinical characteristics have been published elsewhere (Loeffen et al 1998), and a detailed report of our complex I deficient patient group will be published elsewhere (Loeffen et al 2000). In this patient group the *NDUFA1*, *NDUFS4*, *NDUFS5*, and *NDUFB6* cDNA were previously examined by direct DNA sequencing (Loeffen et al 1998, Smeitink et al 1998b, van den Heuvel et al 1998, Loeffen et al 1999). In one patient a mutation was found in the *NDUFS4* gene. Neither major mitochondrial DNA rearrangements nor common pathogenic mtDNA mutations (A3243G [MELAS], T3271C [MELAS], A4317G [MELAS], A8344G [MERRF], T8993G/C [NARP/Leigh syndrome]) were present in this patient group.

#### *Commercially purchased materials*

Molecular size markers, *Taq* DNA polymerase, Superscript II RNAse H<sup>-</sup> reverse transcriptase, *BalI* restriction endonuclease, and custom-made oligonucleotide primers were obtained from Life Technologies, *PvuAI* restriction endonuclease from Promega, a d-Rhodamine DyeDeoxy Terminator Sequencing Kit from Perkin Elmer, gel purification systems from Qiagen, a poly A<sup>+</sup> RNA pool and a Poly A<sup>+</sup> RNA master blot from Clontech, and RNazol from Biosolve BV.

### *Software*

Consensus-pattern searches in the *NDUFS8* amino acid sequence were performed with PROSITE. Sequence alignments were performed with Sequence Navigator (Perkin Elmer). Hydrophathy and secondary structure were plotted by means of methods based on the procedures described by Chou and Fasman 1978, Kyte and Doolittle 1982, and Nishikawa 1983. Computer software was obtained from the National Centre for Computer-Aided Chemistry and Bioinformatics (CAOS/CAMM).

### *Tissue culture and enzyme measurements*

In our patient group, biochemical enzyme measurements of respiratory-chain complexes were performed on skin fibroblasts cultured according to standard procedures. Enzyme assay procedures were slightly modified from those used for muscle tissue (Bentlage et al 1996).


The autopsy tissue materials of the patient described in this article were obtained <1 h after death and immediately deep frozen in liquid nitrogen and kept at -80°C until enzyme assays were performed. The enzyme assays described in this paper were based on the following methods (slightly modified): NADH ubiquinone oxidoreductase according to Fischer et al (1986), succinate cytochrome *c* oxidoreductase according to Fischer et al (1985), cytochrome *c* oxidase according to Cooperstein and Lazarow (1951), citrate synthase according to Srere (1969), and PDHc according to van Laack et al (1988). Control tissue specimens were handled and stored under conditions similar to those of the patient. In our experience, loss of respiratory-chain enzyme activities in deep-frozen tissue samples obtained <2 h after death is negligible. Control values and number of controls are listed in Table 9.1. Values in fibroblasts are expressed on cytochrome *c* oxidase base (cytochrome *c* oxidase and citrate synthase are expressed on a protein base). We chose cytochrome *c* oxidase as a marker instead of citrate synthase, because in the presented patient enzyme activities were measured in fibroblasts mitochondria enriched fractions. In our experience, citrate synthase can be artificially decreased in mitochondria enriched fractions, since it is a mitochondrial matrix enzyme.

### *Mutational analysis of the NDUFS8 cDNA*

Patient RNA was extracted from cultured skin fibroblasts according to methods described by Chomczynski and Sacchi 1987. Wild-type RNA was commercially obtained and consisted of pooled poly A<sup>+</sup> RNA from 12 healthy Caucasian males and females, age range 12–78 years. The RNA was reverse transcribed to cDNA by superscript II RNase H<sup>-</sup> reverse transcriptase with oligo(dT) and random hexamer primers (Ploos van Amstel et al 1996).

Oligonucleotide primers were designed according to the *NDUFS8* cDNA sequence published by Procaccio et al (1997, GenBank accession number U65579). The primer oligonucleotides F(oward)1 (5' TGGCCGAATGGCAGCGTC 3') and R(everse)3 (5' TTTTATTGGGCAGCAGGGGC 3') were applied in PCR to amplify the complete open reading frame (ORF). PCR was performed in a reaction volume of 25 µl containing 1 µl of cDNA template, 0.5 unit of *Taq* DNA polymerase, 2.5 µl of 10× PCR buffer, 1.5 mM of MgCl<sub>2</sub>, 50 ng of F1 and R3, and 2.5 mM of dNTPs. PCR parameters were 35 cycles of 1 min denaturation at 94°C, 1 min annealing at 58°C, and 1 min extension at 72°C. The cycles were preceded by an initial denaturation step of 1 min at 94°C and were followed by a final extension step of 10 min. The amplification

product was purified from a 2% agarose gel. Sequence reactions using the DyeDeoxy Terminator Sequencing Kit were performed with oligonucleotide primers F1, F2 (5'-CCTACAAGTATGTGAACATGC-3'), F3 (5'-CATTGCCTGCAAGCTCTGCG-3'), R1 (5'-AGTTGATGGTGGCCGGTTCC-3'), R2 (5'-GATGTCATAGCGGGTGGTCC-3'), and R3 (Fig. 9.1). The cDNA sequence analysis was performed on the automated ABI 377 sequencer according to the protocol provided by the manufacturer.



**Fig. 9.1** Human *NDUF58* cDNA and amino acid sequence (Procaccio et al 1997). Primers used for amplification of the ORF were F1 and R3; all primers were used in DNA sequence reactions. The ORF is printed bold and is capitalised, and both consensus 4Fe4S ferredoxin clusters are in italic and underlined. Mutations are shown above the cDNA sequence, substitutions below the amino acid sequence.

*Restriction enzyme endonuclease analysis.*

Both mutations were confirmed by restriction endonuclease analysis of the *NDUF58* cDNA fragment obtained with oligonucleotide primers F1 and R3. C236T was cleaved with restriction enzyme *BalI* (recognition site 5'-TGG/CCA-3') and G305A with *PinA*I (recognition site 5'-A/CCGGT-3') (The forward slash [/] indicates the break point as created by the restriction enzymes). The transition mutations present in our patient (position underlined in the digestion recognition site) introduce the restriction sites. For both digestions, conditions were used as recommended by the manufacturer.

#### *Tissue distribution of the NDUF58 mRNA.*

A human RNA master blot was used to quantify the expression of *NDUF58* mRNA in a range of human adult and foetal tissues. The quantity of RNA spotted for each tissue onto the master blot was normalised using eight different housekeeping gene transcripts as probes (ribosomal protein S9, ubiquitin, 23 kDa highly basic protein, hypoxanthine guanine phosphoribosyl transferase, tubulin,  $\beta$ -actin, phospholipase, and glyceraldehyde triphosphate dehydrogenase). Using a standard hybridisation solution (Sambrook et al 1989), we hybridised the master blot with an  $\alpha$ [ $^{32}$ P]-dCTP-labelled cDNA probe. The blot was washed twice with  $2\times$  SSC, 1% SDS, at 65°C and was subjected to autoradiography.

### **Results.**

#### *Biochemical measurements*

In our patient group (n=20), residual complex I activity measured in cultured skin fibroblasts was 24%-73% of the lowest reference value (expressed on a cytochrome *c* oxidase base). The other respiratory-chain complexes showed normal activities in all patients. In most patients, respiratory-chain complex activities were also measured in other tissues apart from fibroblasts. In the case of the patient with two compound heterozygous transition mutations in the *NDUF58* gene, enzyme activities were measured in a quadriceps muscle biopsy specimen, in cultured skin fibroblasts, and in liver, brain, and heart tissue. In all of these tissues complex I activity was markedly reduced, whereas other complexes of the electron transport chain were essentially within the normal range (Table 9 I).

#### *Mutational analysis of the NDUF58 cDNA*

PCR with oligonucleotide primers F1 and R3 produced a cDNA fragment of 757 bp, including the complete ORF of the *NDUF58* subunit. Direct DNA sequence analysis of amplified pooled control *NDUF58* cDNA confirmed the published wild-type cDNA sequence. Amplified *NDUF58* patient cDNA was then cycle sequenced and analysed. In one patient this revealed two heterozygous transitions. The first mutation, a C→T at bp position 236, resulted in an amino acid change of proline into leucine (amino acid position 79). In the second mutation, a G→A at bp position 305, arginine had been replaced by histidine (amino acid position 102). The presence of the first and second mutation in the common population was checked by restriction endonuclease analysis. In 35 controls (70 alleles), C236T and/or G305A were not present. The other 19 patients with enzymatic complex I deficiency all displayed the wildtype *NDUF58* cDNA sequence.


	Muscle tissue		Skin fibroblasts		Heart tissue		Liver tissue		Brain tissue	
	PAT	CON	PAT	CON	PAT	CON	PAT	CON	PAT	CON
Complex I	1.7 <sup>a</sup>	4.4-19 (31)	0.069 <sup>b</sup>	0.11-0.28 (14)	± 0 <sup>a</sup>	4.5-41 (6)	2.5 <sup>a</sup>	4.7-9.2 (7)	0.16 <sup>a</sup>	5.1-19 (5)
Complex IV	170 <sup>a</sup>	73-284 (21)	181 <sup>a</sup>	147-252 (14)	174 <sup>a</sup>	73-412 (7)	53 <sup>a</sup>	13.9-108 (11)	58 <sup>a</sup>	26-181 (14)
Suc. cyt c oxidored.	24 <sup>a</sup>	22-78 (39)	0.33 <sup>b</sup>	0.21-0.44 (14)	26.3 <sup>a</sup>	11.2-62 (7)	14 <sup>a</sup>	6.0-51 (9)	14 <sup>a</sup>	11-40 (6)
Citrate synthase	87 <sup>a</sup>	48-146 (43)	154 <sup>a</sup>	144-257 (14)	316 <sup>a</sup>	208-490 (7)	37 <sup>a</sup>	13.7-96 (10)	216 <sup>a</sup>	53-207 (10)
PDHc	2.5 <sup>a</sup>	2.8-8.0 (15)	-	-	9.1 <sup>a</sup>	2.3-21 (6)	1.1 <sup>a</sup>	0.38-7.4 (24)	-	-

**Table 9.1** Respiratory chain enzyme activities in index patient's tissue specimens. Patient's individual respiratory-chain enzyme and PDHc activities measured in skeletal muscle tissue, cultured skin fibroblasts, heart tissue, liver tissue, and brain tissue. Complex I activity is severely reduced in all tissue specimens. Numbers in parentheses denote how many controls were used for each enzyme assay. Suc. cyt c oxidored. = succinate:cytochrome c oxidoreductase. <sup>a</sup> = mU/mg protein; <sup>b</sup> = mU/mU cytochrome c oxidase.

*Confirmation of mutations by restriction endonuclease analyses.*

RNA isolated from whole blood of both parents and three healthy siblings (two boys, one girl) was reverse transcribed to cDNA. Oligonucleotide primers used for cloning of the complete ORF of the *NDUFS8* subunit were applied in PCR. The PCR fragment was digested with restriction enzymes *BalI* (C236T) and *PinAI* (G305A). The results were visualised on a 4% agarose gel. Since both restriction endonucleases cut in the region containing the mutation, the wild-type *NDUFS8* cDNA fragment remained intact. In the patient both mutations were heterozygous, and after cleavage with *BalI* they expressed three bands (a wild-type cDNA fragment, one fragment of 325 bp, and one fragment of 432 bp). Incubation with *PinAI* again revealed three fragments (a wild-type cDNA fragment, one band of 365 bp, and one band of 392 bp). When *BalI* and *PinAI* were added simultaneously, the corresponding four digestion fragments were seen, which implies that the two mutations are on different alleles (data not shown). Three bands corresponding to the patient's were expressed in the father's cDNA after incubation with *BalI*, and a single wild-type band was expressed when *PinAI* was applied. The mother's cDNA showed an undigested wild-type band after incubation with *BalI* and three bands (similar to the patient's) when *PinAI* was used. An older brother had the same digestion pattern as the father, a younger sister the same fragment pattern as the mother, and the youngest son showed only wild-type bands after digestion with *BalI* and *PinAI* (Fig. 9.2).





**Fig. 9.2** Restriction endonuclease analysis pattern. Wild-type and Sib 3 *NDUF58* cDNA is undigested; patient is a carrier of C236T and G305A, father and sib 1 are carriers of C236T, and mother and sib 2 are carriers of G305A. The marker (m) is Lambda *Pst*I. For each person, the first lane contains the fragments after digestion with *Bcl*I (B), and the second lane the fragments after *Pst*I (P) was applied.

#### *Tissue distribution of the NDUF58 mRNA.*


Hybridisation of the [ $^{32}$ P]-dCTP-labelled *NDUF58* cDNA probe to the RNA master blot revealed a ubiquitous expression pattern in human adult and foetal tissues. Adult tissue dots with relatively higher intensities are, in decreasing order, heart, skeletal muscle, pituitary gland, adrenal gland, kidney, caudate nucleus, putamen, substantia nigra, and lung. Among foetal tissues, heart expressed the highest dot intensity (Fig. 9.3).

#### **Discussion.**

The clinically, biochemically, and genetically heterogeneous group of OXPHOS disorders (estimated incidence 1:10,000 live births (Bourgeron et al 1995) has a main contributor in Leigh syndrome combined with isolated complex I deficiency. In the late 1980s and early 1990s, several mtDNA mutations associated with complex I deficiency were identified (Wallace et al 1988, Holt et al 1989, Poulton and Gardiner 1989, Zeviani et al 1989, Goto et al 1990, Holt et al 1990, Tanaka et al 1990, Zeviani et al 1991, Shoffner et al 1992). Yet, in many patients with isolated complex I deficiency, mtDNA mutations cannot be found (Buddiger et al 1997, Loeffen et al 1999). Recently, we found the first mutation (a 5-bp duplication in the *NDUF54* (18 kDa) gene to be identified in a nuclear-encoded subunit of complex I (van den Heuvel et al 1998). These findings make further studies of mutations in nuclear-encoded subunits of complex I necessary.

	1	2	3	4	5	6	7	8
a	whole brain	amygdala	caudate nucleus	cerebellum	cerebral cortex	frontal lobe	hippocampus	medulla oblongata
b	occipital lobe	putamen	substantia nigra	temporal lobe	thalamus	subthal. nucleus	spinal cord	
c	heart	aorta	skeletal muscle	colon	bladder	uterus	prostate	stomach
d	testis	ovary	pancreas	pituitary gland	adrenal gland	thyroid gland	salivary gland	mammary gland
e	kidney	liver	small intestine	spleen	thymus	peripheral leukocyte	lymph node	bone marrow
f	appendix	lung	trachea	placenta				
g	foetal brain	foetal heart	foetal kidney	foetal liver	foetal spleen	foetal thymus	foetal lung	
h	yeast RNA	yeast tRNA	<i>E. coli</i> rRNA	<i>E. coli</i> DNA	poly r(A) 100 ng	human C <sub>0</sub> t1 DNA 100 ng	human DNA 100 ng	human DNA 500 ng

**Fig. 9.3a** Multiple tissue master blot. The type and position of poly(A<sup>+</sup>) RNAs and controls dotted on the positively charged nylon membrane.



**Figure 9.3b** Tissue distribution of *NDUF58* mRNA with a poly A<sup>+</sup> RNA master blot. *NDUF58* is ubiquitously expressed in human tissues, with a relatively higher expression in the human heart, skeletal muscle, gland tissue, kidney, caudate nucleus and putamen.

We chose the NDUF58 subunit for mutational analysis studies for several reasons. In the first place, the NDUF58 subunit is highly conserved among species, with, for example, 93% amino acid identity between humans and *B. taurus*. It is also one of the 14 subunits that together constitute the minimal structural unit for enzymatic activity, as found in *E. coli*, which stresses its possible functional significance. Finally, it contains two consensus 4Fe4S ferredoxin patterns, which have long been considered to be binding sites for iron-sulphur cluster N-2. These findings make this protein a strong candidate gene for isolated complex I deficiency. Cycle sequencing of the NDUF58 cDNA in our complex I-deficient patient group revealed two compound heterozygous mutations in a patient neuropathologically diagnosed with Leigh syndrome. The clinical phenotype of this patient and the results of additional laboratory and imaging studies are highly suggestive of an OXPHOS disorder, and diagnosis (isolated complex I deficiency) was biochemically confirmed in muscle tissue, cultured skin fibroblasts, and heart, liver, and brain tissue. The first transition (C236T) resulted in an amino acid substitution of leucine for proline. It is well known that proline markedly influences protein architecture. A Chou-Fasman plot comparison of NDUF58 wild types and NDUF58 containing this specific mutation clearly revealed the disturbance of an  $\alpha$  helix by a  $\beta$ -sheet. Although it remains purely speculative which conformation the NDUF58 protein will have when incorporated in the entire complex, proline is very important for secondary and tertiary structure, and thus the disappearance of this amino acid will likely disturb the protein structure. The second mutation (G305A) replaced arginine with histidine. Histidine contains an imidazole side chain that can readily switch between uncharged and positively charged to catalyse the making and breaking of bonds. A Basic Local Alignment Search Tool (BLAST) search at the server of the National Centre for Biotechnology Information with the human NDUF58 amino acid sequence revealed an extremely strong conservation of the region containing the arginine, which is mutated in the patient. This region of 24 amino acids is  $\pm 100\%$  conserved in, among others, *B. taurus*, *N. crassa*, *Paracoccus denitrificans*, *Rhodobacter capsulatus*, and *Nicotiana tabacum*. This stresses the possible significance of this region, which is located just prior to the first cysteine-rich 4Fe-4S ferredoxin consensus pattern (eight amino acid residues between the mutated arginine and the consensus cluster). An arginine-to-histidine mutation is the main genetic cause in another disease associated with complex I deficiency, namely, Leber hereditary optic neuropathy (Wallace et al 1988, Singh et al 1989). Although both amino acids are basic, they are clearly not, in all cases, exchangeable. Since neither mutation is present in 70 control alleles and in the remaining 19 complex I-deficient patients, it is unlikely that these mutations represent population polymorphisms. These two mutations with an autosomal recessive inheritance pattern, combined with the lethal clinical course within the early months of life, provide further evidence for the functional importance of this iron-sulphur cluster binding pattern containing nuclear-encoded complex I subunit.

Restriction endonuclease analysis performed on NDUF58 cDNA of all members of the patient's family showed that mutation C236T was inherited from the father and mutation G305A from the mother. In the oldest son (carrier of C236T), the activity of respiratory chain enzyme complexes was measured in a skeletal muscle biopsy specimen, and that of each

complex was within the normal range. While the mother was pregnant with the younger sister (carrier of G305A), chorionic villi were obtained for biochemical measurements of the respiratory-chain complex activities, which were again within normal limits (no muscle biopsy was performed in the younger sister). It seems likely, therefore, that both mutations are necessary to reduce the enzymatic activity of NADH ubiquinone oxidoreductase.

Leigh syndrome has been linked, by biochemical enzyme assays, to several single enzyme and enzyme complex deficiencies, including deficiencies in biotinidase, PDHc, NADH ubiquinone oxidoreductase, succinate dehydrogenase, cytochrome *c* oxidase, and ATP synthase. However, molecular genetic defects have been described in only a few subunits of PDHc, the FP subunit of succinate dehydrogenase, subunit 6 of ATP synthase, and some mitochondrially encoded tRNAs. Recent mutational analysis of all 10 nuclear encoded subunits of cytochrome *c* oxidase (complex IV of the OXPHOS system) in a Leigh syndrome patient with cytochrome *c* oxidase deficiency revealed no mutations (Adams et al 1997). The patient described in the present article provides the first genetic link between a nuclear-encoded subunit of complex I and Leigh syndrome. Since complex I deficiency is a large contributor to Leigh syndrome, other patients with isolated complex I deficiency in whom a similar clinical phenotype is expressed should be screened for *NDUFS8* mutations as well.

The tissue expression of the *NDUFS8* cDNA showed dots with relatively high intensity in heart, skeletal muscle, kidney, pituitary gland, adrenal gland, caudate nucleus, putamen, and lung. All of these tissues have a relatively high energy demand and are therefore likely to be affected by reduced energy availability. The patient with Leigh syndrome reported here had symptoms that strongly correlate with the high-intensity dots present on the *NDUFS8* master blot, such as hypertrophic cardiomyopathy, hypotonia, convulsions, and episodes of respiratory distress. The specific neuropathology seen in Leigh syndrome can be hypothesised to be the result of oxidative stress caused by a diminished activity of complex I. It would be reasonable to assume that oxygen radicals are generated in the vicinity of an iron-sulphur cluster. A defective *NDUFS8* subunit, as seen in our patient, is a likely source of malfunctioning electron transport and therefore a possible source of free radicals. The review by Robinson (1998) concerning oxygen free radicals and human complex I deficiency states that *NDUFS8* would be a prime candidate for an electron donor for superoxide formation. Future research is necessary to investigate the possible relationship between the specific neuropathology present in Leigh syndrome and malfunction of the *NDUFS8* subunit.

In conclusion, we have described herein the first mutations identified in the nuclear-encoded *NDUFS8* subunit of complex I (possible binding site for iron-sulphur cluster N-2) in a patient with isolated complex I deficiency whose condition was neuropathologically diagnosed as Leigh syndrome. Our analysis of these compound heterozygous transitions is the second report of genetic defects in nuclear-encoded subunits of complex I. The frequency of these mutations in complex I deficient patients in general and, more specifically, in patients diagnosed with Leigh syndrome must be further established. These findings contribute to possibilities for genetic counselling and prenatal diagnosis, which are of utmost importance since therapeutic intervention in complex I disease is very unsatisfactory. We will continue to search for other candidate genes for complex I deficiency.

## **Acknowledgements.**

We are very grateful to Grazia Maureci, Antoon Janssen, Frans van den Brandt, Melan Bakker, and Carin Buskens for technical assistance. This study was financially supported by the Stichting Voor Kinderen Die Wel Willen Maar Niet Kunnen and the Prinses Beatrix Fonds (to J.S. and L.vd.H.).

## Reference List.

- Adams PL, Lightowlers RN, Turnbull DM.** 1997 Molecular analysis of cytochrome c oxidase deficiency in Leigh's syndrome *Ann Neurol* 41 268-270
- Albracht PJ, Mariette A, Jong de Ph.** 1997 Bovine-heart NADH ubiquinone oxidoreductase is a monomer with 8 Fe-S clusters and 2 FMN groups *Biochim Biophys Acta* 1318 92-106
- Baumgartner ER, Suormala TM, Wick H, Probst A, Blauenstein U, Bachmann C, Vest M.** 1989 Biotinidase deficiency a cause of subacute necrotising encephalomyelopathy (Leigh syndrome) Report of a case with lethal outcome *Pediatr Res* 26 260-266
- Bentlage H, Wendel U, Schagger H, ter Laak H, Janssen A, Trijbels F.** 1996 Lethal infantile mitochondrial disease with isolated complex I deficiency in fibroblasts with combined complex I and IV deficiencies in muscle *Neurology* 47 243-248
- Berkovic SF, Shoubridge EA, Andermann F, Andermann E, Carpenter S, Karpatis G.** 1991 Clinical spectrum of mitochondrial DNA mutation at base pair 8344 *Lancet* 338 457
- Bourgeron T, Rustin P, Chretien D, Birch-Machin M, Bourgeois M, Viegas-Pequignot E, Munnich A, Rotig A.** 1995 Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency *Nat Genet* 11 144-149
- Buddiger P, Ruitenbeek W, Scholte HR, van Oost BA, Smeets HJM, de Coo R.** 1997 Molecular genetic analysis of complex I genes in patients with a deficiency of complex I of the respiratory chain *Am J Hum Genet* supplement to vol 61 A305
- Chalmers RM, Lamont PJ, Nelson I, Ellison DW, Thomas NH, Harding AE, Hammans SR.** 1997 A mitochondrial DNA tRNA(Val) point mutation associated with adult-onset Leigh syndrome *Neurology* 49 589-592
- Chevallet M, Dupuis A, Lunardi J, van Belzen R, Albracht SP, Issartel JP.** 1997 The NuoL subunit of the *Rhodobacter capsulatus* respiratory Complex I (equivalent to the bovine TYKY subunit) is required for proper assembly of the membranous and peripheral domains of the enzyme *Eur J Biochem* 250 451-458
- Chomczynski P and Sacchi N.** 1987 Single step method of RNA isolation by acid guanidium thiocyanate phenol-chloroform extraction *Anal Biochem* 162 156-159
- Chomyn A, Cleeter MWJ, Ragan CI, Riley M, Doolittle RF, Attardi G.** 1986 URF6, Last unidentified reading frame of human mtDNA, codes for an NADH dehydrogenase subunit *Science* 234 614-618
- Chomyn A, Mariottini P, Cleeter MWJ, Ragan CI, Matsuno-Yagi A, Hatefi Y, Doolittle RF, Attardi G.** 1985 Six unidentified reading frames of human mitochondrial DNA encode components of the respiratory-chain NADH dehydrogenase *Nature* 314 592-597
- Chou PY and Fasman GD.** 1978 Prediction of the secondary structure of proteins from their amino acid sequence *Adv Enzymol Rel Ar Mol Biol* 47 45-148
- Cooperstein SJ and Lazarow A.** 1951 A microspectrophotometry method for the determination of cytochrome c oxidase *J Biol Chem* 189 665-670
- DiMauro S and De Vivo DC.** 1996 Genetic heterogeneity in Leigh syndrome *Ann Neurol* 40 57
- Duarte M, Finel M, Videira A.** 1996 Primary structure of a ferredoxin-like iron-sulphur subunit of complex I from *Neurospora crassa* *Biochim Biophys Acta* 1275 151-153
- Duarte M, Schulte U, Videira A.** 1997 Identification of the TYKY homologous subunit of complex I from *Neurospora crassa* *Biochim Biophys Acta* 1322 237-241
- Dupuis A, Skehel JM, Walker JE.** 1991 A homologue of a nuclear-coded iron-sulphur protein subunit of bovine mitochondrial complex I is encoded in chloroplast genomes *Biochemistry* 30 2954-2960
- Fischer JC, Ruitenbeek W, Berden JA, Trijbels JM, Veerkamp JH, Stadhouders AM, Sengers RC, Janssen AJ.** 1985 Differential investigation of the capacity of succinate oxidation in human skeletal muscle *Clin Chim Acta* 153 23-36
- Fischer JC, Ruitenbeek W, Trijbels JM, Veerkamp JH, Stadhouders AM, Sengers RC, Janssen AJ.** 1986 Estimation of NADH oxidation in human skeletal muscle mitochondria *Clin Chim Acta* 155 263-273
- Friedrich T.** 1998 The NADH ubiquinone oxidoreductase (complex I) from *Escherichia coli* *Biochim Biophys Acta* 1364 134-146
- Goto Y, Nonaka I, Horai S.** 1990 A mutation in the

- tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. *Nature* 348 651-653.
- Graeber MB and Muller U.** 1998. Recent developments in the molecular genetics of mitochondrial disorders. *J Neurol Sci* 153:251-263.
- Grigorieff N.** 1998. Three-dimensional structure of bovine NADH:Ubiquinone oxidoreductase (Complex I) at 2.2 Å in Ice. *J Mol Biol* 277:1033-1046.
- Hamman SR, Sweeney MG, Brockington M, Lennox GG, Lawton NF, Kennedy CR, Morgan-Hughes JA, Harding AE.** 1993. The mitochondrial DNA transfer RNA(Lys)A→G(8344) mutation and the syndrome of myoclonic epilepsy with ragged red fibres (MERRF). Relationship of clinical phenotype to proportion of mutant mitochondrial DNA. *Brain* 116 617-632.
- Holt IJ, Harding AE, Cooper JM, Schapira AH, Toscano A, Clark JB, Morgan-Hughes JA.** 1989. Mitochondrial myopathies: clinical and biochemical features of 30 patients with major deletions of muscle mitochondrial DNA. *Ann Neurol* 26:699-708.
- Holt IJ, Harding AE, Petty RK, Morgan-Hughes JA.** 1990. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. *Am J Hum Genet* 46:428-433.
- Kyte J and Doolittle RF.** 1982. A simple method for displaying the hydropathic character of a protein. *J Mol Biol* 157:105-132.
- Leigh D.** 1951. Subacute necrotising encephalomyelopathy in an infant. *J Neurol Neurosurg Psychiatr* 14 216-221.
- Loeffen J, Smeets R, Smeitink J, Ruitenbeek W, Janssen A, Mariman E, Sengers R, Trijbels F, van den Heuvel L.** 1998. The X-chromosomal NDUFA1 gene of complex I in mitochondrial encephalomyopathies: tissue expression and mutation detection. *J Inher Metab Dis* 21:210-215.
- Loeffen J, Smeets R, Smeitink J, Triepels R, Sengers R, Trijbels F, van den Heuvel L.** 1999. The human NADH ubiquinone oxidoreductase NDUF55 (15 kDa) subunit: cDNA cloning, chromosomal localisation, tissue distribution and the absence of mutations in isolated complex I-deficient patients. *J Inher Metab Dis* 22 19-28.
- Loeffen J, Smeitink J, Trijbels F, Janssen A, Triepels R, Sengers R, van den Heuvel B.** 2000. Isolated complex I deficiency in children: clinical, biochemical and genetic aspects. *Hum Mutat* 15:123-134.
- Masui R, Wakabayashi S, Matsubara H, Hatefi Y.** 1991. The amino acid sequences of two 13 kDa polypeptides and partial amino acid sequence of 30 kDa polypeptide of complex I from bovine heart mitochondria: possible location of iron-sulphur clusters. *J Biochem (Tokyo)* 109 534-543.
- Matthews PM, Marchington DR, Squier M, Land J, Brown RM, Brown GK.** 1993. Molecular genetic characterisation of an X-linked form of Leigh's syndrome. *Ann Neurol* 33 652-655.
- Morris AA, Leonard JV, Brown GK, Bidouki SK, Bindoff LA, Woodward CE, Harding AE, Lake BD, Harding BN, Farrell MA, Bell JE, Mirakhur M, Turnbull DM.** 1996. Deficiency of respiratory chain complex I is a common cause of Leigh disease. *Ann Neurol* 40:25-30.
- Nishikawa K.** 1983. Assessment of the secondary-structure prediction of proteins. *Biochim Biophys Acta* 748:285-299.
- Ohnishi T.** 1998. Iron-sulfur clusters/semiquinones in Complex I. *Biochim Biophys Acta* 1364:186-206.
- Ploos van Amstel JK, Bergman AJW, van Beurden EACM, Roijers JFM, Peelen T, van den Berg IET, Poll-The BT, Kvittingen EA, Berger R.** 1996. Hereditary tyrosinemia type I: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationship. *Hum Genet* 97:51-59.
- Poulton J and Gardiner RM.** 1989. Non-invasive diagnosis of mitochondrial myopathy. *Lancet* 1:961-961.
- Procaccio V, Depetris D, Soularue P, Mattei MG, Lunardi J, Issartel JP.** 1997. cDNA sequence and chromosomal localisation of the NDUF58 human gene coding for the 23 kDa subunit of the mitochondrial complex I. *Biochim Biophys Acta* 1351:37-41.
- Rahman S, Blok RB, Dahl HH, Danks DM, Kirby DM, Chow CW, Christodoulou J, Thorburn DR.** 1996. Leigh syndrome: clinical features and biochemical and DNA abnormalities. *Ann Neurol* 39:343-351.
- Robinson BH.** 1998. Human complex I deficiency: clinical spectrum and involvement of oxygen free radicals in the pathogenicity of the defect. *Biochim Biophys Acta* 1364 271-286.
- Sambrook J, Fritsch EF, Maniatis E (eds).** 1989. *Molecular cloning: a laboratory manual*, 2<sup>nd</sup> edn. Cold Spring Harbor: Cold Spring Harbor

Laboratory Press.

- Santorelli FM, Tanji K, Sano M, Shanske S, El-Shahawi M, Kranz-Eble P, DiMauro S, De VD.** 1997 Maternally inherited encephalopathy associated with a single-base insertion in the mitochondrial tRNATrp gene *Ann Neurol* 42:256-260
- Shoffner JM, Fernhoff PM, Krawiecki NS, Caplan DB, Holt PJ, Koontz DA, Takei Y, Newman NJ, Ortiz RG, Polak M.** 1992. Subacute necrotising encephalopathy: oxidative phosphorylation defects and the ATPase 6 point mutation. *Neurology* 42:2168-2174.
- Singh G, Lott MT, Wallace DC.** 1989. A mitochondrial DNA mutation as a cause of Leber's hereditary optic neuropathy *N Engl J Med* 320:1300-1305
- Smeitink J, Loeffen J, Triepels R, Smeets R, Trijbels F, van den Heuvel L.** 1998a. Nuclear genes of human complex I of the mitochondrial electron transport chain: state of the art. *J Mol Genet* 7:1573-1579.
- Smeitink J, Loeffen J, Smeets HJM, Trijbels F, van den Heuvel L.** 1998b B17 subunit of human NADH ubiquinone oxidoreductase: cDNA cloning, tissue distribution and mutation detection in isolated complex I deficient patients. *Hum Genet* 103:245-250
- Srere PA.** 1969. Citrate synthase, EC 4.1.3.7 citrate oxaloacetate lyase (C0-A-acetylating) *Method enzymol* XIII:3-11
- Tanaka M, Ino H, Ohno K, Hattori K, Sato W, Ozawa T, Tanaka T, Itoyama S.** 1990 Mitochondrial mutation in fatal infantile cardiomyopathy. *Lancet* 336:1452-1452.
- Tatuch Y, Christodoulou J, Feigenbaum A, Clarke JT, Wherret J, Smith C, Rudd N, Petrova-Benedict R, Robinson BH.** 1992. Heteroplasmic mtDNA mutation (T→G) at 8993 can cause Leigh disease when the percentage of abnormal mtDNA is high. *Am J Hum Genet* 50:852-858
- van den Heuvel L, Ruitenbeek W, Smeets R, Gelman-Kohan Z, Elpeleg O, Loeffen J, Trijbels F, Mariman E, de Bruijn D, Smeitink J.** 1998 Demonstration of a new pathogenic mutation in human complex I deficiency: a 5-bp duplication in the nuclear gene encoding the 18-kD (AQDQ) subunit *Am J Hum Genet* 62:262-268.
- van Laack HL, Ruitenbeek W, Trijbels JM, Sengers RC, Gabreels FJ, Janssen AJ, Kerkhof CM.** 1988. Estimation of pyruvate dehydrogenase (E1) activity in human skeletal muscle, three cases with E1 deficiency *Clin Chim Acta* 171:109-118
- Walker JE.** 1992 The NADH:ubiquinone oxidoreductase (complex I) of respiratory chains. *Q Rev Biophys* 25:253-324.
- Walker JE.** 1995 Determination of the structures of respiratory enzyme complexes from mammalian mitochondria *Biochim Biophys Acta* 1271:221-227
- Walker JE, Skehel JM, Buchanan SK.** 1995 Structural analysis of NADH:Ubiquinone oxidoreductase from bovine heart mitochondria. *Method Enzymol* 260:14-34.
- Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, Elsas LJ2, Nikoskelainen EK.** 1988. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy *Science* 242:1427-1430
- Weidner U, Geier S, Ptock A, Friedrich T, Leif H, Weiss H.** 1993. The gene locus of the proton-translocating NADH ubiquinone oxidoreductase in *Escherichia coli*. Organisation of the 14 genes and relationship between the derived proteins and subunits of mitochondrial complex I *J Mol Biol* 233:109-122.
- Weiss H, Friedrich T, Hofhaus G, Preis D.** 1991. The respiratory-chain NADH dehydrogenase (complex I) of mitochondria *Eur J Biochem* 197:563-576.
- Willems JL, Monnens LA, Trijbels JM, Veerkamp JH, Meyer AE, van Dam K, van Haelst U.** 1977 Leigh's encephalomyelopathy in a patient with cytochrome c oxidase deficiency in muscle tissue *Pediatrics* 60:850-857
- Yamaguchi M and Hatefi Y.** 1993 Mitochondrial NADH ubiquinone oxidoreductase (complex I): proximity of the subunits of the flavoprotein and the iron-sulphur protein subcomplexes. *Biochemistry* 32:1935-1939.
- Zeviani M, Servidei S, Gellera C, Bertini E, DiMauro S, DiDonato S.** 1989. An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region *Nature* 339:309-311.
- Zeviani M, Gellera C, Antozzi C, Rimoldi M, Morandi L, Villani F, Tiranti V, DiDonato S.** 1991. Maternally inherited myopathy and cardiomyopathy association with mutation in mitochondrial DNA tRNA<sup>Leu</sup> *Lancet* 338:143-147



### MUTATIONS IN THE COMPLEX I *NDUFS2* GENE ARE ASSOCIATED WITH HYPERTROPHIC CARDIOMYOPATHY AND ENCEPHALOMYOPATHY

*Submitted*

#### **Abstract.**

Human complex I is built up and regulated by genes encoded by the mitochondrial DNA (mtDNA) as well as the nuclear DNA (nDNA). In recent years, attention mainly focussed on the relation between complex I deficiency and mtDNA mutations. However, several aspects of our isolated complex I deficient patient group make a nuclear-genetic cause likely (high percentage of consanguinity, autosomal-recessive mode of inheritance, absence of common mtDNA mutations). The nuclear encoded *NDUFS2* (49 kDa, NuoD) protein is part of complex I of many pro- and eukaryotes. Hypothesised functions of the *NDUFS2* are participation in proton translocation and ubiquinone binding. The gene coding for the *NDUFS2* protein is therefore an important candidate for mutational detection studies in enzymatic complex I deficient patients. Screening of patient *NDUFS2* cDNA by RT-PCR in combination with direct DNA sequencing revealed three missense mutations resulting in the substitution of conserved amino acids in three families.

## Introduction.

The genetic causes of oxidative phosphorylation (OXPHOS) disorders in general and more specific of isolated complex I deficiency (OMIM 252010) remain largely to be elucidated. The mitochondrial DNA encodes for several structural components of the OXPHOS system (13 polypeptides which are incorporated in complex I, III, IV and V) as well as 22 tRNAs and 2 rRNAs (Anderson et al 1981). The nucleus however, encodes for the majority of the structural complex components, but also for all non-structural OXPHOS system proteins, like e.g. transcription and translation factors, chaperone proteins and assembly proteins. This dual genetic control makes adequate genetic counselling in OXPHOS disorders difficult. Several mtDNA mutations have clearly been linked to important OXPHOS system disorders, but in the majority of adult patients (60%) and children (>90%) common mtDNA mutations are not encountered (Shoffner 1996).

Isolated complex I deficiency is a serious inborn error of metabolism, often presenting in infancy or early childhood. A diversity of clinical phenotypes has been described to occur in complex I deficient patients like Leigh(-like) syndrome, fatal infantile lactic acidosis, cardiomyopathy and lactic acidosis with or without cataract, macrocephaly with leukodystrophy and hepatopathy with tubulopathy (Rahman et al 1996, Pitkanen et al 1996, Kirby et al 1999, Loeffen et al 2000). The common divisor in these patients is the prominent place of symptoms of central nervous system and muscular disease. The mean age of presentation encountered in our patient group is ~5 months (Loeffen et al 2000). The inheritance pattern in the majority of families (no affected children in the maternal lineage, high percentage of consanguinity) makes autosomal-recessive inheritance and therefore a nuclear-genetic cause likely.

Human complex I consists of at least 42 different proteins (~35 nuclearly encoded, seven mitochondrially encoded (Chomyn et al 1986), which makes it one of the most complex multi-protein constructions in the human cell (Smetink and van den Heuvel 1999). The main function of complex I is oxidation of NADH. Electrons, which are freed by this oxidation, are transported to free-moving ubiquinone. This electron transport is coupled to a yet unknown mechanism, by which protons are translocated from the mitochondrial matrix into the intermembrane space. Several important aspects of these functions have (partly) been elucidated. NADH binds to the NDUFV1 subunit of complex I (Chen and Guillory 1981, Deng et al 1990), electrons are then transported through the flavin mononucleotide (FMN, Pilkington et al 1991) and at least six Iron-Sulphur (Fe-S) clusters which have been detected by electron paramagnetic resonance studies (Ohnishi 1998). The proton translocation process as well as the ubiquinone binding and reduction process remain poorly understood.

The NDUF2 (49 kDa, OMIM 602985) subunit of complex I is a highly conserved protein, with homologues present in many pro- and eukaryotes. In *Neurospora crassa*, the 49 kDa subunit has been located in the peripheral part of complex I near the membrane domain (Guenebaut et al 1997). This is further illustrated by characterisation studies performed with *Escherichia coli* complex I which showed that NuoD (the equivalent of NDUF2 in prokaryotes) is situated in the connecting part, which possibly functions as a bridge between the NADH dehydrogenase fragment and the membrane fragment (Braun et al 1998). The


following two findings concerning the NDUF52 subunit are indicative for possible functions of this protein. At first, there may be an evolutionary relationship between the NDUF52 and hydrogenases thought to function as proton translocators, which is suggestive for the NDUF52 subunit to play a role in the proton translocation process (Friedrich 1998). Secondly, Darrouzet and colleagues presented a piericidin-resistant mutant of the bacterium *Rhodobacter capsulatus*, which contained a V407M substitution in the highly conserved C-terminal part of NuoD (Darrouzet et al 1998). The complex I inhibiting properties of piericidin probably result from antagonism of the ubiquinone binding site (Degli Esposti 1998). It is therefore well possible that NuoD participates in the binding of ubiquinone. Hence, the NDUF52 subunit is a major candidate gene for mutational analysis studies in isolated complex I deficient patients.

In this study we present the results of mutational detection studies performed with cDNA of isolated complex I deficient patients in whom major mtDNA rearrangements and eleven common mtDNA mutations have been excluded. This revealed missense mutations in four patients (three families). These findings increase our possibilities for adequate genetic counselling and prenatal diagnostics and in the future may also result in more information concerning the proton translocation and ubiquinone binding process.

### **Patients, Material and Methods.**


**Family A** Family A consists of three children whose parents are consanguineous (Fig. 10.1). Two of these children suffered from an isolated complex I deficiency. The oldest child in this family is healthy and currently alive (A1, female). The early neonatal period of the second child (A2, male) was normal, but after six months neurological regression was noted. He stopped smiling and holding objects and was unable to track moving items. Investigation of the eyes revealed a fine horizontal nystagmus and bilateral optic atrophy. Muscle tone was axially decreased while this was increased in all extremities with brisk tendon reflexes. An EEG was normal, while a brain CT scan revealed bilateral hypodensities in basal ganglia. An echocardiogram showed left ventricular hypertrophy. Lactate levels were severely increased in blood (9.9 mM, normal 0.6-2.1 mM) and CSF (7.8 mM, normal 1.4-1.9 mM). The patient's neurologic condition deteriorated steadily and he became gradually lethargic with episodes of apnoea eventually leading to death at the age of 24 months. The third child (A3, female) expressed a phenotype resembling her brother's, though the age of presentation was earlier and the course of deterioration faster. The blood lactic acid level was found elevated at the second day of life (12 mM). She suffered from severe neurological regression, axial hypotonia with pyramidal signs and failure to thrive. Prolonged latencies seen in Visual Evoked Potentials (VEP) and an abnormal electroretinogram (ERG) pointed towards optic atrophy and problems with the photoreceptors, respectively. Brainstem Auditory Evoked Potentials (BAEP) showed prolonged conduction in the brain stem region. The cerebral CT scan disclosed marked generalised atrophy with ventriculomegaly. An echocardiogram made at birth was normal, but at the age of three months a hypertrophic cardiomyopathy was demonstrated. She died at the age of 18 months due to cardiorespiratory failure. Both patients expressed an isolated complex I deficiency in cultured skin fibroblasts (Table 10.1). Enzyme

assays were also performed in skeletal muscle tissue of patient A2 which again revealed isolated complex I deficiency (muscle tissue of patient A3 was not available).



**Figure 10.1** Family tree of family A. The oldest child is not affected (A1). Patient A2 and A3 suffered from a complex I deficiency and were homozygous for the G683A mutation while both parents are heterozygous.


*Family B.* There were no signs of genetic diseases within this family. Patient B1 (male; family tree Fig. 10.2) exhibited respiratory insufficiency during the first day of life. Lactic acid was severely increased in blood (24 mM) leading to acidosis (pH 6.9). Echocardiography performed in the early neonatal period showed a hypertrophic cardiomyopathy, which was confirmed at autopsy. The child died after four days due to cardiorespiratory failure. Biochemical investigation of the OXPHOS system revealed an isolated complex I deficiency in cultured skin fibroblasts and skeletal muscle tissue (Table 10.1).



**Figure 10.2** Family tree of family B. The complex I deficient patient is homozygous for the C686A mutation while both parents are heterozygous.

*Family C.* Family C (consanguineous parents (Fig. 10.3), negative family history for neuromuscular disorders) consists of four children, three of whom died of a clinical phenotype resembling an OXPHOS disorder. Measurement of enzyme activities of the respiratory chain, PDHc and citrate synthase revealed an isolated complex I deficiency in the second child (C2) in cultured fibroblasts as well as muscle tissue (Table 10.1). Unfortunately, tissue specimens of patient C1 and C3 were not available. The first patient (C1; male) presented at 7 months

with repeated vomiting and failure to thrive. Physical examination showed horizontal nystagmus, mild ataxia, muscle hypotonia and pallor of the optic discs. Cognitive development was age appropriate, yet motor delay was prominent. Lactate level was increased in blood (4.2 mM). A brain CT scan disclosed areas of white matter hypodensities. The patient died at the age of 18 months. The second index patient (C2, male) presented at the age of 10 months with a phenotype strongly resembling the phenotype of his brother. Recurrent vomiting, failure to thrive, nystagmus and generalised hypotonia with mild cognitive impairment but marked motor delay were present. Lactic acid was elevated in blood (5.0 mM), as well as in CSF (3.3 mM). From the age of 2.5 years he developed recurrent episodes of sleep apnoea. Brain CT scan and MRI revealed progressive hypodensity of basal ganglia and midbrain. The course deteriorated steadily necessitating mechanical ventilation. The child died at the age of 3 years. The third patient (C3, male) presented at birth with severe metabolic acidosis (lactic acid 12.5 mM). The clinical characteristics and course were similar to the phenotype of his brothers and he died at the age of two years. The fourth child of this family was born after egg cell donation and is alive and healthy.



**Figure 10.3** Family tree of family C. The first three sons died of complex I deficiency. The fourth son was born after egg cell donation and is alive and healthy. Patient C2 is homozygous for the T1237C mutation, while both parents are heterozygous. Unfortunately, DNA and RNA from C1, C3 and C4 were not available.

#### *Biochemical enzyme assays*

The respiratory chain enzyme complex activities, PDHc and citrate synthase in skeletal muscle tissue and skin fibroblasts (culture) were assayed using the following methods (slightly modified). NADH ubiquinone oxidoreductase and succinate cytochrome *c* oxidoreductase as described by Fischer et al 1985 and 1986, cytochrome *c* oxidase by Cooperstein and Lazarow 1951, citrate synthase by Srere 1969 and PDHc according to van Laack et al 1988. In case of cultured fibroblasts, enzyme measurements were performed in mitochondria enriched fractions (Bentlage et al 1996), while in case of muscle tissue 600×g supernatant of crude homogenates was used.

#### *Mutational analysis*

Patient total RNA isolated from cultured fibroblasts was reverse transcribed to cDNA by superscript II RNase H<sup>-</sup> reverse transcriptase after addition of oligo(dT) and random hexamer

primers (Ploos van Amstel et al 1996) Wildtype and patient *NDUFS2* cDNA was amplified and sequenced as published previously (Loeffen et al 1998a) All patients have been screened for major mtDNA rearrangements by a previously developed long template PCR technique (Li et al 1995) Furthermore, the following common pathogenic mtDNA mutations have been excluded in fibroblasts in our patient group by a combination of PCR and RFLP 14484T→C (ND-6), 14459G→A (ND-6), 11778G→A (ND-4), 8993T→G/C (ATPase 6), 8356T→C (tRNA<sup>Lys</sup>), 8344A→G (tRNA<sup>Lys</sup>), 4317A→G (tRNA<sup>Gln</sup>); 4160T→A (ND-1); 3460G→A (ND-1), 3271T→C (tRNA<sup>Leu</sup>), 3243A→G (tRNA<sup>Leu</sup>) Procedures were followed as recommended by the restriction enzyme manufacturer

#### *Restriction Fragment Length Polymorphism (RFLP).*

An *NDUFS2* nDNA fragment of 294 base pairs (Genbank accession no AF183172) of all members of family A and B was amplified using oligonucleotides 5'-AAGATGTTTGAGTTCTACGAGCG-3' (forward) and 5'-ACTGATAAATGTCATCCATAAGCC-3' (reverse) The 683G→A mutation destroys an *MspI* restriction site (recognition site C<sup>+</sup>CGG), while the 686C→A mutation destroys an *HaeIII* restriction site (recognition site GG<sup>+</sup>CC) In case of the parents of family C as well as patient C2 a nDNA fragment of 342 base pairs was amplified (Genbank accession no AF183173) using oligonucleotides 5'-AGACCATATGTAGAGTAGGTAGC-3' (forward) and 5'-TTAGTTAAGACTTGCAAGGTGGG-3' (reverse) The 1237T→C mutation introduces a *BanI* restriction site (recognition site G<sup>+</sup>GYRCC) In all RFLP assays, conditions were used as recommended by the manufacturer

#### *Northern blot and multiple tissue dot blot*

In order to check the specificity of an  $\alpha$ [<sup>32</sup>P]-dCTP-labelled *NDUFS2* cDNA probe, we hybridised the probe to a multiple tissue Northern blot commercially purchased from Clontech, USA (heart, brain, placenta, lung, liver, skeletal muscle, kidney, pancreas), using a standard hybridisation solution based on procedures described in Sambrook et al 1989 The blot was washed twice with 2× SSC, 0.1% SDS, at 65°C and was subjected to autoradiography. To visualise the distribution of *NDUFS2* mRNA in a large range of human adult and foetal tissues, the same probe was hybridised to a multiple tissue RNA Master blot The quantity of RNA spotted for each tissue on the Master blot was normalised using eight different housekeeping gene transcripts as probes (ribosomal protein S9, ubiquitin, 23 kDa highly basic protein, hypoxanthine guanine phosphoribosyl transferase, tubulin,  $\beta$ -actin, phospholipase, and glyceraldehyde triphosphate dehydrogenase)

## **Results.**

#### *Biochemical enzyme assays*

The enzyme assays of citrate synthase and respiratory chain enzymes were performed in cultured skin fibroblasts of all patients and additionally in fresh muscle tissue in case of patient B and C2 and in muscle tissue which has been stored in liquid nitrogen of patient A2 (in muscle tissue of patient A2 and B PDHc activity was also measured and found normal)

This revealed in all cases an isolated complex I deficiency (complex I enzyme activities of all patients are listed in Table 10.1).

	NADH:ubiquinone oxidoreductase (complex I)	
	Fibroblasts 0.11-0.28 <sup>a</sup> (14)	Muscle 70-250 <sup>b</sup> (20) 101-389 <sup>c</sup> (13)
<b>Patient A2</b>	0.043	40 <sup>c</sup>
<b>Patient A3</b>	0.060	-
<b>Patient B</b>	0.040	17 <sup>b</sup>
<b>Patient C2</b>	0.045	48 <sup>b</sup>

**Table 10.1** Residual complex I activity of the patients in cultured fibroblasts and muscle tissue. All patients expressed an isolated complex I deficiency. Complex I activity is referred to cytochrome *c* oxidase base in case of fibroblasts<sup>a</sup> (mU/mU cytochrome *c* oxidase), to citrate synthase (mU/U citrate synthase) when measured in fresh muscle tissue<sup>b</sup> and to cytochrome *c* oxidase (U/mU cytochrome *c* oxidase) when measured in 600×g supernatant of muscle tissue which has been deep frozen in liquid nitrogen<sup>c</sup>. Numbers of controls used for each assay are listed in parentheses.

*Mutational analysis studies.*

RT-PCR followed by direct DNA sequencing of the *NDUFS2* cDNA revealed missense mutations in four patients (three families). In family A we found a homozygous G→A transition at position 683 in both complex I deficient patients (A2 and A3). As a consequence of this mutation a conserved arginine is substituted into a glutamine (Table 10.2). The *NDUFS2* cDNA of the index patient in family B contained a homozygous 686C→A transversion, which leads on protein level to the substitution of a conserved proline into a glutamine (Table 10.2). Finally, in patient 2 of family C, we encountered a homozygous T→C transition at position 1237. This mutation results in the replacement of a conserved serine residue by a proline (Table 10.2).

*Restriction Length Polymorphism (RFLP) analysis.*

We confirmed the presence of the mutations found in the index patients on nDNA by means of RFLP analysis (Fig. 10.4). To prove the presence of the mutation found in patient A2 and A3, we amplified and sequenced an *NDUFS2* nDNA fragment of the region containing the mutation (294 base pairs; Genbank accession no. AF183172), which revealed two recognition sites for *MspI* in control cDNA, one of which is destroyed by the 683G→A mutation. Complete digestion with *MspI* results in three bands in the control and the healthy sib A1 (203, 57 and 34 base pairs), confirming the presence of two wildtype alleles. Two bands were found in both patients (203 and 91 base pairs), who contain two mutated alleles and finally four bands were seen in case of the heterozygous parents (203, 91, 57 and 34 base pairs). The same wildtype *NDUFS2* nDNA fragment as generated for all members of family A (Genbank accession no. AF183172) contains three *HaeIII* recognition sites. Since one *HaeIII* site is destroyed by the 686C→A mutation, only two cleavage sites remain in patient B1.

Complete digestion of control *NDUFS2* nDNA therefore results in four bands (161, 60, 57 and 16 base pairs, Fig 10 4), in case of our patient three bands are seen (161, 117 and 16 base pairs, two mutant alleles), while the heterozygously mutated parents express five bands (161, 117, 60, 57 and 16 base pairs) The 60 and 57 bands are not separated from each other and the 16 base pair band is not visible.

The 1237T→C mutation found in patient C2 introduces a *BanI* restriction site A control *NDUFS2* nDNA fragment (342 base pairs, Genbank accession no AF183173) remains therefore undigested, while the nDNA fragment of the patient is cleaved in two fragments of 175 and 167 base pairs The nDNA fragment of both parents is partly digested resulting in three bands of 342, 175 and 167 base pairs The 175 and 167 bands are not separated Unfortunately, nDNA as well as cDNA of patient C1 and C3 are not available.

All three mutations have been excluded in nDNA fragments of 85 controls (170 alleles)


	226	227	228	229	230
<b>683G→A</b>	Y	I	R	P	G
<b>Wildtype</b>	tat	atc	cgg	cca	gga
<b>Patients A</b>	tat	atc	cag	cca	gga
	Y	I	Q	P	G
	227	228	229	230	231
<b>686C→A</b>	I	R	P	G	G
<b>Wildtype</b>	atc	cgg	cca	gga	gga
<b>Patient B</b>	atc	cgg	caa	gga	gga
	I	R	Q	G	G
	411	412	413	414	415
<b>1237T→C</b>	L	V	S	D	G
<b>Wildtype</b>	ctg	gtg	tct	gat	ggc
<b>Patient C</b>	ctg	gtg	cct	gat	ggc
	L	V	P	D	G

**Table 10.2** *NDUFS2* wildtype and patients cDNA and amino acid sequence of the regions containing the mutations

*RNA tissue distribution*

Hybridisation of the radioactively labelled *NDUFS2* cDNA probe to the multiple tissue Northern blot revealed a single band for each tissue present on the blot, which confirms the specificity of the probe (data not shown) In order to evaluate the *NDUFS2* RNA distribution in a variety of tissues, we hybridised the same probe to a multiple tissue Master blot (Fig 10 5) This revealed a similar pattern (slight differences) as seen for other nuclear encoded complex I subunits The *NDUFS2* cDNA probe is ubiquitously expressed, with a relative higher expression in the following tissues adult and foetal heart, kidney, skeletal muscle, adrenal gland and liver Also the human and *E coli* DNA dots (H4, H7 and H8) were positive






**Figure 10.4** *Top:* RFLP pattern of family A after digestion with *MspI*. Complete digestion results in three bands in the control and A1 (203, 57 and 34 bp (latter band faint), two bands in the index patients (203 and 91 bp) and four in case of their parents (203, 91, 57 and 34 bp). *Middle:* The family B nDNA RFLP pattern after digestion with *HaeIII*. Complete digestion results in four bands when control DNA is used as template (161, 60, 57 and 16 bp), three bands in case of our index patient (161, 117 and 16 bp) and five when nDNA of the parents is used as template (161, 117, 60, 57 and 16 bp). The 60 and 57 bands are not separated from each other, the 16 bp band is not visible). *Bottom:* The 1237T→C mutation introduces a *BanI* restriction site. The control *NDUFS2* nDNA fragment (342 bp, Genbank accession no. AF183173) remains therefore undigested, while the nDNA fragment of the index patient is cleaved in two fragments of 175 and 167 bp. Nuclear DNA fragments of both parents are partly digested resulting in three bands of 342, 175 and 167 bp. The 175 and 167 bands are not separated. The DNA size marker (M) is Puc18/*HaeIII* (band sizes are listed right from the image), Mo = mother, Fa = father, Co = control, bp = base pairs.

	1	2	3	4	5	6	7	8
a	whole brain	amygdala	caudate nucleus	cerebellum	cerebral cortex	frontal lobe	hippocampus	medulla oblongata
b	occipital lobe	putamen	substantia nigra	temporal lobe	thalamus	subthal. nucleus	spinal cord	
c	heart	aorta	skeletal muscle	colon	bladder	uterus	prostate	stomach
d	testis	ovary	pancreas	pituitary gland	adrenal gland	thyroid gland	salivary gland	mammary gland
e	kidney	liver	small intestine	spleen	thymus	peripheral leukocyte	lymph node	bone marrow
f	appendix	lung	trachea	placenta				
g	foetal brain	foetal heart	foetal kidney	foetal liver	foetal spleen	foetal thymus	foetal lung	
h	yeast RNA	yeast tRNA	<i>E. coli</i> rRNA	<i>E. coli</i> DNA	poly r(A) 100 ng	human C <sub>ot</sub> 1 DNA 100 ng	human DNA 100 ng	human DNA 500 ng

**Figure 10.5a** Multiple tissue Master blot. The type and position of poly(A<sup>+</sup>) RNAs and controls dotted on the positively charged nylon membrane. subthal. = subthalamic.



**Figure 10.5b** Tissue distribution of *NDUF52* mRNA visualised on a poly A<sup>+</sup> RNA master blot. The *NDUF52* cDNA probe is ubiquitously expressed in human tissues, with a relatively higher expression in the human and foetal heart, kidney, skeletal muscle, adrenal gland tissue, whole brain and liver tissue.

## Discussion.

Mitochondriocytopathies have an incidence of about 1 in 10,000 live births (Bourgeron et al 1995). The exact prevalence of one of the mitochondrial disorders, complex I deficiency, is at the moment unknown. However, we know that complex I deficiency is one of the most frequently occurring OXPHOS enzyme disorders in children (Loeffen et al 2000).

The clinical phenotype observed in patients with complex I deficiency, often develops devastating, with early onset, rapid progression and death within a few years after birth. Successful therapeutic possibilities are currently not available. It is therefore important to locate the genetic causes of this disease to offer at least the possibility of adequate genetic counselling and prenatal diagnostics. In previous years, several nuclear mutations resulting in deficient activity of one of the respiratory chain complexes, have been found. These genes concerned structural genes in case of complex I deficiency (van den Heuvel et al 1998, Loeffen et al 1998b, Schuelke et al 1999, Triepels et al 1999), and complex II deficiency (Bourgeron et al 1995), but also mutations in assembly genes have been described (in relation to complex IV deficiency, Zhu et al 1998, Tiranti et al 1998, Coenen et al 2000, Smeitink et al 2000). Yet, for a large part of our complex I deficient patients, gene defects remain to be identified.

The *NDUFS2* subunit is the third largest complex I subunit. Its mRNA contains an open reading frame of 1392 base pairs, coding for 463 amino acids. Electron microscopy studies performed in *N. crassa* using Fab fragments of antibodies directed against the 49 kDa subunit located this protein in the extramembraneous part of complex I, near the membrane domain (Guenebaut et al 1997). Disruption of this subunit results in the complete absence of the peripheral arm of complex I (Guenebaut et al 1997). Recent studies revealed interesting aspects of the *NDUFS2* subunit. The identification of a *R. capsulatus* mutant containing a V407→M substitution in NuoD (prokaryotic equivalent of *NDUFS2*), which is partially resistant to piericidin, is an indication for a possible role of NuoD in ubiquinone binding (Darrouzet et al 1998). This amino acid substitution is located in the conserved C-terminal part of the protein. The structure of piericidin is similar to the structure of ubiquinone, both containing a polar and an aliphatic part. It is therefore possible, that the inhibiting function of piericidin results from antagonism of the ubiquinone-binding site. Darrouzet and colleagues hypothesise that NuoD interacts with the polar part of piericidin while the aliphatic component interacts with NuoH, which is located in the membranous part of complex I. The piericidin resistant mutants are also partially resistant to rotenone. It seems likely that piericidin and rotenone share at least partially a common binding site. This was also seen in competition experiments performed by Okun and co-workers, which showed that the hydrophobic part of piericidin and rotenone share a common binding domain with partially overlapping sites (Okun et al 1999).

The *NDUFS2* protein is highly conserved in many species (95% in *Bos taurus*, 62% in *Neurospora crassa* and 38% in *Escherichia coli*) which indicates its overall functional importance (Loeffen et al 1998a). The *NDUFS2* subunit has also weak homology with several proteins involved in the transport of protons, like HycE (subunit of formate hydrogenlyase)

and HyfG (subunit of Ni-Fe hydrogenase), so there might be an evolutionary relationship between these proteins. This implicates that there might be a role for the *NDUFS2* subunit in proton transport (Friedrich and Weiss 1997).

Hybridisation of the *NDUFS2* cDNA probe to the RNA Master blot showed spots at all adult and foetal tissues present on the blot. Dots with a relative higher intensity are tissues with a high metabolic activity like heart, kidney and skeletal muscle tissue. Hybridisation of the probe to the multiple tissue Northern blot confirmed the probe's specificity. The human DNA dots (H7 and H8) were also positive on the RNA Master blot. This can be caused by the presence of relatively large exons, which hybridise to a substantial part of the probe or the presence of pseudogenes. Also the *E. coli* dot (H4) showed a faint signal. This can be caused by the high percentage of homology between the *NDUFS2* subunit and NuoD. The hybridisation of the probe to the DNA dots is however not a problem for the interpretation of the RNA dots, since the RNA dots on the blot contain virtually no DNA (guaranteed by the manufacturer).

The amino acid substitution present in family A (R228Q) is located just prior to the amino acid, which has been changed in family B (P229Q). These substituted amino acids are conserved in many pro- and eukaryotes (Table 10.3). The high conservation of the bases flanking these substituted amino acids (RPGGV) is reflected by their conservation (partially) in some proteins, which are involved in proton pumping like e.g. HycE of *Mycobacterium tuberculosis*. However, functional aspects of such an amino acid pattern have not been described. Chou-Fasman plots (Chou and Fasman 1978) calculated with the *NDUFS2* wildtype and mutated proteins (R228Q as well as P229Q), show replacement of  $\alpha$ -helix by  $\beta$ -sheet in the region prior to the proline at position 229. When this region is functionally important, it is thinkable that conformational peptide changes alter the overall function of the *NDUFS2* protein. The amino acid which is substituted in family C (S413P) is also conserved in many species (Table 10.3). The biochemical characteristics of the substituted amino acids clearly differ from those of their substitutes. These different characteristics can have serious consequences for the functionality of the *NDUFS2* protein and therefore on the overall complex I activity. It is unlikely that the missense mutations encountered in our index patients are population polymorphisms since they were not encountered in 170 control alleles. In addition, a BLAST search in the human EST database of the National Centre for Biotechnology Information (NCBI) with a cDNA fragment containing the mutations, only revealed wildtype EST fragments (5 ESTs were present containing the region which is mutated in family A and B, and 30 in the region which is mutated in family C). Definite proof of the pathogenicity of the mutations found in our index patients has to come from rescue of the complex I activity by introducing a vector containing the wildtype *NDUFS2* cDNA into our patient fibroblasts. These experiments are however rather difficult and time consuming since we need up to 10 million cells to perform our enzyme assays accurately.

Several clinical aspects of the phenotypes found in the patients described in this article are worth discussing. The patients of family A (A2 and A3) and the patient in family B suffered from a hypertrophic cardiomyopathy. In patient B the cardiomyopathy was present at birth, while in patient A3 it developed in the first months of life (in case of patient A2 the presence

or absence of the cardiomyopathy at birth was not investigated). The multiple tissue dot blot autoradiograph showed the highest expression of *NDUF52* mRNA in cardiac tissue. Cardiomyopathy is not an uncommon clinical finding in patients with mitochondrial encephalomyopathies. In our group of isolated complex I deficient patients, 30% suffered from cardiomyopathy (mainly hypertrophic). Besides the cardiomyopathy, ocular symptoms were frequent among our index patients. Both patients in family A (A2 and A3) as well as patient C1 showed signs of optic atrophy. Horizontal nystagmus was seen in patient A2, A3, C1, C2 and C3. Since patient B1 died four days after birth, time was too short to detect possible visual defects.

Species	Mutation A (R228Q) ↓			Mutation B (P229Q) ↓			Mutation C (S413P) ↓		
PT	222	MHAAYIQPGGVHQ	234	223	HAAYIRQGGVHQD	235	407	FGVYLVDPGSSRP	419
WT	222	MHAAYIRPGGVHQ	234	223	HAAYIRPGGVHQD	235	407	FGVYLVSDGSSRP	419
BT	187	MHAAYVRPGGVHQ	199	188	HAAYVRPGGVHQD	200	372	FGVYLVSDGSSRP	384
NC	237	LHAAYVRPGGVHQ	249	238	HAAYVRPGGVHQD	250	422	MGVYVSDGSERP	434
WT	153	MHASFIRPGGVAQ	165	154	HASFIRPGGVAQD	166	338	FGVFLVSNNGSNRP	350
MT	183	MNSAYIRPGGVAQ	195	184	NSAYIRPGGVAQD	196	384	LGVHMSDGGTRP	396
SM	151	MHAAYFRPGGVHQ	163	152	HAAYFRPGGVHQD	164	340	FGVYLVSDGTNKP	352
PD	169	LHAAYFRPGGVHQ	181	170	HAAYFRPGGVHQD	182	357	FGVYLVADGTNKP	369
EC	165	MHPAWFRIGGVAH	177	166	HPAWFRIGGVAHD	178	544	NSYYLTSDGSTMS	556

**Table 10.3** The extent of conservation of the substituted amino acids (R228Q, P229Q and S413P) in several pro- and eukaryotes (PT = patient; WT = wildtype human; BT = *Bos taurus*; NC = *Neurospora crassa*; WT = *Wood tobacco*; MT = *Mycobacterium tuberculosis*; SM = *Sinorhizobium meliloti*; PD = *Paracoccus denitrificans*; EC = *Escherichia coli*).

In summary, we found missense mutations in the highly conserved *NDUF52* mRNA in four isolated complex I deficient patients (three families). The identification of this gene as a possible host for mutations causing complex I deficiency increases our possibilities for genetic counselling and prenatal diagnostics. Future cellular studies with fibroblasts of these patients might increase our insight in the binding and reduction of ubiquinone by complex I as well as the hypothesised proton translocating function of the *NDUF52* subunit.

**Electronic database information.**

Genbank accession numbers *NDUF52* / 49 kDa / *NuoD*:  
Homo sapiens NP\_004541, O75306; *Bos taurus* P17694; *Neurospora crassa* P22142; *Wood tobacco* S57332; *Mycobacterium tuberculosis* CAB06291; *Sinorhizobium meliloti* CAB51623; *Paracoccus denitrificans* P29916; *Escherichia coli* P33600.

## Reference List.

- Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG. 1981. Sequence and organisation of the human mitochondrial genome. *Nature* 290 457-465
- Bentlage H, Wendel U, Schagger H, ter Laak H, Janssen A, Trijbels F. 1996 Lethal infantile mitochondrial disease with isolated complex I deficiency in fibroblasts with combined complex I and IV deficiencies in muscle. *Neurology* 47 243-248
- Bourgeron T, Rustin P, Chretien D, Birch-Machin M, Bourgeois M, Viegas-Pequignot E, Munnich A, Rötig A. 1995. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency *Nat Genet* 11 144-149
- Braun M, Bungert S, Friedrich T. 1998 Characterisation of the overproduced NADH dehydrogenase fragment of the NADH:ubiquinone oxidoreductase (complex I) from *Escherichia coli* *Biochemistry* 37:1861-1867
- Chen S and Guillory RJ. 1981. Studies on the interaction of arylazido-beta-alanyl NAD<sup>+</sup> with the mitochondrial NADH dehydrogenase *J Biol Chem* 256 8318-8323.
- Chomyn A, Cleeter MWJ, Ragan CI, Riley M, Doolittle RF, Attardi G. 1986. URF6, Last unidentified reading frame of human mtDNA, codes for an NADH dehydrogenase subunit. *Science* 234:614-618.
- Chou PY and Fasman GD. 1978. Prediction of the secondary structure of proteins from their amino acid sequence. *Adv Enzymol Rel A Mol Biol* 47:45-148.
- Coenen MJH, van den Heuvel LP, Nijtmans LGJ, Morava E, Marquardt I, Girschick HJ, Trijbels FJ, Grivell LA, Smeitink JAM. 2000. SURFEIT-1 gene analysis and two-dimensional blue native gel electrophoresis in cytochrome c oxidase deficiency *Biochem Biophys Res Commun* 265 339-344.
- Cooperstein SJ and Lazarow A. 1951 A microspectrophotometry method for the determination of cytochrome c oxidase *J Biol Chem* 189:665-670
- Darrouzet E, Issartel JP, Lunardi J, Dupuis A. 1998 The 49-kDa subunit of NADH-ubiquinone oxidoreductase (Complex I) is involved in the binding of piericidin and rotenone, two quinone-related inhibitors. *FEBS Lett* 431 34-38
- Degli Esposti M. 1998 Inhibitors of NADH-ubiquinone reductase: an overview. *Biochim Biophys Acta* 1364:222-235
- Deng PS, Hatefi Y, Chen S. 1990 N-arylazido-beta-alanyl-NAD<sup>+</sup>, a new NAD<sup>+</sup> photoaffinity analogue Synthesis and labelling of mitochondrial NADH dehydrogenase. *Biochemistry* 29:1094-1098
- Fischer JC, Ruitenbeek W, Berden JA, Trijbels JM, Veerkamp JH, Stadhouders AM, Sengers RC, Janssen AJ. 1985 Differential investigation of the capacity of succinate oxidation in human skeletal muscle *Clin Chim Acta* 153:23-36.
- Fischer JC, Ruitenbeek W, Trijbels JM, Veerkamp JH, Stadhouders AM, Sengers RC, Janssen AJ. 1986. Estimation of NADH oxidation in human skeletal muscle mitochondria *Clin Chim Acta* 155:263-273.
- Friedrich T and Weiss H. 1997 Modular evolution of the respiratory NADH:ubiquinone oxidoreductase and the origin of its modules *J Theor Biol* 187 529-540
- Friedrich T. 1998. The NADH:ubiquinone oxidoreductase (complex I) from *Escherichia coli* *Biochim Biophys Acta* 1364:134-146
- Guenebaut V, Vincentelli R, Mills D, Weiss H, Leonard KR. 1997. Three-dimensional structure of NADH dehydrogenase from *Neurospora crassa* by electron microscopy and conical tilt reconstruction *J Mol Biol* 265 409-418
- Kirby DM, Crawford M, Cleary MA, Dahl HH, Dennett X, Thorburn DR. 1999. Respiratory chain complex I deficiency: an underdiagnosed energy generation disorder. *Neurology* 52 1255-1264
- Li YY, Hengstenberg C, Maisch B. 1995. Whole mitochondrial genome amplification reveals basal level multiple deletions in mtDNA of patients with dilated cardiomyopathy. *Biochem Biophys Res Commun* 210:211-218.
- Loeffen J, van den Heuvel L, Smeets R, Triepels R, Sengers R, Trijbels F, Smeitink J. 1998a cDNA sequence and chromosomal localisation of the remaining three human nuclear encoded iron sulphur protein (IP) subunits of complex I: the human IP fraction is completed. *Biochem Biophys Res Commun* 247:751-758.
- Loeffen J, Smeitink J, Triepels R, Smeets R, Schuelke M, Sengers R, Trijbels F, Hamel B, Mullaart R, van den Heuvel L. 1998b. The First Nuclear-Encoded Complex I Mutation in a Patient

- with Leigh Syndrome. *Am J Hum Genet* 63:1598-1608
- Loeffen J, Smeitink J, Trijbels F, Janssen A, Triepels R, Sengers R, van den Heuvel B.** 2000 Isolated complex I deficiency in children: clinical, biochemical and genetic aspects. *Hum Mutat* 15:123-134.
- Ohnishi T.** 1998 Iron-sulphur clusters/semiquinones in complex I. *Biochim Biophys Acta* 1364:186-206.
- Okun JG, Lemmen P, Brandt U.** 1999. Three classes of inhibitors share a common binding domain in mitochondrial complex I (NADH:Ubiquinone oxidoreductase). *J Biol Chem* 274:2625-2630.
- Pilkington SJ, Skehel JM, Gennis RB, Walker JE.** 1991 Relationship between mitochondrial NADH-ubiquinone reductase and a bacterial NAD-reducing hydrogenase. *Biochemistry* 30:2166-2175
- Pitkänen S, Feigenbaum A, Laframboise R, Robinson BH.** 1996 NADH-coenzyme Q reductase (complex I) deficiency: heterogeneity in phenotype and biochemical findings. *J Inher Metab Dis* 19:675-686
- Ploos van Amstel JK, Bergman AJIW, van Beurden EACM, Roijers JFM, Peelen T, van den Berg IET, Poll-The BT, Kvittingen EA, Berger R.** 1996. Hereditary tyrosinemia type I: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene, variability of the genotype-phenotype relationship. *Hum Genet* 97:51-59
- Rahman S, Blok RB, Dahl HH, Danks DM, Kirby DM, Chow CW, Christodoulou J, Thorburn DR.** 1996 Leigh syndrome: clinical features and biochemical and DNA abnormalities. *Ann Neurol* 39:343-351.
- Sambrook J, Fritsch EF, Maniatis E (eds).** 1989. *Molecular cloning: a laboratory manual*, 2<sup>nd</sup> edn. Cold Spring Harbor: Cold Spring Harbor Laboratory Press.
- Schuelke M, Smeitink J, Mariman E, Loeffen J, Plecko B, Trijbels F, Stockler-Ipsiroglu S, van den Heuvel L.** 1999. Mutations in the NADH-binding subunit of mitochondrial complex I (NDUFV1) cause severe leukodystrophic encephalopathy with myoclonic epilepsy. *Nature Genet* 21:260-261
- Shoffner JM.** 1996 Maternal inheritance and the evaluation of oxidative phosphorylation diseases. *Lancet* 348:1283-1288
- Smeitink J and van den Heuvel L.** 1999 Human mitochondrial complex I in health and disease. *Am J Hum Genet* 64:1505-1510.
- Smeitink JAM, Sengers RCA, Trijbels JMF, van den Heuvel LP.** 2000 Oxidative phosphorylation disorders: a review. *Eur J Pediatr.* in press
- Srere PA.** 1969 Citrate synthase, EC 4.1.3.7 citrate oxaloacetate lyase (C0-A-acetylating). *Method enzymol* XIII:3-11.
- Tiranti V, Hoertnagel K, Carrozzo R, Galimberti C, Munaro M, Granatiero M, Zelante L, Gasparini P, Marzella R, Rocchi M, Bayona-Bafaluy MP, Enriquez JA, Uziel G, Bertini E, Dionisi-Vici C, Franco B, Meitinger T, Zeviani M.** 1998. Mutations of SURF-1 in Leigh Disease Associated with Cytochrome c Oxidase Deficiency. *Am J Hum Genet* 63:1609-1621.
- Triepels RH, van den Heuvel LP, Loeffen JL, Buskens CA, Smeets RJ, Rubio Gozalbo ME, Budde SM, Mariman EC, Wijburg FA, Barth PG, Trijbels JM, Smeitink JA.** 1999. Leigh syndrome associated with a mutation in the NDUF57 (PSST) nuclear encoded subunit of complex I. *Ann Neurol* 45:787-790
- van den Heuvel L, Ruitenbeek W, Smeets R, Gelman-Kohan Z, Elpeleg O, Loeffen J, Trijbels F, Mariman E, de Bruijn D, Smeitink J.** 1998. Demonstration of a new pathogenic mutation in human complex I deficiency: a 5-bp duplication in the nuclear gene encoding the 18-kD (AQDQ) subunit. *Am J Hum Genet* 62:262-268.
- van Laack HL, Ruitenbeek W, Trijbels JM, Sengers RC, Gabreels FJ, Janssen AJ, Kerkhof CM.** 1988. Estimation of pyruvate dehydrogenase (E1) activity in human skeletal muscle; three cases with E1 deficiency. *Clin Chim Acta* 171:109-118
- Zhu Z, Yao J, Johns T, Fu K, De Bie I, Macmillan C, Cuthbert AP, Newbold RF, Wang J, Chevette M, Brown GK, Brown RM, Shoubridge EA.** 1998 SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. *Nat Genet* 20:337-343.





### MUTATIONAL ANALYSIS STUDIES OF FOUR NUCLEAR ENCODED SUBUNITS OF THE COMPLEX I IRON-SULPHUR PROTEIN (IP) FRACTION: WHICH GENES NEXT?

*Submitted*

#### **Abstract.**

Human complex I consists of at least 42 different proteins, of which 35 are encoded by nuclear genes. With the use of chaotropic agents, complex I can be subdivided in a Flavoprotein (FP), Iron-Sulphur protein (IP), and Hydrophobic protein (HP) fraction. The IP fraction is situated in the part of complex I, which protrudes into the mitochondrial matrix and contains together with the FP fraction almost all known redox groups.

We performed mutational analysis studies on cDNA level of four IP subunits (NDUFS1, NDUFS3, NDUFS6 and NDUF45) in 20 isolated complex I deficient patients, which revealed no pathological mutations. With the results presented in this study, all 35 known nuclear encoded complex I subunits have been checked for mutations in our initial patient group. Altogether these mutational analysis studies revealed mutations in genes of five different subunits (NDUFV1, NDUFS2, NDUFS4, NDUFS7, NDUFS8), in seven out of eighteen pedigrees (39%). Three of these subunits (four pedigrees) belong to the IP fraction.

## Introduction.

Isolated complex I deficiency is one of the main enzyme defects of the mitochondrial respiratory chain found in children clinically presenting with a mitochondrial encephalomyopathy (Loeffen et al 2000a). Various drugs and combinations of drugs have been supplied to complex I deficient patients such as riboflavine (precursor FAD), nicotinamide (precursor NAD) and succinate (complex II substrate) (Scholte et al 1995). These therapies have only been described to benefit individual or small number of patients. Elucidation of the genetic cause(s) in complex I deficient patients, the main aim of our current investigations, may be worthwhile in this context for several reasons. In the first place it will give us the opportunity to offer adequate genetic counselling and prenatal diagnostics. Secondly, pathophysiological studies performed with tissues of patients in whom the genetic defect has been elucidated may enhance our understanding of the cell biological consequences of complex I deficiency and eventually may contribute to accurate disease models, necessary for developing adequate therapy strategies.

Studies of the genetics of complex I deficiency are complicated by the fact that this complex is under double genomic control in eukaryotes (Walker 1992). Seven of the ~42 subunits of human complex I are encoded on the mitochondrial DNA (mtDNA, Anderson et al 1981). This implicates that the remaining 35 subunits are encoded by nuclear genes. The last two years, we searched for mutations in the nuclear encoded subunits of complex I in a group of isolated complex I deficient patients. Pre-screening for major rearrangements (long template PCR technique (Li et al 1995)) and for eleven common mtDNA mutations in these patients revealed no abnormalities (Loeffen et al 2000a).

The cDNA and amino acid sequence of unidentified human complex I subunits were elucidated using the high percentage of identity with bovine complex I subunits. Recently the 35<sup>th</sup> nuclear encoded bovine complex I subunit has been identified (Skehel et al 1998). Equivalents of these 35 subunits have been found in humans (Loeffen et al 1998a, Triepels et al 2000). Strikingly, mutational analysis studies performed thus far in our patient group mainly revealed mutations in those subunits, which are highly conserved in evolution as illustrated by their presence in prokaryotic lifeforms (Loeffen et al 2000a).

In this study we focussed mutational analysis on four subunits of the Iron-Sulphur protein (IP) fraction, namely the NDUF51, NDUF53, NDUF56 and NDUF55. The IP fraction contains ~8 subunits and constitutes the main part of complex I which protrudes in the mitochondrial matrix (Galante & Hatefi 1978 and 1979, Belogradov and Hatefi 1996). The largest subunit of the IP fraction is the NDUF51 (Chow et al 1991). It contains one 2Fe 2S cluster binding site (cluster N1b) and probably two 4Fe-4S cluster binding sites (cluster N4 and N5, Ohnishi 1998). The second largest subunit is the NDUF52, which is believed to influence proton transport and ubiquinone binding (Loeffen et al 2000b). Little is currently known of the function of the NDUF53 subunit, but its high conservation during evolution implicates importance (Loeffen et al 1998b). The NDUF54 subunit contains a cAMP regulated phosphorylation site, and probably plays a role in the regulation of complex I activity (Papa et al 1996). Another subunit, which is likely to contribute to the electron transport is the NDUF58. This subunit contains highly conserved patterns for two 4Fe 4S cluster-binding

sites Of the other three subunits (NDUFS5, NDUFS6 and NDUF A5) is functionally little known (Pata et al 1997, Russell et al 1997, Loeffen et al 1998b, Loeffen et al 1999)

In this study we present the results of mutational analysis studies of four nuclear encoded IP subunits (NDUFS1, NDUFS3, NDUFS6 and NDUF A5) in a group of 20 isolated complex I deficient patients, which revealed no pathological mutations. This study completes mutational analysis of the eight subunits present in the IP fraction. With the results of this study, all currently known 35 nuclear encoded complex I subunits in our initial complex I deficient patient group have been checked for mutations.

## **Patients, material and methods.**

### *Patient group*

Twenty isolated complex I deficient patients (age range 0-26 months, measured in all cases in cultured skin fibroblasts) were selected for mutational analysis studies of nuclear encoded complex I subunits. Clinical characteristics of this patient group have recently been published (Loeffen et al 2000a).

### *Material*

DNA Taq polymerase, superscript II RNase H reverse transcriptase and oligonucleotide primers were purchased from Life Technologies Inc, gel purification systems from Qiagen, dRhodamine Dye Terminator Sequencing Kit from Perkin Elmer, poly A<sup>+</sup> RNA pool from Clontech and RNazol from Biosolve BV.

### *Tissue culture*

Skin fibroblasts were cultured in a humidified atmosphere of 95% air, 5% CO<sub>2</sub> at 37°C in medium 199 with Earle's salts supplemented with 10%(v/v) foetal calf serum (FCS) and 100 IU penicillin/ml and 100 µg streptomycin/ml. The cells were grown to confluence.

### *Biochemical measurements*

Fibroblasts were harvested according to standard procedures and suspended in a concentration of  $1 \times 10^7$  cells/ml 1% Foetal Calf Serum in Phosphate Buffered Saline (FCS-PBS). A mitochondrial-enriched fraction was isolated from these fibroblasts as described by Bentlage and co-workers in 1996.

All individual enzyme assays have been performed in mitochondrial enriched fractions. Pyruvate dehydrogenase complex (PDHc) activity is estimated by measurement of the production rate of <sup>14</sup>CO<sub>2</sub> by PDHc under basal and activated conditions, in presence of [1-<sup>14</sup>C]-pyruvate, CoA and NAD<sup>+</sup> according to van Laack et al 1988. Citrate synthase activity is estimated by the extent of complex formation between CoA and 5',5'-dithiobis-2-nitrobenzoate (DTNB) which is measured spectrophotometrically at 412 nm according to Srere in 1969. NADH O<sub>2</sub> oxidoreductase and NADH Q1 oxidoreductase are measured by following NADH oxidation spectrophotometrically at 340 nm in presence of O<sub>2</sub> or Q1 as electron acceptor in presence and absence of rotenone as described by Fischer et al 1986,

succinate:cytochrome *c* oxidoreductase is estimated by following the reduction of cytochrome *c* at 550 nm in presence of succinate, rotenone, antimycine A and KCN according to Fischer et al 1985. Cytochrome *c* oxidase activity is determined by measurement of the oxidation rate of completely reduced cytochrome *c* spectrophotometrically at 550 nm as described by Cooperstein and Lazarow 1951.

Mutational analysis.

Control RNA was obtained from commercially purchased pooled poly A<sup>+</sup> RNA from 12 healthy Caucasian males and females, age range 12-78 years. Patient RNA was extracted from cultured skin fibroblasts according to methods described by Chomczynski and Sacchi 1987. cDNA was made by reverse transcription of RNA by superscript II RNase H<sup>-</sup> reverse transcriptase, with oligo(dT) and random hexamer primers (Ploos van Amstel et al 1996). The complete open reading frame (ORF) of the NDUFS1 subunit was divided in four overlapping fragments, which were separately amplified (F1+R2, F3+R4, F5+R6, F7+R8) in a volume of 50 µl, containing 2 µl cDNA template, 5 µl 10× PCR buffer, 100 ng forward and reverse primer, 0.25 mM MgCl<sub>2</sub>, 0.25mM dNTPs and 1.0 unit Taq DNA polymerase. In case of the NDUFS3 (F1+R3), NDUFS6 (F1+R1) and NDUFA5 (F1+R1) subunit, one fragment containing the complete ORF was amplified in a volume of 25 µl, containing 1 µl cDNA template, 2.5 µl 10× PCR buffer, 50 ng forward and reverse primer, 0.25 mM MgCl<sub>2</sub>, 0.25mM dNTPs and 0.5 unit Taq DNA polymerase. All reaction conditions and primer sequences used are listed in Table 11.1 and 11.2. PCR products were purified using the QIAquick PCR purification kit or GEL extraction kit. Control and patient PCR fragments were sequenced with the ABI PRISM™ 377 using the sequence primers for each individual subunit, which are listed in table 11.1. Procedures were followed as recommended by the manufacturer.

Subunits		Forward oligonucleotides		Reverse oligonucleotides
NDUFS1	F1	CGGACAGTTT TAGCAGAACAG	R1	GGCACAAGCAGCTACAACC
	F2	GGTTGTCTGTTGCTGGAAAC	R2	CCCAAATCATCTACTCCTGC
	F3	GTGGAAGACAAGAACATTGG	R3	CACTCTTCATTGATGTCCTC
	F4	GATGTAATGGATGCGGTTGG	R4	CAAATCTGTGCCAGCTCCTG
	F5	GTGGACTCTGACACCTTATG	R5	GAATTGCTGCTCCATCATTTT
	F6	GGTGGTTTTAGGCAGTTCTG	R6	CTCTACCCTCAGTGTTGAC
	F7	GCTGATGTTATTC'TCCCAGG	R7	GAGGCTCTGCTAATCGAATC
	F8	CCCAGTGTTCACCTCAG	R8	GGATCACTGCACTACAGTTG
NDUFS3	F1	CATCTGAGTAACATGGCGGC	R1	CTGTGCATTGGTGTGATCCC
	F2	GTTAGAGGTCTGTATCCATCC	R2	GGATCCTTCTTAGATCAGGG
	F3	AGCCAACTGGTATGAAAGGG	R3	GGACACTCAATCATAGATAAGG
NDUFS6	F1	AAATGGCGGCGGCGATGACC	R1	GCACAGAACCAGCGAGCTTCAC
NDUFA5	F1	GTCACCGAGTCGTTGGCG	R1	CAGTTTCCCATGAACACACC

Table 11.1 Sequence of primers used in the PCR reactions and of those used in sequence reactions (all primers).

PCR conditions	
<b>NDUFS1F1+R2</b>	92°C/1 min.; 92°C/1 min., 56 °C/1 min., 72 °C/1 min. (40 cycles); 72 °C/10 min.
<b>NDUFS1F3+R4</b>	92°C/1 min.; 92°C/1 min., 58 °C/1 min., 72 °C/1 min. (40 cycles); 72 °C/10 min.
<b>NDUFS1F5+R6</b>	92°C/1 min.; 92°C/1 min., 56 °C/1 min., 72 °C/1 min. (40 cycles); 72 °C/10 min.
<b>NDUFS1F7+R8</b>	92°C/1 min.; 92°C/1 min., 58 °C/1 min., 72 °C/1 min. (40 cycles); 72 °C/10 min.
<b>NDUFS3F1+R3</b>	94°C/1 min.; 94°C/1 min., 60 °C/1 min., 72 °C/1 min. (34 cycles); 72 °C/10 min.
<b>NDUFS6F1+R1</b>	94°C/1 min.; 94°C/1 min., 60 °C/1 min., 72 °C/1 min. (34 cycles); 72 °C/10 min.
<b>NDUFA5F1+R1</b>	94°C/1 min.; 94°C/1 min., 55 °C/1 min., 72 °C/1 min. (34 cycles); 72 °C/10 min.

**Table 11.2** Conditions of the PCR reactions used in the amplification of each subunit.

## Results and discussion.

Cycle sequencing of the wildtype amplified *NDUFS1* cDNA revealed an open reading frame (ORF) of 2184 base pairs (including stopcodon) coding for 727 amino acids. We found two mutations in the ORF of our wildtype and patient cDNA sequences compared to the published *NDUFS1* cDNA sequence (Chow et al 1991). It concerned a 1248A→T and 1249T→A, which change the published tryptophane residue at position 417 into an arginine (W417R). The *NDUFS1* subunit has a molecular weight of 79.5 kDa deducted from its amino acid sequence. The bovine homologue (75-kDa subunit) contains a presequence of 23 amino acids (Runswick et al 1989) and is believed to contain at least two Iron-Sulphur cluster bindings sites (4Fe-4S (N4) and 2Fe-2S (N1b); Runswick et al 1989), but probably another 4Fe-4S binding site is present (Ohnishi 1998). The presence of these clusters implicates an important role for the *NDUFS1* in the transport of electrons and is therefore one of the major candidate genes in isolated complex I deficiency. Belugrodov and co-workers showed by ligand blotting that the bovine 75 kDa subunit has a close interaction with the 51-kDa (NADH binding site, FMN, 4Fe-4S) and 24-kDa (2Fe-2S) subunit and therefore likely accepts the electrons from the Flavoprotein fraction (FP; Belugrodov and Hatefi 1996). Sequence analysis of patient *NDUFS1* cDNA of 20 isolated complex I deficient patients revealed however no pathological mutations. We did encounter several silent mutations, namely a 414T→C (D138D) heterozygously in one patient, a homozygous 966T→G (A322A) also in one patient (also heterozygously in the wildtype) and a 1251G→A (R417R) in several patients and wildtype (homozygous as well as heterozygous). Finally, we found a heterozygous 1291C→G mutation, which leads to the substitution of a leucine into a valine (L431V) in one patient. The wildtype *NDUFS3* subunit contains an ORF of 795 base pairs coding for 264 amino acids (Loeffen et al 1998b). Like the *NDUFS1*, this subunit is present in the prokaryotic complex I which is indicative for functional importance. Currently nothing is known about the function of this subunit. Mutational analysis studies revealed neither mutations nor polymorphisms. The *NDUFS6* (ORF 375 base pairs) and *NDUFA5* (ORF 348 base pairs) wildtype cDNA sequence has been published by Loeffen et al in 1998b and Pata et al in 1997, respectively. Cycle sequencing of amplified cDNA of all patients again revealed neither mutations nor polymorphisms.

At this moment mutational analysis studies have been performed of all currently known 35

nuclear encoded subunits of complex I in an initial group of 20 isolated complex I deficient patients (18 pedigrees). In case of subunits present in the flavoprotein (FP) fraction these studies revealed compound heterozygous mutations leading to a nonsense mutation and two single amino acid substitutions in the *NDUFV1* subunit (R59X and T423M in two brothers with an encephalomyopathy and a homozygous mutation resulting in an A341V in a girl with macrocephaly and leukodystrophy (Schuelke et al 1999)). Mutational analysis studies performed with the *NDUFV2* and *NDUFV3* cDNA revealed no pathological mutations (unpublished results). Similar studies performed with subunits of the IP fraction revealed amino acid substitutions in the *NDUFS2* subunit in three pedigrees (R228Q, P229Q and S413P), however the patient in whom the P229Q substitution has been found did not belong to the initial patient group (Loeffen et al 2000b). In the *NDUFS4* gene a 5-bp duplication was found in a boy with Leigh-like syndrome. Finally, the *NDUFS8* cDNA contained mutations in a boy with Leigh syndrome leading to a P79L and R102H amino acid substitution. Screening of the remaining large group of the Hydrophobic Protein (HP) fraction (24 subunits) revealed an amino acid substitution (V122M) in two brothers with Leigh syndrome (Triepeles et al 1999 and 2000). In summary, mutations were found in 7 of the initial 18 pedigrees (39%), all of which co-segregated within the family and were excluded in a large control population.

This study completes the mutational analysis studies of the currently known nuclear encoded complex I subunits in our initial complex I deficient patient group (n=20). In contrary to cytochrome *c* oxidase deficiency where no mutations were found in the nuclear encoded subunits (Adams et al 1997, Jaksch et al 1998) mutations have been found in those of complex I. Since the number of subunits is not definitely determined in cow (now 42 known, and one announced, Skehel et al 1998) there might be other mutations present in undetected nuclear encoded subunits. Similar experiments to determine the number of subunits like those performed in cow (e.g. electrospray mass spectrometry) still have to be performed in humans. These studies will give the definite number of subunits of which human complex I is composed.

The nuclear encoded complex I genes were clear candidates for mutational analysis studies in our complex I deficient patient group. The elucidation of the gene defects in patients in whom no mutations were encountered in the cDNAs of the nuclear encoded complex I subunits will however be more complicated. Several approaches can be followed to tackle this problem. One can try to find homologues of human genes, which have been linked to the biogenesis of complex I in lower species and consequently perform mutational analysis studies. Good candidates for this approach would be the CIA30 and CIA84 complex I chaperone/assembly proteins described in *Neurospora crassa* (Kuffner et al 1998). This method has been successfully applied by Papadopoulou and co-workers in 1999 for complex IV deficiency, but can lead to many candidate genes. The other more structural approach comprises the establishment of complementation groups as has been performed for complex IV deficiency (Tiranti et al 1995). This process can be followed by the combination of techniques like microcell-mediated chromosome transfer, deletion mapping and positional cloning which led to the solution of cytochrome *c* oxidase deficient patients with Leigh syndrome in whom mutations were found in the *SURF1* gene (Zhu et al 1998, Tiranti et al 1998).

Mutations might also be present in one of the ND genes or tRNA genes encoded by the

mtDNA in our “unsolved” complex I deficient patients. We checked for major rearrangements and eleven common point mutations, but this does not cover the complete area. At this moment it might be wise to exclude or prove mutations in the mtDNA by complementation studies with  $p^0$  cells as described by King and Attardi in 1989.

In summary, we checked for mutations in the cDNA of four Iron-Sulphur protein fraction subunits, namely the NDUFS1, NDUFS3, NDUFS6 and NDUF5 in our isolated complex I deficient patient group. This revealed no disease-causing mutations. Currently all known 35 nuclear encoded complex I subunits have been analysed for mutations in a group of twenty isolated complex I deficient patients. This revealed mutations in seven of the eighteen pedigrees (39%). Techniques like microcell-mediated chromosome transfer and positional/functional cloning should elucidate the genetic defect in the remaining patients.

### **Acknowledgements.**

Antoon Janssen and Frans van den Brandt are gratefully acknowledged for their technical assistance. This study was funded by the “Stichting voor kinderen die wel willen maar niet kunnen” and the “Prinses Beatrix Fonds” granted to JS and BVDH.

## Reference List.

- Adams PL, Lightowlers RN, Turnbull DM.** 1997 Molecular analysis of cytochrome *c* oxidase deficiency in Leigh's syndrome. *Ann Neurol* 41 268-270.
- Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG.** 1981 Sequence and organisation of the human mitochondrial genome. *Nature* 290:457-465
- Belogradov G and Hatefi Y.** 1996 Intersubunit interactions in the bovine mitochondrial complex I as revealed by ligand blotting. *Biochem Biophys Res Commun* 227 135-139
- Bentlage H, Wendel U, Schagger H, ter Laak H, Janssen A, Trijbels F.** 1996. Lethal infantile mitochondrial disease with isolated complex I deficiency in fibroblasts with combined complex I and IV deficiencies in muscle. *Neurology* 47 243-248
- Chomczynski P and Sacchi N.** 1987 Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. *Anal Biochem* 162:156-159.
- Chow W, Ragan CI, Robinson BH.** 1991 Determination of the cDNA sequence for the human mitochondrial 75-kDa Fe-S protein of NADH-coenzyme Q reductase. *Eur J Biochem* 201 547-550
- Cooperstein SJ and Lazarow A.** 1951 A microspectrophotometry method for the determination of cytochrome *c* oxidase. *J Biol Chem* 189 665-670
- Fischer JC, Ruitenbeek W, Berden JA, Trijbels JM, Veerkamp JH, Stadhouders AM, Sengers RC, Janssen AJ.** 1985 Differential investigation of the capacity of succinate oxidation in human skeletal muscle. *Clin Chim Acta* 153 23-36
- Fischer JC, Ruitenbeek W, Trijbels JM, Veerkamp JH, Stadhouders AM, Sengers RC, Janssen AJ.** 1986 Estimation of NADH oxidation in human skeletal muscle mitochondria. *Clin Chim Acta* 155:263-273
- Galante YM and Hatefi Y.** 1978. Resolution of complex I and isolation of NADH dehydrogenase and an iron-sulphur protein. *Method Enzymol* 53:15-21
- Galante YM and Hatefi Y.** 1979 Purification and molecular and enzymatic properties of mitochondrial NADH dehydrogenase. *Arch Biochem Biophys* 192:559-568.
- Jaksch M, Hofmann S, Kleine S, Liechti-Gallati S, Pongratz DE, Muller-Hocker J, Jedele KB, Meitinger T, Gerbitz KD.** 1998. A systematic mutation screen of 10 nuclear and 25 mitochondrial candidate genes in 21 patients with cytochrome *c* oxidase (COX) deficiency shows tRNA(Ser)(UCN) mutations in a subgroup with syndromal encephalopathy. *J Med Genet* 35 895-900.
- King MP and Attardi G.** 1989 Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. *Science* 246 500-503.
- Kuffner R, Rohr A, Schmiede A, Krull C, Schulte U.** 1998 Involvement of two novel chaperones in the assembly of mitochondrial NADH:ubiquinone oxidoreductase (Complex I). *J Mol Biol* 283:409-417
- Li YY, Hengstenberg C, Maisch B.** 1995. Whole mitochondrial genome amplification reveals basal level multiple deletions in mtDNA of patients with dilated cardiomyopathy. *Biochem Biophys Res Commun* 210:211-218
- Loeffen JL, Triepels RH, van den Heuvel LP, Schuelke M, Buskens CA, Smeets RJ, Trijbels JM, Smeitink JA.** 1998a cDNA of eight nuclear encoded subunits of NADH:ubiquinone oxidoreductase: human complex I cDNA characterisation completed? *Biochem Biophys Res Commun* 253:415-422.
- Loeffen J, van den Heuvel L, Smeets R, Triepels R, Sengers R, Trijbels F, Smeitink J.** 1998b cDNA sequence and chromosomal localisation of the remaining three human nuclear encoded iron sulphur protein (IP) subunits of complex I: the human IP fraction is completed. *Biochem Biophys Res Commun* 247 751-758
- Loeffen J, Smeitink J, Smeets R, Triepels R, Sengers R, Trijbels F, van den Heuvel L.** 1999 The human NADH: ubiquinone oxidoreductase NDUF55 (15 kDa) subunit cDNA cloning, chromosomal localisation, tissue distribution and the absence of mutations in isolated complex I-deficient patients. *J Inherit Metab Dis* 22 19-28.
- Loeffen J, Smeitink J, Trijbels F, Janssen A, Triepels R, Sengers R, van den Heuvel L.** 2000a Isolated complex I deficiency in children: clinical, biochemical and genetic aspects. *Hum Mutat* 15:123-134
- Loeffen J, Elpeleg O, Smeitink J, Smeets R,**



- Stockler-Ipsiroglu S, Mandel H, Sengers R, Trijbels F, van den Heuvel L.** 2000b Mutations in the complex I *NDUFS2* gene are associated with hypertrophic cardiomyopathy and encephalomyopathy *Submitted*
- Ohnishi T.** 1998 Iron sulphur clusters/semiquinones in complex I *Biochim Biophys Acta* 1364 186-206
- Papa S, Sardanelli AM, Cocco T, Speranza F, Scacco SC, Technikova-Dobrova Z.** 1996 The nuclear encoded 18 kDa (IP) AQDQ subunit of bovine heart complex I is phosphorylated by the mitochondrial cAMP-dependent protein kinase *FEBS Lett* 379 299-301
- Papadopoulou LC, Sue CM, Davidson MM, Tanji K, Nishino I, Sadlock JE, Krishna S, Walker W, Selby J, Glerum DM, Coster RV, Lyon G, Scalais E, Lebel R, Kaplan P, Shanske S, De VD, Bonilla E, Hirano M, DiMauro S, Schon EA.** 1999 Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in *SCO2*, a COX assembly gene *Nat Genet* 23 333-337
- Pata I, Tensing K, Metspalu A.** 1997 A human cDNA encoding the homologue of NADH ubiquinone oxidoreductase subunit B13 *Biochim Biophys Acta* 1350 115-118
- Ploos van Amstel JK, Bergman AJW, van Beurden EACM, Roijers JFM, Peelen T, van den Berg IET, Poll-The BT, Kvittingen EA, Berger R.** 1996 Hereditary tyrosinemia type I novel missense nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene variability of the genotype phenotype relationship *Hum Genet* 97 51-59
- Runswick MJ, Gennis RB, Fearnley IM, Walker JE.** 1989 Mitochondrial NADH ubiquinone reductase complementary DNA sequence of the import precursor of the bovine 75 kDa subunit *Biochemistry* 28 9452-9459
- Russell MW, du MS, Collins FS, Brody LC.** 1997 Cloning of the human NADH ubiquinone oxidoreductase subunit B13 localisation to chromosome 7q32 and identification of a pseudogene on 11p15 *Mamm Genome* 8 60-61
- Scholte HR, Busch HF, Bakker HD, Bogaard JM, Luyt-Houwen IE, Kuyt LP.** 1995 Riboflavin responsive complex I deficiency *Biochim Biophys Acta* 1271 75-83
- Schuelke M, Smeitink J, Mariman E, Loeffen J, Plecko B, Trijbels F, Stockler-Ipsiroglu S, van den Heuvel L.** 1999 Mutant *NDUFV1* subunit of mitochondrial complex I causes leukodystrophy and myoclonic epilepsy *Nat Genet* 21 260-261
- Skehel JM, Fearnley IM, Walker JE.** 1998 NADH ubiquinone oxidoreductase from bovine heart mitochondria sequence of a novel 17.2 kDa subunit *FEBS Lett* 438 301-305
- Srere PA.** 1969 Citrate synthase, EC 4.1.3.7 citrate oxaloacetate lyase (C0-A-acetylating) *Method enzymol* XIII 3-11
- Tiranti V, Munaro M, Sandona D, Lamantea E, Rimoldi M, DiDonato S, Bisson R, Zeviani M.** 1995 Nuclear DNA origin of cytochrome c oxidase deficiency in Leigh's syndrome genetic evidence based on patient's-derived rho negative transformants *Hum Mol Genet* 4 2017-2023
- Tiranti V, Hoertnagel K, Carrozzo R, Galimberti C, Munaro M, Granatiero M, Zelante L, Gasparini P, Marzella R, Rocchi M, Bayona-Bafaluy MP, Enriquez JA, Uziel G, Bertini E, Dionisi-Vici C, Franco B, Meitinger T, Zeviani M.** 1998 Mutations of *SURF1* in Leigh Disease Associated with Cytochrome c Oxidase Deficiency *Am J Hum Genet* 63 1609-1621
- Triepels R, van den Heuvel L, Loeffen J, Buskens C, Smeets R, Rubio-Gozalbo M, Budde S, Mariman E, Wijburg F, Barth P, Trijbels F, Smeitink J.** 1999 Leigh syndrome associated with a mutation in the *NDUFS7* (PSST) nuclear encoded subunit of complex I *Ann Neurol* 45 787-790
- Triepels R, Smeitink J, Loeffen J, Smeets R, Buskens C, Trijbels F, van den Heuvel L.** 2000 Characterisation of the human complex I *NDUFB7* and 17.2 kDa cDNAs and mutational analysis of 19 genes of the HP fraction in complex I deficient patients *Hum Genet* in press
- van Laack HL, Ruitenbeek W, Trijbels JM, Sengers RC, Gabreels FJ, Janssen AJ, Kerkhof CM.** 1988 Estimation of pyruvate dehydrogenase (E1) activity in human skeletal muscle, three cases with E1 deficiency *Clin Chim Acta* 171 109-118
- Walker JE.** 1992 The NADH ubiquinone oxidoreductase (complex I) of respiratory chains *Q Rev Biophys* 25 253-324
- Zhu Z, Yao J, Johns T, Fu K, De Bie I, Macmillan C, Cuthbert AP, Newbold RF, Wang J, Chevrete M, Brown GK, Brown RM, Shoubridge EA.** 1998 *SURF1*, encoding a factor involved in the biogenesis of cytochrome c oxidase is mutated in Leigh syndrome *Nat Genet* 20 337-343



**CONSIDERATIONS, CONCLUSIONS AND FUTURE PERSPECTIVES**

## Human complex I: structural and functional aspects.

Over 50 years ago, mitochondria were for the first time identified to host oxidative phosphorylation (Kennedy and Lehninger 1948). Adequate oxidative phosphorylation requires synthesis of a few rRNAs, tRNAs and proteins by the mitochondrion itself (for a review see Taanman 1999) as well as importation of many proteins encoded by the nuclear DNA into these mitochondria (Koehler et al 1999). This dual genetic origin demands a delicately tuned nuclear and mitochondrial collaboration, which partly has been elucidated (Butow and Bahassi 1999).

Complex I or NADH ubiquinone oxidoreductase is the first, largest and most complicated complex of the OXPHOS system (Walker 1992, Smeitink et al 1998). Currently, its subunit composition has been elaborately studied in several prokaryotes and eukaryotes: *Escherichia coli* (Leif et al 1993, Weidner et al 1993, Leif et al 1995, Friedrich et al 1995, Friedrich 1998), *Rhodobacter capsulatus* (Dupuis et al 1995), *Thermus thermophilus* (Yano et al 1997), *Paracoccus denitrificans* (Xu et al 1993), *Helicobacter pylori* (Finel 1998), *Neurospora crassa* (Videira 1998), *Bos taurus* (Walker et al 1992, Walker 1992) and now also *Homo sapiens* (this thesis, and references therein).

In general, the number of subunits seems to increase when species ascend the evolutionary ladder. Prokaryotes are considered to have a fourteen subunit complex I (Leif et al 1993), however in some bacteria like *E. coli*, NuoC and NuoD are fused to NuoCD which leaves it with thirteen subunits (Braun et al 1998). Sodium Dodecyl Sulphate (SDS) gel electrophoresis revealed that there are at least 35 subunits present in *N. crassa* complex I (Weiss et al 1991), however at this moment they have not been all genetically characterised. It is striking that several subunits present in complex I of *N. crassa* do not seem to have a homologue in *B. taurus* and *H. sapiens* and vice versa. It could be possible that the genes coding for these subunits diverged very fast, with the result that the interspecies homology is lost. The core of fourteen subunits present in prokaryotes is however highly conserved in *N. crassa* again illustrating the functional importance of this part. The number of subunits of *B. taurus* was believed to be 41 in 1992 (Walker 1992). Electrospray mass spectrometry experiments however, revealed that there are at least 43 subunits, which is likely to be the final number (Skehel et al 1998). The existence of at least one of these additional proteins in complex I has been confirmed with two-dimensional gel electrophoresis and has subsequently been characterised on cDNA and amino acid level (Skehel et al 1998). The amino acid sequence of the 43<sup>rd</sup> subunit has yet to be identified. Similar experiments with human tissue specimens are not yet performed, so the final number of human complex I subunits remains to be elucidated. At this moment, all 42 amino acid sequences of complex I subunits that have been found in cow are also characterised in humans (Table 12.1), of which eighteen have been characterised by our research group. Gene/protein names were assigned according to the database for human gene nomenclature (<http://www.gene.ucl.ac.uk/nomenclature> (White et al 1997)). At present, the chromosomal localisation of 30 nuclear encoded complex I subunits is known, which shows a random distribution across the chromosomes (Table 12.1, Spencer et al 1992, Duncan et al 1992, Ali et al 1993, Baens et al 1993, de Coo et al 1995, Hattori et al 1995, Hyslop et al 1996, Zhuchenko et al 1996, Russell et al 1997, de Coo et al 1997, Dunbar et al 1997, de Sury

et al 1998, Loeffen et al 1998a, Emahazion et al 1998, Triepels et al 1998, Procaccio et al 1998, Loeffen et al 1999)

Based on sequence similarity with homologues in lower species, functional aspects can be attributed to several human complex I subunits (Table 12.2). Yet, in the lion's share of the proteins, the function remains unknown for the time being. Especially little is known about the additional subunits on top of the fourteen "minimal" subunits. Several theories concerning these "plus" subunits have been postulated in literature. Alignment of the structure of *E. coli* and *N. crassa* complex I revealed that most of the additional proteins are moulded around the conserved core (Friedrich 1998). It therefore seems that many of these additional proteins in eukaryotes function in stabilising the complex (Guenebaut et al 1997, Friedrich et al 1998) and/or shielding the redoxgroups from oxygen, which prevents these groups from premature reoxidation by oxygen.

Known exceptions to this are the NDUFB1 and the NDUFA9 proteins, which both are believed to have a biosynthetic function. The first shows resemblance to a family of acylcarrier proteins (ACP). It contains a phosphopantetheine binding site which (when bound) can act as docking site for fatty acids and amino acids. ACPs are therefore thought to participate in fatty acid and polypeptide biosynthesis (Cortes et al 1990, Runswick et al 1991). Disruption of the ACP gene in *N. crassa* prevents the formation of the extramembranous arm (Schneider et al 1995). The NDUFA9 shows homology to a group of isomerases/reductases and is thought to have a nucleotide-binding site. Furthermore it is proposed to participate in the synthesis of a recently discovered new redoxgroup (Schulte et al 1999).

Studies performed with specimens of LHON patients revealed interesting indications for possible functions of the ND subunits. Lymphoblasts of LHON patients carrying the homoplasmic mtDNA 3460 (ND 1) mutation showed reduced electron transfer capacity in the presence of a ubiquinone analogue, but not in presence of ferricyanide as electron acceptor (Majander et al 1991). LHON patients with a defect in ND-4 (11778 mutation) did not have a defective electron transfer, yet did have reduced ATP synthesis when complex I substrates were used, but not after usage of complex II substrates (Majander et al 1991, Hofhaus & Attardi 1993). ND-2, ND-4 and ND-5 do have some degree of homology, which led to the speculation that these subunits participate in proton transport in some way. If this assumption is correct, mutations in the genes coding for these latter subunits, can result in a decreased contribution of complex I to the proton-motive force (PMF), but the electron transport will be undisturbed. Degli Esposti demonstrated that the 11778 mutation in ND 4 alters the affinity of complex I for ubiquinone and reduces the complex I inhibition capacity of rotenone (Degli Esposti et al 1994). Photoaffinity labelling studies with [ $^3\text{H}$ ]dihydrorotenone indicated that ND 1 is probably also involved in the binding of rotenone (Earley et al 1987), while Friedrich postulated that the ND-1 subunit is involved in ubiquinone binding (Friedrich et al 1990). Based on the results of these studies one may speculate that the possibility exists that not all patients with a malfunctioning complex I will be detected with the used complex I enzyme assay. Whenever complex I is capable of transporting the electrons from NADH to a ubiquinone analogue, the results of such assays will be normal, while proton transport may be seriously affected.

<i>Homo sapiens</i>			<i>NCBI no.</i>	<i>Escherichia coli</i>		<i>Neurospora crassa</i>		<i>Bos taurus</i>	
Name	kDa	Chr.	human subunit	Name	kDa	Name	kDa	Name	kDa
NDUFV1	51.0	11q13	NUBM_HUMAN	NuoF	49.3	51 kDa	54.3	51 kDa (FP)	50.7
NDUFV2	27.4	18p11.31-p11.2	NUHM_HUMAN	NuoE	18.6	24 kDa	28.8	24 kDa (FP)	27.3
NDUFV3	12.0	21q22.3	NUOM_HUMAN	-	-	-	-	10 kDa (FP)	11.9
NDUFS1	79.6	2q33-q34	NUAM_HUMAN	NuoG	100.3	78 kDa	81.7	75 kDa (IP)	79.4
NDUFS2	52.5	1q23	NUCM_HUMAN	NuoD	68.7 <sup>1</sup>	49 kDa	54.0	49 kDa (IP)	49.2
NDUFS3	30.2	11p11.11	NUGM_HUMAN	NuoC	68.7 <sup>1</sup>	31 kDa	32.3	30 kDa (IP)	30.3
NDUFS4	20.1	5q11.1	NUYM_HUMAN	-	-	21.3 kDa	24.5	AQDQ (IP)	19.8
NDUFS5	12.5	1p34.2-p33	NP_004543	-	-	-	-	15 kDa (IP)	12.7
NDUFS6	13.7	5pter-p15.33	NUMM_HUMAN	-	-	-	-	13 kDa (IP)	13.4
NDUFS7	18.0	19p13	NUKM_HUMAN	NuoB	25.1	19.3 kDa	25.0	PSST	23.8
NDUFS8	23.7	11q13.1-q13.3	NUIM_HUMAN	Nuol	20.5	23 kDa	24.9	TYKY (IP)	23.9
NDUFA1	8.1	Xq24	NP_004532	-	-	-	-	MWFE	8.1
NDUFA2	10.9	5q31.2	NP_002479	-	-	10.5 kDa	10.5	B8	11.1
NDUFA3	9.3	?	NP_004533	-	-	-	-	B9	9.3
NDUFA4	9.4	?	NP_002480	-	-	-	-	MLRQ	9.3
NDUFA5	13.5	7q32	NUFM_HUMAN	-	-	29.9 kDa	30.9	B13 (IP)	13.3
NDUFA6	15.1	22q13.2-q13.31	NP_002481	-	-	14.8 kDa	14.8	B14	15.1
NDUFA7	12.6	19p13.2	N4AM_HUMAN	-	-	-	-	B14.5a	12.7
NDUFA8	20.1	9q33.2-q34.11	AF044953_1	-	-	20.8 kDa	20.9	PGIV	20.1
NDUFA9	42.5	12p13.3	NUEM_HUMAN	-	-	40 kDa	43.0	39 kDa	42.8
NDUFA10	40.8	12p	NUDM_HUMAN	-	-	-	-	42 kDa	39.3
NDUFAB1	17.4	16p12.3-p12.1	NP_004994	-	-	9.6 kDa	14.5	SDAP	10.1
NDUFB1	7.0	14q31.3	NP_004536	-	-	-	-	MNLL	7.0
NDUFB2	12.1	7q34-q35	NP_004537	-	-	12 kDa	12.3	AGGG	12.3
NDUFB3	11.4	?	NP_002482	-	-	-	-	B12	11.1
NDUFB4	15.2	3 <sup>a</sup>	NP_004538	-	-	-	-	B15	15.2
NDUFB5	21.8	?	NP_002483	-	-	-	-	SGDH	21.6
NDUFB6	15.5	9p13.2	NP_002484	-	-	-	-	B17	15.5
NDUFB7	16.4	19p13.12-13.11	AAF17188	-	-	-	-	B18	16.4
NDUFB8	21.8	10q23.2-q23.33	NP_004995	-	-	-	-	ASHI	21.7
NDUFB9	21.8	8q24-21	NP_004996	-	-	-	-	B22	21.8
NDUFB10	20.8	16p13.3	NP_004539	-	-	12.3 kDa	12.3	PDSW	21.0
NDUFC1	8.7	4q28.2-q28.3	NP_002485	-	-	-	-	KFYI	8.8
NDUFC2	14.2	11 <sup>b</sup>	NP_004540	-	-	-	-	B14.5b	14.1
17.2HUM	17.1	?	AAF17196	-	-	-	-	B17.2	17.1
ND-1	35.7	mtDNA	ND1_12188	NuoH	36.2	ND-1	41.6	ND-1	35.7
ND-2	39.0	mtDNA	ND2_12188	NuoN	45.7	ND-2	65.8	ND-2	39.3
ND-3	13.2	mtDNA	ND3_12188	NuoA	16.5	ND-3	6.0	ND-3	13.1
ND-4	51.6	mtDNA	ND4_12188	NuoM	56.5	ND-4	-	ND-4	53.8
ND-4L	10.7	mtDNA	NULM_HUMAN	NuoK	10.8	ND-L4	9.8	ND-4L	10.8
ND5	67.0	mtDNA	ND5_12188	NuoL	66.4	ND-5	79.8	ND-5	68.3
ND-6	18.6	mtDNA	ND6_12188	NuoJ	19.9	ND-6	-	ND-6	19.2
-	-	-	-	-	-	17.8 kDa	20.1	-	-
-	-	-	-	-	-	21 kDa	21.0	-	-
-	-	-	-	-	-	12 kDa	12.3	-	-
-	-	-	-	-	-	21.3 kDa	21.3	-	-
-	-	-	-	-	-	9.5 kDa	9.3	-	-
-	-	-	-	-	-	21.3 kDa	21.4	-	-
-	-	-	-	-	-	18.3 kDa	21.8	-	-

**Table 12.1** Complex I subunit composition of *E. coli*, *N. crassa*, *B. taurus* and *H. sapiens*. <sup>a</sup> = STS G29346  
<sup>b</sup> = STS G25213. Genbank accession numbers refer to human subunits. Nuo = NADH:ubiquinone oxidoreductase; Sequence similarities between species were found with use of the BLAST program provided by the National Centre for Biotechnology Information (Altschul et al 1990). <sup>1</sup> NuoC and D are fused in *Escherichia coli*.

Subunit	Function/characteristic	Reference
<b>NDUFV1/51 kDa</b>	NADH binding site FMN binding site 4Fe-4S cluster (N3)	Chen & Guillory 1981, Deng et al 1990 Patel et al 1991, Schuelke et al 1998 Ohnishi et al 1985, Ohnishi 1998
<b>NDUFV2/24 kDa</b>	2Fe-2S cluster (N1a) G-protein	Ohnishi et al 1985, Ohnishi 1998 Hegde 1998
<b>NDUFS1/ 75 kDa</b>	2Fe-2S cluster (N1b) 4Fe-4S cluster (N4) 4Fe-4S cluster (N5*)	Ohnishi 1998 Ohnishi 1998 Ohnishi 1998
<b>NDUFS2/49 kDa</b>	proton transport ubiquinone binding	Darrouzet et al 1998
<b>NDUFS4/ 18 kDa</b>	phosphorylation site for a cAMP dependent protein kinase	Papa et al 1996
<b>NDUFS7/PSST</b>	4Fe-4S cluster (N2)	Ohnishi 1998
<b>NDUFS8/TYKY</b>	2× 4Fe-4S cluster	Walker 1992
<b>NDUFA9/39 kDa</b>	Family of NAD(P)H reductases/isomerases	Schulte et al 1999
<b>NDUFAB1/SDAP</b>	acyl carrier protein	Runswick et al 1989
<b>ND-1</b>	binding site rotenone binding site ubiquinone	Earley et al 1987 Friedrich et al 1990
<b>ND-4</b>	binding site rotenone binding site ubiquinone	Degli Esposti et al 1994

**Table 12.2** Functional aspects of human complex I subunits. Part of this data is based on homology with complex I subunits of lower evolutionary species, from which functional aspects have been studied.

\* The presence of cluster N5 in the NDUFS1 subunit is subject of debate.

A piericidin A and rotenone resistant mutant of *Rhodobacter capsulatus* contained a V407M amino acid substitution in NuoD. Reintroduction of this amino acid substitution into the parental strain resulted in a similar resistance to piericidin A and rotenone as the original mutant (Darrouzet et al 1998). The authors propose a model in which NuoD forms the binding site for the polar head of piericidin A/ubiquinone and NuoH docks the hydrophobic isoprenyl tail. Okun and colleagues tested members of the three groups of complex I inhibitors (piericidin A (class I/A type), rotenone (class II/B type) and capsaicin (C type), as proposed by Degli Esposti and Ghelli in 1994) for competition. They found that the rotenone site overlaps with the piericidin A site and the capsaicin site, but the latter two do not seem to overlap each other (Okun et al 1999). They suggest a fairly large binding site for ubiquinone of complex I, with different points of action for inhibitors.

### Genetic counselling and prenatal diagnostics.

In our experience, patients suffering from isolated complex I deficiency have a very poor prognosis (Loeffen et al 2000a) and currently no widely applicable treatment besides supportive, exists. Eventually, in most patients early death will be inevitable. This leaves us at

the moment with little more to offer but the opportunity of genetic counselling. Several factors make this counselling extremely difficult. Firstly, the genetic cause of the disease can be situated in the mtDNA as well as the nDNA. The majority of mtDNA point mutations are heteroplasmic, which results in different amounts of mutated mtDNA between individual patients as well as between different tissues within the same patient. In addition, the phenotype often has a threshold dependency on the content of mutated mtDNA. Chinnery showed that the mutant load of the A3243G mutation present in muscle tissue corresponds with the severity of the symptoms, however the mutant load in blood did not (Chinnery et al 1997). The amount of mtDNA transmitted to the next generation can also be variable. According to the bottle neck theory a small number of mtDNA molecules are preferentially amplified to repopulate the oocyte (Hauswirth and Laipis 1982). These factors implicate that the percentage of mutated mtDNA can vary considerably within families and prediction of chance on disease presentation is usually not possible. Some exceptions to this seem to exist. Recently, White and colleagues reviewed 56 T8993G/C pedigrees in which they examined the relation between the severity of the clinical phenotype and mutant load and predicted clinical outcome of individual patients based on their percentage mutated mtDNA (White et al 1999). They found a strong positive relation between the mother's blood mutant load and amount of heteroplasmy of the 8993 mutation in her offspring. However, there is a wide 95% range of predicted probabilities, which indicates variation in mutant load in children of mother's with the T8993G/C mutation. Leber's hereditary optic neuropathy (LHON) is usually associated with a homoplasmic mutation within the mitochondrially encoded ND genes, which increases the accuracy of molecular-genetic prenatal diagnosis performed in chorionic villi. However, not all patients carrying an LHON mutation actually become ill. This implicates that additional (possibly nuclear) factors must contribute to the phenotype (Shoubridge 1998). Harding and colleagues estimated the recurrence risk of LHON to be 6-10% for female offspring and 30-46% for male progeny (Harding et al 1995). Many large deletions and duplications within the mtDNA are sporadic and are therefore not encountered in the mtDNA of relatives.

The majority of isolated complex I deficiencies seen in our centre seems to follow an autosomal recessive mode of inheritance (recurrence risk 25%). From the end of the eighties until now our centre has gained experience with the measurement of respiratory chain enzyme activities in chorionic villi (CV) and amniocytes. These measurements were for years the only opportunity for prenatal diagnostics in this patient group. Chorionic villi biopsies are usually performed between the 10-12<sup>th</sup> week of pregnancy. Enzyme assay procedures used in CV (slightly modified) are for NADH:ubiquinone oxidoreductase according to Fischer et al 1985 and 1986, cytochrome *c* oxidase according to Cooperstein and Lazarow 1951, citrate synthase as described by Srere in 1969 and PDHc is measured as described by Sperl et al in 1990. Studies performed in our centre in the early nineties, compared enzymatic findings in CV biopsies of 20 pregnancies (18 families). Three respiratory chain deficiencies were found (3x cytochrome *c* oxidase with Leigh syndrome). Respiratory chain enzyme assays performed in fibroblasts of these three infants confirmed the complex IV deficiency which was found in CV. None of the other pregnancies resulted in infants with an OXPHOS disorder (Ruitenbeek



et al 1992) The last few years however, we encountered some conflicting results when complex I activities of native CV are compared to values obtained from cultured CV of the same pregnancy In some cases enzyme measurements in cultured CV reveal a deficient complex I activity, while in native chorionic villi complex I activity is normal We have currently no explanation for this phenomenon In summary, it is possible to measure respiratory chain enzyme activities in CV However, for complex I activity, results are at this moment not always conclusive and demand additional investigation

DNA and RNA are easily extracted from cultured chorionic villi and therefore in abundance available It is of course necessary to check for maternal contamination The latter can be avoided by careful dissection of the maternal decidua from the chorionic and by the simultaneous amplification of a suitable polymorphism The interpretation of results obtained from molecular-genetic prenatal diagnostics is considerably easier than those obtained with biochemical enzyme measurements Consequently, the search for molecular-genetic causes of complex I deficiency is of utmost importance

### **Evidence pathogenicity mutations.**

The complete characterisation of the human complex I subunits on cDNA level made mutational analysis studies possible. As described previously, our enzyme assay for complex I in fibroblasts is based on measurement of the conversion of NADH to NAD<sup>+</sup> in mitochondrial enriched fractions in presence of a ubiquinone analogue and in presence/absence of the selective complex I inhibitor rotenone Since the peripheral arm of complex I contains all known redox centres (Friedrich et al 1998, Skehel et al 1998), the FP and IP fraction remain the most important candidates for mutational analysis studies in our patient group. We focussed these studies on subunits present in the Iron-Sulphur protein fraction, which revealed different mutations in five pedigrees, which cosegregate within the family (chapter 8, 9 and 10) Except for the 5-bp duplication found in the NDUF54 subunit, these mutations concerned subunits present in the minimal form of complex I as encountered in prokaryotes The point mutations resulted in the substitution of conserved amino acids while the 5-bp duplication resulted in a frameshift with destruction of the C-terminal part of the protein All mutations were excluded in a large control population In our patient group, mutations were also found in the NDUFV1 subunit present in the FP fraction in two pedigrees (Schuelke et al 1999), and in the NDUF57 subunit of the HP fraction in one pedigree (Triepels et al 1999) At this moment all 42 complex I subunits have been checked for mutations on cDNA level in our patients (this thesis, Triepels et al 2000) So ultimately, we found mutations in 8 of 25 pedigrees described in chapter 2 (32%) The finding of these mutations offer the parents of these patients adequate prenatal counselling during subsequent pregnancies Currently, the cDNA of the subunits in which mutations have been encountered is screened for mutations by means of RT-PCR and direct DNA sequencing in new complex I deficient patients presented to our centre, in order to investigate the frequency of these and possibly other mutations within these subunits Recently, in two new patients frameshift mutations have been found in the NDUF54 subunit (Budde et al 2000)

Although we believe that the observed mutations are certainly pathogenic, definite proof has

to come from complex I deficiency rescue experiments performed with fibroblasts of our index patients. Rescue experiments were performed with fibroblasts of the patient described in chapter 9. We introduced a plasmid vector containing the *NDUFS4* cDNA construct into a portion of patient fibroblasts using a multi-component lipid-based transfection reagent. However, the used transient transfection method failed to result in sufficient cells containing the plasmid for complex I measurement. Important problems are therefore the large amount of transfected fibroblasts needed for our complex I and cytochrome *c* oxidase assay (about 10 million) and the low yield of fibroblasts containing the construct after transfection. Currently we are immortalising our patient cell lines, which will be used in a permanent transfection procedure. The group of Yagi restored complex I activity in two Chinese hamster cell lines, which both contained mutations in the *NDUFA1* subunit (a deletion and a point mutation) by introducing the *NDUFA1* cDNA (Seo et al 1999). This procedure restored complex I activity to 100% in the cell line with the deletion, while the cell line with the point mutation only regained 40%. It was suggested that the defective subunit still occupied its position in complex I and thereby inhibited complete restoration of the complex I activity. This problem has to be taken into consideration when we perform our transfection experiments in the future. Another method to rescue the complex I deficiency is introducing the wildtype chromosome on which the mutated gene is situated (or a more accurate reduced part of this chromosome) into our patient fibroblasts by microcell-mediated chromosome transfer (Cuthbert et al 1995, Zhu et al 1998). Since many complex I deficient fibroblast cell lines do not grow in media containing galactose instead of glucose (Robinson 1996), one might observe whether or not growth recovers in galactose containing media after introduction of the correct chromosome. This may be considered as an indirect indication for rescue. Other studies like e.g. normalisation of complex I subunit distribution visualised with Western blotting could also function as indication for rescue.

An important step in order to obtain additional information concerning possible consequences of the mutations found in our patients will be investigating the steady state levels of the corresponding mutated transcripts by northern blot or RT-PCR. Besides RNA studies, it is also possible to analyse consequences of mutations by use of specific antibodies against the mutated subunits. Both of these approaches are currently investigated.

### **The quest for new candidate genes.**

Mutational analysis studies of all known 35 nuclear encoded complex I subunits revealed mutations in about 40% of our patients, which implicates that in ~60% of our patients the genetic cause remains unsolved. One can consider the possible involvement of mtDNA mutations in this residual group. As a screening of “unsolved” and new complex I deficient patients (but also combined respiratory chain deficiencies) we can investigate a mtDNA genetic cause by fusion of patient cell lines with  $\rho^0$  cells (cells depleted of mtDNA by long term exposure to ethidium bromide (King and Attardi 1989)). Procaccio used  $\rho^0$  cells, which needed uridine and pyruvate in the medium to grow and in addition, they were insensitive to bromodeoxyuridine (brdU). Cells of patients and controls do grow in uridine and pyruvate free medium but are sensitive to brdU. After fusion of the  $\rho^0$  cells with the patient and control

fibroblasts, they were able to select the fused cells by adding brdU to the medium and leaving uridine and pyruvate out (Procaccio et al 1999). This fusion of patient fibroblasts with  $\rho^0$  cells should lead to rescue of the complex I deficiency in case of a nuclear cause, while nothing will happen in case the mutation is situated in the mtDNA. Vice versa introduction of patient mitochondria by fusion of enucleated patient fibroblasts with  $\rho^0$  cells results in complex I deficiency in case of mutations in the mtDNA, while activity remains normal in case of a nuclear cause (this latter strategy was used by Raha and colleagues with fibroblasts of a patient with hypertrophic cardiomyopathy and a mutation in the mitochondrially encoded tRNA<sup>Gly</sup> gene (Raha et al 1999)). After fusion of  $\rho^0$  cells with the patient cell lines, several aspects like growth characteristics of cells, antibodies against mitochondrially encoded subunits and OXPHOS system enzyme measurements can be used to check whether or not complementation has occurred. The use of  $\rho^0$  cells has also been successfully applied in demonstrating the nuclear-genetic cause in a cytochrome *c* oxidase deficient patient (Tiranti et al 1995). Since the ND genes strongly contribute to the total amount of mtDNA mutations found in complex I deficient patients, it is also possible to search for mutations in these genes by means of PCR combined with direct DNA sequencing or Single Strand Conformation Polymorphisms (SSCP). Sequencing of all ND genes in eight complex I deficient patients carried out in our centre by de Vries and colleagues in 1994 however, did not reveal any mutations (de Vries, thesis).

One of the most direct methods to find nuclear encoded candidate genes is to search for human homologues of genes, which have been linked to the function of complex I in lower species. These genes can code for a diversity of proteins involved in the functioning of complex I like transcription and translation factors of e.g. complex I subunits, proteins which participate in the targeting and importation of complex I subunits into mitochondria, proteins which assist in the assembly and incorporation of complex I into the inner mitochondrial membrane, proteins which have a function in the synthesis of factors associated to complex I like i.e. the flavin mononucleotide (FMN) and the iron sulphur clusters, but also nuclear genes controlling the perpetuation, propagation and expression of the mitochondrial genome. The approach of candidate gene search in lower species has been successfully applied for complex I (Loeffen et al 1998b, van den Heuvel et al 1998, Schuelke et al 1999, Triepels et al 1999, Loeffen et al 2000b) and complex IV (Papadopoulou et al 1999). One of the major problems is choosing the right gene for mutational analysis in the large pool of candidate genes available by this approach. For complex I, important future candidates are the human homologues of complex I intermediate associated proteins (CIA) 30 and 84, which have been associated with the large assembly intermediate of the membrane arm of complex I in *N. crassa* (Kuffner et al 1998). Deletion of one of these genes in *N. crassa* resulted in disruption of the assembly process (Kuffner et al 1998). Other important candidate genes involved in the biogenesis of complexes of the OXPHOS system obtained via homology searches with yeast proteins are BCS1, PET112, SCO1, COX15 and COX11 (Petrizzella et al 1998).

A very elegant step in elucidating the genetic cause in our remaining complex I deficient patients would be the investigation of existence of individual complementation groups as has been performed for cytochrome *c* oxidase deficiency by Munaro et al in 1997. First, the

existence of a nuclear cause should be proved in the patient group by use of  $p^0$  cells as described before. Subsequently two patient fibroblast cell lines can be fused with i.e. polyethylene glycol (PEG). Selection of hybrids can be obtained by making each of the two cell lines resistant to a different antibiotic before fusion by introducing a recombinant vector expressing a resistance-inducing gene (Double-antibiotic selection, Munaro et al 1997). These cells can then be cultivated in medium containing both antibiotics until an adequate amount of cells is available for measurement of the enzymes of the OXPHOS system. If both patients are affected by mutations in the same gene, rescue of the complex I deficiency will not occur, while rescue will take place when both patients are affected by different genes.

Several other methods are available to categorise our patients in different groups. By using antibodies directed against different complex I subunits, we can analyse protein expression patterns in mitochondrial preparations by Western blotting. Procaccio defined two different protein patterns in two complex I deficient patients by this approach, one expressing lowered amounts of the NDUFV1 and NDUFV2 subunits while the other tested subunits were expressed in normal amounts, and a patient who expressed reduced protein contents of all tested subunits (Procaccio et al 1999). Von Kleist-Retzow used this approach of immunoblot analysis with antibodies against nine complex IV subunits in 17 cytochrome *c* oxidase deficient patients. This revealed mainly patterns with overall decreased protein levels, but in individual patients distinct patterns were also found (von Kleist-Retzow et al 1999). This approach can be expanded by using the technique of two-dimensional blue native gel electrophoresis (Nijtmans et al 1998). Coenen successfully showed with this technique that different two dimensional gel electrophoresis patterns exist for cytochrome *c* oxidase deficient patients with a mutation in the *SURF1* gene and those who do not (Coenen et al 1999). Specific patterns may well be present among complex I deficient patients.

The finishing touch in elucidating the genetic cause in a complementation group of complex I deficient patients can be provided by the tremendous technique of microcell mediated chromosome transfer, successfully applied by Zhu and colleagues who found the link between the *SURF1* gene and cytochrome *c* oxidase deficient patients with Leigh syndrome (Zhu et al 1998). By fusing human rodent hybrid cell lines containing single human chromosomes (Cuthbert et al 1995), rescue of the enzyme deficiency will occur after introduction of the chromosome on which the gene defect in the patient is situated. After establishment of the correct chromosome, one can reduce the size of the fragment on which the candidate gene is situated by analysing hybrids with deleted versions of this chromosome. Zhu beautifully used the fact that introduced chromosomes delete and rearrange after fusion, by choosing informative markers in hybrids which compensate and clones which don't compensate to narrow the area of the gene of interest (deletion mapping, Zhu et al 1998). Finally positional/functional cloning might reduce the area containing the candidate gene to a 'reasonable' size for direct DNA sequencing. Preparations to introduce this technique in order to elucidate the genetic defects in our remaining complex I deficient patients are currently undertaken in collaboration with the researchgroup of Eric Shoubbridge.

## Pathophysiological aspects of complex I deficiency.

A decreased production of ATP can be an important pathophysiological consequence of complex I deficiency. Complex I contributes to the proton motive force (PMF) that is used by complex V to generate ATP. When complex I malfunctions, this can lead to a decrease of the PMF and therefore to less available ATP. MERRF and MELAS mutations lead to a generally decreased mitochondrial protein synthesis (Chomyn et al 1992, King et al 1992, Masucci et al 1995), often resulting in a combined complex I and IV deficiency. In MERRF cells the aminoacylation capacity of tRNA<sup>lys</sup> is decreased leading to an impairment of mitochondrial protein synthesis (Enriquez et al 1995). The specific pathophysiological mechanism occurring in cells harbouring the A3243G (MELAS) mutation remains unclear for the time being. Theoretically, the decreased proton pumping by the respiratory chain can result in a decreased mitochondrial membrane potential ( $\Delta\psi_m$ ) and PMF. James et al used the lipophilic cation TPMP (which accumulation is related to the membrane potential) to estimate this mitochondrial membrane potential. This revealed a clear decrease in membrane potential in MERRF as well as MELAS fibroblasts (James et al 1996). Moudy and colleagues used quantitative fluorescence imaging to measure the membrane potential of individual mitochondria of fibroblasts loaded with the dual emission dye JC-1. This revealed significantly reduced J aggregates in MELAS fibroblasts (JC-1 specifically labels mitochondria and expresses mitochondrial membrane potential as a function of the state of dye aggregation) indicative for reduced mitochondrial membrane potentials in these cells (Moudy et al 1995). Moudy also measured the ATP concentration in these cells, which was within the normal range. James and colleagues hypothesised that once one increases the ATP turnover in quiescent fibroblasts, patient fibroblasts have less reserve capacity to replenish this ATP compared to control fibroblasts (James et al 1999). They measured oligomycin-sensitive ATP production by fibroblasts permeabilised with digitonine and found a decreased ability to synthesise ATP in cells derived from MERRF and MELAS patients. However the amount of ATP in MERRF and MELAS fibroblasts (measured with the luciferase/luciferin technique) was similar to that of controls, which also counts for the ATP/ADP ratio. To increase the ATP turnover, gramicidin ( $\text{Na}^+$  and  $\text{K}^+$  ionophore) was added which indirectly increases the activity of the plasmamembrane  $\text{Na}^+/\text{K}^+$  ATPase resulting in an increased ATP turnover. They found that cells carrying the MELAS and MERRF mutations have problems to maintain their ATP/ADP ratio at gramicidin concentrations when control cells have no problems at all (James et al 1999).

Quiescent fibroblasts strongly depend on glycolysis instead of oxidative phosphorylation for their ATP production (Robinson 1993, Robinson 1996). James et al found that the culture medium of MELAS cells acidified faster compared to controls. Measurement of lactate dehydrogenase (referred to citrate synthase activity) revealed increased activity pointing towards anaerobic respiration (James et al 1996). Fibroblasts cultured in glucose medium first convert glucose into pyruvate and lactate and when glucose is running out, the conversion of pyruvate into acetyl-CoA is accelerated which increases the contribution of the OXPHOS system to the production of ATP (Robinson 1996). This is further illustrated by the

experiment where in fibroblast culture medium glucose is exchanged for galactose in equimolar amounts. The conversion of galactose to glucose-1-phosphate is limited so cells will increasingly depend on the OXPHOS system instead of glycolysis. Complex I deficient fibroblasts will therefore grow poorly on galactose containing culture medium (Robinson 1996). This strong dependence on glycolysis could explain why resting ATP levels were found normal in MELAS and MERRF fibroblasts, since this part of the energy-providing system is not affected.

Adequate ATP steady state and production measurements ideally should be performed in tissues, which often are affected in complex I deficient patients like brain, heart and skeletal muscle tissue. A favourable improvement would be the applicability of myoblast cultures (Shoubridge et al 1996) in our OXPHOS enzyme assays, but also other pathophysiological studies. One of the problems we encounter in culturing myoblasts is their rapid terminal differentiation into multinucleated myotubes. This limits the number of culture passages and therefore the use of myoblasts in many pathophysiological experiments, including our OXPHOS enzyme assays. Another major problem in culturing myoblasts is the contamination of these cultures with fibroblasts. Myoblast cultures were successfully applied in the measurement of ATP and ADP of patients with the 3243A→G (MELAS) mutation, which both were found to be decreased (Rusanen et al 2000).

Last year, Barrientos and Moraes published studies in which they examined pathophysiological aspects of complex I deficiency using a model of human ape xenomitochondrial hybrids (HXC cells, 40% complex I deficiency) as well as a drug-induced-model (rotenone, 40% complex I deficiency) (Barrientos and Moraes 1999). These models showed similar results as described previously. Cells used in both models grew poorly on galactose-containing medium compared to glucose-containing medium. They also measured  $\Delta\Psi_m$  of individual mitochondria using the JC-1 probe, which revealed a mild decrease of  $\Delta\Psi_m$  in rotenone treated cells as well as in HXC cells.

Another important damage inflicting mechanism possibly involved in complex I deficiency is abundant generation of reactive oxygen species (ROS) with as most prominent members superoxide ( $O_2^-$ ), hydrogen peroxide ( $H_2O_2$ ) and the hydroxyl radical ( $OH^\bullet$ ). This process probably results from interaction of oxygen with semiquinone molecules (Robinson 1998) and is therefore indirectly the result from the one electron reduction events taking place in complex I. The first reactive oxygen compound likely to be generated is  $O_2^-$  by interaction of oxygen with semiquinone (in physiological as well as pathophysiological conditions). Superoxide dismutase (SOD) scavenges  $O_2^-$  by converting them two at a time to  $H_2O_2$  and  $O_2$ , which is normally further processed by catalase in peroxisomes and glutathion peroxidase in mitochondria and cytosol. When  $H_2O_2$  has a close encounter with free iron or copper, it can be converted into the highly reactive  $OH^\bullet$ . This latter radical is believed to generate most of the damage attributed to biological macromolecules, like lipid peroxidation, protein aggregation and DNA hydroxylation. One can speculate that malfunctioning of electron transport chain complexes leads to excessive escape of electrons from these complexes and therefore to a surplus of ROS. Much data about involvement of excessive ROS formation in complex I deficiency has been generated by the research group of Robinson. Pitkanen et al

showed with Southern blotting that mtDNA isolated from fibroblasts of complex I deficient patients with cataract and cardiomyopathy contains many multiple deletions in contrast to control fibroblasts (Pitkanen et al 1996), indicating free oxygen radical damage. Furthermore, they showed with western blot analysis as well as with an enzymatic assay that the mitochondrial Mn-SOD levels were elevated in these patients. Later this group used the luminometric probe lucigenin in order to measure the  $O_2^-$  production on addition of NADH in isolated fibroblast mitochondrial membranes of complex I deficient patients. Their results revealed a spectrum with on one side elevated  $O_2^-$  levels combined with reduced Mn-SOD values (phenotype of cataract and developmental delay) while on the other side patients expressed reduced  $O_2^-$  levels with increased values of Mn-SOD (phenotype of cataract and cardiomyopathy, Pitkanen and Robinson 1996). Measurement of  $O_2^-$  production in control fibroblasts treated with rotenone revealed increased production rates. The authors hypothesise that complex I deficiency increases the formation of ROS, though variable induction of Mn-SOD influences this rate. Luo and colleagues demonstrated increased production of OH $\cdot$  in complex I deficient patients expressing cataract and cardiomyopathy by using the aromatic hydroxylation assay with salicylate as a probe (Luo et al 1997). Furthermore Luo showed overproduction of aldehydes (indicative of lipid peroxidation) in fibroblasts of these patients. Barrientos and Moraes used  $H_2DCF$  (converted to a fluorescent product after oxidation by  $H_2O_2$ ) and found increased ROS formation in cells from the HXC as well as the rotenone model (Barrientos and Moraes 1999). Future studies must be performed to entangle the influence of excessive ROS formation in the pathophysiology of complex I deficiency.

An important future topic in the study of the pathogenesis of complex I deficiency will be the role of calcium. In normal cells, the cytoplasmic calcium concentration ( $[Ca^{2+}]_c$ ) is kept strictly at  $10^{-7}$  M. Several factors influence cellular calcium homeostasis like  $Ca^{2+}$  pumping (e.g.  $insP_3$  receptor in the ER membrane) and leaking mechanisms (Hofer et al 1998). Another organelle capable of calcium sequestration is the mitochondrion. Despite the low affinity of mitochondria for calcium, increases of  $[Ca^{2+}]_c$  are transmitted into mitochondria because of close contact between mitochondria and endoplasmic reticulum (ER) (Rizzuto et al 1998). This indicates the importance of the intracellular distribution of the mitochondrion, which can be disturbed in OXPHOS disorders. The uptake of calcium by mitochondria is strongly dependent on the  $\Delta\psi_m$ , which can be reduced in complex I deficiency. Moudy monitored the cytosolic calcium handling ( $[Ca^{2+}]_c$ ) with confocal microscopy within single fibroblasts loaded with the fluorescent probe FURA-2 of patients with MELAS syndrome (Moudy et al 1995). They found that MELAS cells have an elevated resting  $[Ca^{2+}]_c$  and in addition express a disturbed sequestration of  $[Ca^{2+}]_c$  after inositol triphosphate ( $IP_3$ ) mediated stimulation. Padua and colleagues performed similar experiments with fibroblasts of a patient with a pyruvate dehydrogenase complex (PDHc) deficiency (Padua et al 1998). They found equal resting  $[Ca^{2+}]_c$  between controls and patients, however bradykinine stimulated increase of  $[Ca^{2+}]_c$  resulted in reduced  $[Ca^{2+}]_m$  transients in PDHc deficient fibroblasts (~4% of controls) indicating that these mitochondria have decreased ability to sequester cytosolic calcium.

We monitored the  $[Ca^{2+}]_c$  handling of cultured skin fibroblasts suspensions of 5 complex I deficient patients with mutations in nuclear encoded complex I subunits, 3 SURF1 patients

and 5 controls, with the ratiometric  $\text{Ca}^{2+}$  probe FURA-2. Bradykinine stimulation of  $[\text{Ca}^{2+}]_i$  in calcium-free medium and calcium containing medium revealed bound FURA-2/unbound FURA-2 (340 nm/380 nm) ratio peaks (averaged for each subgroup) which were highest in controls, followed by complex I deficient fibroblasts and were lowest in SURF1 cell suspensions (100%, 78%, 67%, respectively, unpublished results). The ascending and descending slope of the spike as well as the wide were comparable in all three groups. Agonist stimulation of cells in calcium containing medium results in a higher 340/380 ratio after the peak, probably due to capacitative calcium entry (Berridge 1995). Strikingly, this effect was highest in controls, followed by complex I deficient cells and lowest in SURF1 fibroblasts (unpublished results). In order to study the calcium maintenance more specifically within these cells we used the inhibitor of the endoplasmic reticulum calcium ATPase (SERCA family) thapsigargin. Subsequently, passive leakage of calcium out of the ER results in a temporary increase of  $[\text{Ca}^{2+}]_i$ . The 340/380 ratio showed a steeper slope in the ascending as well as descending part of the curve in controls compared to complex I and SURF1 fibroblasts. This could be explained by decreased uptake capabilities for calcium of patient mitochondria. To study this mechanism of different calcium kinetics after thapsigargin suppletion in controls and complex I and SURF1 deficient fibroblasts we want to target the ratiometric calcium probe MAG-FURA-2 (low affinity for calcium) into the ER after which the emptying of the ER can be studied (Hofer 1999). Landolfi showed in intact cells using this technique that uncoupling of mitochondria with CCCP immediately reduces the ER emptying (Landolfi et al 1998). The exact mechanism of this effect is unknown, however the decreased slope of the ascending part of the curve obtained after addition of thapsigargin to the medium in our complex I and SURF1 deficient fibroblasts could be caused by a similar phenomenon. Hofer showed that leakage of calcium from the ER after blockage of the SERCA pump is specifically regulated by the ATP concentration (Hofer et al 1996). The leakage rate diminishes when the ATP concentration is lowered. This could explain why the leak of calcium from the ER after similar SERCA blocking is reduced in our patient fibroblasts. Recently, Jouaville and colleagues described a powerful technique by which they can measure cytosolic and mitochondrial ATP levels with the specifically targeted ATP dependent protein luciferase (Jouaville et al 1999). Rizzuto already showed that agonist stimulated calcium increase in the cytosol are followed by large calcium increases in the mitochondrial matrix (Rizzuto et al 1998). With the combined usage of aequorin (fluorescent protein which can visualise calcium fluctuations) and luciferase (reflects ATP content) which both can be targeted into mitochondria, Jouaville showed that following agonist stimulation,  $[\text{Ca}^{2+}]_i$  increases, which is directly followed by an increase of mitochondrial calcium concentration ( $[\text{Ca}^{2+}]_m$ ). In addition, this increase of  $[\text{Ca}^{2+}]_m$  is followed by an increase of ATP production, which sustains after the calcium peak disappeared (Jouaville et al 1999). This phenomenon can partly be explained by the fact that several mitochondrial enzymes like PDHc, isocitrate dehydrogenase and  $\alpha$  ketoglutarate dehydrogenase are regulated by calcium. The results of these experiments (calcium peaks in mitochondria and subsequent ATP increases in mitochondria and cytosol) were more pronounced in myotubes compared to HeLa cells (in resting culture conditions). Brini and colleagues subsequently showed with this technique that



IP<sub>3</sub> stimulated  $[Ca^{2+}]_i$  increases were equal between controls and 100% mutated MERRF fibroblasts, but the consequent rise in  $[Ca^{2+}]_m$  is severely diminished in the MERRF fibroblasts (Brini et al 1999). They also saw, that ATP increase after IP<sub>3</sub> stimulation is diminished in MERRF fibroblasts.

Several studies performed in the last few years have shown that excessive (slow) uptake of calcium by mitochondria leads to opening of the so-called mitochondrial permeability transition pore (MTP), probably leading to calcium induced cell death (Crompton 1999). Normally, the  $[Ca^{2+}]_m$  is kept below 10  $\mu$ M. When calcium exceeds a limit of 200  $\mu$ M in the presence of ADP, the pore opens. Three components have been identified to participate in the MT pore formation, namely the Adenine Nucleotide Translocase (ANT), Cyclophilin-D (CyP-D) and the Voltage Dependent Anion Channel (VDAC). Several processes influence the opening and closing of the MT pore like the mitochondrial membrane potential, the redox state, matrix pH, reactive oxygen species (ROS) and adenine nucleotides (Fontaine et al 1998). *In vitro*, the opening of the MT pore leads to collapse of PMF, disruption of ionic homeostasis, mitochondrial swelling and ATP hydrolysis by complex V (Fontaine et al 1998). Eventually nuclear apoptosis is initiated. Fontaine and co-workers summarised several mechanisms by which MTP opening can lead to cell damaging pathways like decreased levels of cellular ATP, increase of  $[Ca^{2+}]_i$ , release of apoptosis inducing factor (AIF) and release of cytochrome *c*. Interestingly, they saw that the sensitivity of the MT pore for calcium as monitored by a decrease of the mitochondrial membrane potential after calcium loading was much higher when complex I substrates were used, compared to complex II substrates. This increased sensitivity for calcium seemed to depend mainly on the rate of electron flux through complex I. Barrientos and Moraes showed that rotenone induced cell death is strongly reduced by cyclosporine A and the phospholipase A<sub>2</sub> inhibitor ArA (both act synergistically in inhibiting MT pore opening). This indicates that some pathophysiological consequences of complex I deficiency eventually lead to MT pore opening and cell death (Barrientos and Moraes 1999).

### Therapy for complex I deficiency: utopia or...?

Isolated complex I deficiency in children often leads to a devastating clinical course, usually resulting in death of the child. Several therapeutic procedures have been tested in the past, usually with little effect. Finding a cure for these patients should however be one of the main goals in future research. Scholte and co-workers listed successful drugs which have been supplied to (mainly individual) patients with complex I deficiency. Examples are riboflavin, succinate, nicotinamide, and menadione + succinate therapy (Scholte et al 1995). In general, these forms of therapy have only been described to work in individual cases. Additionally, little is known about the natural cause of the diverse clinical phenotypes associated with complex I deficiency, so benefits are difficult to assign.

A completely different approach has been developed by the research group of Shoubridge. Many tRNA point mutations are distributed between tissues in a heteroplasmic way. In muscle

tissue, high percentages of mutated mtDNA are often found in mature muscle fibres, while undifferentiated satellite cells contain undetectable amounts (Shoubridge et al 1997). MtDNA analysis of cultured muscle cells obtained from two biopsies taken from the biceps muscle of a patient (cytochrome *c* oxidase deficient) with a point mutation in the mitochondrially encoded tRNA<sup>Leu</sup> gene, showed that mature muscle fibres contained 95% mutated mtDNA, while this was nearly undetectable in simultaneously cultured satellite cells. Fu and co-workers proposed that elimination of the mutated mtDNA could be achieved by stimulation of the regeneration of muscle tissue (Fu et al 1996). This patient was rebiopsied at the site of the original biopsy and regenerating muscle fibres were stained for cytochrome *c* oxidase activity which was almost invariably positive (Shoubridge et al 1997). Single fibre PCR analysis revealed that all regenerating muscle fibres had no detectable mutated mtDNA. Clark and colleagues had similar results by inducing muscle fibre regeneration chemically in a patient with a point mutation in the tRNA<sup>Leu</sup> gene (Clark et al 1997). Taivassalo and co-workers expanded this approach by inducing a form of gene shifting therapy using concentric muscle training to promote muscle fibre regeneration (Taivassalo et al 1999). This approach led to a dramatic increase in the wildtype/mutated mtDNA ratio in regenerating muscle fibres.

Taylor and colleagues also try to develop a therapy based on the heteroplasmy aspect of mtDNA. Their goal is to develop a method to selectively inhibit the replication of mtDNA containing a mutation, which subsequently results in propagation of wildtype mtDNA. To prove the possibility of this approach they synthesised peptide nucleic acids (PNAs) complementary to human mutated mtDNA templates (Taylor et al 1997). They showed that these antigenomic PNAs inhibited replication of mutated mtDNA but not of wildtype DNA, and that these PNAs indeed are taken up by myoblasts.

Since these latter two approaches have their fundament in the principle of mtDNA heteroplasmy, it is not applicable in patients with mutations in nuclear DNA.

A revolutionary approach has been performed by Seo and co-workers who successfully introduced the internal NADH quinone oxidoreductase of *Saccharomyces cerevisiae* (rotenone-insensitive) into a complex I deficient hamster cell line. In addition, they showed that the transfected cell lines had normal complex I activity, while the non-transfected remained deficient (Seo et al 1998). In later studies they proved that this enzyme is transcribed and translated in human cells, despite the presence of human complex I (Seo et al 1999). This tremendous approach might eventually lead to a successful therapy.

Finally, I would like to focus on one of the ultimate ways to study pathophysiological and therapeutical aspects of complex I deficiency, namely an animal model. A mouse in which one of the nuclear genes coding for a complex I subunit has been knocked out or modified, will lead to enormous progress in our understanding of the consequences of complex I deficiency. Of course this model can also figure as an important test model to investigate benefits and disadvantages of several therapeutic models. In addition, such a model provides tissues, which are often affected in patients, yet difficult to obtain like heart, brain and liver tissue.

Much is said by quoting one of the major energy providers in the world  
complex I is on the move

## Reference List.

- Ali ST, Duncan AMV, Schappert K, Heng HHQ, Tsui LC, Chow W, Robinson BH. 1993. Chromosomal localisation of the human gene encoding the 51-kDa subunit of mitochondrial complex I (NDUFV1) to 11q13. *Genomics* 18:435-439.
- Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. *J Mol Biol* 215:403-410.
- Baens M, Chaffanet M, Cassiman JJ, van den Berghe H, Marynen P. 1993. Construction and evaluation of a hncDNA library of human 12p transcribed sequences derived from a somatic cell hybrid. *Genomics* 16:214-218.
- Barrientos A and Moraes CT. 1999. Titrating the effects of mitochondrial complex I impairment in the cell physiology. *J Biol Chem* 274:16188-16197.
- Berridge MJ. 1995. Capacitative calcium entry. *Biochem J* 312 1-11.
- Braun M, Bungert S, Friedrich T. 1998. Characterisation of the overproduced NADH dehydrogenase fragment of the NADH:ubiquinone oxidoreductase (complex I) from *Escherichia coli*. *Biochemistry* 37:1861-1867.
- Brini M, Pinton P, King MP, Davidson M, Schon EA, Rizzuto R. 1999. A calcium signalling defect in the pathogenesis of a mitochondrial DNA inherited oxidative phosphorylation deficiency. *Nat Med* 5:951-954.
- Budde SMS, van den Heuvel LP, Janssen AJ, Smeets RJP, Buskens CAF, DeMeirleir L, Baethmann M, Trijbels JMF, Smeitink JAM. Novel mutations in the NDUF54 subunit cause combined complex I and moderate complex III deficiency. *Submitted*.
- Butow RA and Bahassi EM. 1999. Orchestrating mitochondrial biogenesis. *Curr Biol* 9 R767-R769.
- Chen S and Guillory RJ. 1981. Studies on the interaction of arylazido-beta-alanyl NAD<sup>+</sup> with the mitochondrial NADH dehydrogenase. *J Biol Chem* 256 8318-8323.
- Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. 1997. Molecular pathology of MELAS and MERRF. The relationship between mutation load and clinical phenotypes. *Brain* 120:1713-1721.
- Chomyn A, Martinuzzi A, Yoneda M, Daga A, Hurko O, Johns D, Lai ST, Nonaka I, Angelini C, Attardi G. 1992. MELAS mutation in mtDNA binding site for transcription termination factor causes defects in protein synthesis and in respiration but no change in levels of upstream and downstream mature transcripts. *Proc Natl Acad Sci USA* 89 4221-4225.
- Clark KM, Bindoff LA, Lightowlers RN, Andrews RM, Griffiths PG, Johnson MA, Brierley EJ, Turnbull DM. 1997. Reversal of a mitochondrial DNA defect in human skeletal muscle. *Nat Genet* 16:222-224.
- Coenen MJH, van den Heuvel LP, Nijtmans LGJ, Morava E, Marquardt I, Girschick HJ, Trijbels FJ, Grivell LA, Smeitink JAM. 2000. SURFEIT-1 gene analysis and two-dimensional blue native gel electrophoresis in cytochrome c oxidase deficiency. *Biochem Biophys Res Commun* 265 339-344.
- Cooperstein SJ and Lazarow A. 1951. A microspectrophotometry method for the determination of cytochrome c oxidase. *J Biol Chem* 189:665-670.
- Cortes J, Haydock SF, Roberts GA, Bevilacqua DJ, Leadlay PF. 1990. An unusually large multifunctional polypeptide in the erythromycin-producing polyketide synthase of *Saccharopolyspora erythraea*. *Nature* 348 176-178.
- Crompton M. 1999. The mitochondrial permeability transition pore and its role in cell death. *Biochem J* 341:233-249.
- Cuthbert AP, Trott DA, Ekong RM, Jezard S, England NL, Themis M, Todd CM, Newbold RF. 1995. Construction and characterisation of a highly stable human:rodent monochromosomal hybrid panel for genetic complementation and genome mapping studies. *Cytogenet Cell Genet* 71:68-76.
- Darrouzet E, Issartel JP, Lunardi J, Dupuis A. 1998. The 49-kDa subunit of NADH-ubiquinone oxidoreductase (Complex I) is involved in the binding of piericidin and rotenone, two quinone-related inhibitors. *FEBS Lett* 431 34-38.
- de Coo R, Buddiger P, Smeets HJM, Geurts van Kessel A, Morgan-Hughes J, Olde Weghuis D, Overhauser J, van Oost BA. 1995. Molecular cloning and characterisation of the active human mitochondrial NADH ubiquinone oxidoreductase 24-kDa gene (NDUFV2) and its pseudogene. *Genomics* 26:461-466.
- de Coo R, Buddiger P, Smeets HJM, van Oost BA. 1997. Molecular cloning and characterisation of the human mitochondrial NADH oxidoreductase 10-kDa gene (NDUFV3). *Genomics* 45:434-437.

- de Sury R, Martinez P, Procaccio V, Lunardi J, Issartel JP. 1998 Genomic structure of the human NDUFS8 gene coding for the iron- sulphur TYKY subunit of the mitochondrial NADH ubiquinone oxidoreductase. *Gene* 215:1-10
- Degli Esposti M, Carelli V, Ghelli A, Ratta M, Crimi M, Sangiorgi S, Montagna P, Lenaz G, Lugaresi E, Cortelli P. 1994. Functional alterations of the mitochondrially encoded ND4 subunit associated with Leber's hereditary optic neuropathy. *FEBS Lett* 352:375-379
- Degli EM and Ghelli A. 1994 The mechanism of proton and electron transport in mitochondrial complex I *Biochim Biophys Acta* 1187 116-120.
- Deng PS, Hatefi Y, Chen S. 1990 N-arylazido-beta-alanyl-NAD<sup>+</sup>, a new NAD<sup>+</sup> photoaffinity analogue. Synthesis and labelling of mitochondrial NADH dehydrogenase *Biochemistry* 29 1094-1098
- Dunbar DR, Shibasaki Y, Dobbie L, Andersson B, Brookes AJ. 1997 In situ hybridisation mapping of genomic clones for five human respiratory chain complex I genes. *Cytogenet Cell Genet* 78:21-24.
- Duncan AM, Chow W, Robinson BH. 1992 Localisation of the human 75-kDa Fe-S protein of NADH-coenzyme Q reductase gene (*NDUFS1*) to 2q33----q34. *Cytogenet Cell Genet* 60:212-213
- Dupuis A, Peinnequin A, Chevallet M, Lunardi J, Darrouzet E, Pierrard B, Procaccio V, Issartel JP. 1995. Identification of five *Rhodobacter capsulatus* genes encoding the equivalent of ND subunits of the mitochondrial NADH-ubiquinone oxidoreductase. *Gene* 167 99-104
- Earley FG, Patel SD, Ragan I, Attardi G. 1987 Photolabelling of a mitochondrially encoded subunit of NADH dehydrogenase with [<sup>3</sup>H]dihydrorotenone. *FEBS Lett* 219 108-112
- Emahazion T, Beskow A, Gyllenstein U, Brookes AJ. 1998 Intron based radiation hybrid mapping of 15 complex I genes of the human electron transport chain *Cytogenet Cell Genet* 82:115-119
- Enriquez JA, Chomyn A, Attardi G. 1995 MtDNA mutation in MERRF syndrome causes defective aminoacylation of tRNA(Lys) and premature translation termination *Nat Genet* 10 47-55
- Finel M. 1998 Does NADH play a central role in energy metabolism in *Helicobacter pylori*? *Trends Biochem Sci* 23 412-413
- Fischer JC, Ruitenbeek W, Berden JA, Trijbels JM, Veerkamp JH, Stadhouders AM, Sengers RC, Janssen AJ. 1985. Differential investigation of the capacity of succinate oxidation in human skeletal muscle. *Clin Chim Acta* 153:23-36
- Fischer JC, Ruitenbeek W, Trijbels JM, Veerkamp JH, Stadhouders AM, Sengers RC, Janssen AJ. 1986. Estimation of NADH oxidation in human skeletal muscle mitochondria *Clin Chim Acta* 155:263-273
- Fontaine E, Eriksson O, Ichas F, Bernardi P. 1998 Regulation of the permeability transition pore in skeletal muscle mitochondria Modulation By electron flow through the respiratory chain complex I *J Biol Chem* 273 12662-12668
- Friedrich T, Strothdeicher M, Hofhaus G, Preis D, Sahm H, Weiss H. 1990 The same domain motif for ubiquinone reduction in mitochondrial or chloroplast NADH dehydrogenase and bacterial glucose dehydrogenase *FEBS Lett* 265 37-40
- Friedrich T, Steinmuller K, Weiss H. 1995 The proton-pumping respiratory complex I of bacteria and mitochondria and its homologue in chloroplasts *FEBS Lett* 367:107-111
- Friedrich T. 1998 The NADH:ubiquinone oxidoreductase (complex I) from *Escherichia coli*. *Biochim Biophys Acta* 1364 134-146
- Friedrich T, Abelmann A, Brors B, Guenebaut V, Kintscher L, Leonard K, Rasmussen T, Scheide D, Schlitt A, Schulte U, Weiss H. 1998 Redox components and structure of the respiratory NADH-ubiquinone oxidoreductase (complex I). *Biochim Biophys Acta* 1365 215-219
- Fu K, Hartlen R, Johns T, Genge A, Karpati G, Shoubbridge EA. 1996. A novel heteroplasmic tRNA<sup>Leu</sup>(CUN) mtDNA point mutation in a sporadic patient with mitochondrial encephalomyopathy segregates rapidly in skeletal muscle and suggests an approach to therapy *Hum Mol Genet* 5 1835-1840.
- Guenebaut V, Vincentelli R, Mills D, Weiss H, Leonard KR. 1997. Three-dimensional structure of NADH-dehydrogenase from *Neurospora crassa* by electron microscopy and conical tilt reconstruction *J Mol Biol* 265:409-418
- Harding AE, Sweeney MG, Govan GG, Riordan-Eva P. 1995. Pedigree analysis in Leber hereditary optic neuropathy families with a pathogenic mtDNA mutation *Am J Hum Genet* 57 77-86
- Hattori N, Suzuki H, Wang Y, Minoshima S, Shimizu N, Yoshino H, Kurashima R, Tanaka M, Ozawa T, Mizuno Y. 1995 Structural organisation and chromosomal localisation of the human nuclear gene (*NDUFV2*) for the 24-kDa iron-sulphur subunit of complex I in mitochondrial respiratory chain *Biochem Biophys Res Commun* 216 771-777

- Hauswirth WW and Laipis PJ.** 1982. Mitochondrial DNA polymorphism in a maternal lineage of Holstein cows. *Proc Natl Acad Sci U S A* 79:4686-4690
- Hegde R.** 1998. The 24-kDa subunit of the bovine mitochondrial NADH:ubiquinone oxidoreductase is a G protein. *Biochem Biophys Res Commun* 244:620-629.
- Hofer AM, Curci S, Machen TE, Schulz I.** 1996. ATP regulates calcium leak from agonist-sensitive internal calcium stores. *FASEB J* 10:302-308
- Hofer AM, Landolfi B, Debellis L, Pozzan T, Curci S.** 1998. Free  $[Ca^{2+}]$  dynamics measured in agonist-sensitive stores of single living intact cells: a new look at the refilling process. *EMBO J* 17:1986-1995
- Hofer AM.** 1999. Measurement of free  $[Ca^{2+}]$  changes in agonist-sensitive internal stores using compartmentalised fluorescent indicators. *Methods Mol Biol* 114:249-265
- Hofhaus G and Attardi G.** 1993. Lack of assembly of mitochondrial DNA-encoded subunits of respiratory NADH dehydrogenase and loss of enzyme activity in a human cell mutant lacking the mitochondrial ND4 gene product. *EMBO J* 12:3043-3048.
- Hyslop SJ, Duncan AMV, Pitkänen S, Robinson BH.** 1996. Assignment of the PSST subunit gene of human mitochondrial complex I to chromosome 19p13. *Genomics* 37:375-380.
- James AM, Wei YH, Pang CY, Murphy MP.** 1996. Altered mitochondrial function in fibroblasts containing MELAS or MERRF mitochondrial DNA mutations. *Biochem J* 318:401-407
- James AM, Sheard PW, Wei YH, Murphy MP.** 1999. Decreased ATP synthesis is phenotypically expressed during increased energy demand in fibroblasts containing mitochondrial tRNA mutations. *Eur J Biochem* 259:462-469
- Jouaville LS, Pinton P, Bastianutto C, Rutter GA, Rizzuto R.** 1999. Regulation of mitochondrial ATP synthesis by calcium: Evidence for a long-term metabolic priming. *Proc Natl Acad Sci U S A* 96:13807-13812
- Kennedy and Lehninger.** 1948. *J Biol Chem* 179:957-972
- King MP and Attardi G.** 1989. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. *Science* 246:500-503.
- King MP, Koga Y, Davidson M, Schon EA.** 1992. Defects in mitochondrial protein synthesis and respiratory chain activity segregate with the tRNA(Leu(UUR)) mutation associated with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. *Mol Cell Biol* 12:480-490
- Koehler CM, Merchant S, Schatz G.** 1999. How membrane proteins travel across the mitochondrial intermembrane space. *Trends Biochem Sci* 24:428-432.
- Kuffner R, Rohr A, Schmiede A, Krull C, Schulte U.** 1998. Involvement of two novel chaperones in the assembly of mitochondrial NADH:Ubiquinone oxidoreductase (Complex I). *J Mol Biol* 283:409-417
- Landolfi B, Curci S, Debellis L, Pozzan T, Hofer AM.** 1998.  $Ca^{2+}$  homeostasis in the agonist-sensitive internal store: functional interactions between mitochondria and the ER measured in situ in intact cells. *J Cell Biol* 142:1235-1243.
- Leif H, Weidner U, Berger A, Spehr V, Braun M, van Heek P, Friedrich T, Ohnishi T, Weiss H.** 1993. *Escherichia coli* NADH dehydrogenase I, a minimal form of the mitochondrial complex I. *Biochem Soc Trans* 21:998-1001.
- Leif H, Sled VD, Ohnishi T, Weiss H, Friedrich T.** 1995. Isolation and characterisation of the proton-translocating NADH:ubiquinone oxidoreductase from *Escherichia coli*. *Eur J Biochem* 230:538-548.
- Loeffen J, van den Heuvel L, Smeets R, Triepels R, Sengers R, Trijbels F, Smeitink J.** 1998a. cDNA sequence and chromosomal localisation of the remaining three human nuclear encoded iron sulphur protein (IP) subunits of complex I: the human IP fraction is completed. *Biochem Biophys Res Commun* 247:751-758.
- Loeffen J, Smeitink J, Triepels R, Smeets R, Schuelke M, Sengers R, Trijbels F, Hamel B, Mullaart R, van den Heuvel L.** 1998b. The First Nuclear-Encoded Complex I Mutation in a Patient with Leigh Syndrome. *Am J Hum Genet* 63:1598-1608.
- Loeffen J, Smeets R, Smeitink J, Triepels R, Sengers R, Trijbels F, van den Heuvel L.** 1999. The human NADH: ubiquinone oxidoreductase NDUF55 (15 kDa) subunit cDNA cloning, chromosomal localisation, tissue distribution and the absence of mutations in isolated complex I-deficient patients. *J Inher Metab Dis* 22:19-28.
- Loeffen J, Smeitink J, Trijbels F, Janssen A, Triepels R, Sengers R, van den Heuvel L.** 2000a. Isolated complex I deficiency in children: clinical, biochemical and genetic aspects. *Hum Mutat*

- 15 123-134
- Loeffen J, Elpeleg O, Smeitink J, Smeets R, Stockler-Ipsiroglu S, Mandel H, Sengers R, Trijbels F, van den Heuvel L.** 2000b. Mutations in the complex I *NDUFS2* gene are associated with hypertrophic cardiomyopathy and encephalomyopathy. *Submitted*.
- Luo X, Pitkänen S, Kassovska-Bratinova S, Robinson BH, Lehotay DC.** 1997. Excessive formation of hydroxyl radicals and aldehydic lipid peroxidation products in cultured skin fibroblasts from patients with complex I deficiency *J Clin Invest* 99:2877-2888
- Majander A, Huoponen K, Savontaus ML, Nikoskelainen E, Wikstrom M.** 1991. Electron transfer properties of NADH:ubiquinone reductase in the ND1/3460 and the ND4/11778 mutations of the Leber hereditary optic neuroretinopathy (LHON) *FEBS Lett* 292:289-292.
- Masucci JP, Davidson M, Koga Y, Schon EA, King MP.** 1995. In vitro analysis of mutations causing myoclonus epilepsy with ragged-red fibres in the mitochondrial tRNA(Lys) gene: two genotypes produce similar phenotypes. *Mol Cell Biol* 15:2872-2881.
- Moudy AM, Handran SD, Goldberg MP, Ruffin N, Karl I, Kranz-Eble P, DeVivo DC, Rothman SM.** 1995. Abnormal calcium homeostasis and mitochondrial polarisation in a human encephalomyopathy *Proc Natl Acad Sci U S A* 92 729-733
- Munaro M, Tiranti V, Sandona D, Lamantea E, Uziel G, Bisson R, Zeviani M.** 1997. A single cell complementation class is common to several cases of cytochrome c oxidase-defective Leigh's syndrome *Hum Mol Genet* 6:221-228.
- Nijtmans LG, Taanman JW, Muijsers AO, Speijer D, Van den Bogert C.** 1998. Assembly of cytochrome-c oxidase in cultured human cells *Eur J Biochem* 254 389-394.
- Ohnishi T, Ragan CI, Hatefi Y.** 1985. EPR studies of iron-sulphur clusters in isolated subunits and subfractions of NADH-ubiquinone oxidoreductase. *J Biol Chem* 260 2782-2788.
- Ohnishi T.** 1998. Iron-sulphur clusters/semiquinones in Complex I *Biochim Biophys Acta* 1364:186-206
- Okun JG, Lemmen P, Brandt U.** 1999. Three classes of inhibitors share a common binding domain in mitochondrial complex I (NADH:Ubiquinone oxidoreductase) *J Biol Chem* 274 2625-2630
- Padua RA, Baron KT, Thyagarajan B, Campbell C, Thayer SA.** 1998. Reduced  $\text{Ca}^{2+}$  uptake by mitochondria in pyruvate dehydrogenase- deficient human diploid fibroblasts. *Am J Physiol* 274 C615-22
- Papa S, Sardanelli AM, Cocco T, Speranza F, Scacco SC, Technikova-Dobrova Z.** 1996. The nuclear-encoded 18 kDa (IP) AQDQ subunit of bovine heart complex I is phosphorylated by the mitochondrial cAMP-dependent protein kinase *FEBS Lett* 379:299-301.
- Papadopoulou LC, Sue CM, Davidson MM, Tanji K, Nishino I, Sadlock JE, Krishna S, Walker W, Selby J, Glerum DM, Coster RV, Lyon G, Scalais E, Lebel R, Kaplan P, Shanske S, De VD, Bonilla E, Hirano M, DiMauro S, Schon EA.** 1999. Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in *SCO2*, a COX assembly gene. *Nat Genet* 23:333-337.
- Patel SD, Aebersold R, Attardi G.** 1991. cDNA-derived amino acid sequence of the NADH-binding 51-kDa subunit of the bovine respiratory NADH dehydrogenase reveals striking similarities to a bacterial NAD(+)-reducing hydrogenase. *Proc Natl Acad Sci U S A* 88 4225-4229
- Petruzzella V, Tiranti V, Fernandez P, Ianna P, Carrozzo R, Zeviani M.** 1998. Identification and characterisation of human cDNAs specific to BCS1, PET112, SCO1, COX15, and COX11, five genes involved in the formation and function of the mitochondrial respiratory chain *Genomics* 54:494-504
- Pitkänen S, Merante F, McLeod DR, Applegarth D, Tong T, Robinson BH.** 1996. Familial cardiomyopathy with cataracts and lactic acidosis: a defect in complex I (NADH-dehydrogenase) of the mitochondria respiratory chain. *Pediatr Res* 39:513-521.
- Pitkänen S and Robinson BH.** 1996. Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. *J Clin Invest* 98 345-351
- Procaccio V, de Sury R, Martinez P, Depetris D, Rabilloud T, Soularue P, Lunardi J, Issartel J.** 1998. Mapping to 1q23 of the human gene (*NDUFS2*) encoding the 49-kDa subunit of the mitochondrial respiratory Complex I and immunodetection of the mature protein in mitochondria *Manus Genome* 9 482-484
- Procaccio V, Mousson B, Beugnot R, Duborjal H, Feillet F, Putet G, Pignot-Paintrand I, Lombes A, de Coo R, Smeets H, Lunardi J, Issartel JP.** 1999.

- Nuclear DNA origin of mitochondrial complex I deficiency in fatal infantile lactic acidosis evidenced by transnuclear complementation of cultured fibroblasts. *J Clin Invest* 104:83-92.
- Raha S, Merante F, Shoubridge E, Myint AT, Tein I, Benson L, Johns T, Robinson BH.** 1999. Repopulation of rho<sup>0</sup> cells with mitochondria from a patient with a mitochondrial DNA point mutation in tRNA(Gly) results in respiratory chain dysfunction. *Hum Mutat* 13:245-254.
- Rizzuto R, Pinton P, Carrington W, Fay FS, Fogarty KE, Lifshitz LM, Tuft RA, Pozzan T.** 1998. Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca<sup>2+</sup> responses. *Science* 280:1763-1766.
- Robinson BH.** 1993. Lacticacidemia. *Biochim Biophys Acta* 1182:231-244.
- Robinson BH.** 1996. Use of fibroblast and lymphoblast cultures for detection of respiratory chain defects. *Methods Enzymol* 264:454-464.
- Robinson BH.** 1998. Human complex I deficiency: clinical spectrum and involvement of oxygen free radicals in the pathogenicity of the defect. *Biochim Biophys Acta* 1364:271-286.
- Ruitenbeek W, Sengers RC, Trijbels JM, Janssen AJ, Bakkeren JA.** 1992. The use of chorionic villi in prenatal diagnosis of mitochondrialopathies. *J Inher Metab Dis* 15:303-306.
- Runswick MJ, Gennis RB, Fearnley IM, Walker JE.** 1989. Mitochondrial NADH:ubiquinone reductase: complementary DNA sequence of the import precursor of the bovine 75-kDa subunit. *Biochemistry* 28:9452-9459.
- Runswick MJ, Fearnley IM, Skehel JM, Walker JE.** 1991. Presence of an acyl carrier protein in NADH:ubiquinone oxidoreductase from bovine heart mitochondria. *FEBS Lett* 286:121-124.
- Rusanen H, Majamaa K, Hassinen IE.** Increased activities of antioxidant enzymes and decreased ATP concentration in cultured myoblasts with the 3243A→G mutation in mitochondrial DNA. *Biochim Biophys Acta* 1500:10-16.
- Russell MW, du MS, Collins FS, Brody LC.** 1997. Cloning of the human NADH:ubiquinone oxidoreductase subunit B13. localisation to chromosome 7q32 and identification of a pseudogene on 11p15. *Mamm Genome* 8:60-61.
- Schneider R, Massow M, Lisowsky T, Weiss H.** 1995. Different respiratory-defective phenotypes of *Neurospora crassa* and *Saccharomyces cerevisiae* after inactivation of the gene encoding the mitochondrial acyl carrier protein. *Curr Genet* 29:10-17.
- Scholte HR, Busch HF, Bakker HD, Bogaard JM, Luyt-Houwen IE, Kuyt LP.** 1995. Riboflavin-responsive complex I deficiency. *Biochim Biophys Acta* 1271:75-83.
- Schuelke M, Loeffen J, Mariman E, Smeitink J, van den Heuvel L.** 1998. Cloning of the human mitochondrial 51 kDa subunit (NDUFV1) reveals a 100% antisense homology of its 3'UTR with the 5'UTR of the gamma-interferon inducible protein (IP-30): precursor is this a link between mitochondrial myopathy and inflammation? *Biochem Biophys Res Commun* 245:599-606.
- Schuelke M, Smeitink J, Mariman E, Loeffen J, Plecko B, Trijbels F, Stockler-Ipsiroglu S, van den Heuvel L.** 1999. Mutant NDUFV1 subunit of mitochondrial complex I causes leukodystrophy and myoclonic epilepsy. *Nat Genet* 21:260-261.
- Schulte U, Haupt V, Abelmann A, Fecke W, Brors B, Rasmussen T, Friedrich T, Weiss H.** 1999. A reductase/isomerase subunit of mitochondrial NADH ubiquinone oxidoreductase (complex I) carries an NADPH and is involved in the biogenesis of the complex. *J Mol Biol* 292:569-580.
- Seo BB, Kitajima-Ihara T, Chan EK, Scheffler IE, Matsuno-Yagi A, Yagi T.** 1998. Molecular remedy of complex I defects: rotenone-insensitive internal NADH-quinone oxidoreductase of *Saccharomyces cerevisiae* mitochondria restores the NADH oxidase activity of complex I- deficient mammalian cells. *Proc Natl Acad Sci USA* 95:9167-9171.
- Seo BB, Matsuno-Yagi A, Yagi T.** 1999. Modulation of oxidative phosphorylation of human kidney 293 cells by transfection with the internal rotenone-insensitive NADH-quinone oxidoreductase (NDI1) gene of *Saccharomyces cerevisiae*. *Biochim Biophys Acta* 1412:56-65.
- Shoubridge EA, Johns T, Boulet L.** 1996. Use of myoblast cultures to study mitochondrial myopathies. *Methods Enzymol* 264:465-475.
- Shoubridge EA, Johns T, Karpati G.** 1997. Complete restoration of a wild-type mtDNA genotype in regenerating muscle fibres in a patient with a tRNA point mutation and mitochondrial encephalomyopathy. *Hum Mol Genet* 6:2239-2242.
- Shoubridge EA.** 1998. Mitochondrial encephalomyopathies. *Curr Opin Neurol* 11:491-496.
- Skehel JM, Fearnley IM, Walker JE.** 1998. NADH:ubiquinone oxidoreductase from bovine

- heart mitochondria sequence of a novel 17.2-kDa subunit *FEBS Lett* 438 301-305
- Smeitink J, Loeffen J, Triepels R, Smeets R, Trijbels F, van den Heuvel L.** 1998 Nuclear genes of human complex I of the mitochondrial electron transport chain state of the art *J Mol Genet* 1998 7 1573-1579
- Spencer SR, Taylor JB, Cowell IG, Xia CL, Pemble SE, Ketterer B.** 1992 The human mitochondrial NADH ubiquinone oxidoreductase 51 kDa subunit maps adjacent to the glutathione S-transferase P1-1 gene on chromosome 11q13 *Genomics* 14 1116-1118
- Sperl W, Ruitenbeek W, Kerkhof CM, Sengers RC, Trijbels JM, Guggenbichler JP, Janssen AJ, Bakkeren JA.** 1990 Deficiency of the alpha and beta subunits of pyruvate dehydrogenase in a patient with lactic acidosis and unexpected sudden death *Eur J Pediatr* 149 487-492
- Srere PA.** 1969 Citrate synthase EC 4.1.3.7 citrate oxaloacetate lyase (CO-A-acetylating) *Method enzymol* XIII 3-11
- Taanman JW.** 1999 The mitochondrial genome structure, transcription translation and replication *Biochim Biophys Acta* 1410 103-123
- Taivassalo T, Fu K, Johns T, Arnold D, Karpati G, Shoubridge EA.** 1999 Gene shifting a novel therapy for mitochondrial myopathy *Hum Mol Genet* 8 1047-1052
- Taylor RW, Chinnery PF, Turnbull DM, Lightowlers RN.** 1997 Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids *Nat Genet* 15 212-215
- Tiranti V, Munaro M, Sandona D, Lamantea E, Rimoldi M, DiDonato S, Bisson R, Zeviani M.** 1995 Nuclear DNA origin of cytochrome c oxidase deficiency in Leigh's syndrome genetic evidence based on patient's-derived rho degrees transformants *Hum Mol Genet* 4 2017-2023
- Triepels R, van den Heuvel L, Loeffen J, Smeets R, Trijbels F, Smeitink J.** 1998 The nuclear-encoded human NADH ubiquinone oxidoreductase NDUFA8 subunit cDNA cloning, chromosomal localisation, tissue distribution, and mutation detection in complex I deficient patients *Hum Genet* 103 557-563
- Triepels R, van den Heuvel L, Loeffen J, Buskens C, Smeets R, Rubio-Gozalbo M, budde S, Mariman E, Wijburg F, Barth P, Trijbels F, Smeitink J.** 1999 Leigh syndrome associated with a mutation in the NDUFS7 (PSST) nuclear encoded subunit of complex I *Ann Neurol* 45 787-790
- Triepels R, Smeitink J, Loeffen J, Smeets R, Buskens C, Trijbels F, van den Heuvel L.** 2000 Characterisation of the human complex I *NDUFB7* and *17.2 kDa* cDNAs and mutational analysis of 19 genes of the HP fraction in complex I-deficient patients *Hum Genet in press*
- van den Heuvel L, Ruitenbeek W, Smeets R, Gelman-Kohan Z, Elpeleg O, Loeffen J, Trijbels F, Mariman E, de Bruijn D, Smeitink J.** 1998 Demonstration of a new pathogenic mutation in human complex I deficiency a 5-bp duplication in the nuclear gene encoding the 18-kD (AQDQ) subunit *Am J Hum Genet* 62 262-268
- Videira A.** 1998 Complex I from the fungus *Neurospora crassa* *Biochim Biophys Acta* 1364 89-100
- von Kleist-Retzow JC, Vial E, Chantrel-Groussard K, Rotig A, Munnich A, Rustin P, Taanman JW.** 1999 Biochemical genetic and immunoblot analyses of 17 patients with an isolated cytochrome c oxidase deficiency *Biochim Biophys Acta* 1455 35-44
- Walker JE.** 1992 The NADH ubiquinone oxidoreductase (complex I) of respiratory chains *Q Rev Biophys* 25 253-324
- Walker JE, Arizmendi JM, Dupuis A, Fearnley IM, Finel M, Medd SM, Pilkington SJ, Runswick MJ, Skehel JM.** 1992 Sequences of 20 subunits of NADH Ubiquinone oxidoreductase from bovine heart mitochondria *J Mol Biol* 226 1051-1072
- Weidner U, Geier S, Ptock A, Friedrich T, Leif H, Weiss H.** 1993 The gene locus of the proton-translocating NADH ubiquinone oxidoreductase in *Escherichia coli* Organisation of the 14 genes and relationship between the derived proteins and subunits of mitochondrial complex I *J Mol Biol* 233 109-122
- Weiss H, Friedrich T, Hofhaus G, Preis D.** 1991 The respiratory-chain NADH dehydrogenase (complex I) of mitochondria *Eur J Biochem* 197 563-576
- White JA, McAlpine PJ, Antonarakis S, Cann H, Eppig JT, Frazer K, Frezal J, Lancet D, Nahmias J, Pearson P, Peters J, Scott A, Scott H, Spurr N, Talbot CJ, Povey S.** 1997 Guidelines for human gene nomenclature (1997) HUGO Nomenclature Committee *Genomics* 45 468-471
- White SL, Collins VR, Wolfe R, Cleary MA, Shanske S, DiMauro S, Dahl HH, Thorburn DR.**



1999. Genetic counselling and prenatal diagnosis for the mitochondrial DNA mutations at nucleotide 8993. *Am J Hum Genet* 65:474-482.
- Xu X, Matsuno-Yagi A, Yagi T.** 1993. DNA sequencing of the seven remaining structural genes of the gene cluster encoding the energy-transducing NADH-quinone oxidoreductase of *Paracoccus denitrificans*. *Biochemistry* 32:968-981.
- Yano T, Chu SS, Sled VD, Ohnishi T, Yagi T.** 1997. The proton-translocating NADH-quinone oxidoreductase (NDH-1) of thermophilic bacterium *Thermus thermophilus* HB-8. Complete DNA sequence of the gene cluster and thermostable properties of the expressed NQO2 subunit. *J Biol Chem* 272 4201-4211
- Zhu Z, Yao J, Johns T, Fu K, De Bie I, Macmillan C, Cuthbert AP, Newbold RF, Wang J, Chevrette M, Brown GK, Brown RM, Shoubridge EA.** 1998. SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. *Nat Genet* 20 337-343
- Zhuchenko O, Wehnert M, Bailey J, Sheng Sun Z, Chi Lee C.** 1996. Isolation, mapping and genomic structure of an X-Linked gene for a subunit of human mitochondrial complex I. *Genomics* 37 281-288.



## Samenvatting.

### Introductie.

In de humane cel vinden zeer veel biochemische reacties plaats. Veel van deze reacties verlopen spontaan, omdat de toestand na de reactie energetisch gunstiger is dan voor de reactie. In dit laatste geval is de vrije energie ( $\Delta G$ ) van de reactie negatief. Veel biochemische reacties verlopen echter niet spontaan omdat ze energetisch ongunstig zijn ( $\Delta G$  is positief). Een biochemisch energetisch ongunstig verlopende reactie kan toch verlopen wanneer deze gekoppeld wordt aan een energetisch gunstig verlopende reactie, zodat de som van beide reacties resulteert in een negatieve  $\Delta G$ . In cellen worden reacties met een positieve  $\Delta G$  vaak gekoppeld aan de hydrolyse van adenosine trifosfaat (ATP). De  $\Delta G$  van deze laatste reactie is  $-7.3$  kcal/mol. ATP wordt daarom wel de brandstof van de humane cel genoemd. De vrije energie in een ATP molecuul zit opgesloten in de fosfo-anhydride binding. Hydrolyse van deze binding resulteert in het vrijkomen van energie die ongebruikt vrijgegeven wordt in de vorm van warmte. Veel enzymen kunnen deze energie echter gebruiken en aldus energetisch ongunstige reacties toch laten verlopen.

ATP kan uit veel voedingsbestanddelen worden gevormd, met als belangrijkste glucose en vetzuren. Nadat glucose is opgenomen door de cel, wordt het in drie etappes afgebroken, waarbij het energierijke ATP wordt gevormd. Deze drie etappes zijn de glycolyse, de citroenzuurcyclus en de oxidatieve fosforylering. Vetzuren worden na opname in de cel omgezet in acyl-CoA, dat al of niet in de vorm van een carnitine ester naar de mitochondrien wordt getransporteerd en aldaar verder wordt geoxideerd via een proces genaamd  $\beta$ -oxidatie. De  $\beta$ -oxidatie levert uiteindelijk hetzelfde substraat op als glucose voor de citroenzuurcyclus, namelijk acetyl-CoA. De glycolyse vindt plaats in het cytosol van de cel, de citroenzuurcyclus en oxidatieve fosforylering vinden plaats in de mitochondrien. Tijdens de glycolyse,  $\beta$ -oxidatie en citroenzuurcyclus worden de substraten (NADH en  $FADH_2$ ) voor de laatste etappe van de energieproductie gevormd: de oxidatieve fosforylering.

Het oxidatieve (OXPHOS) fosforyleringssysteem bestaat uit vijf enzymcomplexen en is gesitueerd in de binnenmembraan van mitochondrien. Complex I tot en met IV voorzien in het transport van elektronen van NADH en  $FADH_2$  naar zuurstof. De energie die vrijkomt bij het transport van deze elektronen wordt geconserveerd door het gelijktijdige transport van protonen van de mitochondriële matrix naar de tussenmembraan ruimte. Dit transport resulteert in een elektrochemische gradient, die gebruikt wordt door het vijfde complex, ATP synthase om ATP te vormen.

Sommige kinderen worden geboren met een stoornis in een of meerdere enzymcomplex(en) van de oxidatieve fosforylering. Cellen van deze kinderen zijn dus niet in staat om in de behoefte aan ATP te voorzien. Dit uit zich onder meer in zeer ernstige multi-orgaan aandoeningen, waarbij organen die veel energie verbruiken als skeletspieren, hart en centraal zenuwstelsel het ernstigst zijn aangedaan. Het onderzoek dat beschreven staat in dit proefschrift, richt zich op kinderen met een stoornis in het eerste complex van de oxidatieve fosforylering: het NADH ubiquinon oxidoreductase (complex I).

Complex I voorziet in het transport van elektronen van NADH naar ubiquinon en gekoppeld

hieraan het transport van protonen over de mitochondriële binnenmembraan naar de tussenmembraanruimte. Hierdoor levert complex I een bijdrage aan de elektrochemische protongradiënt over de binnenmembraan van mitochondrien, welke gebruikt wordt door complex V om ATP te synthetiseren. Bij de mens bestaat complex I uit tenminste 42 verschillende eiwitten, waarvan er zeven door het mitochondriële DNA (mtDNA) gecodeerd worden, de rest door het kern DNA (nDNA).

### **Patiëntengroep.**

Het is mogelijk om in diverse weefsels van patiënten verdacht van een stoornis in de energiestofwisseling (b.v. in gekweekte huidfibroblasten, skeletspier-, hartspier-, lever- en hersenweefsel), de overall capaciteit van het oxidatieve fosforyleringssysteem m.b.t. de productie van ATP uit diverse substraten, alsmede de oxidatiesnelheden van diverse substraten te meten. Daarnaast is het mogelijk om de enzymactiviteit van de individuele complexen van dit systeem te meten.

Voor onze studies selecteerden we 27 patiënten met een geïsoleerde complex I deficiëntie (in alle gevallen gemeten in gekweekte huidfibroblasten en in het merendeel van de patienten ook in skeletspierweefsel). De sekse verdeling liet een mannelijke meerderheid zien: 3,3 : 1. Klinische karakterisering van deze patiënten leverde een subclassificatie op in zes groepen. Een groot deel van de patienten (26%) leed aan het syndroom van Leigh. Een ongeveer even groot deel leed aan een syndroom dat sterke gelijkenis vertoont met het syndroom van Leigh (22%; Leigh-like), maar bij deze patiënten zijn postmortaal geen neuropathologische studies uitgevoerd die de diagnose Leigh syndroom hadden kunnen bevestigen. Verder vertoonde een deel van de patiënten bij de geboorte een neonatale cardiomyopathie en lactaat acidose (11%; NCLA) of fatale neonatale lactaat acidose (11%; FILA). Tenslotte vertoonde een klein deel van de patiënten macrocefalie en progressieve leukodystrofie (7%; MLD) en was het in een substantieel deel van de patiënten niet mogelijk een encefalomyopathie verder te specificeren (22%). Veel voorkomende symptomen in onze patiënten groep zijn: hypotonie; psychomotore retardatie; respiratoire stoornissen; epilepsie; voedingsproblemen; tekenen van ziekte aan de piramidebanen; nystagmus en cardiomyopathie. De gemiddelde leeftijd waarop symptomen zich manifesteerden was 4,6 maanden. De gemiddelde overlevingsduur na openbaring van de ziekte was 8,6 maanden. Op vijf kinderen na, zijn alle kinderen in de eerste vijf levensjaren overleden, 67% zelfs binnen de eerste twee levensjaren. De klinische kenmerken van de patiëntengroep staan beschreven in hoofdstuk 2 van dit proefschrift.

Aangezien er nauwelijks succesvolle therapeutische mogelijkheden voor deze kinderen beschikbaar zijn, is het van het grootste belang om de genetische oorzaken op te sporen, zodat adequate en betrouwbare genetische counseling en prenatale diagnostiek kan worden aangeboden. Het overervingpatroon lijkt op grond van het hoge percentage consanguiniteit (26%) en de verdeling van aangedane en niet aangedane kinderen binnen de families in deze patiëntengroep autosomaal-recessief te zijn. Verder blijkt uit de literatuur dat veel voorkomende mutaties in het mitochondriële DNA die aanleiding kunnen geven tot OXPHOS stoornissen, slechts in een klein percentage van kinderen met een dergelijke ziekte voorkomen (~5%). In onze patiëntengroep zijn grote mutaties in het mtDNA uitgesloten door middel van de "long template PCR" techniek. Verder zijn elf veel voorkomende pathogene puntmutaties

in het mtDNA eveneens uitgesloten door middel van polymerase kettingreactie (PCR) gecombineerd met restrictie enzym analyse. Door dit alles lijken de genetische oorzaken van de complex I deficientie in deze patientengroep zich grotendeels te bevinden in het kern DNA en niet in het mitochondriële DNA. Een belangrijke groep kandidaat genen is dan natuurlijk de kerngecodeerde subeenheden die daadwerkelijk onderdeel uitmaken van complex I. Voordat mutatie analyse studies in deze patientengroep uitgevoerd konden worden, moesten eerst de kerngecodeerde subeenheden gekarakteriseerd worden.

### **Karakterisatie van humane complex I subeenheden.**

Het complex I van prokaryoten wordt gezien als de minimale functionele variant van dit enzym complex. Het bestaat uit 14 subeenheden, welke tezamen zowel het elektronen als het protonentransport verzorgen. Eukaryoten als b.v. *Neurospora crassa*, *Bos taurus* en *Homo sapiens* hebben een gecompliceerder complex I bestaande uit respectievelijk  $\geq 35$ ,  $\geq 42$  en nogmaals  $\geq 42$  subeenheden. Op dit moment zijn alle 42 subeenheden van *Bos taurus* gekarakteriseerd op cDNA- en aminozuurniveau. De sterke homologie tussen complex I eiwitten van de koe en de mens is gebruikt om de equivalenten van deze eiwitten bij de mens te karakteriseren. Momenteel zijn alle 42 humane subeenheden gekarakteriseerd, waarvan 18 door onze onderzoeksgroep. Van deze 18 subeenheden, staan er 14 in dit proefschrift beschreven (hoofdstuk 4, 5, 6, 7 en 8).

Nadat de cDNA structuur van deze kerngecodeerde complex I subeenheden opgehelderd was, werd een start gemaakt met mutatie analyse studies in onze patientengroep. De biochemische enzym assay welke gebruikt werd om de complex I activiteit in fibroblasten te bepalen, is gebaseerd op meting van de omzetting van NADH naar  $\text{NAD}^+$  in een geïsoleerde mitochondriële eiwitfractie, in aanwezigheid van een ubiquinon-analoog in aan- en afwezigheid van de specifieke complex I remmer rotenon. Dit impliceert dat een verlaagde activiteit van complex I vastgesteld met behulp van deze assay in wezen een stoornis in het transport van elektronen van NADH naar ubiquinon weerspiegelt. Het flavoproteïne (FP) deel en het ijzerzwavel proteïne (IP) deel welke op een na alle bekende katalytische centra van complex I bevatten, werden geselecteerd voor mutatie analyse studies. In dit proefschrift staan de resultaten van de op cDNA niveau uitgevoerde mutatie detectie studies, van subeenheden aanwezig in de IP fractie, beschreven.

### **Mutatie analyse studies van subeenheden van de IP fractie van complex I.**

Indien men complex I fragmenteert met chaotrope agentia, kan men drie subfracties onderscheiden: de genoemde flavoproteïne fractie en de ijzerzwavel proteïne fractie, welke tezamen het deel van complex I vormen dat uitsteekt in de mitochondriële matrix, en de hydrofobe proteïne fractie die het membraan deel van complex I vormt.

De ijzerzwavel proteïne fractie bestaat uit de volgende zeven of acht eiwitten: de NDUF51-6, de NDUF58 en de NDUF45 (de aanwezigheid van het NDUF58 eiwit in deze fractie is onderwerp van discussie). Bekend is dat het NDUF51 eiwit ten minste twee ijzerzwavel cluster bindingsplaatsen bevat, de NDUF58 mogelijk ook twee, en de NDUF52 zou betrokken zijn bij het binden van ubiquinon en rotenon. Bij het rund is onlangs bewezen dat het NDUF54 eiwit via een cAMP gereguleerde proteïne kinase gefosforyleerd wordt. Dit eiwit

bevat in het C-terminale deel een consensus fosforyleringsplaats die geconserveerd is in *N. crassa* en de mens. Deze fosforyleringsplaatsen hebben vaak een regulerende functie. Van de overige eiwitten is in functioneel opzicht nog niets bekend. Mutatie analyse studies d m v RT-PCR gecombineerd met DNA sequentie-analyse van alle acht bovengenoemde subeenheden in onze patientengroep leverden de volgende resultaten op.

Als eerste werd een homozygote duplicatie van vijf baseparen gevonden in het *NDUFS4* gen van een mannelijke patient die presenteerde met ernstig braken, groeiachterstand en spierhypotonie op een leeftijd van 8 maanden. Dit beeld verslechterde progressief tot de dood volgde op een leeftijd van 16 maanden. De *NDUFS4* subeenheid is een eiwit bestaande uit 175 aminozuren waarvan studies gedaan met rund complex I hebben aangetoond dat deze een cAMP gereguleerde fosforyleringsplaats bevat. De duplicatie bevindt zich direct na base 470 van het cDNA. Het gevolg van deze duplicatie is dat door de ontstane "frameshift", de 18 C-terminale aminozuren van het eiwit veranderen (met verlies van de consensus fosforyleringsplaats). Bovendien verdwijnt door de "frameshift" het reguliere stopcodon, zodat translatie verder gaat tot een volgend stopcodon, hetgeen resulteert in een eiwit dat 14 aminozuren langer is. Met behulp van polyacrylamide gel elektroforese werd de homozygote aanwezigheid van de duplicatie in het nDNA van de index patient bevestigd. Beide ouders bleken heterozygoot te zijn voor de duplicatie en het niet aangedane broertje bleek de mutatie niet te hebben. Dit is de eerste mutatie ooit gevonden in een kerngecodeerde subeenheid van complex I. Details van deze studie staan beschreven in hoofdstuk 8 van dit proefschrift.

De tweede mutatie in een kerngecodeerde subeenheid van complex I werd gevonden in het *NDUFS8* gen. Het open reading frame van de *NDUFS8* bestaat uit 633 baseparen coderend voor 210 aminozuren. Het betrof een patient lijdend aan het syndroom van Leigh, die presenteerde op een leeftijd van 5 weken met voedingsproblemen en perioden van apnoe en cyanose. Ook deze patient vertoonde een progressief ziektebeloop en overleed op een leeftijd van 11 weken als gevolg van cardiorespiratoir falen. Bij het syndroom van Leigh was eerder reeds vastgesteld dat een geïsoleerde complex I deficiëntie een van de belangrijkste oorzaken is, echter genetische oorzaken waren nooit aangetoond. In de bovengenoemde patient werden twee puntmutaties in het *NDUFS8* cDNA aangetroffen. Het betrof een C236T mutatie leidend tot aminozuursubstitutie van proline naar leucine op positie 79 en een G305A mutatie leidend tot substitutie van arginine naar histidine op positie 102. Restrictie-enzym analyse bevestigde dat beide mutaties bij deze patient in verschillende allelen voorkwamen. De vader van dit kind bleek drager van de C236T mutatie evenals het oudste broertje, de moeder was draagster van de G305A mutatie evenals het jongere zusje. Het jongste broertje bleek geen van beide mutaties te bezitten. Deze mutaties zijn de eerste ooit gevonden in een kerngecodeerde subeenheid van complex I in een patient met het syndroom van Leigh. De resultaten van deze studie staan beschreven in hoofdstuk 9 van dit proefschrift.

Sequentie-analyse van het *NDUFS2* cDNA (open reading frame van 1392 baseparen coderend voor 463 aminozuren) in onze patientengroep leverde opnieuw mutaties op. Het betrof hier drie families waarvan de ouders in twee families verwant waren. De eerste familie bestond uit drie kinderen waarvan de laatste twee (een jongen en een meisje) leden aan een geïsoleerde complex I deficiëntie. Het oudste kind is tot heden gezond. In beide aangedane kinderen vonden we een homozygote G683A mutatie die leidt tot substitutie van arginine naar

glutamine op positie 228. Beide kinderen leden aan een progressieve encefalomyopathie met hypertrofische cardiomyopathie en opticus atrofie en overleden op een leeftijd van respectievelijk 24 en 18 maanden. De mutatie werd bevestigd op nDNA niveau met behulp van restrictie-enzym analyse en was homozygoot aanwezig in beide index patienten, heterozygoot in beide ouders en afwezig in het gezonde oudste kind.

In een tweede familie werd eveneens een mutatie gevonden in het *NDUFS2* gen. Het betrof hier een patientje dat leed aan een neonatale hypertrofische cardiomyopathie en lactaat acidose. Het kind overleed vier dagen na de geboorte als gevolg van cardiorespiratoir falen. In het *NDUFS2* cDNA van deze patient werd een homozygote C686A mutatie gevonden leidend tot substitutie van proline in glutamine op positie 229. Restrictie-enzym analyse op nDNA niveau bevestigde dat de patient homozygoot is voor de mutatie en dat beide ouders heterozygoot zijn. In het gezin zijn verder geen kinderen.

De derde familie bestaat uit vier kinderen waarvan de eerste drie (allen jongens) leden aan een complex I deficientie. Het vierde kind werd gezond geboren na eiceldonatie. Alle drie de aangedane kinderen leden aan een beeld van progressieve encefalomyopathie en overleden twee tot drie jaar na de geboorte. In het tweede kind werd bij sequentie-analyse van het *NDUFS2* cDNA een homozygote T1237C mutatie gevonden (leidend tot substitutie van serine in proline ter hoogte van aminozuurpositie 413). Beide ouders bleken heterozygoot te zijn voor de mutatie. Helaas was van de andere kinderen geen DNA of RNA beschikbaar.

Alle drie de mutaties resulteren in de substitutie van aminozuren die door de evolutie heen in vele soorten geconserveerd zijn, wat een indicatie is voor het functionele belang van deze aminozuren. De resultaten van deze mutatie analyse studie staan beschreven in hoofdstuk 10 van dit proefschrift. Alle gevonden mutaties (hoofdstuk 8, 9 en 10) zijn uitgesloten in een grote controle populatie.

cDNA amplificatie gevolgd door sequentie-analyse van de overige subeenheden van de IP fractie, *NDUFS1*, *NDUFS3*, *NDUFS5*, *NDUFS6* en *NDUFA5*, leverde geen ziekte veroorzakende mutaties op. De resultaten van deze studies staan beschreven in hoofdstuk 5 en 11 van dit proefschrift.

### **Mutatie analyse studies met *NDUFA1* en *NDUFB6* cDNA en chromosomale lokalisatie van het *NDUFS2*, *NDUFS3*, *NDUFS4* en *NDUFS5* gen.**

Tenslotte hebben we nog het cDNA bestudeerd van twee subeenheden aanwezig in de hydrofobe fractie, namelijk *NDUFA1* en *NDUFB6*. De *NDUFA1* subeenheid is momenteel het enige complex I eiwit waarvan het bekend is dat het gen gelegen is op het X-chromosoom. Het feit dat het merendeel van onze complex I patienten uit mannen bestaat, wijst op mogelijke betrokkenheid van een X-gekoppelde factor. We hebben om die reden de chromosomale lokalisatie bepaald van 4 genen coderend voor complex I subeenheden beschreven in dit proefschrift, namelijk de *NDUFS2*, *NDUFS3*, *NDUFS4* en *NDUFS5*. Op dit moment is de chromosomale lokalisatie van 30 van de 35 kerngecodeerde subeenheden van complex I bekend, wat een random verdeling over de chromosomen laat zien. Mutatie analyse van het *NDUFA1* en *NDUFB6* cDNA leverde geen mutaties op in onze patienten. De resultaten van deze studies staan beschreven in hoofdstuk 3 en 4 van dit proefschrift.

## **Conclusies en toekomst.**

Als eerste stap in de opheldering van de veronderstelde nucleair-genetische oorzaken bij kinderen met een geïsoleerde complex I deficiëntie hebben we alle onbekende nucleair gecodeerde eiwitten van complex I gekarakteriseerd. Mutatie analyse studies van het cDNA van de complex I subeenheden aanwezig in de ijzerzwavel proteïne fractie, leverde mutaties op in vijf families. Alle mutaties zijn gelegen in genen coderend voor subeenheden die sterk geconserveerd zijn gedurende de evolutie wat het belang van deze subeenheden illustreert. Verder cosegregeerden alle mutaties in de families en werden ze uitgesloten in een grote controlepopulatie, hetgeen populatiepolymorfismen onwaarschijnlijk maakt. Toekomstige expressiestudies moeten de pathogeniciteit van de gevonden mutaties definitief bewijzen. Eveneens moeten de frequentie van deze mutaties, alsmede de betrokkenheid van mogelijke andere mutaties binnen deze gemuteerde subeenheden in een grote groep complex I deficiënte patiënten bepaald worden. Het vinden van genetische oorzaken leidt tot een meer betrouwbare genetische counseling in het algemeen en prenatale diagnostiek in het bijzonder.

Op dit moment zijn alle 35 bekende kerngecodeerde subeenheden van complex I onderzocht op de aanwezigheid van mutaties in onze patiëntengroep. Dit bracht in  $\pm 40\%$  de genetische oorzaak aan het licht. Hoe nu verder om in de overige patiënten het genetische defect op te helderen? Een van de mogelijkheden is het creëren van complementatiegroepen waarbij patiënten die tot een bepaalde complementatiegroep behoren het defect in hetzelfde gen hebben liggen. De techniek van "microcell-mediated chromosome transfer" stelt ons in staat om in zo'n complementatiegroep "gezonde" chromosomen één voor één in te brengen tot herstel van de complex I activiteit optreedt, waardoor vastgesteld wordt op welk chromosoom het gemuteerde gen ligt. Een aantal technieken als "deletion mapping" en positioneel/functioneel clonen stellen ons dan in staat om het gemuteerde gen op te sporen. Naast het ophelderen van het genetische defect in complex I deficiënte patiënten, zijn studies naar de pathofysiologische consequenties van deze mutaties van uitermate groot belang. Factoren die een rol spelen bij de pathofysiologie van complex I deficiëntie zijn onder andere een verminderde ATP productie, een verlaging van de mitochondriële membraanpotentiaal, radikaalvorming en een gestoorde cellulaire calciumhuishouding. Hopelijk leidt meer inzicht in deze processen uiteindelijk tot een rationele therapie waar patiënten profijt van hebben. Genezing van deze patientjes is immers het uiteindelijke doel.

De conclusies en toekomstperspectieven staan beschreven in hoofdstuk 12 van dit proefschrift.



## Summary.

### Introduction.

Many biochemical reactions take place within human cells. Some of these reactions run spontaneously, because conditions after the reaction are energetically favourable with respect to conditions before. In this case, the reaction's free energy ( $\Delta G$ ) is negative. Other biochemical reactions do not run spontaneously because they are energetically unfavourable ( $\Delta G$  is positive). A biochemical energetically unfavourable reaction can run when it is linked to a biochemical favourable reaction. The sum of these reactions then results in a negative  $\Delta G$ . Within cells, reactions with a positive  $\Delta G$  are often linked to the hydrolysis of adenosine triphosphate (ATP). The  $\Delta G$  of this latter reaction is  $-7.3$  kcal/mol. Therefore ATP is often called the energy source of human cells. The free energy of an ATP molecule is situated in its phosphoanhydride bond. Hydrolysis of this bond results in the release of free energy, which (when unused) is released as heat. However, many enzymes can use this energy to make energetically unfavourable reactions possible.

ATP can be synthesised from many food components, with as main contributors glucose and fatty acids. After glucose is taken up by the cell, it is degraded in three stages: glycolysis, citric acid cycle and oxidative phosphorylation. After entering the cell, fatty acids are converted into acyl-CoA and can be transported in the form of a carnitine ester into mitochondria, where they are further oxidised by a process which is called  $\beta$ -oxidation. This  $\beta$ -oxidation eventually results in the same substrate as degradation of glucose does, namely acetyl CoA, which can enter the citric acid cycle. Glycolysis takes place in the cytosol of the cell, the citric acid cycle and oxidative phosphorylation take place in mitochondria. During glycolysis,  $\beta$ -oxidation and citric acid cycle, the substrates (NADH and  $FADH_2$ ) are formed for the last stage of energy production: oxidative phosphorylation.

The oxidative phosphorylation (OXPHOS) system, which is localised in the inner mitochondrial membrane, is composed of five enzyme complexes. Complex I to IV transport electrons from NADH and  $FADH_2$  to oxygen. The energy that is released by the transport of these electrons is conserved by the simultaneous transport of protons from the mitochondrial matrix into the intermembrane space. This transport results in an electrochemical gradient, which is used by the fifth complex (ATP synthase) to generate ATP.

Some children are born with a disturbance of one or more enzyme complex(es) of the OXPHOS system. Cells of these children are therefore incapable to meet their need for ATP. This expresses (amongst others) as serious multiple-organ disease, with most prominent involvement of organs with high-energy demands like heart, central nervous system and skeletal muscle. The research described in this thesis, focuses on children with a disturbance in the first complex of the OXPHOS system: NADH ubiquinone oxidoreductase (complex I). Complex I transports electrons from NADH to ubiquinone and simultaneously to this electron transport, protons are translocated across the inner mitochondrial membrane to the intermembrane space. Because of this, complex I contributes to the electrochemical proton gradient across the inner membrane of mitochondria, which is used by complex V to synthesise ATP. In humans, complex I exists of at least 42 different proteins, of which seven

are encoded by the mitochondrial DNA (mtDNA). The remainder are encoded by nuclear DNA (nDNA).

### **Patientgroup.**

The overall capacity of the oxidative phosphorylation system with regard to the production of ATP from several substrates, as well as the oxidation rates of substrates can be measured in several tissues (like cultured skin fibroblasts, skeletal muscle, brain, heart and liver tissue) of patients suspected to suffer from a disturbance in the cellular energy production. Furthermore, it is possible to measure the enzyme activity of the individual complexes of this system.

We selected 27 patients suffering from an isolated complex I deficiency (measured in all cases in cultured skin fibroblasts and in the majority of these patients also in skeletal muscle tissue). The sex distribution showed a strong male preponderance: 3.3 : 1. Clinical characterisation of these patients resulted in a classification into six subgroups. A large part of the patients suffered from Leigh syndrome (26%). A similar percentage suffered from a syndrome, which has strong resemblance to Leigh syndrome (22%; Leigh-like syndrome), however autopsy has not been performed in these patients, which could have confirmed the diagnosis Leigh syndrome. Furthermore, a part of our isolated complex I deficient patients suffered at birth from a hypertrophic cardiomyopathy and lactic acidosis (11%; NCLA) or fatal infantile lactic acidosis (11%; FILA). Finally, a small part of our patients suffers from macrocephaly and progressive leukodystrophy (7%; MLD). In a substantial part of our patients it was not possible to specify an encephalomyopathy (unspecified encephalomyopathy (UE); 22%). Frequent symptoms observed in our patient group are: hypotonia; psychomotor retardation; respiratory disturbances; epilepsy; feeding problems; pyramidal signs; nystagmus and cardiomyopathy. Mean age of disease presentation within our patientgroup was 4.6 months. The mean survival interval after disease presentation was 8.6 months. All but five children died within the first five years of life, 67% died within the first two years. The clinical characteristics of our patient group are described in chapter 2 of this thesis.

Since there are no successful therapeutic possibilities for these children available, it is of utmost importance to find the genetic causes, which will give us the opportunity to offer adequate genetic counselling and prenatal diagnostics. On the basis of the high percentage of consanguinity (26%) and the distribution of affected and non-affected children within families with isolated complex I deficient patients, the inheritance pattern seems to be autosomal-recessive. Furthermore, recent literature revealed that common mtDNA mutations, which can result in OXPHOS disturbances, are usually not present in children with such a disease. In our patientgroup, major rearrangements of mtDNA are excluded with the long mtDNA template polymerase chain reaction (PCR) technique. Furthermore, eleven common pathogenic mtDNA mutations have been excluded by means of PCR combined with restriction enzyme analysis. The factors mentioned in this paragraph concerning the possible genetic origin of isolated complex I deficiency in our patient group, make mutations in the nuclear DNA compared to mutations in the mtDNA, more likely. An important group candidate genes are therefore the nuclear genes, which encode subunits which are part of complex I. Before mutational analysis studies could be performed in our patientgroup, we had to elucidate the cDNA and amino acid sequence of these nuclear encoded subunits.

### Characterisation of human complex I subunits.

Prokaryotic complex I is generally considered to be the minimal functional version of this enzyme complex. It consists of fourteen subunits, which together take care of the electron- and protontransport. Eukaryotes like *Neurospora crassa*, *Bos taurus* and *Homo sapiens* have a more complicated complex I, consisting of  $\geq 35$ ,  $\geq 42$  and again  $\geq 42$  subunits, respectively. At this moment, all 42 subunits of *Bos taurus* have been characterised at cDNA and amino acid level. The strong resemblance between subunits of cow and humans has been used to characterise the human equivalents of these bovine subunits. Currently, all 42 human subunits have been characterised, of which 18 by our researchgroup. Of these latter subunits, 14 are described in this thesis (chapter 4, 5, 6, 7 and 8).

When the cDNA structure of all nuclear encoded complex I subunits was elucidated, we started with mutational analysis studies within our patient group. The biochemical enzyme assay we used to measure the complex I activity in fibroblasts, is based on the conversion of NADH to NAD<sup>+</sup> in an isolated mitochondrial protein fraction in the presence of a ubiquinone analogue and in presence or absence of the specific complex I inhibitor rotenone. This implicates that a reduced complex I activity according to this assay actually reflects a disturbance in the transport of electrons from NADH to ubiquinone. The flavoproteine (FP) fraction and the iron-sulphur protein (IP) fraction, which contain all but one known catalytic centres of complex I, were selected for mutational analysis studies. In this thesis the results of these studies (at cDNA level) are described.

### Mutational analysis studies of subunits present in the IP fraction of complex I.

It is possible to fragment complex I with chaotropic agents, which results in three subfractions: the previously mentioned flavoprotein (FP) and iron-sulphur protein fraction, which together constitute the part of complex I which protrudes into the mitochondrial matrix, and a hydrophobic protein fraction (HP), which largely forms the membranous part of complex I.

The iron-sulphur protein fraction consists of seven or eight proteins: NDUFS1-6, NDUFS8 and NDUF5A (the presence of the NDUFS8 subunit in this fraction is subject of debate). It is known that the NDUFS1 subunit contains at least two iron-sulphur cluster binding sites, the NDUFS8 possibly also two and the NDUFS2 is hypothesised to participate in ubiquinone and rotenone binding. Recently, it was found that the NDUFS4 subunit of *Bos taurus* is phosphorylated by a cAMP dependent protein kinase. The NDUFS4 contains a consensus phosphorylation site in the C-terminal part of the protein, which is conserved in *N. crassa* and humans. These phosphorylation sites often have a regulating function. Currently, nothing is known of the function of the other proteins present in the iron-sulphur protein fraction. Mutational analysis studies by means of RT-PCR and DNA sequence analysis of these eight subunits revealed the following results.

The first mutation we found was a homozygous 5 bp duplication in the *NDUFS4* gene of a male patient who presented at the age of eight months with serious vomiting, failure to thrive and muscle hypotonia. The clinical course was rapidly progressive, until the child's death at the age of 16 months. The NDUFS4 protein consists of 175 amino acids. As mentioned previously, the bovine equivalent of the NDUFS4 subunit contains a cAMP regulated

phosphorylation site. The duplication is present directly after cDNA base 470. The results of this duplication (due to the frameshift) for the translation product are change of the 18 C-terminal amino acids (with destruction of the cAMP consensus phosphorylation site) and destruction of the stop codon, which theoretically results in elongation of the translation product until the next inframe stop codon, which elongates the *NDUFS4* in this patient with 14 amino acids. We confirmed the homozygous presence of the duplication in the nuclear DNA (nDNA) of the index patient with polyacrylamide gel electrophoresis. Both parents were heterozygous for the duplication while nDNA of the healthy sibling only contained wildtype alleles. This duplication was the first mutation found in a nuclear gene encoding a subunit of complex I. Details of this study are described in chapter 8 of this thesis.

The second mutation we found in a nuclear encoded subunit of complex I was located in the *NDUFS8* subunit. The open reading frame (ORF) of the *NDUFS8* cDNA contains 633 base pairs, encoding 210 amino acids. It concerned a patient who suffered from Leigh syndrome, who presented at the age of 5 weeks with feeding difficulties and periods of apnoea and cyanosis. This patient expressed a progressive clinical course and died at the age of eleven weeks as a consequence of cardiorespiratory failure. Isolated complex I deficiency was previously recognised as a frequent cause of Leigh syndrome, however genetic links had never been found. We found two compound heterozygous mutations in the *NDUFS8* cDNA of the patient described in this paragraph. It concerned a C236T mutation leading to the substitution of proline into leucine at position 79 and a G305A mutation leading to the substitution of arginine to histidine at position 102. Restriction enzyme analysis performed with amplified *NDUFS8* cDNA of this patient confirmed that both mutations were located on different alleles. The father of this child is carrier of the C236T mutation just as the younger brother, while the mother is carrier of the G305A mutation just as the younger sister. The youngest brother does not contain either of the two mutations. These mutations were the first to be found in a nuclear encoded subunit of complex I in a patient with Leigh syndrome. The results of this study are described in chapter 9 of this thesis.

Sequence analysis of the *NDUFS2* cDNA (ORF of 1392 base pairs encoding 463 amino acids) in our patient group again revealed mutations. These mutations were encountered in three families, of which two were known with consanguinity. The first family consisted of three children, of whom the latter two suffered from isolated complex I deficiency. The oldest child is currently alive and healthy. Both complex I deficient children contained a homozygous base substitution in their *NDUFS2* cDNA (G683A) leading to the substitution of arginine into glutamine at position 228. Both children suffered from a progressive encephalomyopathy, hypertrophic cardiomyopathy and optic atrophy and died at the age of 24 and 18 months, respectively. The mutation was confirmed to be homozygously present in the nuclear DNA of both patients by means of restriction enzyme analysis, while both parents turned out to be heterozygous for the mutation, and the healthy child contained only wildtype alleles.

We found a homozygous C686A mutation leading to the substitution of proline into glutamine at position 229 in a complex I deficient child of a second family. The child suffered from a neonatal cardiomyopathy and lactic acidosis and died 4 days after birth of cardiorespiratory failure. Restriction enzyme analysis with amplified nDNA fragments confirmed the presence of the homozygous mutation in the patient, while both parents turned out to be heterozygous

carriers. There were no other siblings in this family.

The third family consisted of four children, of whom the oldest three (all boys) suffered from isolated complex I deficiency. The fourth child was born healthy after egg cell donation. All three affected children suffered from a clinical phenotype of progressive encephalomyopathy and died two to three years after birth. We found in the second affected child by means of sequence analysis with amplified *NDUFS2* cDNA a homozygous T1237C mutation leading to the substitution of serine into proline at amino acid position 413. This mutation was also homozygously present in the nDNA of this patient, while both parents are heterozygous carriers. Unfortunately, DNA and RNA of the other three children were unavailable.

All three mutations result in the substitution of amino acids, which are highly conserved in many species during evolution, which is indicative for the functional importance of these amino acids. The results of these mutational analysis studies are described in chapter 10 of this thesis. All found mutations (chapter 8, 9 and 10) have been excluded in a large control population.

cDNA amplification followed by sequence analysis of the other subunits of the IP fraction (*NDUFS1*, *NDUFS3*, *NDUFS5*, *NDUFS6* and *NDUFA5*) did not reveal any disease causing mutations. The results of these studies are described in chapter 5 and 11 of this thesis.

#### **Mutational analysis studies of *NDUFA1* and *NDUFB6* cDNA and chromosomal localisation of the *NDUFS2*, *NDUFS3*, *NDUFS4* and *NDUFS5* gene.**

Finally we checked the cDNA for mutations of two subunits present in the hydrophobic subfraction, namely the *NDUFA1* and *NDUFB6* subunit. The *NDUFA1* subunit is presently the only complex I protein, whose gene is located on the X-chromosome. The fact that the majority of our complex I deficient patients is male, points to the possible involvement of an X-linked factor. For this reason we performed the chromosomal localisation of four genes encoding complex I subunits, namely the *NDUFS2*, *NDUFS3*, *NDUFS4* and *NDUFS5*. At this moment the chromosomal localisation of 30 of the 35 nuclear encoded subunits of complex I is known, which shows a random distribution across the chromosomes. Mutational analysis studies of the *NDUFA1* and *NDUFB6* cDNA revealed no mutations within our patients. The results of these studies are described in chapter 3 and 4 of this thesis.

#### **Conclusions and future perspectives.**

As a first step in the elucidation of the hypothesised nuclear-genetic causes in children with an isolated complex I deficiency we characterised all unknown nuclear encoded subunits of complex I. Mutational analysis studies on cDNA level of the subunits present in the iron-sulphur protein fraction revealed mutations in five pedigrees. All mutations are present in subunits that are highly conserved during evolution. All mutations cosegregated within the families and were excluded in a large control population, which makes the mutations being rare population polymorphisms unlikely. Future expression studies should prove the pathogenicity of the found mutations. Likewise the frequency of these mutations in a large group of complex I deficient patients as well as the presence of new mutations in these mutated subunits has to be investigated. The elucidation of genetic causes of complex I deficiency leads to a more accurate genetic counselling and prenatal diagnostics.

At this moment, all 35 known nuclear encoded subunits of complex I have been checked for mutations in our initial group of 20 isolated complex I deficient patients. This revealed the genetic cause in ~40%. Which path should we follow next in order to elucidate the genetic cause in our remaining patients? One of the possibilities is the generation of complementation groups (patients belonging to the same complementation group carry the genetic defect in the same gene). The technique of microcell-mediated chromosome transfer will give us the opportunity to introduce “healthy” chromosomes one by one in cells of patients belonging to the same complementation group. When the introduction of a specific chromosome results in recovery of the complex I activity, the mutated gene is located on that specific chromosome. Techniques like deletion mapping and positional/functional cloning give us the opportunity to locate the mutated gene.

Besides the elucidation of the genetic causes of complex I deficiency, studies of the pathophysiological consequences of this disease are very important. Factors which play a role in the pathophysiology of complex I deficiency are amongst others diminished ATP production, reduction of the mitochondrial membrane potential, reactive oxygen species (ROS) formation and a disturbed cellular calcium maintenance. Hopefully these studies lead to increased understanding of these processes, which may result in a rational therapy. Cure of our patients is after all our final goal.

The conclusions and future perspectives are described in chapter 12 of this thesis.







## Dankwoord.

Eindelijk ben ik bij het laatste en leukste deel van dit proefschrift aangekomen. Niet alleen leuk omdat nu eindelijk een eind komt aan dat eindeloze geram op mijn toetsenbord, maar ook omdat ik het leuk vind om mensen die (al dan niet bewust) een steentje hebben bijgedragen aan de totstandkoming van dit proefschrift persoonlijk te bedanken. Allereerst wil ik mijn geweten zuiveren door mijn excuses aan te bieden aan eenieder die hier niet genoemd wordt en wel genoemd had moeten worden.

**Ouders en patiëntjes.** Allereerst wil ik alle ouders en patiëntjes bedanken voor hun medewerking. Zonder hun welwillende hulp zal het onderzoek op welk vakgebied dan ook altijd in de kinderschoenen blijven staan.

**Promotor Prof. dr. ir. JMF Trijbels.** Geachte prof. Trijbels, ik wil u graag bedanken voor het feit dat u me drie jaar geleden de gelegenheid bood om mijn "onderzoekskunsten" te mogen komen vertonen op uw laboratorium. Uw grote kennis met betrekking tot de mitochondriële myopathieën hebben mijn onderzoek enorm vooruit geholpen. Dankzij uw grote kennis van de Engelse en Nederlandse taal heeft u menig spel- en grammaticafout in mijn artikelen en andere schrijfsels getraceerd en geëlimineerd. Verder hebt u zonder al te veel succes drie jaar tegen mij gezegd dat u getutoyeerd wil worden en aangesproken wil worden met Frans in plaats van professor Trijbels. Daar wil ik op dit moment dan toch verandering in brengen. Dus: Frans bedankt!

**Prof. dr. RCA Sengers.** Geachte prof. Sengers, zonder uw steun had dit proefschrift nooit het levenslicht gezien. U hebt samen met prof. Trijbels het huidige centrum voor mitochondriële ziekten in Nijmegen opgericht en zo de basis gelegd voor het in dit proefschrift beschreven onderzoek. Uw grote kennis met betrekking tot dit vakgebied alsmede uw nimmer aflatend enthousiasme en steun voor wetenschappelijk onderzoek in het algemeen en mitochondriële encefalomyopathieën in het bijzonder hebben mijn onderzoek een grote sprong voorwaarts doen maken. Ook wil ik u bedanken voor de steun die ik van u ontvangen heb bij mijn overstap van het laboratoriumwerk naar de klinische Kindergeneeskunde.

**Copromotor dr. JAM Smeitink.** Beste Jan, een jaar of vijf geleden klopte ik voor het eerst op jouw deur (destijds stond die deur nog in Utrecht). We werkten samen aan een project betreffende de toepasbaarheid van de orale glucose tolerantie test bij kinderen verdacht van een ademhalingsketendefect. We hebben daar destijds zelfs een artikel uit gedestilleerd (moeten we toch eens opsturen). Daarna vertrok jij naar Nijmegen. Ook daar bleef ik je lastig vallen met verzoeken om gezamenlijke projecten uit te voeren. Uiteindelijk gaf je gehoor aan deze verzoeken en bood je mij de kans om binnen de subafdeling Metabole ziekten promotieonderzoek te komen verrichten. Daar ben ik je uiteraard nog steeds enorm dankbaar voor. Ik heb je leren kennen als iemand die met buitenaardse gedrevenheid zijn vak uitoefent, nooit nee zegt wanneer men met een zinnig verzoek komt en wat ik het allerbelangrijkste vind, je bent een man van je woord. Verder heb je grote diplomatieke en organisatorische kwaliteiten die eenieder van ons grote voordelen opgeleverd hebben (buitenlandse congressen, stageplaatsen etc.) en in de toekomst op zullen leveren. Jan, bedankt voor alles. Ik hoop dat we nog vele jaren zaken kunnen doen.

**Copromotor dr. LP van den Heuvel.** Beste Bert, drie jaar geleden kwam Jan aanzetten met een student die hij nog kende vanuit Utrecht en die op jouw deel van het laboratorium LKN

geplaatst moest worden. Geneeskunde student nog wel, lab ervaring nul. Ik wil je bedanken voor het feit dat je je gezonde scepsis opzij hebt gezet en mij de gelegenheid hebt gegeven om onderzoek te komen doen. Ik heb veel respect voor de manier waarop jij vele AIO's en promovendi begeleidt op verschillende vakgebieden. Ondanks de vele commissies waar je zitting in hebt konden wij altijd bij je terecht voor vragen, verzoeken of gewoon een potje klagen. Je grote kennis van DNA- en eiwitonderzoek vormt het fundament waarop ons onderzoek is gebouwd. Bert, bedankt voor alle hulp.

**Roel "de Loer" Smeets.** Beste Roel, drie jaar geleden kreeg jij mij in de maag gesplitst. Jij moest mij binnen drie weken inwijden in de DNA geheimen. Dit heeft uiteindelijk drie jaar geduurd, en nog steeds kan ik niet zonder jou hulp. Gezamenlijk zijn we gestart met ons onderzoek (zo zie ik het toch een beetje) en het eerste deel wordt met dit boekje afgerond. Ik wil je bedanken voor alle hulp die je verleend hebt en het geduld waarmee je al mijn stomme vragen hebt beantwoord. Het is vanzelfsprekend dat jij één van de twee paranymphen bent. Het feit dat we over een soortgelijke humor beschikken (die overigens door veel mensen niet als humor bestempeld wordt, maar dat terzijde), leverde vele, door sommigen onbegrepen, lachsalvo's op. Ik hoop dat we in de toekomst nog vele malen gezamenlijk gaan stappen, niet meer als collega's maar als vrienden.

**Ralf "de Rug" Triepels.** Beste Ralf, als medepromovendus op het gebied van complex I zaten we dicht bij elkaar in het onderzoeksvaarwater. Dat leidde soms wel eens tot kleine meningsverschillen maar door de bank genomen hebben wij de zaken prima opgelost. De vele therapeutische gesprekken die we voerden in de Radboudschool deden ons beider nachtrust goed. Je "recht voor zijn raap" humor heeft vele malen geleid tot hilarische taferelen waardoor de stemming er op en buiten het werk altijd goed in zat. Ik wens je alle succes met het verdere verloop van je onderzoek en wanneer je hulp nodig hebt weet je me te vinden.

**Carin Buskens.** Beste Carin, ik wil jou speciaal bedanken voor alle keren dat je mij veilig en wel in Oss afzette na een avondje stappen met alle lab collega's. Iedere keer wanneer ik weer eens vroeg om mee te mogen rijden, zei je altijd direct ja. Hartstikke bedankt daarvoor!

**De squash bende.** Roel, Maarten "Koning P" Smit, Erik "de Knaning" Stevens, Erwin, en Ralf. Twee jaar hebben we aan onze conditie gewerkt op de squashbaan. Ik zal het hardwerkende XAT personeel en onze stimulerende gesprekken na het squashen missen.

**DNA lab en AIO's.** Ik wil graag alle mensen van het DNA lab waar ik mee heb samengewerkt bedanken voor alle hulp en gezellige uitstapjes die we samen gemaakt hebben. Dit was zonder meer de gezelligste werkplek waar ik tot nu toe gepositioneerd ben geweest! Belinda, Carin B, Erik J, Erik S, Henk van D, Henny, Iwan, Jacqueline, Karin A, Karin L, Lambert, Leo, Lydia, Maarten, Manlio, Marieke, Markus, Marije, Marjan, Maroushka, Nathalie, Peter, Roel, Ralf, Raoul, Sandra, Sander, Sandy en de studenten Anouk H, Bianca, Cicilia, Gijs, Gracia, Joep, Liesbeth, Martine van B, Nicole.

**Anouk en Jorrit.** Bedankt voor jullie inzet tijdens jullie onderzoeksstages op het gebied van complex I. Anouk, dat je maar een goede kinderdokter mag worden!

**Spiergroep en Weefselweek.** Hoewel we zelf (deel van de DNA groep) ook tot de spiergroep behoren wordt nog steeds met deze naam de groep van de mitochondriële enzymdiagnostiek aangeduid. Anneke, Antoon, Christine, Diana en Liesbeth, jullie werk vormt de basis van het mitochondriële onderzoek. Bedankt voor alle hulp en voor het rustig





## Curriculum vitae.

Johannes Lambertus Christianus Mana Loeffen werd geboren op 6 mei 1970 te Oss. Na het voltooien van de opleiding VWO- $\beta$  aan het Titus Brandsma Lyceum te Oss werd wegens uitloting voor de studie Geneeskunde aangevangen met de studie Gezondheidswetenschappen te Nijmegen. In de loop van het studiejaar deed de gelegenheid zich voor over te stappen naar de studie Geneeskunde te Utrecht. Het doctoraal examen Geneeskunde werd in 1995 afgelegd, wat gevolgd werd door het artsexamen in april 1997. Tijdens de opleiding tot arts participeerde hij in diverse wetenschappelijke projecten bij de afdeling Interne Geneeskunde (Diakonessenhuis te Utrecht), afdeling Kindergeneeskunde, subafdeling voedingsallergieën (Wilhelmina Kinderziekenhuis te Utrecht), afdeling Kindergeneeskunde, subafdeling Stofwisselingsziekten (Wilhelmina Kinderziekenhuis te Utrecht) en het laboratorium voor Kindergeneeskunde en Neurologie (Universitair Medisch Centrum St. Radboud).

Van april 1997 tot en met december 1999 was hij als artsonderzoeker verbonden aan het Laboratorium voor Kindergeneeskunde en Neurologie (hoofd Prof. dr. ir. JMF. Trijbels) en de subafdeling Metabole Ziekten (hoofd Dr. JAM. Smeitink) van de afdeling Kindergeneeskunde (hoofd Prof. dr. RCA. Sengers) van het Universitair Medisch Centrum St. Radboud, alwaar het in dit proefschrift beschreven onderzoek is uitgevoerd. Vanaf 1 april 2000 is hij teruggekeerd naar de klinische patientenzorg en werkt hij als arts bij de afdeling Kindergeneeskunde van het Universitair Medisch Centrum St. Radboud te Nijmegen.

## List of publications.

**Mutations in the complex I *NDUFS2* gene are associated with hypertrophic cardiomyopathy and encephalomyopathy.**

Loeffen J, Elpeleg O, Smeitink J, Smeets R, Stockler-Ipsiroglu S, Mandel H, Sengers R, Trijbels F, van den Heuvel L 2000 *Submitted*

**Mutational analysis studies of four nuclear encoded subunits of the complex I Iron-Sulphur protein (IP) fraction: which genes next?**

Loeffen J, Smeitink J, Smeets R, Triepels R, Trijbels F, van den Heuvel L 2000 *Submitted*

**Characterisation of the human complex I *NDUFB7* and 17.2-kDa cDNAs and mutational analysis of 19 genes of the HP fraction in complex I-deficient patients.**

Triepels R, Smeitink J, Loeffen J, Smeets R, Buskens C, Trijbels F, van den Heuvel L  
*Human Genetics* 2000, *in press*

**Isolated complex I deficiency in children: clinical, biochemical and genetic aspects.**

Loeffen J, Smeitink J, Trijbels F, Janssen A, Triepels R, Sengers R, van den Heuvel L  
*Human Mutation* 2000 15 123-134

**Leigh syndrome associated with a mutation in the *NDUFS7* (PSST) nuclear encoded subunit of complex I.**

Triepels R, van den Heuvel L, Loeffen J, Buskens C, Smeets R, Rubio-Gozalbo M, Budde S, Mariman E, Wijburg F, Barth P, Trijbels F, Smeitink J  
*Annals of Neurology* 1999 45 787-790

**The human nuclear encoded acyl carrier subunit (*NDUFAB1*) of the mitochondrial complex I in human pathology.**

Triepels R, Smeitink J, Loeffen J, Smeets R, Buskens C, Trijbels F, van den Heuvel L  
*Journal of Inherited Metabolic Disease* 1999 22 163-173

**Mutant *NDUFV1* subunit of mitochondrial complex I causes leukodystrophy and myoclonic epilepsy.**

Schuelke M, Smeitink J, Mariman E, Loeffen J, Plecko B, Trijbels F, Stockler-Ipsiroglu S, van den Heuvel L  
*Nature Genetics* 1999 21 260-261

**The human NADH:ubiquinone oxidoreductase *NDUFS5* (15 kDa) subunit: cDNA cloning, chromosomal localisation, tissue distribution and the absence of mutations in isolated complex I-deficient patients.**

Loeffen J, Smeets R, Smeitink J, Triepels R, Sengers R, Trijbels F, van den Heuvel L  
*Journal of Inherited Metabolic Disease* 1999 22 19-28

**cDNA of eight nuclear encoded subunits of NADH:ubiquinone oxidoreductase: human complex I cDNA characterisation completed?**

Loeffen J, Triepels R, van den Heuvel L, Schuelke M, Buskens C, Smeets R, Trijbels F, Smeitink J  
*Biochemical and Biophysical Research Communications* 1998 253 415-422

**The nuclear-encoded human NADH:ubiquinone oxidoreductase NDUF A8 subunit: cDNA cloning, chromosomal localisation, tissue distribution, and mutation detection in complex-I-deficient patients.**

Triepels R, van den Heuvel L, Loeffen J, Smeets R, Trijbels F, Smeitink J  
*Human Genetics* 1998 103 557-563

**The first nuclear-encoded complex I mutation in a patient with Leigh syndrome.**

Loeffen J, Smeitink J, Triepels R, Smeets R, Schuelke M, Sengers R, Trijbels F, Hamel B, Mullaart R, van den Heuvel L  
*American Journal of Human Genetics* 1998 63 1598-1608

**Molecular characterisation and mutational analysis of the human B17 subunit of the mitochondrial respiratory chain complex I.**

Smeitink J, Loeffen J, Smeets R, Triepels R, Ruitenbeek W, Trijbels F, van den Heuvel L  
*Human Genetics* 1998 103 245-250

**Nuclear genes of human complex I of the mitochondrial electron transport chain: state of the art.**

Smeitink J, Loeffen J, Triepels R, Smeets R, Trijbels J, van den Heuvel L  
*Human Molecular Genetics* 1998 7 1573-1579

**The X-chromosomal NDUF A1 gene of complex I in mitochondrial encephalomyopathies: tissue expression and mutation detection.**

Loeffen J, Smeets R, Smeitink J, Ruitenbeek W, Janssen A, Mariman E, Sengers R, Trijbels F, van den Heuvel L  
*Journal of Inherited Metabolic Disease* 1998 21 210-215

**cDNA sequence and chromosomal localisation of the remaining three human nuclear encoded iron sulphur protein (IP) subunits of complex I: the human IP fraction is completed.**

Loeffen J, van den Heuvel L, Smeets R, Triepels R, Sengers R, Trijbels F, Smeitink J  
*Biochemical and Biophysical Research Communications* 1998 247 751-758

**Cloning of the human mitochondrial 51 kDa subunit (NDUF V1) reveals a 100% antisense homology of its 3'UTR with the 5'UTR of the gamma-interferon inducible protein (IP-30) precursor: is this a link between mitochondrial myopathy and inflammation?**

Schuelke M, Loeffen J, Mariman E, Smeitink J, van den Heuvel L  
*Biochemical and Biophysical Research Communications* 1998 245 599-606

**Demonstration of a new pathogenic mutation in human complex I deficiency: a 5-bp duplication in the nuclear gene encoding the 18-kD (AQDQ) subunit.**

van den Heuvel L, Ruitenbeek W, Smeets R, Gelman-Kohan Z, Elpeleg O, Loeffen J, Trijbels F, Mariman E, de Bruijn D, Smeitink J  
*American Journal of Human Genetics* 1998 62 262-268















